article_title,journal_title,journal_abbre,article_date,abstract,article_type,pub_days,citation,abstract_clean,Breast Cancer,Lung Cancer,Leukemia,Prostate Cancer,Colorectal Cancer,Lymphoma,Bone Cancer,Melanoma,Liver Cancer,Kidney Cancer,Ovarian Cancer,Pancreatic Cancer,Brain Tumor,Head and Neck Cancer,Acute Myeloid Leukemia (AML),Multiple Myeloma,Sarcoma,Bladder Cancer,Skin Cancer,Gastric Cancer,Gastrointestinal Tumor,Endometrial Cancer,Acute Lymphoblastic Leukemia (ALL),Chronic Lymphocytic Leukemia (CLL),Cardiac Tumors,Cervical Cancer,Esophageal Cancer,Thyroid Cancer,Rectal Cancer,text_clean_seq,text_length,pmid,title_clean,bert_similarity_rank_pituitary_tumor,bert_similarity_rank_pituitary_tumor_percentile
MR imaging characteristics of amyloid deposits in pituitary adenoma.,AJNR. American journal of neuroradiology,AJNR Am J Neuroradiol,2002-03-01,"Although cases of pituitary adenomas containing amyloid deposits have been described in the literature, to our knowledge this is the first report to describe MR imaging characteristics of a pituitary adenoma containing almost entirely amyloid tissue.",Case Reports,6535.0,9.0,cases pituitary adenomas containing amyloid deposits described literature knowledge report MR imaging characteristics pituitary adenoma containing entirely amyloid tissue,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[242, 140, 1, 2751, 1101, 6655, 7626, 47, 85, 1027, 4, 3, 789, 6, 114, 922, 26, 16, 3, 157, 414, 6, 897, 1638, 270, 374, 1, 8, 2434, 1101, 2214, 6848, 6655, 246]",228.0,11901001,MR imaging characteristics amyloid deposits pituitary adenoma,3,0.02830188679245283
Genotype-phenotype analysis in multiple endocrine neoplasia type 1.,"Archives of surgery (Chicago, Ill. : 1960)",Arch Surg,2002-06-01,"Multiple endocrine neoplasia type 1 (MEN 1) syndrome is an autosomal dominant disorder caused by germline mutations in the MEN1 gene and characterized by multiple endocrine tumors, most notably in the parathyroid glands, pituitary, and pancreas. The syndrome demonstrates variable expressivity and considerable genetic heterogeneity. Patient data were examined for possible associations between genotype and phenotype. We reviewed recorded medical data from 1975 to 2001 on patients with MEN 1 and compared specific types and locations of MEN1 gene mutations with manifestations of the syndrome. We identified 109 affected patients from 24 MEN 1 kindreds. The phenotypic expression of MEN 1 in affected individuals included hyperparathyroidism in 74%, pancreatic endocrine tumors in 51%, and pituitary tumors in 35%. Twelve of 14 insulinomas occurred in patients with pituitary tumors. Mutation analysis was completed in 14 of 24 kindreds (80 of the 109 patients). Mutations were most common in exons 2 (31%), 9 (15%), and 10 (23%). All 21 patients with frameshift mutations (and known pancreatic endocrine tumor status) had such tumors. Pituitary tumors were associated with frameshift mutations in exon 2. The type and location of MEN1 mutations may be associated with the phenotypic expression of specific tumors. Such information may assist in the genetic counseling and surveillance of at-risk patients. A specific genotype-phenotype correlation is unlikely because of the heterogeneity of the mutations in the MEN1 gene.",Journal Article,6443.0,,Multiple endocrine neoplasia type 1 MEN 1 syndrome autosomal dominant disorder caused germline MEN1 characterized multiple endocrine notably parathyroid glands pituitary pancreas syndrome demonstrates variable expressivity considerable genetic heterogeneity Patient examined possible associations genotype phenotype reviewed recorded medical 1975 2001 patients MEN 1 compared specific types locations MEN1 manifestations syndrome identified 109 affected patients 24 MEN 1 kindreds phenotypic expression MEN 1 affected individuals included hyperparathyroidism 74 pancreatic endocrine 51 pituitary 35 14 insulinomas occurred patients pituitary completed 14 24 kindreds 80 109 patients common exons 2 31 9 15 10 23 21 patients frameshift known pancreatic endocrine status Pituitary associated frameshift exon 2 type location MEN1 associated phenotypic expression specific information assist genetic counseling surveillance at-risk patients specific genotype-phenotype correlation unlikely heterogeneity MEN1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[232, 1293, 2298, 267, 14, 325, 14, 681, 16, 35, 6084, 2156, 2645, 1546, 20, 1009, 138, 4, 3, 7923, 145, 2, 765, 20, 232, 1293, 57, 96, 2552, 4, 3, 3966, 2, 3, 681, 1902, 1347, 42949, 2, 2658, 336, 1144, 69, 74, 11, 409, 9, 899, 685, 59, 1183, 2, 1005, 21, 446, 1872, 484, 74, 29, 7585, 6, 1758, 23, 7, 5, 325, 14, 2, 72, 112, 630, 2, 4069, 1, 7923, 145, 138, 5, 4282, 1, 3, 681, 21, 108, 3486, 1424, 7, 29, 259, 325, 14, 10141, 3, 3290, 55, 1, 325, 14, 4, 1424, 869, 159, 9630, 4, 794, 1293, 57, 4, 725, 2, 57, 4, 465, 2544, 1, 213, 24465, 489, 4, 7, 5, 57, 258, 65, 10, 781, 4, 213, 1, 259, 10141, 493, 1, 3, 3486, 7, 138, 11, 96, 186, 4, 3885, 18, 456, 83, 167, 2, 79, 382, 62, 239, 7, 5, 9425, 138, 2, 440, 1293, 30, 156, 42, 225, 57, 57, 11, 41, 5, 9425, 138, 4, 1725, 18, 3, 267, 2, 1147, 1, 7923, 138, 68, 40, 41, 5, 3, 3290, 55, 1, 112, 57, 225, 487, 68, 3425, 4, 3, 336, 2011, 2, 617, 1, 28, 43, 7, 8, 112, 1183, 1005, 816, 16, 3568, 408, 1, 3, 1144, 1, 3, 138, 4, 3, 7923, 145]",1404.0,12049533,Genotype-phenotype multiple endocrine neoplasia type 1,0,0.0
Preirradiation endocrinopathies in pediatric brain tumor patients determined by dynamic tests of endocrine function.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2002-09-01,"To prospectively evaluate pediatric patients with localized primary brain tumors for evidence of endocrinopathy before radiotherapy (RT). Seventy-five pediatric patients were evaluated with the arginine tolerance test and L-dopa test for growth hormone secretory capacity and activity; thyroid-stimulating hormone surge and thyrotropin-releasing hormone stimulation test for the hypothalamic-thyroid axis; the 1-microg adrenocorticotropin hormone (ACTH) and metyrapone test for ACTH reserve; and, depending on age, a gonadotropin-releasing hormone stimulation test to determine gonadotropin response. The study included 38 male and 37 female patients, age 1-21 years with ependymoma (n = 35), World Health Organization (WHO) Grade I-II astrocytoma (n = 18), WHO Grade III-IV astrocytoma (n = 10), craniopharyngioma (n = 7), optic pathway tumor (n = 4), and germinoma (n = 1). Seven patients receiving dexamethasone at the time of the evaluation were excluded from the final analysis. Of 68 assessable patient, 45 (66%) had evidence of endocrinopathy before RT, including 15 of 32 patients (47%) with posterior fossa tumors. Of the 45 patients, 38% had growth hormone deficiency, 43% had thyroid-stimulating hormone secretion abnormality, 22% had an abnormality in ACTH reserve, and 13% had an abnormality in age-dependent gonadotropin secretion. The incidence of pre-RT endocrinopathy in pediatric brain tumor patients is high, including patients with tumors not adjacent to the hypothalamic-pituitary unit. These data suggest an overestimation in the incidence of radiation-induced endocrinopathy. Baseline endocrine function should be determined for brain tumor patients before therapy. The potential for radiation-induced endocrinopathy alone cannot be used as an argument for alternatives to RT for most patients. Pre-RT endocrinopathy may be an early indicator of central nervous system damage that will influence the functional outcome unrelated to RT.",Journal Article,6351.0,63.0,prospectively evaluate pediatric patients localized primary brain evidence endocrinopathy radiotherapy RT Seventy-five pediatric patients evaluated arginine tolerance test L-dopa test growth hormone secretory capacity activity thyroid-stimulating hormone surge thyrotropin-releasing hormone stimulation test hypothalamic-thyroid axis 1-microg adrenocorticotropin hormone ACTH metyrapone test ACTH reserve depending age gonadotropin-releasing hormone stimulation test determine gonadotropin response included 38 male 37 female patients age 1-21 years ependymoma n 35 World Health Organization Grade I-II astrocytoma n 18 Grade III-IV astrocytoma n 10 craniopharyngioma n 7 optic pathway n 4 germinoma n 1 Seven patients receiving dexamethasone time evaluation excluded final 68 assessable patient 45 66 evidence endocrinopathy RT including 15 32 patients 47 posterior fossa 45 patients 38 growth hormone deficiency 43 thyroid-stimulating hormone secretion abnormality 22 abnormality ACTH reserve 13 abnormality age-dependent gonadotropin secretion incidence pre-RT endocrinopathy pediatric brain patients high including patients adjacent hypothalamic-pituitary unit suggest overestimation incidence radiation-induced endocrinopathy Baseline endocrine function determined brain patients therapy potential radiation-induced endocrinopathy argument alternatives RT patients Pre-RT endocrinopathy early indicator central nervous damage influence functional outcome unrelated RT,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[6, 1143, 376, 815, 7, 5, 909, 86, 342, 57, 9, 241, 1, 13011, 348, 310, 240, 2073, 365, 815, 7, 11, 194, 5, 3, 5392, 2614, 412, 2, 805, 27876, 412, 9, 129, 785, 7106, 2162, 2, 128, 11260, 2122, 785, 15515, 2, 16665, 5586, 785, 2503, 412, 9, 3, 7531, 11260, 2310, 3, 14, 2440, 30299, 785, 14784, 2, 43016, 412, 9, 14784, 8316, 2, 3221, 23, 89, 8, 6501, 5586, 785, 2503, 412, 6, 223, 6501, 51, 3, 45, 159, 519, 1045, 2, 567, 1061, 7, 89, 14, 239, 60, 5, 4214, 78, 465, 1956, 341, 2533, 54, 88, 70, 215, 3822, 78, 203, 54, 88, 316, 478, 3822, 78, 79, 7205, 78, 67, 5670, 308, 30, 78, 39, 2, 12292, 78, 14, 648, 7, 357, 1217, 28, 3, 98, 1, 3, 451, 11, 1800, 29, 3, 1457, 65, 1, 806, 3120, 69, 512, 700, 42, 241, 1, 13011, 348, 240, 141, 167, 1, 531, 7, 662, 5, 3028, 5100, 57, 1, 3, 512, 7, 519, 42, 129, 785, 2299, 601, 42, 11260, 2122, 785, 2935, 3698, 350, 42, 35, 3698, 4, 14784, 8316, 2, 233, 42, 35, 3698, 4, 89, 470, 6501, 2935, 3, 287, 1, 671, 240, 13011, 4, 815, 342, 30, 7, 16, 64, 141, 7, 5, 57, 44, 2086, 6, 3, 7531, 12098, 2712, 46, 74, 309, 35, 18810, 4, 3, 287, 1, 121, 277, 13011, 330, 1293, 343, 257, 40, 509, 9, 342, 30, 7, 348, 36, 3, 174, 9, 121, 277, 13011, 279, 122, 44, 40, 95, 22, 35, 17140, 9, 6295, 6, 240, 9, 96, 7, 671, 240, 13011, 68, 40, 35, 191, 3287, 1, 854, 1880, 398, 1350, 17, 303, 1054, 3, 583, 228, 2092, 6, 240]",1890.0,12182973,Preirradiation endocrinopathies pediatric brain patients determined dynamic tests endocrine function,36,0.33962264150943394
Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate.,Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2002-07-19,"Preclinical data indicate that progestational agents (progesterone, medroxyprogesterone acetate and megestrol acetate) interact with p-glycoprotein (P-gp) and reverse P-gp-associated resistance to vinca alkaloids and other natural products. Based on these data, we performed a phase I study of high-dose oral megestrol acetate and vinblastine to evaluate the safety of this regimen. Enrolled in the study were 61 patients with advanced solid tumors, refractory to standard therapy. Cohorts of patients received megestrol acetate according to the following escalation scheme (loading dose/maintenance dose, twice daily for 7 days): 750 mg/250 mg, 750 mg/375 mg, 1000 mg/500 mg, 1500 mg/1000 mg, 3000 mg/2000 mg, 4500 mg/3000 mg, 6000 mg/4000 mg, and 7500 mg/5000 mg. They also received 1.5 mg/m(2) per day of vinblastine by continuous infusion for 5 days (days 2 to 6). Of the 61 patients, 59 were evaluable for toxicity. A maximum tolerated dose (MTD) was not reached. The regimen was well tolerated. Of the 59 patients, 10 (17%) experienced grade 4 leukopenia. All of these cases were at dose levels 3 to 8. There was an increase in the steady-state concentration (Css) of megestrol acetate with increasing dose up to the sixth dose level. Further increases in the dose produced no change in the megestrol acetate Css. Only 2.4% of megestrol acetate was free in the plasma as compared to 65.6% in RPMI culture medium. Megestrol acetate administration was associated with profound suppression of ACTH and cortisol levels. The combination of vinblastine and megestrol acetate was well tolerated. An MTD for this combination was not achieved as a result of the saturable absorption of megestrol acetate. Although potentially therapeutic serum concentrations of megestrol acetate were achieved, it is unlikely that MDR was reversed given the high protein-binding of the drug. Profound suppression of the pituitary-adrenal axis was also observed during the administration of megestrol acetate.",Clinical Trial,6395.0,5.0,Preclinical indicate progestational agents progesterone medroxyprogesterone acetate megestrol acetate interact p-glycoprotein P-gp reverse P-gp-associated resistance vinca alkaloids natural products Based performed phase high-dose oral megestrol acetate vinblastine evaluate safety regimen Enrolled 61 patients advanced solid refractory standard therapy Cohorts patients received megestrol acetate according following escalation scheme loading dose/maintenance dose twice daily 7 days 750 mg/250 mg 750 mg/375 mg 1000 mg/500 mg 1500 mg/1000 mg 3000 mg/2000 mg 4500 mg/3000 mg 6000 mg/4000 mg 7500 mg/5000 mg received 1.5 mg/m 2 day vinblastine continuous infusion 5 days days 2 6 61 patients 59 evaluable toxicity maximum tolerated dose MTD reached regimen tolerated 59 patients 10 17 experienced grade 4 leukopenia cases dose levels 3 8 increase steady-state concentration Css megestrol acetate increasing dose sixth dose level increases dose produced change megestrol acetate Css 2.4 megestrol acetate free plasma compared 65.6 RPMI culture medium Megestrol acetate administration associated profound suppression ACTH cortisol levels combination vinblastine megestrol acetate tolerated MTD combination achieved saturable absorption megestrol acetate potentially therapeutic serum concentrations megestrol acetate achieved unlikely MDR reversed given high protein-binding drug Profound suppression pituitary-adrenal axis observed administration megestrol acetate,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[693, 74, 1008, 17, 24500, 183, 2143, 18815, 3424, 2, 9740, 3424, 4491, 5, 19, 4455, 19, 5407, 2, 1772, 19, 5407, 41, 251, 6, 12729, 18187, 2, 127, 1504, 2766, 90, 23, 46, 74, 21, 173, 8, 124, 70, 45, 1, 64, 61, 518, 9740, 3424, 2, 5413, 6, 376, 3, 367, 1, 26, 477, 346, 4, 3, 45, 11, 713, 7, 5, 131, 537, 57, 430, 6, 260, 36, 736, 1, 7, 103, 9740, 3424, 768, 6, 3, 366, 1125, 4633, 4717, 61, 1146, 61, 936, 391, 9, 67, 162, 4506, 81, 2039, 81, 4506, 81, 4175, 81, 2345, 81, 1666, 81, 7204, 81, 2345, 81, 11264, 81, 1081, 81, 21002, 81, 11264, 81, 16187, 81, 10660, 81, 2, 33288, 81, 10410, 81, 491, 120, 103, 14, 33, 81, 188, 18, 379, 218, 1, 5413, 20, 1314, 904, 9, 33, 162, 162, 18, 6, 49, 1, 3, 713, 7, 728, 11, 859, 9, 155, 8, 689, 421, 61, 961, 10, 44, 1300, 3, 477, 10, 149, 421, 1, 3, 728, 7, 79, 269, 592, 88, 39, 3904, 62, 1, 46, 140, 11, 28, 61, 148, 27, 6, 66, 125, 10, 35, 344, 4, 3, 4152, 1309, 1227, 2687, 1, 9740, 3424, 5, 602, 61, 126, 6, 3, 7462, 61, 301, 195, 1106, 4, 3, 61, 1687, 77, 707, 4, 3, 9740, 3424, 2687, 158, 18, 39, 1, 9740, 3424, 10, 115, 4, 3, 554, 22, 72, 6, 556, 49, 4, 21064, 2099, 3759, 9740, 3424, 634, 10, 41, 5, 4399, 1332, 1, 14784, 2, 9572, 148, 3, 150, 1, 5413, 2, 9740, 3424, 10, 149, 421, 35, 961, 9, 26, 150, 10, 44, 513, 22, 8, 757, 1, 3, 25960, 6125, 1, 9740, 3424, 242, 751, 189, 524, 1003, 1, 9740, 3424, 11, 513, 192, 16, 3568, 17, 4186, 10, 3682, 447, 3, 64, 178, 791, 1, 3, 234, 4399, 1332, 1, 3, 12098, 2987, 2310, 10, 120, 164, 190, 3, 634, 1, 9740, 3424]",1938.0,12203099,Phase pharmacokinetic vinblastine high-dose megestrol acetate,0,0.0
A study on the radiation tolerance of the optic nerves and chiasm after stereotactic radiosurgery.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2003-04-01,"To evaluate the risk of clinically significant radiation optic neuropathy (RON) for patients having stereotactic radiosurgery of benign tumors adjacent to the optic apparatus. We reviewed the dose plans and clinical outcomes of 218 gamma knife procedures (215 patients) for tumors of the sellar and parasellar region (meningiomas, n = 122; pituitary adenomas, n = 89; craniopharyngiomas, n = 7 patients). Previous surgery or radiation therapy was performed in 156 (66%) and 24 (11%) patients, respectively. Median follow-up was 40 months (range 4-115). The median maximum radiation dose to the optic nerve was 10 Gy (range 0.4-16.0). Four patients (1.9%) developed RON at a median of 48 months after radiosurgery. All had prior surgery, and 3 of 4 had external beam radiotherapy (EBRT) in their management either before (n = 2) or adjuvantly (n = 1). The risk of developing a clinically significant RON was 1.1% for patients receiving 12 Gy or less. Patients receiving prior or concurrent EBRT had a greater risk of developing RON after radiosurgery (p = 0.004). RON occurred in less than 2% of our patients, despite the majority (73%) receiving more than 8 Gy to a short segment of the optic apparatus. Knowledge of the dose tolerance of these structures permits physicians to be more aggressive in treating patients with sellar or parasellar tumors, especially those with hormone-producing pituitary adenomas that appear to require higher doses to achieve biochemical remission.",Journal Article,6139.0,223.0,evaluate risk clinically significant radiation optic neuropathy RON patients stereotactic radiosurgery benign adjacent optic apparatus reviewed dose plans clinical outcomes 218 gamma knife procedures 215 patients sellar parasellar region meningiomas n 122 pituitary adenomas n 89 craniopharyngiomas n 7 patients Previous surgery radiation therapy performed 156 66 24 11 patients respectively Median follow-up 40 months range 4-115 median maximum radiation dose optic nerve 10 Gy range 0.4-16.0 patients 1.9 developed RON median 48 months radiosurgery prior surgery 3 4 external beam radiotherapy EBRT management n 2 adjuvantly n 1 risk developing clinically significant RON 1.1 patients receiving 12 Gy Patients receiving prior concurrent EBRT greater risk developing RON radiosurgery p 0.004 RON occurred 2 patients despite majority 73 receiving 8 Gy short segment optic apparatus Knowledge dose tolerance structures permits physicians aggressive treating patients sellar parasellar especially hormone-producing pituitary adenomas appear require higher doses achieve biochemical remission,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 3, 43, 1, 505, 93, 121, 5670, 1751, 5877, 9, 7, 1041, 1729, 2192, 1, 1002, 57, 2086, 6, 3, 5670, 10180, 21, 446, 3, 61, 1853, 2, 38, 123, 1, 6070, 1705, 8045, 1369, 6511, 7, 9, 57, 1, 3, 14479, 2, 18260, 1053, 3718, 78, 3285, 2751, 78, 887, 10708, 78, 67, 7, 698, 152, 15, 121, 36, 10, 173, 4, 5693, 700, 2, 259, 175, 7, 106, 52, 166, 126, 10, 327, 53, 184, 39, 3670, 3, 52, 689, 121, 61, 6, 3, 5670, 2476, 10, 79, 381, 184, 13, 39, 245, 13, 294, 7, 14, 83, 276, 5877, 28, 8, 52, 1, 576, 53, 50, 2192, 62, 42, 324, 152, 2, 27, 1, 39, 42, 1455, 1345, 310, 1883, 4, 136, 284, 361, 348, 78, 18, 15, 24592, 78, 14, 3, 43, 1, 931, 8, 505, 93, 5877, 10, 14, 14, 9, 7, 357, 133, 381, 15, 299, 7, 357, 324, 15, 750, 1883, 42, 8, 378, 43, 1, 931, 5877, 50, 2192, 19, 13, 1520, 5877, 489, 4, 299, 76, 18, 1, 114, 7, 550, 3, 686, 803, 357, 80, 76, 66, 381, 6, 8, 978, 4610, 1, 3, 5670, 10180, 922, 1, 3, 61, 2614, 1, 46, 2414, 8504, 1261, 6, 40, 80, 571, 4, 1367, 7, 5, 14479, 15, 18260, 57, 1093, 135, 5, 785, 3787, 2751, 17, 1322, 6, 1353, 142, 415, 6, 1359, 1487, 734]",1396.0,12654424,radiation tolerance optic nerves chiasm stereotactic radiosurgery,2,0.018867924528301886
"Menin associates with FANCD2, a protein involved in repair of DNA damage.",Cancer research,Cancer Res.,2003-07-01,"Multiple endocrine neoplasia type I (MEN1) is an inherited tumor syndrome characterized by tumors in multiple endocrine organs including the parathyroids, pancreatic islets, and the pituitary. The gene mutated in MEN1 patients, Men1, encodes a protein of 610 amino acid residues, menin, and mutations in the Men1 gene lead to the MEN1 syndrome. Although the chromosomal instability in the peripheral lymphocytes from the MEN1 patients has been reported previously, it is not clear whether menin is involved in repair of DNA damage. Here we show that menin specifically interacts with FANCD2, a protein encoded by a gene involved in DNA repair and mutated in patients with an inherited cancer-prone syndrome, Fanconi anemia. The interaction between menin and FANCD2 is enhanced by gamma-irradiation. Moreover, loss of menin expression in mouse embryonic fibroblasts leads to increased sensitivity to DNA damage. Furthermore, menin is localized to chromatin and nuclear matrix, and the association with nuclear matrix is enhanced by gamma-irradiation. Together, these results suggest that menin plays a critical role in repair of DNA damage in concert with FANCD2.",Journal Article,6048.0,121.0,Multiple endocrine neoplasia type MEN1 inherited syndrome characterized multiple endocrine organs including parathyroids pancreatic islets pituitary MEN1 patients Men1 encodes 610 amino acid residues menin Men1 lead MEN1 syndrome chromosomal instability peripheral lymphocytes MEN1 patients reported previously clear menin involved repair DNA damage menin specifically interacts FANCD2 encoded involved DNA repair patients inherited cancer-prone syndrome Fanconi anemia interaction menin FANCD2 enhanced gamma-irradiation loss menin expression mouse embryonic fibroblasts leads increased sensitivity DNA damage Furthermore menin localized chromatin nuclear matrix association nuclear matrix enhanced gamma-irradiation suggest menin plays critical role repair DNA damage concert FANCD2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[232, 1293, 2298, 267, 70, 7923, 16, 35, 2986, 30, 681, 765, 20, 57, 4, 232, 1293, 2285, 141, 3, 53644, 12746, 2, 3, 3, 145, 1185, 4, 7923, 7, 7923, 4322, 8, 178, 1, 11302, 3078, 971, 6418, 9191, 2, 138, 4, 3, 7923, 145, 1122, 6, 3, 7923, 681, 242, 3, 1860, 1753, 4, 3, 672, 1594, 29, 3, 7923, 7, 71, 85, 210, 373, 192, 16, 44, 885, 317, 9191, 16, 646, 4, 972, 1, 261, 1350, 467, 21, 514, 17, 9191, 1225, 5528, 5, 8949, 8, 178, 4587, 20, 8, 145, 646, 4, 261, 972, 2, 1185, 4, 7, 5, 35, 2986, 12, 7104, 681, 8057, 1545, 3, 915, 59, 9191, 2, 8949, 16, 651, 20, 1705, 1104, 1393, 407, 1, 9191, 55, 4, 830, 5390, 3921, 1940, 6, 101, 485, 6, 261, 1350, 798, 9191, 16, 909, 6, 2287, 2, 928, 2248, 2, 3, 248, 5, 928, 2248, 16, 651, 20, 1705, 1104, 1162, 46, 99, 309, 17, 9191, 1698, 8, 740, 200, 4, 972, 1, 261, 1350, 4, 10562, 5, 8949]",1118.0,12874027,Menin associates FANCD2 involved repair DNA damage,2,0.018867924528301886
Final height and body mass index among adult survivors of childhood brain cancer: childhood cancer survivor study.,The Journal of clinical endocrinology and metabolism,J. Clin. Endocrinol. Metab.,2003-10-01,"The objectives of this study were 1) to compare final height and body mass index (BMI) between adult survivors of childhood brain cancer and age- and sex-matched population norms, 2) to quantify the effects of treatment- and cancer-related factors on the risk of final height below the 10th percentile (adult short stature) or having a BMI of 30 kg/m(2) or more (obesity). Treatment records were abstracted and surveys completed by 921 adults aged 20-45 yr who were treated for brain cancer as children and were participants in the multicenter Childhood Cancer Survivor Study. Nearly 40% of childhood brain cancer survivors were below the 10th percentile for height. The strongest risk factors for adult short stature were young age at diagnosis and radiation treatment involving the hypothalamic-pituitary axis (HPA). The multivariate odds ratio for adult short stature among those 4 yr of age or younger at diagnosis, relative to ages 10-20 yr, was 5.67 (95% confidence interval, 3.6-8.9). HPA radiation exposure increased the risk of adult short stature in a dose-response fashion (trend test, P < 0.0001). Adjuvant chemotherapy was not an independent risk factor for adult short stature. BMI distribution in survivors did not differ appreciably from that of population norms; however, in females, young age at diagnosis and HPA radiation dose (trend test, P < 0.001) were associated with risk of obesity. Except for patients treated with surgery only, survivors of childhood brain cancer are at very high risk for adult short stature, and this risk increases with radiation dose involving the HPA. We did not find a corresponding elevated risk for obesity.",Journal Article,5956.0,119.0,objectives 1 compare final height body mass index BMI adult survivors childhood brain age- sex-matched population norms 2 quantify effects treatment- cancer-related factors risk final height 10th percentile adult short stature BMI 30 kg/m 2 obesity Treatment records abstracted surveys completed 921 adults aged 20-45 yr treated brain children participants multicenter Childhood Survivor Nearly 40 childhood brain survivors 10th percentile height strongest risk factors adult short stature young age diagnosis radiation treatment involving hypothalamic-pituitary axis HPA multivariate odds ratio adult short stature 4 yr age younger diagnosis relative ages 10-20 yr 5.67 95 confidence interval 3.6-8.9 HPA radiation exposure increased risk adult short stature dose-response fashion trend test P 0.0001 Adjuvant chemotherapy independent risk factor adult short stature BMI distribution survivors differ appreciably population norms females young age diagnosis HPA radiation dose trend test P 0.001 associated risk obesity patients treated surgery survivors childhood brain high risk adult short stature risk increases radiation dose involving HPA corresponding elevated risk obesity,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2409, 1, 26, 45, 11, 14, 6, 932, 1457, 4594, 2, 642, 782, 558, 1140, 59, 780, 332, 1, 864, 342, 12, 2, 89, 2, 1035, 655, 266, 9875, 18, 6, 3091, 3, 176, 1, 24, 2, 12, 139, 130, 23, 3, 43, 1, 1457, 4594, 2736, 3, 14199, 6392, 780, 978, 13576, 15, 1041, 8, 1140, 1, 201, 503, 188, 18, 15, 80, 1661, 24, 1064, 11, 4106, 2, 3666, 781, 20, 15223, 857, 1032, 179, 512, 2830, 54, 11, 73, 9, 342, 12, 22, 541, 2, 11, 776, 4, 3, 1570, 864, 12, 2628, 45, 1857, 327, 1, 864, 342, 12, 332, 11, 2736, 3, 14199, 6392, 9, 4594, 3, 3311, 43, 130, 9, 780, 978, 13576, 11, 1169, 89, 28, 147, 2, 121, 24, 1267, 3, 7531, 12098, 2310, 14513, 3, 331, 610, 197, 9, 780, 978, 13576, 107, 135, 39, 2830, 1, 89, 15, 773, 28, 147, 580, 6, 2165, 79, 179, 2830, 10, 33, 598, 48, 307, 268, 27, 49, 66, 83, 14513, 121, 645, 101, 3, 43, 1, 780, 978, 13576, 4, 8, 61, 51, 3240, 853, 412, 19, 13, 488, 249, 56, 10, 44, 35, 306, 43, 161, 9, 780, 978, 13576, 1140, 1395, 4, 332, 205, 44, 1505, 13303, 29, 17, 1, 266, 9875, 137, 4, 2451, 1169, 89, 28, 147, 2, 14513, 121, 61, 853, 412, 19, 13, 144, 11, 41, 5, 43, 1, 1661, 2187, 9, 7, 73, 5, 152, 158, 332, 1, 864, 342, 12, 32, 28, 923, 64, 43, 9, 780, 978, 13576, 2, 26, 43, 1106, 5, 121, 61, 1267, 3, 14513, 21, 205, 44, 2469, 8, 1734, 804, 43, 9, 1661]",1616.0,14557448,Final height body mass index adult survivors childhood brain childhood survivor,11,0.10377358490566038
Sarcomatous change after sellar irradiation in a growth hormone-secreting pituitary adenoma.,The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,Can J Neurol Sci,2003-11-01,"Although the benefits of radiotherapy for pituitary adenomas are well-documented, post-irradiation sarcomas of the sella are rarely seen, with only 20 cases (mainly of fibrosarcoma) reported in the medical literature. We describe a case of post-irradiation sarcoma five years after surgery followed by external-beam irradiation for an extensive and locally invasive growth hormone-secreting tumor. The patient was subsequently given pegvisomant, an antagonist of growth hormone receptor, to control symptoms of growth hormone excess. The patient underwent transsphenoidal resection of the recurrent tumor, followed by adjuvant chemotherapy. This led to significant relief in the patient's symptoms including radiological evidence of tumor shrinkage, but the tumor regrew when, owing to dose-limiting toxicity, chemotherapy was stopped. Post-irradiation sarcomas of the pituitary are well-recognized but rare. They should be suspected in patients following sellar irradiation who show abrupt onset of new symptoms and appropriate radiological findings, and such tumors may respond to cytotoxic chemotherapy.",Case Reports,5925.0,18.0,benefits radiotherapy pituitary adenomas well-documented post-irradiation sarcomas sella rarely seen 20 cases mainly fibrosarcoma reported medical literature case post-irradiation sarcoma years surgery followed external-beam irradiation extensive locally invasive growth hormone-secreting patient subsequently given pegvisomant antagonist growth hormone receptor control symptoms growth hormone excess patient underwent transsphenoidal resection recurrent followed adjuvant chemotherapy led significant relief patient 's symptoms including radiological evidence shrinkage regrew owing dose-limiting toxicity chemotherapy stopped Post-irradiation sarcomas pituitary well-recognized rare suspected patients following sellar irradiation abrupt onset new symptoms appropriate radiological findings respond cytotoxic chemotherapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[242, 3, 1141, 1, 310, 9, 2751, 32, 149, 1405, 539, 1104, 1479, 1, 3, 22175, 32, 2416, 527, 5, 158, 179, 140, 2615, 1, 8378, 210, 4, 3, 484, 789, 21, 897, 8, 473, 1, 539, 1104, 365, 60, 50, 152, 370, 20, 1455, 1345, 1104, 9, 35, 1344, 2, 795, 416, 129, 785, 5052, 30, 3, 69, 10, 1611, 447, 53899, 35, 3137, 1, 129, 785, 153, 6, 182, 507, 1, 129, 785, 2612, 3, 69, 208, 14214, 170, 1, 3, 387, 30, 370, 20, 249, 56, 26, 836, 6, 93, 4586, 4, 3, 69, 292, 507, 141, 4298, 241, 1, 30, 4973, 84, 3, 30, 33566, 198, 3421, 6, 61, 817, 155, 56, 10, 4403, 539, 1104, 1479, 1, 3, 32, 149, 1904, 84, 622, 491, 257, 40, 2768, 4, 7, 366, 14479, 1104, 54, 514, 19616, 1707, 1, 217, 507, 2, 870, 4298, 272, 2, 225, 57, 68, 1892, 6, 759, 56]",1061.0,14672272,Sarcomatous change sellar irradiation growth hormone-secreting pituitary adenoma,0,0.0
Improvement in sexual function after reduction of chronic high-dose opioid medication in a cancer survivor.,"Pain medicine (Malden, Mass.)",Pain Med,2003-12-01,"To demonstrate improvement in sexual function after reduction of opioids. This was a retrospective examination of a single patient at the cancer pain management clinic at M.D. Anderson Cancer Center in Houston, Texas. The patient was a 58-year-old male, free of cancer for 12 years, with chronic low back pain from a prior retroperitoneal mass. Changes in scores from the Brief Male Sexual Inventory and visual analog scale pain questionnaires were used to evaluate the patient. In this patient, a decrease in morphine-equivalent daily dose from 690 mg to 20 mg resulted in a significant increase in sexual function. Sexual inventory scores increased from 4 to 43. Reduction in opioid consumption can dramatically increase libido and sexual function. A possible mechanism involves opioid-related effects on the hypothalamic-pituitary-gonadal axis.",Case Reports,5895.0,13.0,demonstrate improvement sexual function reduction opioids retrospective examination single patient pain management clinic M.D Anderson Center Houston Texas patient 58-year-old male free 12 years chronic low pain prior retroperitoneal mass Changes scores Brief Male Sexual Inventory visual analog scale pain questionnaires evaluate patient patient decrease morphine-equivalent daily dose 690 mg 20 mg resulted significant increase sexual function Sexual inventory scores increased 4 43 Reduction opioid consumption dramatically increase libido sexual function possible mechanism involves opioid-related effects hypothalamic-pituitary-gonadal axis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 608, 767, 4, 2232, 343, 50, 628, 1, 4353, 26, 10, 8, 459, 1385, 1, 8, 226, 69, 28, 3, 12, 559, 284, 1188, 28, 188, 427, 1929, 12, 574, 4, 6212, 2738, 3, 69, 10, 8, 717, 111, 1095, 1045, 115, 1, 12, 9, 133, 60, 5, 442, 154, 4636, 559, 29, 8, 324, 2591, 782, 400, 4, 703, 29, 3, 3190, 1045, 2232, 3818, 2, 3046, 3497, 1124, 559, 2956, 11, 95, 6, 376, 3, 69, 4, 26, 69, 8, 775, 4, 5896, 2017, 391, 61, 29, 11648, 81, 6, 179, 81, 627, 4, 8, 93, 344, 4, 2232, 343, 2232, 3818, 703, 101, 29, 39, 6, 601, 628, 4, 2742, 2421, 122, 2729, 344, 16647, 2, 2232, 343, 8, 899, 670, 2921, 2742, 139, 176, 23, 3, 7531, 12098, 7999, 2310]",834.0,14750918,Improvement sexual function reduction chronic high-dose opioid medication survivor,0,0.0
Hypothalamic dysfunction after chemotherapy.,Journal of pediatric endocrinology & metabolism : JPEM,J. Pediatr. Endocrinol. Metab.,2004-01-01,"Cranial irradiation with or without chemotherapy can cause hypothalamic-pituitary dysfunction. Chemotherapy without cranial irradiation has not been thought to cause such deficiency. In order to determine whether chemotherapy without cranial irradiation can lead to hormonal deficiency, we reviewed the medical records of 362 childhood cancer patients who underwent full hypothalamic-pituitary evaluation because of altered growth and development after oncological therapy (1987-2002). Of these, 31 received chemotherapy but no cranial or total body irradiation and had no CNS tumor: 18 had hematological malignancy and 13 had a solid tumor of the torso or extremity. Duration of follow-up was 13.0 +/- 4.1 years (mean +/- SD). Growth hormone deficiency (GHD) was identified in 15 (48%), central hypothyroidism (TSH-D) in 16 (52%), and pubertal abnormalities in 10 (32%). Pubertal abnormalities included precocious puberty in two (6%), gonadal failure in five of 27 who were old enough to assess puberty (19%), and gonadotropin deficiency in three of 27 (11%). GHD and TSH-D were co-existent in eight patients (26%). Overall, 81% (n = 25) had GHD, TSH-D, precocious puberty, and/or gonadotropin deficiency. None had ACTH or ADH deficiency or primary hypothyroidism. Of note, this was not a study of prevalence, but rather an evaluation of clinically referred patients. In conclusion, hypothalamic dysfunction may occur in survivors of non-CNS tumors who receive chemotherapy but do not receive cranial irradiation. We recommend at least annual observation of growth rate and pubertal development of all children treated for pediatric malignancies, with evaluation for GHD, TSH-D, pubertal abnormalities, and other hypothalamic dysfunction in all poorly-growing cancer survivors, even those not treated with cranial irradiation.",Journal Article,5864.0,66.0,Cranial irradiation chemotherapy cause hypothalamic-pituitary dysfunction Chemotherapy cranial irradiation thought cause deficiency order determine chemotherapy cranial irradiation lead hormonal deficiency reviewed medical records 362 childhood patients underwent hypothalamic-pituitary evaluation altered growth development oncological therapy 1987-2002 31 received chemotherapy cranial total body irradiation CNS 18 hematological malignancy 13 solid torso extremity Duration follow-up 13.0 +/- 4.1 years mean +/- SD Growth hormone deficiency GHD identified 15 48 central hypothyroidism TSH-D 16 52 pubertal abnormalities 10 32 Pubertal abnormalities included precocious puberty 6 gonadal failure 27 old assess puberty 19 gonadotropin deficiency 27 11 GHD TSH-D co-existent patients 26 Overall 81 n 25 GHD TSH-D precocious puberty and/or gonadotropin deficiency ACTH ADH deficiency primary hypothyroidism note prevalence evaluation clinically referred patients hypothalamic dysfunction occur survivors non-CNS receive chemotherapy receive cranial irradiation recommend annual observation growth rate pubertal development children treated pediatric malignancies evaluation GHD TSH-D pubertal abnormalities hypothalamic dysfunction poorly-growing survivors treated cranial irradiation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2565, 1104, 5, 15, 187, 56, 122, 708, 7531, 12098, 1527, 56, 187, 2565, 1104, 71, 44, 85, 2739, 6, 708, 225, 2299, 4, 1732, 6, 223, 317, 56, 187, 2565, 1104, 122, 1122, 6, 1761, 2299, 21, 446, 3, 484, 1064, 1, 10530, 864, 12, 7, 54, 208, 1647, 7531, 12098, 451, 408, 1, 1495, 129, 2, 193, 50, 5378, 36, 5450, 1544, 1, 46, 456, 103, 56, 84, 77, 2565, 15, 181, 642, 1104, 2, 42, 77, 1025, 30, 203, 42, 2890, 710, 2, 233, 42, 8, 537, 30, 1, 3, 19501, 15, 2678, 654, 1, 166, 126, 10, 233, 13, 39, 14, 60, 313, 1270, 129, 785, 2299, 14863, 10, 108, 4, 167, 576, 854, 4147, 6581, 427, 4, 245, 653, 2, 10467, 1171, 4, 79, 531, 10467, 1171, 159, 26266, 10302, 4, 100, 49, 7999, 496, 4, 365, 1, 428, 54, 11, 1095, 5151, 6, 423, 10302, 326, 2, 6501, 2299, 4, 169, 1, 428, 175, 14863, 2, 6581, 427, 11, 1269, 28189, 4, 659, 7, 432, 63, 865, 78, 243, 42, 14863, 6581, 427, 26266, 10302, 2, 15, 6501, 2299, 1292, 42, 14784, 15, 6245, 2299, 15, 86, 4147, 1, 5739, 26, 10, 44, 8, 45, 1, 1078, 84, 1832, 35, 451, 1, 505, 1995, 7, 4, 1221, 7531, 1527, 68, 1271, 4, 332, 1, 220, 1025, 57, 54, 560, 56, 84, 1022, 44, 560, 2565, 1104, 21, 2237, 28, 506, 2114, 1664, 1, 129, 116, 2, 10467, 193, 1, 62, 541, 73, 9, 815, 441, 5, 451, 9, 14863, 6581, 427, 10467, 1171, 2, 127, 7531, 1527, 4, 62, 1240, 1921, 12, 332, 871, 135, 44, 73, 5, 2565, 1104]",1761.0,14960022,Hypothalamic dysfunction chemotherapy,0,0.0
The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas.,Neurosurgery,Neurosurgery,2004-07-01,"Radiotherapy after aggressive surgical resection of nonfunctional macroadenoma (NFA) of the pituitary remains controversial. Historically, immediate postoperative radiotherapy has been recommended to decrease risk of recurrence. With the availability of high-resolution imaging, most neurosurgeons now withhold radiation until recurrence. There is relatively little evidence to support this practice, however. This study reviews postoperative results in a large number of patients with NFA, the majority of whom did not undergo prophylactic radiation. Of the 258 patients who underwent surgery from 1979 to 1999 for NFA, medical records were available for 176. Forty-four patients were treated with immediate postoperative radiotherapy after tumor resection, and the remaining 132 patients were followed up with serial imaging studies and treated with radiotherapy only when a recurrence was documented by follow-up imaging. Patients in the group that received immediate postoperative radiotherapy at time of initial diagnosis and surgery did not differ significantly with respect to age or sex from those in the group that was observed. Five- and 10-year recurrence rates were 2.3 and 2.3%, respectively, for patients who received immediate postoperative radiotherapy, as compared with 15.2 and 50.5%, respectively, for patients who were followed up and did not receive radiotherapy unless there was evidence of recurrence or progression. No patient had symptomatic recurrence in the group that was observed if consistent follow-up was performed. Of the 26 patients who received radiotherapy at time of tumor recurrence or progression, 18 had adequate follow-up, and in all cases, the tumors either remained stable or regressed. Withholding radiotherapy after a high-percentage resection of NFA leads to a higher recurrence rate, but it avoids exposing all patients to the risks of radiation. Deferring radiotherapy for patients with complete or near-complete resection seems to be a safe and prudent approach, as our data suggest that recurrences may be detected early with high-resolution imaging and treated effectively with radiation at time of recurrence. Therefore, immediate postoperative radiotherapy may be eliminated for patients with complete or near complete resection of NFA and who agree to undergo close follow-up for a long period.",Journal Article,5682.0,101.0,Radiotherapy aggressive surgical resection nonfunctional macroadenoma NFA pituitary remains controversial Historically immediate postoperative radiotherapy recommended decrease risk recurrence availability high-resolution imaging neurosurgeons withhold radiation recurrence relatively little evidence support practice reviews postoperative large number patients NFA majority undergo prophylactic radiation 258 patients underwent surgery 1979 1999 NFA medical records available 176 Forty-four patients treated immediate postoperative radiotherapy resection remaining 132 patients followed serial imaging studies treated radiotherapy recurrence documented follow-up imaging Patients group received immediate postoperative radiotherapy time initial diagnosis surgery differ significantly respect age sex group observed Five- 10-year recurrence rates 2.3 2.3 respectively patients received immediate postoperative radiotherapy compared 15.2 50.5 respectively patients followed receive radiotherapy evidence recurrence progression patient symptomatic recurrence group observed consistent follow-up performed 26 patients received radiotherapy time recurrence progression 18 adequate follow-up cases remained stable regressed Withholding radiotherapy high-percentage resection NFA leads higher recurrence rate avoids exposing patients risks radiation Deferring radiotherapy patients complete near-complete resection safe prudent approach suggest recurrences detected early high-resolution imaging treated effectively radiation time recurrence immediate postoperative radiotherapy eliminated patients complete near complete resection NFA agree undergo close follow-up long period,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[310, 50, 571, 221, 170, 1, 12260, 27905, 24724, 1, 3, 469, 2010, 3578, 2181, 573, 310, 71, 85, 793, 6, 775, 43, 1, 146, 5, 3, 2550, 1, 64, 2125, 270, 96, 12726, 1134, 30618, 121, 1100, 146, 125, 16, 1352, 1215, 241, 6, 538, 26, 758, 137, 26, 45, 2004, 573, 99, 4, 8, 375, 207, 1, 7, 5, 24724, 3, 686, 1, 953, 205, 44, 1251, 1862, 121, 1, 3, 8289, 7, 54, 208, 152, 29, 9444, 6, 2043, 9, 24724, 484, 1064, 11, 390, 9, 5800, 1213, 294, 7, 11, 73, 5, 2181, 573, 310, 50, 30, 170, 2, 3, 1844, 4255, 7, 11, 370, 126, 5, 2108, 270, 94, 2, 73, 5, 310, 158, 198, 8, 146, 10, 1405, 20, 166, 126, 270, 7, 4, 3, 87, 17, 103, 2181, 573, 310, 28, 98, 1, 388, 147, 2, 152, 205, 44, 1505, 97, 5, 2184, 6, 89, 15, 1035, 29, 135, 4, 3, 87, 17, 10, 164, 365, 2, 79, 111, 146, 151, 11, 18, 27, 2, 18, 27, 106, 9, 7, 54, 103, 2181, 573, 310, 22, 72, 5, 167, 18, 2, 212, 33, 106, 9, 7, 54, 11, 370, 126, 2, 205, 44, 560, 310, 6179, 125, 10, 241, 1, 146, 15, 91, 77, 69, 42, 1704, 146, 4, 3, 87, 17, 10, 164, 492, 925, 166, 126, 10, 173, 1, 3, 432, 7, 54, 103, 310, 28, 98, 1, 30, 146, 15, 91, 203, 42, 1658, 166, 126, 2, 4, 62, 140, 3, 57, 361, 958, 585, 15, 12579, 16673, 310, 50, 8, 64, 1150, 170, 1, 24724, 1940, 6, 8, 142, 146, 116, 84, 192, 14139, 14548, 62, 7, 6, 3, 1098, 1, 121, 22214, 310, 9, 7, 5, 236, 15, 1829, 236, 170, 2744, 6, 40, 8, 1165, 2, 10263, 353, 22, 114, 74, 309, 17, 1593, 68, 40, 530, 191, 5, 64, 2125, 270, 2, 73, 1856, 5, 121, 28, 98, 1, 146, 673, 2181, 573, 310, 68, 40, 6173, 9, 7, 5, 236, 15, 1829, 236, 170, 1, 24724, 2, 54, 10473, 6, 1251, 2336, 166, 126, 9, 8, 319, 727]",2303.0,15214978,role radiation therapy surgical resection nonfunctional pituitary macroadenomas,0,0.0
Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study.,The Journal of clinical endocrinology and metabolism,J. Clin. Endocrinol. Metab.,2004-09-01,"GH deficiency is a common late complication in survivors of pediatric malignancies, particularly those who are treated with radiation (RT) to the hypothalamic-pituitary region. Nonetheless, few reports have assessed final height outcomes in survivors treated with GH. In the present study, we investigated which patient and treatment variables correlate with final height and change in height sd score (SDS) in a large cohort of cancer survivors treated with GH. We previously identified 361 participants in the multicenter Childhood Cancer Survivor Study who were treated with GH. Final height data were available in 183 survivors (120 males). Diagnoses included: central nervous system tumors (n = 90), acute leukemia (n = 64), soft tissue sarcomas (n = 23), and miscellaneous (n = 6). The median age at diagnosis of the primary cancer was 4.6 yr, and the median age at start of GH treatment was 11.3 yr. Mean height SDS at start of GH therapy was -2.03 +/- 0.8, and the mean final height SDS was -1.48 +/- 0.10 (P < 0.001). Final height SDS was positively associated with target height and dose of GH but negatively associated with the presence of concomitant endocrinopathies and dose of spinal RT. Change in height SDS (start of GH-final height) was positively associated with male gender, younger bone age at start of GH, and dose of GH; presence of concomitant endocrinopathies and dose of spinal RT were negatively associated with change in height SDS. Risk factors associated with a final height of -2.0 sd or less included lower doses of GH and exposure to higher doses of spinal RT. Thus, to maximize final height, our findings emphasize the importance of beginning GH therapy at the earliest bone age that is clinically feasible; treating with conventional higher doses of GH; and, when possible, minimizing the dose of spinal RT.",Journal Article,5620.0,58.0,GH deficiency common late complication survivors pediatric malignancies particularly treated radiation RT hypothalamic-pituitary region Nonetheless reports assessed final height outcomes survivors treated GH present investigated patient treatment variables correlate final height change height sd score SDS large cohort survivors treated GH previously identified 361 participants multicenter Childhood Survivor treated GH Final height available 183 survivors 120 males Diagnoses included central nervous n 90 acute leukemia n 64 soft tissue sarcomas n 23 miscellaneous n 6 median age diagnosis primary 4.6 yr median age start GH treatment 11.3 yr Mean height SDS start GH therapy -2.03 +/- 0.8 mean final height SDS -1.48 +/- 0.10 P 0.001 Final height SDS positively associated target height dose GH negatively associated presence concomitant endocrinopathies dose spinal RT Change height SDS start GH-final height positively associated male gender younger bone age start GH dose GH presence concomitant endocrinopathies dose spinal RT negatively associated change height SDS Risk factors associated final height -2.0 sd included lower doses GH exposure higher doses spinal RT maximize final height findings emphasize importance beginning GH therapy earliest bone age clinically feasible treating conventional higher doses GH possible minimizing dose spinal RT,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[4579, 2299, 16, 8, 186, 807, 1447, 4, 332, 1, 815, 441, 823, 135, 54, 32, 73, 5, 121, 240, 6, 3, 7531, 12098, 1053, 4648, 1021, 1198, 47, 275, 1457, 4594, 123, 4, 332, 73, 5, 4579, 4, 3, 364, 45, 21, 565, 92, 69, 2, 24, 682, 1513, 5, 1457, 4594, 2, 707, 4, 4594, 1270, 368, 8668, 4, 8, 375, 180, 1, 12, 332, 73, 5, 4579, 21, 373, 108, 9234, 776, 4, 3, 1570, 864, 12, 2628, 45, 54, 11, 73, 5, 4579, 1457, 4594, 74, 11, 390, 4, 6348, 332, 2031, 2296, 2403, 159, 854, 1880, 398, 57, 78, 424, 286, 78, 660, 1214, 246, 1479, 78, 382, 2, 15106, 78, 49, 3, 52, 89, 28, 147, 1, 3, 86, 12, 10, 39, 49, 2830, 2, 3, 52, 89, 28, 2435, 1, 4579, 24, 10, 175, 27, 2830, 313, 4594, 8668, 28, 2435, 1, 4579, 36, 10, 18, 680, 13, 66, 2, 3, 313, 1457, 4594, 8668, 10, 14, 576, 13, 79, 19, 13, 144, 1457, 4594, 8668, 10, 2375, 41, 5, 283, 4594, 2, 61, 1, 4579, 84, 2723, 41, 5, 3, 463, 1, 1781, 12081, 2, 61, 1, 1499, 240, 707, 4, 4594, 8668, 2435, 1, 4579, 1457, 4594, 10, 2375, 41, 5, 1045, 1632, 773, 89, 28, 2435, 1, 4579, 2, 61, 1, 4579, 463, 1, 1781, 12081, 2, 61, 1, 1499, 240, 11, 2723, 41, 5, 707, 4, 4594, 8668, 43, 130, 41, 5, 8, 1457, 4594, 1, 18, 13, 1270, 15, 299, 159, 280, 415, 1, 4579, 2, 645, 6, 142, 415, 1, 1499, 240, 631, 6, 4116, 1457, 4594, 114, 272, 5560, 3, 1187, 1, 2948, 4579, 36, 28, 3, 6995, 89, 17, 16, 505, 1313, 1367, 5, 809, 142, 415, 1, 4579, 2, 198, 899, 4501, 3, 61, 1, 1499, 240]",1765.0,15356041,Factors affect final height change height standard deviation scores survivors childhood treated growth hormone report childhood survivor,0,0.0
Genetic effects of radiotherapy for childhood cancer: gonadal dose reconstruction.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2004-10-01,"To estimate the doses of radiation to organs of interest during treatment of childhood cancer for use in an epidemiologic study of possible heritable diseases, including birth defects, chromosomal abnormalities, cancer, stillbirth, and neonatal and premature death. The study population was composed of more than 25,000 patients with cancer in Denmark and the United States who were survivors of childhood cancer and subsequently had nearly 6,500 children of their own. Radiation therapy records were sought for the survivors who parented offspring who had adverse pregnancy outcomes (>300 offspring), and for a sample of all survivors in a case-cohort design. The records were imaged and centrally abstracted. Water phantom measurements were made to estimate doses for a wide range of treatments. Mathematical phantoms were used to apply measured results to estimate doses to ovaries, uterus, testes, and pituitary for patients ranging in age from newborn to 25 years. Gonadal shielding, ovarian pinning (oophoropexy), and field blocking were taken into account. Testicular radiation doses ranged from <1 to 700 cGy (median, 7 cGy) and ovarian doses from <1 to >2,500 cGy (median, 13 cGy). Ten percent of the records were incomplete, but sufficient data were available for broad characterizations of gonadal dose. More than 49% of the gonadal doses were >10 cGy and 16% were >100 cGy. Sufficient radiation therapy data exist as far back as 1943 to enable computation of gonadal doses administered for curative therapy for childhood cancer. The range of gonadal doses is broad, and for many cancer survivors, is high and just below the threshold for infertility. Accordingly, the epidemiologic study has >90% power to detect a 1.3-fold risk of an adverse pregnancy outcome associated with radiation exposure to the gonads. This study should provide important information on the genetic consequences of radiation exposure to humans.",Journal Article,5590.0,71.0,"estimate doses radiation organs treatment childhood use epidemiologic possible heritable diseases including birth defects chromosomal abnormalities stillbirth neonatal premature death population composed 25,000 patients Denmark United States survivors childhood subsequently nearly 6,500 children Radiation therapy records sought survivors parented offspring adverse pregnancy outcomes 300 offspring survivors case-cohort design records imaged centrally abstracted Water phantom measurements estimate doses wide range treatments Mathematical phantoms apply measured estimate doses ovaries uterus testes pituitary patients ranging age newborn 25 years Gonadal shielding ovarian pinning oophoropexy field blocking taken account Testicular radiation doses ranged 1 700 cGy median 7 cGy ovarian doses 1 2,500 cGy median 13 cGy percent records incomplete sufficient available broad characterizations gonadal dose 49 gonadal doses 10 cGy 16 100 cGy Sufficient radiation therapy exist far 1943 enable computation gonadal doses administered curative therapy childhood range gonadal doses broad survivors high threshold infertility Accordingly epidemiologic 90 power detect 1.3-fold risk adverse pregnancy outcome associated radiation exposure gonads provide important information genetic consequences radiation exposure humans",0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[6, 1191, 3, 415, 1, 121, 6, 2285, 1, 1333, 190, 24, 1, 864, 12, 9, 119, 4, 35, 3609, 45, 1, 899, 6874, 1342, 141, 3809, 2945, 1860, 1171, 12, 23370, 2, 14832, 2, 5682, 273, 3, 45, 266, 10, 3317, 1, 80, 76, 243, 984, 7, 5, 12, 4, 19583, 2, 3, 1088, 907, 54, 11, 332, 1, 864, 12, 2, 1611, 42, 1857, 49, 1666, 541, 1, 136, 4165, 121, 36, 1064, 11, 990, 9, 3, 332, 54, 54369, 8304, 54, 42, 290, 2290, 123, 2036, 8304, 2, 9, 8, 1000, 1, 62, 332, 4, 8, 473, 180, 771, 3, 1064, 11, 5903, 2, 4604, 4106, 4388, 6755, 1685, 11, 1229, 6, 1191, 415, 9, 8, 1019, 184, 1, 640, 7419, 14546, 11, 95, 6, 4930, 644, 99, 6, 1191, 415, 6, 7262, 13100, 2, 9, 7, 2223, 4, 89, 29, 24749, 6, 243, 60, 7999, 16362, 37768, 23371, 2, 1067, 2521, 11, 1633, 237, 1967, 121, 415, 1869, 29, 14, 6, 5692, 3071, 52, 67, 3071, 2, 415, 29, 14, 6, 18, 1666, 3071, 52, 233, 3071, 1618, 714, 1, 3, 1064, 11, 2610, 84, 1952, 74, 11, 390, 9, 2094, 19668, 1, 7999, 61, 80, 76, 739, 1, 3, 7999, 415, 11, 79, 3071, 2, 245, 11, 394, 3071, 1952, 121, 36, 74, 1923, 22, 3272, 4636, 22, 33464, 6, 3047, 19417, 1, 7999, 415, 468, 9, 1075, 36, 9, 864, 12, 3, 184, 1, 7999, 415, 16, 2094, 2, 9, 445, 12, 332, 16, 64, 2, 4673, 2736, 3, 2390, 9, 5901, 4705, 3, 3609, 45, 71, 424, 2349, 6, 1426, 8, 14, 27, 1116, 43, 1, 35, 290, 2290, 228, 41, 5, 121, 645, 6, 3, 23245, 26, 45, 257, 377, 305, 487, 23, 3, 336, 3255, 1, 121, 645, 6, 3218]",1838.0,15380591,Genetic effects radiotherapy childhood gonadal dose reconstruction,28,0.2641509433962264
Endoscopic and minimally invasive microsurgical approaches for treating brain tumor patients.,Journal of neuro-oncology,J. Neurooncol.,,"Recent developments in neuroendoscopy and minimally invasive procedures have greatly impacted the diagnosis and treatment of brain tumors. In this paper, we will review these innovations and discuss how they have influenced our approach to the treatment of intraventricular and pituitary tumors. Finally, the concept of keyhole neurosurgery is illustrated by discussing 'eyebrow orbitotomy' approach as an example. As noninvasive therapeutic alternative become available, future neurosurgeons will be challenged to develop effective and less invasive surgical approaches for the diagnosis and treatment of patients will brain tumors.",Journal Article,,34.0,Recent developments neuroendoscopy minimally invasive procedures greatly impacted diagnosis treatment brain paper review innovations discuss influenced approach treatment intraventricular pituitary Finally concept keyhole neurosurgery illustrated discussing 'eyebrow orbitotomy approach example noninvasive therapeutic alternative available future neurosurgeons challenged develop effective invasive surgical approaches diagnosis treatment patients brain,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[435, 3703, 4, 26341, 2, 2144, 416, 1369, 47, 3510, 4619, 3, 147, 2, 24, 1, 342, 57, 4, 26, 2817, 21, 303, 206, 46, 10081, 2, 1139, 832, 491, 47, 2574, 114, 353, 6, 3, 24, 1, 7199, 2, 57, 1368, 3, 2545, 1, 13229, 13272, 16, 8508, 20, 6003, 54447, 37506, 353, 22, 35, 2685, 22, 2957, 189, 1091, 1417, 390, 508, 12726, 303, 40, 6389, 6, 690, 323, 2, 299, 416, 221, 611, 9, 3, 147, 2, 24, 1, 7, 303, 342, 57]",615.0,15527092,Endoscopic minimally invasive microsurgical approaches treating brain patients,0,0.0
Resolution of diabetes insipidus following gamma knife surgery for a solitary metastasis to the pituitary stalk. Case report.,Journal of neurosurgery,J. Neurosurg.,2004-12-01,"The authors present the case of a 58-year-old woman who presented with symptoms of diabetes insipidus (DI) 1 year after she was found to have a Stage 3 (of 4) estrogen receptor-positive infiltrating ductal adenocarcinoma of the left breast with pulmonary and bone metastases. Magnetic resonance images demonstrated a solitary site of metastasis in the patient's pituitary stalk, and gamma knife surgery (GKS) was performed to treat the lesion. Three months after GKS the patient was able to reduce the medication she required for the DI. There was no evidence of pituitary failure and no negative effect on her vision.",Case Reports,5529.0,17.0,authors present case 58-year-old woman presented symptoms diabetes insipidus DI 1 year Stage 3 4 estrogen receptor-positive infiltrating ductal adenocarcinoma left breast pulmonary bone metastases Magnetic resonance images demonstrated solitary site metastasis patient 's pituitary stalk gamma knife surgery GKS performed treat lesion months GKS patient able reduce medication required DI evidence pituitary failure negative effect vision,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 738, 364, 3, 473, 1, 8, 717, 111, 1095, 2854, 54, 917, 5, 507, 1, 1978, 16366, 6641, 14, 111, 50, 3109, 10, 204, 6, 47, 8, 82, 27, 1, 39, 808, 153, 109, 2097, 1258, 449, 1, 3, 1712, 5, 1087, 2, 196, 1484, 1535, 1572, 264, 8, 3144, 606, 1, 278, 4, 3, 69, 292, 23392, 2, 1705, 8045, 152, 21103, 10, 173, 6, 943, 3, 1180, 169, 53, 50, 21103, 3, 69, 10, 1665, 6, 969, 3, 3012, 3109, 616, 9, 3, 6641, 125, 10, 77, 241, 1, 496, 2, 77, 199, 254, 23, 1084, 5859]",576.0,15597769,Resolution diabetes insipidus following gamma knife surgery solitary metastasis pituitary stalk Case report,3,0.02830188679245283
ACTH deficiency in childhood cancer survivors.,Pediatric blood & cancer,Pediatr Blood Cancer,2005-11-01,"Adrenocorticotropin deficiency (ACTHD) can be clinically subtle, but life-threatening if not recognized. We assessed the prevalence of ACTHD in survivors of childhood cancer according to tumor diagnosis/therapy. Chart review of endocrine/oncology history was performed in 310 childhood cancer survivors. Patients were referred to endocrine clinic because of slow growth, fatigue, or abnormal pubertal timing. Evaluation of growth hormone (GH), thyrotropin (TSH), ACTH, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) was performed. Low response to metyrapone and/or low dose ACTH test defined ACTHD. ACTHD was identified in 56 (18%), [44 of 182 (24%) central nervous system (CNS) tumors, 3 of 18 (17%) non-CNS cranial tumors, 9 of 97 (9%) hematologic malignancies]. Of the 56 with ACTHD, 53 (95%) had received cranial irradiation (mean 45.5 Gy, range 14-70 Gy); three had not: one each with craniopharyngioma, hypothalamic astrocytoma, and brain stem glioma. All but one also had GH deficiency and/or central hypothyroidism. Childhood cancer survivors with greatest risk for ACTHD had craniopharyngioma, other suprasellar tumor, or medulloblastoma or > or =24 Gy cranial irradiation. We recommend annual testing for ACTHD for 10-15 years and continued lifelong surveillance after CNS tumor or cranial irradiation, in patients with other hypothalamic-pituitary deficiencies or symptoms of ACTHD.",Journal Article,5194.0,51.0,Adrenocorticotropin deficiency ACTHD clinically subtle life-threatening recognized assessed prevalence ACTHD survivors childhood according diagnosis/therapy Chart review endocrine/oncology history performed 310 childhood survivors Patients referred endocrine clinic slow growth fatigue abnormal pubertal timing Evaluation growth hormone GH thyrotropin TSH ACTH luteinizing hormone LH follicle-stimulating hormone FSH performed Low response metyrapone and/or low dose ACTH test defined ACTHD ACTHD identified 56 18 44 182 24 central nervous CNS 3 18 17 non-CNS cranial 9 97 9 hematologic malignancies 56 ACTHD 53 95 received cranial irradiation mean 45.5 Gy range 14-70 Gy craniopharyngioma hypothalamic astrocytoma brain stem glioma GH deficiency and/or central hypothyroidism Childhood survivors greatest risk ACTHD craniopharyngioma suprasellar medulloblastoma =24 Gy cranial irradiation recommend annual testing ACTHD 10-15 years continued lifelong surveillance CNS cranial irradiation patients hypothalamic-pituitary deficiencies symptoms ACTHD,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[30299, 2299, 21307, 122, 40, 505, 7543, 84, 358, 3691, 492, 44, 1904, 21, 275, 3, 1078, 1, 21307, 4, 332, 1, 864, 12, 768, 6, 30, 147, 36, 2937, 206, 1, 1293, 413, 532, 10, 173, 4, 8292, 864, 12, 332, 7, 11, 1995, 6, 1293, 1188, 408, 1, 3645, 129, 613, 15, 1668, 10467, 1972, 451, 1, 129, 785, 4579, 16665, 6581, 14784, 8223, 785, 6531, 2, 9109, 2122, 785, 8333, 10, 173, 154, 51, 6, 43016, 2, 15, 154, 61, 14784, 412, 395, 21307, 21307, 10, 108, 4, 664, 203, 584, 1, 5160, 259, 854, 1880, 398, 1025, 57, 27, 1, 203, 269, 220, 1025, 2565, 57, 83, 1, 1015, 83, 813, 441, 1, 3, 664, 5, 21307, 699, 48, 42, 103, 2565, 1104, 313, 512, 33, 381, 184, 213, 431, 381, 169, 42, 44, 104, 296, 5, 7205, 7531, 3822, 2, 342, 452, 945, 62, 84, 104, 120, 42, 4579, 2299, 2, 15, 854, 4147, 864, 12, 332, 5, 2199, 43, 9, 21307, 42, 7205, 127, 13122, 30, 15, 2714, 15, 15, 259, 381, 2565, 1104, 21, 2237, 2114, 471, 9, 21307, 9, 79, 167, 60, 2, 1351, 9590, 617, 50, 1025, 30, 15, 2565, 1104, 4, 7, 5, 127, 7531, 12098, 7159, 15, 507, 1, 21307]",1348.0,15700255,ACTH deficiency childhood survivors,1,0.009433962264150943
Multiple endocrine neoplasia type 1.,Journal of surgical oncology,J Surg Oncol,2005-03-01,"Multiple endocrine neoplasia-1 (MEN-1) is an autosomal dominant inherited syndrome that occurs due to inactivating mutations of the MEN1 gene locus, coding for a tumor-suppressor protein, menin. The components of MEN-1 are hyperparathyroidism due to multiple parathyroid adenomas, pancreatic neuroendocrine tumors, and pituitary adenomas, in addition to some less common neoplastic manifestations. Care of people with MEN-1 requires knowledge of the problems that may arise, and the best approaches to detect and care for the manifestations of this incurable, but manageable, disease.",Journal Article,5439.0,52.0,Multiple endocrine neoplasia-1 MEN-1 autosomal dominant inherited syndrome occurs inactivating MEN1 locus coding tumor-suppressor menin components MEN-1 hyperparathyroidism multiple parathyroid adenomas pancreatic neuroendocrine pituitary adenomas addition common neoplastic manifestations Care people MEN-1 requires knowledge problems arise best approaches detect care manifestations incurable manageable disease,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[232, 1293, 2298, 14, 325, 14, 16, 35, 6084, 2156, 2986, 681, 17, 1780, 520, 6, 6096, 138, 1, 3, 7923, 145, 2474, 3097, 9, 8, 30, 1245, 178, 9191, 3, 1628, 1, 325, 14, 32, 9630, 520, 6, 232, 2751, 1542, 57, 2, 2751, 4, 352, 6, 476, 299, 186, 2000, 4282, 165, 1, 3788, 5, 325, 14, 1706, 922, 1, 3, 2408, 17, 68, 3043, 2, 3, 824, 611, 6, 1426, 2, 165, 9, 3, 4282, 1, 26, 2641, 84, 2808, 34]",538.0,15719382,Multiple endocrine neoplasia type 1,4,0.03773584905660377
Radiosurgery for cranial base chordomas and chondrosarcomas.,Neurosurgery,Neurosurgery,2005-04-01,"To evaluate the efficacy and toxicity of radiosurgery in the treatment of cranial base chordoma and chondrosarcoma. We reviewed 29 patients with cranial base chordoma (n = 25) or chondrosarcoma (n = 4) who underwent stereotactic radiosurgery between September 1990 and December 2002. The median patient age was 45 years (range, 10-81 yr). Nineteen patients also had radiation therapy before or in conjunction with radiosurgery (median dose, 50.4 Gy). The median tumor volume was 14.4 cm3 (range, 0.6-65.1 cm3). The median tumor margin dose was 15 Gy (range, 10-20 Gy); the median maximum radiation dose was 30 Gy (range, 20-40 Gy). Median clinical and imaging follow-up periods were 4.8 and 4.5 years, respectively. Seven chordoma patients (28%) had tumor progression (in-field, n = 3; out-of-field, n = 4), whereas 18 had stable disease or tumor shrinkage. No patient with a chondroid chordoma had tumor enlargement. The actuarial tumor control rates were 89 and 32% at 2 and 5 years, respectively. All 4 patients with chondrosarcoma had tumor control. Clinically, 7 patients (24%) had improvement of pretreatment symptoms, 16 (55%) remained stable, and 6 (21%) worsened. Three patients with tumor progression died. Ten patients (34%) had radiation-related complications. Complications included cranial nerve deficits (n = 6), radiation necrosis (n = 5), and pituitary dysfunction (n = 3). Patients having radiosurgery alone had no toxicity. Cranial base chordomas and chondrosarcomas remain a formidable management challenge. Radiosurgery as an adjunct to surgical resection provides in-field tumor control for some patients, but radiation-related complications are relatively high, especially when radiosurgery is combined with fractionated radiation therapy.",Journal Article,5408.0,91.0,evaluate efficacy toxicity radiosurgery treatment cranial base chordoma chondrosarcoma reviewed 29 patients cranial base chordoma n 25 chondrosarcoma n 4 underwent stereotactic radiosurgery September 1990 December 2002 median patient age 45 years range 10-81 yr Nineteen patients radiation therapy conjunction radiosurgery median dose 50.4 Gy median volume 14.4 cm3 range 0.6-65.1 cm3 median margin dose 15 Gy range 10-20 Gy median maximum radiation dose 30 Gy range 20-40 Gy Median clinical imaging follow-up periods 4.8 4.5 years respectively Seven chordoma patients 28 progression in-field n 3 out-of-field n 4 18 stable disease shrinkage patient chondroid chordoma enlargement actuarial control rates 89 32 2 5 years respectively 4 patients chondrosarcoma control Clinically 7 patients 24 improvement pretreatment symptoms 16 55 remained stable 6 21 worsened patients progression died patients 34 radiation-related complications Complications included cranial nerve deficits n 6 radiation necrosis n 5 pituitary dysfunction n 3 Patients radiosurgery toxicity Cranial base chordomas chondrosarcomas remain formidable management challenge Radiosurgery adjunct surgical resection provides in-field control patients radiation-related complications relatively high especially radiosurgery combined fractionated radiation therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 3, 209, 2, 155, 1, 2192, 4, 3, 24, 1, 2565, 1782, 3911, 2, 6116, 21, 446, 462, 7, 5, 2565, 1782, 3911, 78, 243, 15, 6116, 78, 39, 54, 208, 1729, 2192, 59, 2636, 2289, 2, 1397, 1544, 3, 52, 69, 89, 10, 512, 60, 184, 79, 865, 2830, 3498, 7, 120, 42, 121, 36, 348, 15, 4, 3357, 5, 2192, 52, 61, 212, 39, 381, 3, 52, 30, 433, 10, 213, 39, 7397, 184, 13, 49, 556, 14, 7397, 3, 52, 30, 959, 61, 10, 167, 381, 184, 79, 179, 381, 3, 52, 689, 121, 61, 10, 201, 381, 184, 179, 327, 381, 52, 38, 2, 270, 166, 126, 3338, 11, 39, 66, 2, 39, 33, 60, 106, 648, 3911, 7, 339, 42, 30, 91, 4, 1067, 78, 27, 1205, 1, 1067, 78, 39, 547, 203, 42, 585, 34, 15, 30, 4973, 77, 69, 5, 8, 15590, 3911, 42, 30, 9738, 3, 2361, 30, 182, 151, 11, 887, 2, 531, 28, 18, 2, 33, 60, 106, 62, 39, 7, 5, 6116, 42, 30, 182, 505, 67, 7, 259, 42, 767, 1, 1194, 507, 245, 614, 958, 585, 2, 49, 239, 5890, 169, 7, 5, 30, 91, 1016, 1618, 7, 562, 42, 121, 139, 521, 521, 159, 2565, 2476, 2752, 78, 49, 121, 1523, 78, 33, 2, 1527, 78, 27, 7, 1041, 2192, 279, 42, 77, 155, 2565, 1782, 6790, 2, 11960, 918, 8, 11940, 284, 1745, 2192, 22, 35, 5471, 6, 221, 170, 777, 4, 1067, 30, 182, 9, 476, 7, 84, 121, 139, 521, 32, 1352, 64, 1093, 198, 2192, 16, 397, 5, 3950, 121, 36]",1663.0,15792516,Radiosurgery cranial base chordomas chondrosarcomas,0,0.0
"Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques?","International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2005-10-01,"To calculate treatment plans and compare the dose distributions and dose-volume histograms (DVHs) for photon three-dimensional conformal radiation therapy (3D-CRT), electron therapy, intensity-modulated radiation therapy (IMRT), and standard (nonintensity modulated) proton therapy in three pediatric disease sites. The tumor volumes from 8 patients (3 retinoblastomas, 2 medulloblastomas, and 3 pelvic sarcomas) were studied retrospectively to compare DVHs from proton therapy with 3D-CRT, electron therapy, and IMRT. In retinoblastoma, several planning techniques were analyzed: A single electron appositional beam was compared with a single 3D-CRT lateral beam, a 3D-CRT anterior beam paired with a lateral beam, IMRT, and protons. In medulloblastoma, three posterior fossa irradiation techniques were analyzed: 3D-CRT, IMRT, and protons. Craniospinal irradiation (which consisted of composite plans of both the posterior fossa and craniospinal components) was also evaluated, primarily comparing spinal irradiation using 3D-CRT electrons, 3D-CRT photons, and protons. Lastly, in pelvic sarcoma, 3D-CRT, IMRT, and proton plans were assessed. In retinoblastoma, protons resulted in the best target coverage combined with the most orbital bone sparing (10% was the mean orbital bone volume irradiated at > or =5 Gy for protons vs. 25% for 3D-CRT electrons, 69% for IMRT, 41% for a single 3D lateral beam, 51% for a 3D anterolateral beam with a lens block, and 65% for a 3D anterolateral beam without a lens block). A single appositional electron field was the next best technique followed by other planning approaches. In medulloblastoma, for posterior fossa and craniospinal irradiation, protons resulted in the least dose to the cochlea (for only posterior fossa irradiation at > or =20 Gy, 34% was the mean cochlear volume irradiated for protons, 87% for IMRT, 89% for 3D-CRT) and hypothalamus-pituitary axis (for only posterior fossa irradiation at > or =10 Gy, 21% was the mean hypothalamus-pituitary volume irradiated for protons, 81% for IMRT, 91% for 3D-CRT); additional dose reductions to the optic chiasm, eyes, vertebrae, mandible, thyroid, lung, kidneys, heart, and liver were seen. Intensity-modulated radiotherapy appeared to be the second best technique for posterior fossa irradiation. For spinal irradiation 3D-CRT electrons were better than 3D-CRT photons in sparing dose to the thyroid, heart, lung, kidney, and liver. With pelvic sarcoma, protons were superior in eliminating any dose to the ovaries (0% of mean ovarian volume was irradiated at > or =2 Gy with protons) and to some extent, the pelvic bones and vertebrae. Intensity-modulated radiotherapy did show more bladder dose reduction than the other techniques in pelvic sarcoma irradiation. In the diseases studied, using various techniques of 3D-CRT, electrons, IMRT, and protons, protons are most optimal in treating retinoblastomas, medulloblastomas (posterior fossa and craniospinal), and pelvic sarcomas. Protons delivered superior target dose coverage and sparing of normal structures. As dose-volume parameters are expected to correlate with acute and late toxicity, proton therapy should receive serious consideration as the preferred technique for the treatment of pediatric tumors.",Comparative Study,5225.0,173.0,calculate treatment plans compare dose distributions dose-volume histograms DVHs photon three-dimensional conformal radiation therapy 3D-CRT electron therapy intensity-modulated radiation therapy IMRT standard nonintensity modulated proton therapy pediatric disease sites volumes 8 patients 3 retinoblastomas 2 medulloblastomas 3 pelvic sarcomas studied retrospectively compare DVHs proton therapy 3D-CRT electron therapy IMRT retinoblastoma planning techniques single electron appositional beam compared single 3D-CRT lateral beam 3D-CRT anterior beam paired lateral beam IMRT protons medulloblastoma posterior fossa irradiation techniques 3D-CRT IMRT protons Craniospinal irradiation consisted composite plans posterior fossa craniospinal components evaluated primarily comparing spinal irradiation 3D-CRT electrons 3D-CRT photons protons Lastly pelvic sarcoma 3D-CRT IMRT proton plans assessed retinoblastoma protons resulted best target coverage combined orbital bone sparing 10 mean orbital bone volume irradiated =5 Gy protons vs. 25 3D-CRT electrons 69 IMRT 41 single 3D lateral beam 51 3D anterolateral beam lens block 65 3D anterolateral beam lens block single appositional electron field best technique followed planning approaches medulloblastoma posterior fossa craniospinal irradiation protons resulted dose cochlea posterior fossa irradiation =20 Gy 34 mean cochlear volume irradiated protons 87 IMRT 89 3D-CRT hypothalamus-pituitary axis posterior fossa irradiation =10 Gy 21 mean hypothalamus-pituitary volume irradiated protons 81 IMRT 91 3D-CRT additional dose reductions optic chiasm eyes vertebrae mandible thyroid lung kidneys heart liver seen Intensity-modulated radiotherapy appeared second best technique posterior fossa irradiation spinal irradiation 3D-CRT electrons better 3D-CRT photons sparing dose thyroid heart lung kidney liver pelvic sarcoma protons superior eliminating dose ovaries 0 mean ovarian volume irradiated =2 Gy protons extent pelvic bones vertebrae Intensity-modulated radiotherapy bladder dose reduction techniques pelvic sarcoma irradiation diseases studied techniques 3D-CRT electrons IMRT protons protons optimal treating retinoblastomas medulloblastomas posterior fossa craniospinal pelvic sarcomas Protons delivered superior target dose coverage sparing normal structures dose-volume parameters expected correlate acute late toxicity proton therapy receive consideration preferred technique treatment pediatric,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,"[6, 3232, 24, 1853, 2, 932, 3, 61, 4477, 2, 61, 433, 8638, 16188, 9, 4216, 169, 2201, 2972, 121, 36, 2265, 1089, 4560, 36, 837, 1757, 121, 36, 964, 2, 260, 55081, 1757, 2095, 36, 4, 169, 815, 34, 633, 3, 30, 2225, 29, 66, 7, 27, 18431, 18, 9159, 2, 27, 1110, 1479, 11, 656, 894, 6, 932, 16188, 29, 2095, 36, 5, 2265, 1089, 4560, 36, 2, 964, 4, 392, 1349, 1092, 11, 311, 8, 226, 4560, 44112, 1345, 10, 72, 5, 8, 226, 2265, 1089, 3855, 1345, 8, 2265, 1089, 2882, 1345, 2355, 5, 8, 3855, 1345, 964, 2, 6684, 4, 2714, 169, 3028, 5100, 1104, 1092, 11, 311, 2265, 1089, 964, 2, 6684, 5748, 1104, 92, 1695, 1, 3308, 1853, 1, 110, 3, 3028, 5100, 2, 5748, 1628, 10, 120, 194, 1561, 1430, 1499, 1104, 75, 2265, 1089, 13785, 2265, 1089, 7862, 2, 6684, 6354, 4, 1110, 2265, 1089, 964, 2, 2095, 1853, 11, 275, 4, 6684, 627, 4, 3, 824, 283, 2139, 397, 5, 3, 96, 5549, 1851, 79, 10, 3, 313, 5549, 433, 2398, 28, 15, 33, 381, 9, 6684, 105, 243, 9, 2265, 1089, 13785, 790, 9, 964, 605, 9, 8, 226, 2265, 3855, 1345, 725, 9, 8, 2265, 19622, 1345, 5, 8, 11031, 2381, 2, 556, 9, 8, 2265, 19622, 1345, 187, 8, 11031, 2381, 8, 226, 44112, 4560, 1067, 10, 3, 1305, 824, 1312, 370, 20, 127, 1349, 611, 4, 2714, 9, 3028, 5100, 2, 5748, 1104, 6684, 627, 4, 3, 506, 61, 6, 3, 16350, 9, 158, 3028, 5100, 1104, 28, 15, 179, 381, 562, 10, 3, 313, 15244, 433, 2398, 9, 6684, 912, 9, 964, 887, 9, 2265, 1089, 2, 12717, 12098, 2310, 9, 158, 3028, 5100, 1104, 28, 15, 79, 381, 239, 10, 3, 313, 12717, 12098, 433, 2398, 9, 6684, 865, 9, 964, 970, 9, 2265, 1089, 402, 61, 2153, 6, 3, 5670, 14583, 3799, 7565, 16845, 7143, 2, 11, 527, 837, 1757, 310, 2121, 6, 40, 3, 419, 824, 1312, 9, 3028, 5100, 1104, 9, 1499, 1104, 2265, 1089, 13785, 11, 380, 76, 2265, 1089, 7862, 4, 1851, 61, 6, 3, 2, 5, 1110, 6684, 11, 1123, 4, 6923, 500, 61, 6, 3, 7262, 13, 1, 313, 433, 10, 2398, 28, 15, 18, 381, 5, 6684, 2, 6, 476, 1039, 3, 1110, 7867, 2, 7565, 837, 1757, 310, 205, 514, 80, 61, 628, 76, 3, 127, 1092, 4, 1110, 1104, 4, 3, 1342, 656, 75, 747, 1092, 1, 2265, 1089, 13785, 964, 2, 6684, 6684, 32, 96, 665, 4, 1367, 18431, 9159, 3028, 5100, 2, 5748, 2, 1110, 1479, 6684, 1623, 1123, 283, 61, 2139, 2, 1851, 1, 295, 2414, 22, 61, 433, 1038, 32, 1336, 6, 1513, 5, 286, 2, 807, 155, 2095, 36, 257, 560, 1762, 2415, 22, 3, 2514, 1312, 9, 3, 24, 1, 815, 57]",3015.0,16168831,Treatment planning protons pediatric retinoblastoma medulloblastoma pelvic sarcoma protons compare conformal techniques,0,0.0
Pituitary carcinoma: diagnosis and treatment.,Endocrine,Endocrine,2005-10-01,"Pituitary carcinomas are rare pituitary tumors that by definition have cerebrospinal and/or systemic metastases. Most of the tumors occur in the setting of multiple recurrences of invasive pituitary adenomas. This article reviews the clinical presentation of these tumors, their neuroimaging and pathological features, tumor pathogenesis, and possible treatment modalities.",Journal Article,5225.0,42.0,Pituitary carcinomas rare pituitary definition cerebrospinal and/or systemic metastases occur setting multiple recurrences invasive pituitary adenomas article reviews clinical presentation neuroimaging pathological features pathogenesis possible treatment modalities,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[826, 32, 622, 57, 17, 20, 2470, 47, 5156, 2, 15, 403, 196, 96, 1, 3, 57, 1271, 4, 3, 546, 1, 232, 1593, 1, 416, 2751, 26, 946, 2004, 3, 38, 1031, 1, 46, 57, 136, 7468, 2, 1301, 404, 30, 1384, 2, 899, 24, 1558]",337.0,16311418,Pituitary carcinoma diagnosis treatment,0,0.0
Acute ovarian failure in the childhood cancer survivor study.,The Journal of clinical endocrinology and metabolism,J. Clin. Endocrinol. Metab.,2006-02-21,"Defined as the loss of ovarian function within 5 yr of diagnosis, acute ovarian failure (AOF) is known to develop in a subset of survivors of pediatric and adolescent cancers. Its precise incidence is unknown, and data concerning its risk factors are limited. Our objective was to determine the incidence of and patient/treatment factors associated with AOF in a large cohort of pediatric cancer survivors. We conducted a retrospective cohort, multicenter study. Female participants from the Childhood Cancer Survivor Study who were greater than 18 yr of age were considered for inclusion. We excluded survivors who received cranial irradiation at doses of more than 3000 cGy, those with hypothalamic/pituitary tumors, and survivors who underwent bilateral oophorectomy. Survivors who reported never menstruating or who had ceased having menses within 5 yr after their cancer diagnosis were considered to have AOF. We assessed incidence and risk factors for AOF. Of a total of 3390 eligible survivors, 215 cases (6.3%) developed AOF. Survivors with AOF were older at diagnosis and more likely to have been diagnosed with Hodgkin's lymphoma or to have received abdominal or pelvic radiotherapy than survivors without AOF. Among survivors with AOF, 116 (54%) had received at least 1000-cGy ovarian irradiation. In a multivariable logistic regression model, increasing doses of ovarian irradiation, exposure to procarbazine, and exposure to cyclophosphamide at ages 13-20 yr were independent risk factors for AOF. AOF develops in a small subset of survivors, especially those treated with at least 1000-cGy ovarian radiation. These results will facilitate patient counseling and selection of candidates for newer fertility preservation techniques.",Journal Article,5082.0,272.0,Defined loss ovarian function 5 yr diagnosis acute ovarian failure AOF known develop subset survivors pediatric adolescent precise incidence unknown concerning risk factors limited objective determine incidence patient/treatment factors associated AOF large cohort pediatric survivors conducted retrospective cohort multicenter Female participants Childhood Survivor greater 18 yr age considered inclusion excluded survivors received cranial irradiation doses 3000 cGy hypothalamic/pituitary survivors underwent bilateral oophorectomy Survivors reported menstruating ceased menses 5 yr diagnosis considered AOF assessed incidence risk factors AOF total 3390 eligible survivors 215 cases 6.3 developed AOF Survivors AOF older diagnosis likely diagnosed Hodgkin 's lymphoma received abdominal pelvic radiotherapy survivors AOF survivors AOF 116 54 received 1000-cGy ovarian irradiation multivariable logistic regression model increasing doses ovarian irradiation exposure procarbazine exposure cyclophosphamide ages 13-20 yr independent risk factors AOF AOF develops small subset survivors especially treated 1000-cGy ovarian radiation facilitate patient counseling selection candidates newer fertility preservation techniques,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[395, 22, 3, 407, 1, 343, 262, 33, 2830, 1, 147, 286, 496, 20492, 16, 440, 6, 690, 4, 8, 697, 1, 332, 1, 815, 2, 3678, 163, 211, 3260, 287, 16, 860, 2, 74, 4243, 211, 43, 130, 32, 383, 114, 461, 10, 6, 223, 3, 287, 1, 2, 69, 24, 130, 41, 5, 20492, 4, 8, 375, 180, 1, 815, 12, 332, 21, 426, 8, 459, 180, 1570, 45, 1061, 776, 29, 3, 864, 12, 2628, 45, 54, 11, 378, 76, 203, 2830, 1, 89, 11, 515, 9, 1680, 21, 1800, 332, 54, 103, 2565, 1104, 28, 415, 1, 80, 76, 11264, 3071, 135, 5, 7531, 12098, 57, 2, 332, 54, 208, 1607, 3470, 332, 54, 210, 1737, 38118, 15, 54, 42, 17710, 1041, 15963, 262, 33, 2830, 50, 136, 12, 147, 11, 515, 6, 47, 20492, 21, 275, 287, 2, 43, 130, 9, 20492, 1, 8, 181, 1, 44252, 625, 332, 6511, 140, 49, 27, 276, 20492, 332, 5, 20492, 11, 434, 28, 147, 2, 80, 322, 6, 47, 85, 265, 5, 292, 15, 6, 47, 103, 1467, 15, 1110, 310, 76, 332, 187, 20492, 107, 332, 5, 20492, 3790, 667, 42, 103, 28, 506, 2345, 3071, 1104, 4, 8, 658, 812, 320, 202, 602, 415, 1, 1104, 645, 6, 8860, 2, 645, 6, 1112, 28, 2165, 233, 179, 2830, 11, 306, 43, 130, 9, 20492, 20492, 4734, 4, 8, 302, 697, 1, 332, 1093, 135, 73, 5, 28, 506, 2345, 3071, 121, 46, 99, 303, 1876, 69, 2011, 2, 881, 1, 1931, 9, 2246, 2954, 2224, 1092]",1655.0,16492690,Acute ovarian failure childhood survivor,1,0.009433962264150943
Long-term response of pituitary carcinoma to temozolomide. Report of two cases.,Journal of neurosurgery,J. Neurosurg.,2006-10-01,"Pituitary carcinoma is a rare tumor characterized by poor responsiveness to therapy, leading to early death. Reported responses to standard chemotherapy have only been anecdotal, with no single agent or combination demonstrating consistent efficacy in the treatment of patients with this disease. The authors report rare examples of a persistent response to cytotoxic chemotherapy in two patients with pituitary carcinoma. One patient was a 38-year-old man with visual field loss caused by a luteinizing hormone-secreting pituitary carcinoma that had recurred despite multiple surgeries and radiation therapy. Intradural metastases to the spine that had failed to respond to radiation therapy were pathologically confirmed. The second patient was a 26-year-old man with hyperprolactinemia from a prolactin-secreting pituitary tumor. Spine magnetic resonance images obtained to search for causes of neck pain showed a vertebral tumor, which was later confirmed through pathological analysis to be a metastatic pituitary carcinoma. His disease progressed despite radiation therapy, high-dose bromocriptine, and chemotherapy. Both patients were treated monthly with temozolomide, which was administered orally on the first 5 days of a 28-day cycle. The patient in the first case underwent all 12 treatment cycles without serious side effects, and his visual field deficits improved. The patient in the second case had undergone only 10 cycles when the drug was stopped because of his severe fatigue. Nonetheless, his pain disappeared and his serum prolactin concentration decreased. Both patients continue to have partial responses and have been employed full-time for more than 1 year after discontinuing temozolomide therapy. These two examples demonstrate that temozolomide may be effective in treating pituitary carcinomas and thus should be considered in the treatment algorithm for these difficult cases.",Case Reports,4860.0,117.0,Pituitary carcinoma rare characterized poor responsiveness therapy leading early death Reported responses standard chemotherapy anecdotal single agent combination demonstrating consistent efficacy treatment patients disease authors report rare examples persistent response cytotoxic chemotherapy patients pituitary carcinoma patient 38-year-old man visual field loss caused luteinizing hormone-secreting pituitary carcinoma recurred despite multiple surgeries radiation therapy Intradural metastases spine failed respond radiation therapy pathologically confirmed second patient 26-year-old man hyperprolactinemia prolactin-secreting pituitary Spine magnetic resonance images obtained search causes neck pain showed vertebral later confirmed pathological metastatic pituitary carcinoma disease progressed despite radiation therapy high-dose bromocriptine chemotherapy patients treated monthly temozolomide administered orally 5 days 28-day cycle patient case underwent 12 treatment cycles effects visual field deficits improved patient second case undergone 10 cycles drug stopped severe fatigue Nonetheless pain disappeared serum prolactin concentration decreased patients continue partial responses employed full-time 1 year discontinuing temozolomide therapy examples demonstrate temozolomide effective treating pituitary carcinomas considered treatment algorithm difficult cases,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[134, 16, 8, 622, 30, 765, 20, 334, 3642, 6, 36, 1049, 6, 191, 273, 210, 253, 6, 260, 56, 47, 158, 85, 9244, 5, 77, 226, 420, 15, 150, 2219, 925, 209, 4, 3, 24, 1, 7, 5, 26, 34, 3, 738, 414, 622, 4416, 1, 8, 1882, 51, 6, 759, 56, 4, 100, 7, 5, 134, 104, 69, 10, 8, 519, 111, 1095, 3628, 5, 3046, 1067, 407, 1546, 20, 8, 8223, 785, 5052, 134, 17, 42, 3363, 550, 232, 5305, 2, 121, 36, 14288, 196, 6, 3, 2342, 17, 42, 1551, 6, 1892, 6, 121, 36, 11, 2998, 557, 3, 419, 69, 10, 8, 432, 111, 1095, 3628, 5, 26545, 29, 8, 10841, 5052, 30, 2342, 1484, 1535, 1572, 683, 6, 1901, 9, 1626, 1, 559, 224, 8, 4731, 30, 92, 10, 1559, 557, 298, 1301, 65, 6, 40, 8, 113, 134, 3224, 34, 1839, 550, 121, 36, 64, 61, 55821, 2, 56, 110, 7, 11, 73, 3889, 5, 1537, 92, 10, 468, 1428, 23, 3, 157, 33, 162, 1, 8, 339, 218, 417, 3, 69, 4, 3, 157, 473, 208, 62, 133, 24, 410, 187, 1762, 1152, 176, 2, 3224, 3046, 1067, 2752, 231, 3, 69, 4, 3, 419, 473, 42, 1989, 158, 79, 410, 198, 3, 234, 10, 4403, 408, 1, 3224, 905, 613, 4648, 3224, 559, 14399, 2, 3224, 524, 10841, 1227, 340, 110, 7, 1906, 6, 47, 450, 253, 2, 47, 85, 2516, 1647, 98, 9, 80, 76, 14, 111, 50, 7971, 1537, 36, 46, 100, 4416, 608, 17, 1537, 68, 40, 323, 4, 1367, 826, 2, 631, 257, 40, 515, 4, 3, 24, 2124, 9, 46, 1740, 140]",1820.0,17044568,Long-term response pituitary carcinoma temozolomide Report cases,3,0.02830188679245283
Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.,Human pathology,Hum. Pathol.,2006-10-23,"Administration of temozolomide to a 46-year-old man with an invasive aggressive prolactin (PRL)-secreting pituitary neoplasm resulted in improvement of the clinical condition and significant decrease of blood PRL levels. Histologic, immunohistochemical, and electron microscopic study demonstrated marked morphological differences in the tumor exposed to temozolomide compared with the unexposed tumor. Necrosis, hemorrhagic areas, accumulation of connective tissue, focal inflammatory infiltration, and neuronal transformation were seen. Immunohistochemical prognostic indicators showed a reduction in growth potential. Based on the clinical, laboratory, and morphological findings, we recommend temozolomide therapy in patients with pituitary tumors not responding adequately to other treatment options.",Case Reports,4838.0,90.0,Administration temozolomide 46-year-old man invasive aggressive prolactin PRL -secreting pituitary neoplasm resulted improvement clinical condition significant decrease blood PRL levels Histologic immunohistochemical electron microscopic demonstrated marked morphological differences exposed temozolomide compared unexposed Necrosis hemorrhagic areas accumulation connective tissue focal inflammatory infiltration neuronal transformation seen Immunohistochemical prognostic indicators showed reduction growth potential Based clinical laboratory morphological findings recommend temozolomide therapy patients pituitary responding adequately treatment options,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[634, 1, 1537, 6, 8, 641, 111, 1095, 3628, 5, 35, 416, 571, 10841, 14956, 5052, 2131, 627, 4, 767, 1, 3, 38, 2850, 2, 93, 775, 1, 315, 14956, 148, 884, 1382, 2, 4560, 2984, 45, 264, 2003, 4268, 362, 4, 3, 30, 2234, 6, 1537, 72, 5, 3, 15548, 30, 1523, 6998, 1361, 1835, 1, 10990, 246, 2137, 1291, 2084, 2, 7020, 1392, 11, 527, 1382, 177, 3539, 224, 8, 628, 4, 129, 174, 90, 23, 3, 38, 1624, 2, 4268, 272, 21, 2237, 1537, 36, 4, 7, 5, 57, 44, 3261, 4215, 6, 127, 24, 838]",770.0,17056093,Temozolomide therapy man aggressive prolactin-secreting pituitary neoplasm Morphological findings,1,0.009433962264150943
Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG.,The American journal of surgical pathology,Am. J. Surg. Pathol.,2006-12-01,"The homeodomain transcription factor, NANOG, along with OCT3/4 (POU5F1) and SOX2, is part of the core set of transcription factors that maintain embryonic stem cell self-renewal and pluripotency. Expression of NANOG has been detected in fetal germ cells and in gonadal germ cell tumors. To assess the diagnostic utility of NANOG in central nervous system (CNS) germ cell tumors, we analyzed its expression by immunohistochemistry in a series of 12 CNS germinomas and compared its expression with other stem cell markers. Strong nuclear expression of NANOG was demonstrated in >90% of the tumor cells in all cases. In contrast, expression of OCT3/4 and placental alkaline phosphatase was inconsistent and SOX2 was expressed in only rare cells. NANOG was not detected in tumor types frequently considered in the differential diagnosis of CNS germinoma: pineoblastoma, primitive neuroectodermal tumors, medulloblastoma, lymphoma, pituitary adenoma, atypical teratoid/rhabdoid tumor, Langerhans cell histiocytosis, and gliomas. These findings demonstrate that NANOG is a sensitive and specific marker of CNS germinoma. Compared with other currently used markers, NANOG may have superior diagnostic characteristics and can facilitate identification of germinomas in minute surgical biopsies commonly obtained from these tumors. These findings also suggest a potential biologic role for NANOG in maintenance of CNS germinoma.",Comparative Study,4799.0,35.0,homeodomain transcription factor NANOG OCT3/4 POU5F1 SOX2 core set transcription factors maintain embryonic stem self-renewal pluripotency Expression NANOG detected fetal germ gonadal germ assess diagnostic utility NANOG central nervous CNS germ expression immunohistochemistry series 12 CNS germinomas compared expression stem markers Strong nuclear expression NANOG demonstrated 90 cases contrast expression OCT3/4 placental alkaline phosphatase inconsistent SOX2 expressed rare NANOG detected types frequently considered differential diagnosis CNS germinoma pineoblastoma primitive neuroectodermal medulloblastoma lymphoma pituitary adenoma atypical teratoid/rhabdoid Langerhans histiocytosis gliomas findings demonstrate NANOG sensitive specific marker CNS germinoma Compared currently markers NANOG superior diagnostic characteristics facilitate identification germinomas minute surgical biopsies commonly obtained findings suggest potential biologic role NANOG maintenance CNS germinoma,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 18140, 866, 161, 11851, 1510, 5, 14184, 39, 34181, 2, 4664, 16, 760, 1, 3, 1793, 916, 1, 866, 130, 17, 3040, 5390, 452, 31, 1074, 4495, 2, 13153, 55, 1, 11851, 71, 85, 530, 4, 6698, 2280, 37, 2, 4, 7999, 2280, 31, 57, 6, 423, 3, 752, 1207, 1, 11851, 4, 854, 1880, 398, 1025, 2280, 31, 57, 21, 311, 211, 55, 20, 888, 4, 8, 988, 1, 133, 1025, 14493, 2, 72, 211, 55, 5, 127, 452, 31, 525, 1082, 928, 55, 1, 11851, 10, 264, 4, 424, 1, 3, 30, 37, 4, 62, 140, 4, 748, 55, 1, 14184, 39, 2, 9690, 5355, 2577, 10, 4923, 2, 4664, 10, 570, 4, 158, 622, 37, 11851, 10, 44, 530, 4, 30, 630, 746, 515, 4, 3, 1777, 147, 1, 1025, 12292, 14221, 5594, 7160, 57, 2714, 2434, 1973, 12478, 15458, 30, 15702, 31, 13976, 2, 1287, 46, 272, 608, 17, 11851, 16, 8, 745, 2, 112, 952, 1, 1025, 12292, 72, 5, 127, 694, 95, 525, 11851, 68, 47, 1123, 752, 374, 2, 122, 1876, 911, 1, 14493, 4, 3949, 221, 1154, 841, 683, 29, 46, 57, 46, 272, 120, 309, 8, 174, 1283, 200, 9, 11851, 4, 1146, 1, 1025, 12292]",1371.0,17122519,Comparative germ transcription factors CNS germinoma reveals diagnostic utility NANOG,0,0.0
Rare pathological variants and presentations of primary central nervous system lymphomas.,Neurosurgical focus,Neurosurg Focus,2006-11-15,"Primary central nervous system lymphoma (PCNSL) is a rare form of primary brain neoplasm, accounting for less than 3% of all primary brain tumors. Ninety percent of cases involve a large B-cell lymphoma that presents as a homogeneously enhancing lesion or lesions, typically deep-seated in the brain parenchyma. The authors describe unusual pathological forms of PCNSLs, including low-grade, T-cell, and Burkitt types, and also rare presentations such as neurolymphomatosis and pituitary lymphomas.",Journal Article,4815.0,14.0,Primary central nervous lymphoma PCNSL rare form primary brain neoplasm accounting 3 primary brain Ninety percent cases involve large B-cell lymphoma presents homogeneously enhancing lesion lesions typically deep-seated brain parenchyma authors unusual pathological forms PCNSLs including low-grade T-cell Burkitt types rare presentations neurolymphomatosis pituitary lymphomas,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[86, 854, 1880, 398, 5587, 16, 8, 622, 1297, 1, 86, 342, 2131, 3116, 9, 299, 76, 27, 1, 62, 86, 342, 57, 2493, 714, 1, 140, 3882, 8, 375, 132, 31, 17, 2740, 22, 8, 16207, 2430, 1180, 15, 406, 1969, 2369, 21419, 4, 3, 342, 5388, 3, 738, 897, 4015, 1301, 2377, 1, 24968, 141, 154, 88, 102, 31, 2, 630, 2, 120, 622, 4261, 225, 22, 33679, 2, 1557]",450.0,17134123,Rare pathological presentations primary central nervous lymphomas,0,0.0
Cushing's Syndrome attributable to ectopic secretion of corticotropin in a patient with two neuroendocrine tumors.,Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,Endocr Pract,,"To report a case of ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS) in a patient with two distinct neuroendocrine tumors and to highlight the difficulties of establishing the differential diagnosis of EAS. We describe the clinical presentation of the current case, discuss its management, and report the results of molecular studies undertaken to determine whether the two tumors had a common origin. A 52-year-old woman presented with obvious features of Cushing's syndrome. Findings on hormonal evaluation were consistent with EAS. Pituitary magnetic resonance imaging revealed normal findings. Computed tomographic imaging disclosed two masses, one in the lung and one in the pancreas. Somatostatin receptor scintigraphy showed uptake only in the pancreatic mass, which was surgically removed. It was a well-differentiated neuroendocrine tumor, with negative immunostaining for ACTH. Hypercortisolemia did not resolve after removal of the pancreatic tumor. The lung mass was subsequently excised, and pathology examination showed a carcinoid tumor with immunostaining for ACTH. Thereafter, plasma ACTH became immeasurable. The two tumors had similar patterns of X-chromosome inactivation; thus, whether they arose independently could be neither confirmed nor excluded. This case demonstrates that, in the presence of more than one neuroendocrine tumor, somatostatin receptor scintigraphy may misguide the decision regarding the appropriate surgical course in patients with EAS, and it highlights the need for accurate studies to determine the source of ACTH in patients with EAS.",Case Reports,,5.0,report case ectopic adrenocorticotropic hormone ACTH syndrome EAS patient distinct neuroendocrine highlight difficulties establishing differential diagnosis EAS clinical presentation current case discuss management report molecular studies undertaken determine common origin 52-year-old woman presented obvious features Cushing 's syndrome Findings hormonal evaluation consistent EAS Pituitary magnetic resonance imaging revealed normal findings Computed tomographic imaging disclosed masses lung pancreas Somatostatin receptor scintigraphy showed uptake pancreatic mass surgically removed well-differentiated neuroendocrine negative immunostaining ACTH Hypercortisolemia resolve removal pancreatic lung mass subsequently excised pathology examination showed carcinoid immunostaining ACTH plasma ACTH immeasurable similar patterns X-chromosome inactivation arose independently confirmed excluded case demonstrates presence neuroendocrine somatostatin receptor scintigraphy misguide decision appropriate surgical course patients EAS highlights need accurate studies determine source ACTH patients EAS,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 414, 8, 473, 1, 3647, 22401, 785, 14784, 681, 18491, 4, 8, 69, 5, 100, 834, 1542, 57, 2, 6, 1817, 3, 4679, 1, 4431, 3, 1777, 147, 1, 18491, 21, 897, 3, 38, 1031, 1, 3, 291, 473, 1139, 211, 284, 2, 414, 3, 99, 1, 219, 94, 2789, 6, 223, 317, 3, 100, 57, 42, 8, 186, 1938, 8, 653, 111, 1095, 2854, 917, 5, 6228, 404, 1, 16258, 292, 681, 272, 23, 1761, 451, 11, 925, 5, 18491, 1484, 1535, 270, 553, 295, 272, 1220, 6158, 270, 15891, 100, 2692, 104, 4, 3, 2, 104, 4, 3, 6203, 153, 7577, 224, 1135, 158, 4, 3, 782, 92, 10, 2350, 2264, 192, 10, 8, 149, 1442, 1542, 30, 5, 199, 5027, 9, 14784, 44592, 205, 44, 8244, 50, 2829, 1, 3, 30, 3, 782, 10, 1611, 5076, 2, 1117, 1385, 224, 8, 30, 5, 5027, 9, 14784, 3972, 554, 14784, 3451, 56002, 3, 100, 57, 42, 288, 764, 1, 1006, 1170, 2297, 631, 317, 491, 7268, 1042, 359, 40, 2174, 557, 2110, 1800, 26, 473, 1902, 17, 4, 3, 463, 1, 80, 76, 104, 1542, 30, 6203, 153, 7577, 68, 56003, 3, 948, 666, 3, 870, 221, 906, 4, 7, 5, 18491, 2, 192, 2527, 3, 594, 9, 1481, 94, 6, 223, 3, 2353, 1, 14784, 4, 7, 5, 18491]",1503.0,17229662,Cushing 's Syndrome attributable ectopic secretion corticotropin patient neuroendocrine,0,0.0
Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.,Clinical breast cancer,Clin. Breast Cancer,2007-02-01,"Ovarian function suppression for the treatment of premenopausal breast cancer was first used in the late 19th century. Traditionally, ovarian function suppression had been accomplished irreversibly via irradiation or surgery, but analogues of the luteinizing hormone-releasing hormone (LH-RH) have emerged as reliable and reversible agents for this purpose, especially the LH-RH agonists. Luteinizing hormone-releasing hormone antagonists are in earlier stages of development in breast cancer and are not currently in clinical use. Luteinizing hormonereleasing hormone agonists act by pituitary desensitization and receptor downregulation, thereby suppressing gonadotrophin release. Limited information is available comparing the efficacies of the depot preparations of various agonists, but pharmacodynamic studies have shown comparable suppressive capabilities on estradiol and luteinizing hormone. At present, only monthly goserelin is Food and Drug Administration-approved for the treatment of estrogen receptor-positive, premenopausal metastatic breast cancer in the United States. Luteinizing hormone-releasing hormone agonists have proven to be as effective as surgical oophorectomy in premenopausal advanced breast cancer. They offer similar outcomes compared with tamoxifen, but the endocrine combination appears to be more effective than LH-RH agonists alone. In the adjuvant setting, LH-RH agonists versus no therapy reduce the annual odds of recurrence and death in women aged>50 years with estrogen receptor-positive tumors. Luteinizing hormone-releasing hormone agonists alone or in combination with tamoxifen have shown disease-free survival rates similar to chemotherapy with CMF (cyclophosphamide/methotrexate/5-fluorouracil). Outcomes of chemotherapy with or without LH-RH agonists are comparable, though a few trials favor the combination in young premenopausal women (aged<40 years). Adjuvant LH-RH agonists with or without tamoxifen might be as efficacious as tamoxifen alone, and the additional benefit from chemotherapy is unclear. Adequately powered studies are now studying the relative merits of combining adjuvant tamoxifen or aromatase inhibitors with ovarian function suppression, the additional benefits of adding ovarian function suppression to chemotherapy, and the need for adjuvant chemotherapy for women treated with combined ovarian function suppression and anti-estrogen therapy.",Journal Article,4737.0,,Ovarian function suppression treatment premenopausal breast late 19th century Traditionally ovarian function suppression accomplished irreversibly irradiation surgery analogues luteinizing hormone-releasing hormone LH-RH emerged reliable reversible agents purpose especially LH-RH agonists Luteinizing hormone-releasing hormone antagonists earlier stages development breast currently clinical use Luteinizing hormonereleasing hormone agonists act pituitary desensitization receptor downregulation suppressing gonadotrophin release Limited information available comparing efficacies depot preparations agonists pharmacodynamic studies shown comparable suppressive capabilities estradiol luteinizing hormone present monthly goserelin Food Drug Administration-approved treatment estrogen receptor-positive premenopausal metastatic breast United States Luteinizing hormone-releasing hormone agonists proven effective surgical oophorectomy premenopausal advanced breast offer similar outcomes compared tamoxifen endocrine combination appears effective LH-RH agonists adjuvant setting LH-RH agonists versus therapy reduce annual odds recurrence death women aged 50 years estrogen receptor-positive Luteinizing hormone-releasing hormone agonists combination tamoxifen shown disease-free survival rates similar chemotherapy CMF cyclophosphamide/methotrexate/5-fluorouracil Outcomes chemotherapy LH-RH agonists comparable trials favor combination young premenopausal women aged 40 years Adjuvant LH-RH agonists tamoxifen efficacious tamoxifen additional benefit chemotherapy unclear Adequately powered studies studying relative merits combining adjuvant tamoxifen aromatase inhibitors ovarian function suppression additional benefits adding ovarian function suppression chemotherapy need adjuvant chemotherapy women treated combined ovarian function suppression anti-estrogen therapy,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[343, 1332, 9, 3, 24, 1, 2710, 12, 10, 157, 95, 4, 3, 807, 23403, 7981, 4206, 343, 1332, 42, 85, 5741, 12820, 847, 1104, 15, 152, 84, 4768, 1, 3, 8223, 785, 5586, 785, 6531, 7240, 47, 2054, 22, 2450, 2, 2786, 183, 9, 26, 743, 1093, 3, 6531, 7240, 4774, 8223, 785, 5586, 785, 4444, 32, 4, 1677, 1153, 1, 193, 4, 12, 2, 32, 44, 694, 4, 38, 119, 8223, 56148, 785, 4774, 2559, 20, 9293, 2, 153, 2475, 2267, 4669, 23282, 2008, 383, 487, 16, 390, 1430, 3, 14198, 1, 3, 16724, 7791, 1, 747, 4774, 84, 2424, 94, 47, 443, 1279, 3707, 8190, 23, 4507, 2, 8223, 785, 28, 364, 158, 3889, 12555, 16, 1773, 2, 234, 634, 850, 9, 3, 24, 1, 808, 153, 109, 2710, 113, 12, 4, 3, 1088, 907, 8223, 785, 5586, 785, 4774, 47, 1930, 6, 40, 22, 323, 22, 221, 3470, 4, 2710, 131, 12, 491, 1918, 288, 123, 72, 5, 1105, 84, 3, 1293, 150, 1233, 6, 40, 80, 323, 76, 6531, 7240, 4774, 279, 4, 3, 249, 546, 6531, 7240, 4774, 185, 77, 36, 969, 3, 2114, 610, 1, 146, 2, 273, 4, 117, 1032, 212, 60, 5, 808, 153, 109, 57, 8223, 785, 5586, 785, 4774, 279, 15, 4, 150, 5, 1105, 47, 443, 34, 115, 25, 151, 288, 6, 56, 5, 10713, 1112, 2116, 33, 1404, 123, 1, 56, 5, 15, 187, 6531, 7240, 4774, 32, 1279, 2471, 8, 1021, 143, 4283, 3, 150, 4, 1169, 2710, 117, 1032, 327, 60, 249, 6531, 7240, 4774, 5, 15, 187, 1105, 822, 40, 22, 3289, 22, 1105, 279, 2, 3, 402, 247, 29, 56, 16, 1200, 4215, 6855, 94, 32, 1134, 4559, 3, 580, 4986, 1, 1525, 249, 1105, 15, 2106, 222, 5, 343, 1332, 3, 402, 1141, 1, 2726, 343, 1332, 6, 56, 2, 3, 594, 9, 249, 56, 9, 117, 73, 5, 397, 343, 1332, 2, 312, 808, 36]",2306.0,17386122,Luteinizing hormone-releasing hormone agonists premenopausal hormone receptor-positive breast,0,0.0
Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors.,Cancer research,Cancer Res.,2007-05-01,"The Rb/E2F pathway is deregulated in most human brain tumors, and the finding that loss of E2F1 reduced pituitary tumorigenesis in Rb(+/-) mice suggests that loss of pRb induces brain tumors by activating E2F1. We therefore investigated the role of E2F1 in the development and maintenance of brain cancer using a transgenic mouse model engineered to express E2F1 specifically within glial cells (GFAP-tgE2F1). GFAP-tgE2F1 mice developed a highly penetrant phenotype characterized by neurologic defects, and examination of the brains revealed the presence of brain tumors in 20% of these animals. Importantly, the distribution of tumors according to mouse age suggests the existence of a bimodal pattern of tumor development, forcing a comparison with the human disease. Mice, at an early age, with deregulated E2F1 show the formation of embryonal brain tumors such as medulloblastoma, choroid plexus carcinoma, and primary neuroectodermal tumor. Conversely, at an older age, mice escaping embryonal tumor formation present with malignant gliomas, which are typically identified in the human adult population. Thus, this study offers the first evidence for a global role of E2F1 in the formation and maintenance of multilineage brain tumors, irrefutably establishing E2F1 as an oncogene in the brain.",Journal Article,4648.0,20.0,Rb/E2F pathway deregulated human brain finding loss E2F1 reduced pituitary tumorigenesis Rb +/- mice suggests loss pRb induces brain activating E2F1 investigated role E2F1 development maintenance brain transgenic mouse model engineered express E2F1 specifically glial GFAP-tgE2F1 GFAP-tgE2F1 mice developed highly penetrant phenotype characterized neurologic defects examination brains revealed presence brain 20 animals Importantly distribution according mouse age suggests existence bimodal pattern development forcing comparison human disease Mice early age deregulated E2F1 formation embryonal brain medulloblastoma choroid plexus carcinoma primary neuroectodermal Conversely older age mice escaping embryonal formation present malignant gliomas typically identified human adult population offers evidence global role E2F1 formation maintenance multilineage brain irrefutably establishing E2F1 oncogene brain,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2955, 5391, 308, 16, 5415, 4, 96, 171, 342, 57, 2, 3, 1567, 17, 407, 1, 6112, 405, 1565, 4, 2955, 399, 844, 17, 407, 1, 8734, 1516, 342, 57, 20, 1616, 6112, 21, 673, 565, 3, 200, 1, 6112, 4, 3, 193, 2, 1146, 1, 342, 12, 75, 8, 2862, 830, 202, 2794, 6, 1669, 6112, 1225, 262, 6944, 37, 13154, 44710, 13154, 44710, 399, 276, 8, 561, 10301, 1005, 765, 20, 2543, 2945, 2, 1385, 1, 3, 13859, 553, 3, 463, 1, 342, 57, 4, 179, 1, 46, 2258, 1859, 3, 1395, 1, 57, 768, 6, 830, 89, 844, 3, 5335, 1, 8, 18225, 1177, 1, 30, 193, 34269, 8, 1155, 5, 3, 171, 34, 399, 28, 35, 191, 89, 5, 5415, 6112, 514, 3, 1264, 1, 5239, 342, 57, 225, 22, 2714, 12169, 9576, 134, 2, 86, 7160, 30, 3154, 28, 35, 434, 89, 399, 26578, 5239, 30, 1264, 364, 5, 393, 1287, 92, 32, 1969, 108, 4, 3, 171, 780, 266, 631, 26, 45, 2339, 3, 157, 241, 9, 8, 1648, 200, 1, 6112, 4, 3, 1264, 2, 1146, 1, 12471, 342, 57, 56243, 4431, 6112, 22, 35, 1836, 4, 3, 342]",1265.0,17483310,Transgenic E2F1 expression mouse brain induces human-like bimodal pattern,0,0.0
Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.,Cancer research,Cancer Res.,2007-05-01,"Cell cycle progression from G(1) to S phase depends on phosphorylation of pRb by complexes containing a cyclin (D type or E type) and cyclin-dependent kinase (e.g., cdk2, cdk4, or cdk6). Ink4 proteins function to oppose the action of cdk4/6-cyclin D complexes by inhibiting cdk4/6. We employed genetic and pharmacologic approaches to study the interplay among Ink4 proteins and cdk4/6 activity in vivo. Mouse embryo fibroblasts (MEF) lacking p16(Ink4a) and p18(Ink4c) showed similar growth kinetics as wild-type MEFs despite increased cdk4 activity. In vivo, germline deficiency of p16(Ink4a) and p18(Ink4c) resulted in increased proliferation in the intermediate pituitary and pancreatic islets of adult mice, and survival of p16(Ink4a-/-);p18(Ink4c-/-) mice was significantly reduced due to aggressive pituitary tumors. Compensation among the Ink4 proteins was observed both in vivo in p18(Ink4c-/-) mice and in MEFs from p16(Ink4a-/-), p18(Ink4c-/-), or p16(Ink4a-/-);p18(Ink4c-/-) mice. Treatment with PD 0332991, a specific cdk4/6 kinase inhibitor, abrogated proliferation in those compartments where Ink4 deficiency was associated with enhanced proliferation (i.e., islets, pituitary, and B lymphocytes) but had no effect on proliferation in other tissues such as the small bowel. These data suggest that p16(Ink4a) and p18(Ink4c) coordinately regulate the in vivo catalytic activity of cdk4/6 in specific compartments of adult mice.",Journal Article,4648.0,49.0,cycle progression G 1 phase depends phosphorylation pRb complexes containing cyclin type E type cyclin-dependent kinase e.g. cdk2 cdk4 cdk6 Ink4 function oppose action cdk4/6-cyclin complexes inhibiting cdk4/6 employed genetic pharmacologic approaches interplay Ink4 cdk4/6 activity vivo Mouse embryo fibroblasts MEF lacking p16 Ink4a p18 Ink4c showed similar growth kinetics wild-type MEFs despite increased cdk4 activity vivo germline deficiency p16 Ink4a p18 Ink4c resulted increased proliferation intermediate pituitary pancreatic islets adult mice survival p16 Ink4a-/- p18 Ink4c-/- mice significantly reduced aggressive pituitary Compensation Ink4 observed vivo p18 Ink4c-/- mice MEFs p16 Ink4a-/- p18 Ink4c-/- p16 Ink4a-/- p18 Ink4c-/- mice Treatment PD 0332991 specific cdk4/6 kinase inhibitor abrogated proliferation compartments Ink4 deficiency associated enhanced proliferation i.e. islets pituitary B lymphocytes effect proliferation tissues small bowel suggest p16 Ink4a p18 Ink4c coordinately regulate vivo catalytic activity cdk4/6 specific compartments adult mice,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[31, 417, 91, 29, 499, 14, 6, 695, 124, 3828, 23, 982, 1, 8734, 20, 3817, 1101, 8, 1226, 427, 267, 15, 563, 267, 2, 1226, 470, 216, 563, 499, 4547, 3254, 15, 9518, 19792, 652, 343, 6, 26089, 3, 1578, 1, 3254, 49, 1226, 427, 3817, 20, 2062, 3254, 49, 21, 2516, 336, 2, 2788, 611, 6, 45, 3, 5709, 107, 19792, 652, 2, 3254, 49, 128, 4, 386, 830, 12803, 3921, 16051, 1941, 1932, 6276, 2, 15465, 19052, 224, 288, 129, 3839, 22, 955, 267, 16331, 550, 101, 3254, 128, 4, 386, 1009, 2299, 1, 1932, 6276, 2, 15465, 19052, 627, 4, 101, 457, 4, 3, 919, 2, 12746, 1, 780, 399, 2, 25, 1, 1932, 6276, 15465, 19052, 399, 10, 97, 405, 520, 6, 571, 57, 19095, 107, 3, 19792, 652, 10, 164, 110, 4, 386, 4, 15465, 19052, 399, 2, 4, 16331, 29, 1932, 6276, 15465, 19052, 15, 1932, 6276, 15465, 19052, 399, 24, 5, 333, 19807, 8, 112, 3254, 49, 216, 230, 3728, 457, 4, 135, 6473, 1257, 19792, 2299, 10, 41, 5, 651, 457, 70, 563, 12746, 2, 132, 1594, 84, 42, 77, 254, 23, 457, 4, 127, 742, 225, 22, 3, 302, 1659, 46, 74, 309, 17, 1932, 6276, 2, 15465, 19052, 13845, 2288, 3, 4, 386, 4784, 128, 1, 3254, 49, 4, 112, 6473, 1, 780, 399]",1356.0,17510401,Expression p16Ink4a compensates p18Ink4c loss cyclin-dependent kinase 4/6-dependent tissues,0,0.0
Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission.,Journal of neurosurgery,J. Neurosurg.,2007-05-01,"The authors reviewed outcomes after stereotactic radiosurgery for patients with acromegaly and analyzed factors associated with biochemical remission. Retrospective analysis was performed for 46 consecutive cases of growth hormone (GH)-producing pituitary adenomas treated by radiosurgery between 1991 and 2004. Biochemical remission was defined as a fasting GH less than 2 ng/ml and a normal age- and sex-adjusted insulin-like growth factor-I (IGF-I) level while patients were not receiving any pituitary suppressive medications. The median follow up after radiosurgery was 63 months (range 22-168 months). Twenty-three patients (50%) had biochemical remission documented at a median of 36 months (range 6-63 months) after one radiosurgical procedure. The actuarial rates of biochemical remission at 2 and 5 years after radiosurgery were 11 and 60%, respectively. Multivariate analysis showed that IGF-I levels less than 2.25 times the upper limit of normal (hazard ratio [HR] 2.9, 95% confidence interval [CI] 1.2-6.9, p = 0.02) and the absence of pituitary suppressive medications at the time of radiosurgery (HR 4.2, 95% CI 1.4-13.2, p = 0.01) correlated with biochemical remission. The incidence of new anterior pituitary deficits was 10% at 2 years and 33% at 5 years. Discontinuation of pituitary suppressive medications at least 1 month before radiosurgery significantly improved endocrine outcomes for patients with acromegaly. Patients with GH-producing pituitary adenomas should not undergo further radiation therapy or surgery for at least 5 years after radiosurgery because GH and IGF-I levels continue to normalize over that interval.",Journal Article,4648.0,118.0,authors reviewed outcomes stereotactic radiosurgery patients acromegaly factors associated biochemical remission Retrospective performed 46 consecutive cases growth hormone GH -producing pituitary adenomas treated radiosurgery 1991 2004 Biochemical remission defined fasting GH 2 ng/ml normal age- sex-adjusted insulin-like growth factor-I IGF-I level patients receiving pituitary suppressive medications median follow radiosurgery 63 months range 22-168 months Twenty-three patients 50 biochemical remission documented median 36 months range 6-63 months radiosurgical procedure actuarial rates biochemical remission 2 5 years radiosurgery 11 60 respectively Multivariate showed IGF-I levels 2.25 times upper limit normal hazard ratio HR 2.9 95 confidence interval CI 1.2-6.9 p 0.02 absence pituitary suppressive medications time radiosurgery HR 4.2 95 CI 1.4-13.2 p 0.01 correlated biochemical remission incidence new anterior pituitary deficits 10 2 years 33 5 years Discontinuation pituitary suppressive medications 1 month radiosurgery significantly improved endocrine outcomes patients acromegaly Patients GH-producing pituitary adenomas undergo radiation therapy surgery 5 years radiosurgery GH IGF-I levels continue normalize interval,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 738, 446, 123, 50, 1729, 2192, 9, 7, 5, 28682, 2, 311, 130, 41, 5, 1487, 734, 459, 65, 10, 173, 9, 641, 935, 140, 1, 129, 785, 4579, 3787, 2751, 73, 20, 2192, 59, 3372, 2, 1131, 1487, 734, 10, 395, 22, 8, 5706, 4579, 299, 76, 18, 997, 542, 2, 8, 295, 89, 2, 1035, 586, 1601, 733, 129, 161, 70, 1273, 70, 301, 369, 7, 11, 44, 357, 500, 3707, 2679, 3, 52, 166, 126, 50, 2192, 10, 676, 53, 184, 350, 5359, 53, 737, 169, 7, 212, 42, 1487, 734, 1405, 28, 8, 52, 1, 511, 53, 184, 49, 676, 53, 50, 104, 17749, 1299, 3, 2361, 151, 1, 1487, 734, 28, 18, 2, 33, 60, 50, 2192, 11, 175, 2, 335, 106, 331, 65, 224, 17, 1273, 70, 148, 299, 76, 18, 243, 1072, 3, 1726, 2385, 1, 295, 360, 197, 168, 18, 83, 48, 307, 268, 58, 14, 18, 49, 83, 19, 13, 588, 2, 3, 1127, 1, 3707, 2679, 28, 3, 98, 1, 2192, 168, 39, 18, 48, 58, 14, 39, 233, 18, 19, 13, 355, 438, 5, 1487, 734, 3, 287, 1, 217, 2882, 2752, 10, 79, 28, 18, 60, 2, 466, 28, 33, 60, 2007, 1, 3707, 2679, 28, 506, 14, 811, 348, 2192, 97, 231, 1293, 123, 9, 7, 5, 28682, 7, 5, 4579, 3787, 2751, 257, 44, 1251, 195, 121, 36, 15, 152, 9, 28, 506, 33, 60, 50, 2192, 408, 4579, 2, 1273, 70, 148, 1906, 6, 13633, 252, 17, 268]",1546.0,17542527,Radiosurgery growth hormone-producing pituitary adenomas factors associated biochemical remission,0,0.0
Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer.,Cancer,Cancer,2007-09-01,"Patients with advanced cancer may develop cachexia, which is often treated with megestrol acetate (MA). In addition to thromboembolic disease, MA may cause symptomatic suppression of the hypothalamic pituitary adrenal axis. In male patients with cancer, treatment with MA may also suppress the gonadal axis, resulting in symptomatic androgen deficiency. Three cases are presented to highlight the symptomatic burden of adrenal insufficiency and hypogonadism. Clinicians need an increased awareness of the complication of adrenal insufficiency secondary to MA treatment and a low threshold to test for adrenal and gonadal dysfunction in symptomatic male patients with advanced cancer.",Case Reports,4525.0,32.0,Patients advanced develop cachexia treated megestrol acetate addition thromboembolic disease cause symptomatic suppression hypothalamic pituitary adrenal axis male patients treatment suppress gonadal axis resulting symptomatic androgen deficiency cases presented highlight symptomatic burden adrenal insufficiency hypogonadism Clinicians need increased awareness complication adrenal insufficiency secondary treatment low threshold test adrenal gonadal dysfunction symptomatic male patients advanced,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7, 5, 131, 12, 68, 690, 4807, 92, 16, 629, 73, 5, 9740, 3424, 3687, 4, 352, 6, 4703, 34, 3687, 68, 708, 1704, 1332, 1, 3, 7531, 2987, 2310, 4, 1045, 7, 5, 12, 24, 5, 3687, 68, 120, 3134, 3, 7999, 2310, 1113, 4, 1704, 687, 2299, 169, 140, 32, 917, 6, 1817, 3, 1704, 892, 1, 2987, 4360, 2, 10616, 1490, 594, 35, 101, 3310, 1, 3, 1447, 1, 2987, 4360, 568, 6, 3687, 24, 2, 8, 154, 2390, 6, 412, 9, 2987, 2, 7999, 1527, 4, 1704, 1045, 7, 5, 131, 12]",662.0,17647248,Association megestrol acetate treatment symptomatic adrenal insufficiency hypogonadism male patients,0,0.0
Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty.,Seminars in reproductive medicine,Semin. Reprod. Med.,2007-09-01,"In addition to hyperandrogenism and ovulatory dysfunction, polycystic ovary syndrome (PCOS) is characterized by neuroendocrine abnormalities including a persistently rapid gonadotropin-releasing hormone (GnRH) pulse frequency. Rapid GnRH pulsatility favors pituitary secretion of luteinizing hormone (LH) over that of follicle-stimulating hormone (FSH). Excess LH stimulates ovarian androgen production, whereas relative deficits in FSH impair follicular development. The rapid GnRH pulse frequency is a result of reduced progesterone-mediated feedback inhibition of the GnRH pulse generator secondary to infrequent luteal phase increases in progesterone, as well as reduced hypothalamic sensitivity to progesterone feedback. Progesterone sensitivity is restored by treatment with the androgen receptor blocker flutamide. As such, hyperandrogenemia appears to play an important pathophysiologic role in PCOS. Adolescent hyperandrogenemia is believed to be a precursor to adult PCOS. In addition to increased LH concentrations and pulse frequency, some girls with elevated androgen levels also demonstrate reduced hypothalamic sensitivity to progesterone feedback. We hypothesize that excess peripubertal androgens may reduce the sensitivity of the GnRH pulse generator to sex steroid inhibition in susceptible individuals, resulting in increased GnRH pulse frequency and subsequent abnormalities in gonadotropin secretion, ovarian androgen production, and ovulatory function. Over time, these abnormalities may progress to the clinical hyperandrogenism and chronic oligo-ovulation typical of adult PCOS.",Journal Article,4525.0,77.0,addition hyperandrogenism ovulatory dysfunction polycystic ovary syndrome PCOS characterized neuroendocrine abnormalities including persistently rapid gonadotropin-releasing hormone GnRH pulse frequency Rapid GnRH pulsatility favors pituitary secretion luteinizing hormone LH follicle-stimulating hormone FSH Excess LH stimulates ovarian androgen production relative deficits FSH impair follicular development rapid GnRH pulse frequency reduced progesterone-mediated feedback inhibition GnRH pulse generator secondary infrequent luteal phase increases progesterone reduced hypothalamic sensitivity progesterone feedback Progesterone sensitivity restored treatment androgen receptor blocker flutamide hyperandrogenemia appears play important pathophysiologic role PCOS Adolescent hyperandrogenemia believed precursor adult PCOS addition increased LH concentrations pulse frequency girls elevated androgen levels demonstrate reduced hypothalamic sensitivity progesterone feedback hypothesize excess peripubertal androgens reduce sensitivity GnRH pulse generator sex steroid inhibition susceptible individuals resulting increased GnRH pulse frequency subsequent abnormalities gonadotropin secretion ovarian androgen production ovulatory function time abnormalities progress clinical hyperandrogenism chronic oligo-ovulation typical adult PCOS,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 352, 6, 30354, 2, 21184, 1527, 14153, 3631, 681, 6680, 16, 765, 20, 1542, 1171, 141, 8, 8684, 1321, 6501, 5586, 785, 7926, 7877, 675, 1321, 7926, 38529, 13054, 2935, 1, 8223, 785, 6531, 252, 17, 1, 9109, 2122, 785, 8333, 2612, 6531, 6200, 687, 1529, 547, 580, 2752, 4, 8333, 6267, 1974, 193, 3, 1321, 7926, 7877, 675, 16, 8, 757, 1, 405, 2143, 517, 3983, 297, 1, 3, 7926, 7877, 17706, 568, 6, 4475, 20256, 124, 1106, 4, 2143, 22, 149, 22, 405, 7531, 485, 6, 2143, 3983, 2143, 485, 16, 4138, 20, 24, 5, 3, 687, 153, 8411, 11115, 22, 225, 23414, 1233, 6, 1343, 35, 305, 11575, 200, 4, 6680, 3678, 23414, 16, 3979, 6, 40, 8, 2765, 6, 780, 6680, 4, 352, 6, 101, 6531, 1003, 2, 7877, 675, 476, 5989, 5, 804, 687, 148, 120, 608, 405, 7531, 485, 6, 2143, 3983, 21, 4919, 17, 2612, 38530, 5488, 68, 969, 3, 485, 1, 3, 7926, 7877, 17706, 6, 1035, 3853, 297, 4, 4012, 869, 1113, 4, 101, 7926, 7877, 675, 2, 706, 1171, 4, 6501, 2935, 687, 1529, 2, 21184, 343, 252, 98, 46, 1171, 68, 1466, 6, 3, 38, 30354, 2, 442, 11301, 23193, 3476, 1, 780, 6680]",1550.0,17710731,Neuroendocrine effects androgens adult polycystic ovary syndrome female puberty,0,0.0
Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2007-10-29,"To evaluate the efficacy and complications of stereotactic radiosurgery for patients with nonfunctioning pituitary adenomas (NFA). This was a retrospective review of 62 patients with NFA undergoing radiosurgery between 1992 and 2004, of whom 59 (95%) underwent prior tumor resection. The median treatment volume was 4.0 cm(3) (range, 0.8-12.9). The median treatment dose to the tumor margin was 16 Gy (range, 11-20). The median maximum point dose to the optic apparatus was 9.5 Gy (range, 5.0-12.6). The median follow-up period after radiosurgery was 64 months (range, 23-161). Tumor size decreased for 37 patients (60%) and remained unchanged for 23 patients (37%). Two patients (3%) had tumor growth outside the prescribed treatment volume and required additional treatment (fractionated radiation therapy, n = 1; repeat radiosurgery, n = 1). Tumor growth control was 95% at 3 and 7 years after radiosurgery. Eleven (27%) of 41 patients with normal (n = 30) or partial (n = 11) anterior pituitary function before radiosurgery developed new deficits at a median of 24 months after radiosurgery. The risk of developing new anterior pituitary deficits at 5 years was 32%. The 5-year risk of developing new anterior pituitary deficits was 18% for patients with a tumor volume of < or = 4.0 cm(3) compared with 58% for patients with a tumor volume >4.0 cm(3) (risk ratio = 4.5; 95% confidence interval = 1.3-14.9, p = 0.02). No patient had a decline in visual function. Stereotactic radiosurgery is effective in the management of patients with residual or recurrent NFA, although longer follow-up is needed to evaluate long-term outcomes. The primary complication is hypopituitarism, and the risk of developing new anterior pituitary deficits correlates with the size of the irradiated tumor.",Evaluation Study,4467.0,102.0,evaluate efficacy complications stereotactic radiosurgery patients nonfunctioning pituitary adenomas NFA retrospective review 62 patients NFA undergoing radiosurgery 1992 2004 59 95 underwent prior resection median treatment volume 4.0 cm 3 range 0.8-12.9 median treatment dose margin 16 Gy range 11-20 median maximum point dose optic apparatus 9.5 Gy range 5.0-12.6 median follow-up period radiosurgery 64 months range 23-161 size decreased 37 patients 60 remained unchanged 23 patients 37 patients 3 growth outside prescribed treatment volume required additional treatment fractionated radiation therapy n 1 repeat radiosurgery n 1 growth control 95 3 7 years radiosurgery 27 41 patients normal n 30 partial n 11 anterior pituitary function radiosurgery developed new deficits median 24 months radiosurgery risk developing new anterior pituitary deficits 5 years 32 5-year risk developing new anterior pituitary deficits 18 patients volume 4.0 cm 3 compared 58 patients volume 4.0 cm 3 risk ratio 4.5 95 confidence interval 1.3-14.9 p 0.02 patient decline visual function Stereotactic radiosurgery effective management patients residual recurrent NFA longer follow-up needed evaluate long-term outcomes primary complication hypopituitarism risk developing new anterior pituitary deficits correlates size irradiated,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 3, 209, 2, 521, 1, 1729, 2192, 9, 7, 5, 18461, 2751, 24724, 26, 10, 8, 459, 206, 1, 744, 7, 5, 24724, 479, 2192, 59, 2846, 2, 1131, 1, 953, 728, 48, 208, 324, 30, 170, 3, 52, 24, 433, 10, 39, 13, 494, 27, 184, 13, 66, 133, 83, 3, 52, 24, 61, 6, 3, 30, 959, 10, 245, 381, 184, 175, 179, 3, 52, 689, 741, 61, 6, 3, 5670, 10180, 10, 83, 33, 381, 184, 33, 13, 133, 49, 3, 52, 166, 126, 727, 50, 2192, 10, 660, 53, 184, 382, 5377, 30, 444, 340, 9, 567, 7, 335, 2, 958, 4639, 9, 382, 7, 567, 100, 7, 27, 42, 30, 129, 2513, 3, 2746, 24, 433, 2, 616, 402, 24, 3950, 121, 36, 78, 14, 2334, 2192, 78, 14, 30, 129, 182, 10, 48, 28, 27, 2, 67, 60, 50, 2192, 2627, 428, 1, 605, 7, 5, 295, 78, 201, 15, 450, 78, 175, 2882, 343, 348, 2192, 276, 217, 2752, 28, 8, 52, 1, 259, 53, 50, 2192, 3, 43, 1, 931, 217, 2882, 2752, 28, 33, 60, 10, 531, 3, 33, 111, 43, 1, 931, 217, 2882, 2752, 10, 203, 9, 7, 5, 8, 30, 433, 1, 15, 39, 13, 494, 27, 72, 5, 717, 9, 7, 5, 8, 30, 433, 39, 13, 494, 27, 43, 197, 39, 33, 48, 307, 268, 14, 27, 213, 83, 19, 13, 588, 77, 69, 42, 8, 1858, 4, 3046, 343, 1729, 2192, 16, 323, 4, 3, 284, 1, 7, 5, 753, 15, 387, 24724, 242, 589, 166, 126, 16, 575, 6, 376, 319, 337, 123, 3, 86, 1447, 16, 19832, 2, 3, 43, 1, 931, 217, 2882, 2752, 1871, 5, 3, 444, 1, 3, 2398, 30]",1652.0,18029107,Gamma knife radiosurgery patients nonfunctioning pituitary adenomas 15-year experience,14,0.1320754716981132
Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-03-01,"To estimate the cumulative incidence of specific hormone deficiencies and the influence of hypothalamic-pituitary (HP) axis radiation dose in a cohort of children with embryonal brain tumors treated with risk-adapted craniospinal irradiation (CSI), conformal primary site irradiation, and high-dose chemotherapy. Clinical data and HP axis radiation dosimetry data were obtained from 88 eligible children. All patients received regular endocrine follow-up that included screening tests of thyroid function and stimulation testing for growth hormone deficiency (GHD), and adrenocorticotropin hormone deficiency. The cumulative incidence of GHD, thyroid-stimulating hormone (TSH) deficiency, adrenocorticotropic hormone deficiency, and primary hypothyroidism at 4 years from diagnosis was 93% +/- 4%, 23% +/- 8%, 38% +/- 6%, and 65% +/- 7%, respectively. Radiation dosimetry to the HP axis was associated only with the development of TSH deficiency; the 4-year cumulative incidence was 44% +/- 19% and 11% +/- 8% (P = .014) for those receiving more or less than the median dose to the hypothalamus (>or= 42 v < 42 Gy), respectively. The median dose of CSI for the average-risk (AR) patients was 23.4 and 39.6 Gy (36 to 40.5 Gy) for the high-risk patients. The estimated mean decline in height Z-score after radiation therapy was greater in high-risk patients (-0.65 units/yr) when compared with AR patients (-0.54 units/yr; P = .039). Pediatric patients with CNS embryonal tumors are at high risk for treatment-related hormone deficiencies. GHD and primary hypothyroidism were diagnosed in a majority of subjects relatively soon after the completion of therapy. Radiation dose to the hypothalamus in excess of 42 Gy was associated with an increase in the risk of developing TSH deficiency.",Clinical Trial,4343.0,110.0,estimate cumulative incidence specific hormone deficiencies influence hypothalamic-pituitary HP axis radiation dose cohort children embryonal brain treated risk-adapted craniospinal irradiation CSI conformal primary site irradiation high-dose chemotherapy Clinical HP axis radiation dosimetry obtained 88 eligible children patients received regular endocrine follow-up included screening tests thyroid function stimulation testing growth hormone deficiency GHD adrenocorticotropin hormone deficiency cumulative incidence GHD thyroid-stimulating hormone TSH deficiency adrenocorticotropic hormone deficiency primary hypothyroidism 4 years diagnosis 93 +/- 4 23 +/- 8 38 +/- 6 65 +/- 7 respectively Radiation dosimetry HP axis associated development TSH deficiency 4-year cumulative incidence 44 +/- 19 11 +/- 8 P .014 receiving median dose hypothalamus or= 42 v 42 Gy respectively median dose CSI average-risk AR patients 23.4 39.6 Gy 36 40.5 Gy high-risk patients estimated mean decline height Z-score radiation therapy greater high-risk patients -0.65 units/yr compared AR patients -0.54 units/yr P .039 Pediatric patients CNS embryonal high risk treatment-related hormone deficiencies GHD primary hypothyroidism diagnosed majority subjects relatively soon completion therapy Radiation dose hypothalamus excess 42 Gy associated increase risk developing TSH deficiency,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[6, 1191, 3, 967, 287, 1, 112, 785, 7159, 2, 3, 1054, 1, 7531, 12098, 4622, 2310, 121, 61, 4, 8, 180, 1, 541, 5, 5239, 342, 57, 73, 5, 43, 3716, 5748, 1104, 4293, 2972, 86, 606, 1104, 2, 64, 61, 56, 38, 74, 2, 4622, 2310, 121, 4113, 74, 11, 683, 29, 889, 625, 541, 62, 7, 103, 3316, 1293, 166, 126, 17, 159, 453, 895, 1, 343, 2, 2503, 471, 9, 129, 785, 2299, 14863, 2, 30299, 785, 2299, 3, 967, 287, 1, 14863, 11260, 2122, 785, 6581, 2299, 22401, 785, 2299, 2, 86, 4147, 28, 39, 60, 29, 147, 10, 966, 39, 382, 66, 519, 49, 2, 556, 67, 106, 121, 4113, 6, 3, 4622, 2310, 10, 41, 158, 5, 3, 193, 1, 6581, 2299, 3, 39, 111, 967, 287, 10, 584, 326, 2, 175, 66, 19, 3618, 9, 135, 357, 80, 15, 299, 76, 3, 52, 61, 6, 3, 12717, 15, 595, 603, 595, 381, 106, 3, 52, 61, 1, 4293, 9, 3, 1011, 43, 754, 7, 10, 382, 39, 2, 587, 49, 381, 511, 6, 327, 33, 381, 9, 3, 64, 43, 7, 3, 661, 313, 1858, 4, 4594, 3905, 368, 50, 121, 36, 10, 378, 4, 64, 43, 7, 13, 556, 2960, 2830, 198, 72, 5, 754, 7, 13, 667, 2960, 2830, 19, 5955, 815, 7, 5, 1025, 5239, 57, 32, 28, 64, 43, 9, 24, 139, 785, 7159, 14863, 2, 86, 4147, 11, 265, 4, 8, 686, 1, 976, 1352, 6176, 50, 3, 1438, 1, 36, 121, 61, 6, 3, 12717, 4, 2612, 1, 595, 381, 10, 41, 5, 35, 344, 4, 3, 43, 1, 931, 6581, 2299]",1716.0,18309946,Endocrine outcomes children embryonal brain risk-adapted craniospinal conformal primary-site irradiation high-dose chemotherapy stem-cell rescue SJMB-96 trial,0,0.0
Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia.,Pharmacogenetics and genomics,Pharmacogenet. Genomics,2008-06-01,"Glucocorticoids are used universally in the remission induction therapy for acute lymphoblastic leukemia (ALL). One of the adverse effects of glucocorticoids is hypertension. Our aim was to define the frequency of and clinical and genetic risk factors for steroid-induced hypertension. We determined the genotypes for 203 candidate polymorphisms in genes previously linked to hypertension or to the pharmacokinetics or pharmacodynamics of antileukemic agents. Hypertension was defined according to the guidelines of the American Academy of Pediatrics; patients were evaluated during the 28-day period of prednisone at 40 mg/m2/day during remission induction of childhood ALL. Of the 602 children with newly diagnosed ALL who were normotensive pretherapy, 270 (45%) developed hypertension during remission induction. None of the putative risk factors (age, sex, race, white blood cell count, risk group, body mass index, or serum creatinine) was associated with hypertension. Among the polymorphisms genotyped, we identified eight genes (CNTNAP2, LEPR, CRHR1, NTAN1, SLC12A3, ALPL, BGLAP, and APOB) containing variants that were associated with hypertension (chi2 P values 0.002-0.048), several of which interact with the hypothalamus-pituitary-adrenal axis. Polymorphisms in CYP3A4 and CYP3A5 were not associated with hypertension. Hypertension is common during ALL remission induction and is related to germline genetic variation.",Journal Article,4251.0,31.0,Glucocorticoids universally remission induction therapy acute lymphoblastic leukemia adverse effects glucocorticoids hypertension aim define frequency clinical genetic risk factors steroid-induced hypertension determined genotypes 203 candidate polymorphisms previously linked hypertension pharmacokinetics pharmacodynamics antileukemic agents Hypertension defined according guidelines American Academy Pediatrics patients evaluated 28-day period prednisone 40 mg/m2/day remission induction childhood 602 children newly diagnosed normotensive pretherapy 270 45 developed hypertension remission induction putative risk factors age sex race white blood count risk group body mass index serum creatinine associated hypertension polymorphisms genotyped identified CNTNAP2 LEPR CRHR1 NTAN1 SLC12A3 ALPL BGLAP APOB containing associated hypertension chi2 P values 0.002-0.048 interact hypothalamus-pituitary-adrenal axis Polymorphisms CYP3A4 CYP3A5 associated hypertension Hypertension common remission induction related germline genetic variation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7307, 32, 95, 6813, 4, 3, 734, 504, 36, 9, 286, 1275, 62, 104, 1, 3, 290, 176, 1, 7307, 16, 1824, 114, 1130, 10, 6, 1107, 3, 675, 1, 2, 38, 2, 336, 43, 130, 9, 3853, 277, 1824, 21, 509, 3, 2071, 9, 5426, 1609, 1203, 4, 214, 373, 1199, 6, 1824, 15, 6, 3, 1159, 15, 3587, 1, 4512, 183, 1824, 10, 395, 768, 6, 3, 677, 1, 3, 597, 16378, 1, 12616, 7, 11, 194, 190, 3, 339, 218, 727, 1, 1979, 28, 327, 81, 821, 218, 190, 734, 504, 1, 864, 62, 1, 3, 10588, 541, 5, 732, 265, 62, 54, 11, 34475, 8857, 6666, 512, 276, 1824, 190, 734, 504, 1292, 1, 3, 2743, 43, 130, 89, 1035, 1047, 886, 315, 31, 1276, 43, 87, 642, 782, 558, 15, 524, 3177, 10, 41, 5, 1824, 107, 3, 1203, 3053, 21, 108, 659, 214, 45137, 17276, 31289, 57080, 57081, 57082, 57083, 2, 57084, 1101, 839, 17, 11, 41, 5, 1824, 12474, 19, 1030, 13, 1111, 13, 4969, 392, 1, 92, 4491, 5, 3, 12717, 12098, 2987, 2310, 1203, 4, 6208, 2, 10071, 11, 44, 41, 5, 1824, 1824, 16, 186, 190, 62, 734, 504, 2, 16, 139, 6, 1009, 336, 1380]",1384.0,18496130,Genetic predictors glucocorticoid-induced hypertension children acute lymphoblastic leukemia,0,0.0
Novalis intensity-modulated radiosurgery: methods for pretreatment planning.,Neurosurgery,Neurosurgery,2008-05-01,"The Novalis stereotactic radiotherapy system (BrainLAB, Heimstetten, Germany) allows for precise treatment of cranial base tumors with single-fraction radiosurgery. In some cases, however, proximity of the optic nerve and chiasm is a concern. In these cases, intensity-modulated stereotactic radiosurgery (IMRS) can be used to limit the dose to these structures. IMRS planning can be labor intensive, which poses a problem when it is performed on the day of treatment. We describe our methods and results of preprocedure planning for IMRS for patients with lesions in the cavernous sinus or parasellar regions in whom the dose to the optic nerve or chiasm might exceed our acceptable tolerance dose (8 Gy). Patients whose lesions were more than 4 mm from the optic nerve and chiasm on standard magnetic resonance imaging scans but who were questionable candidates for radiosurgery because of concerns of dose to the optic nerve or chiasm were considered for IMRS. Preprocedure imaging (computed tomography and magnetic resonance imaging) was fused and analyzed using the BrainLAB BrainScan 5.3 treatment planning system. Dynamic conformal arc plans for stereotactic radiosurgery and IMRS were evaluated. Doses to the planning target volume and optic apparatus were assessed by dose-volume histograms and conformality index calculated to characterize the quality of the different plans. When IMRS was used, the preplan allowed for a rapid recalculation on the treatment day, minimizing the time patients were in the head frame before treatment. We describe three patients with recurrent pituitary tumors and three with meningiomas. Doses were 1500 to 2000 cGy prescribed to the 80 to 96% isodose line delivered by eight to 22 fields. Tumor volumes ranged from 2.70 to 8.82 cm (mean, 5.7 cm). In five of the six patients, the dynamic conformal arc plan precluded delivery of therapeutic dose without exceeding optic nerve tolerance. On the basis of 95% coverage of target volume, maximum prescription doses of 7.7 to 20.64 Gy were possible with the dynamic conformal arc plans without exceeding 8 Gy to the optic apparatus. IMRS allowed maximum doses of 20 to 31 Gy using the same optic apparatus dose restriction. No complications have occurred, and all tumors have remained stable since treatment (mean follow-up period, 30 mo). We believe this pretreatment technique streamlines the process for IMRS, allowing for better patient comfort and efficient physician time use.",Journal Article,4282.0,9.0,Novalis stereotactic radiotherapy BrainLAB Heimstetten Germany allows precise treatment cranial base single-fraction radiosurgery cases proximity optic nerve chiasm concern cases intensity-modulated stereotactic radiosurgery IMRS limit dose structures IMRS planning labor intensive poses problem performed day treatment methods preprocedure planning IMRS patients lesions cavernous sinus parasellar regions dose optic nerve chiasm exceed acceptable tolerance dose 8 Gy Patients lesions 4 mm optic nerve chiasm standard magnetic resonance imaging scans questionable candidates radiosurgery concerns dose optic nerve chiasm considered IMRS Preprocedure imaging computed tomography magnetic resonance imaging fused BrainLAB BrainScan 5.3 treatment planning Dynamic conformal arc plans stereotactic radiosurgery IMRS evaluated Doses planning target volume optic apparatus assessed dose-volume histograms conformality index calculated characterize quality different plans IMRS preplan allowed rapid recalculation treatment day minimizing time patients head frame treatment patients recurrent pituitary meningiomas Doses 1500 2000 cGy prescribed 80 96 isodose line delivered 22 fields volumes ranged 2.70 8.82 cm mean 5.7 cm patients dynamic conformal arc plan precluded delivery therapeutic dose exceeding optic nerve tolerance basis 95 coverage target volume maximum prescription doses 7.7 20.64 Gy possible dynamic conformal arc plans exceeding 8 Gy optic apparatus IMRS allowed maximum doses 20 31 Gy optic apparatus dose restriction complications occurred remained stable treatment mean follow-up period 30 mo believe pretreatment technique streamlines process IMRS allowing better patient comfort efficient physician time use,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 19158, 1729, 310, 398, 19159, 57206, 10697, 2333, 9, 3260, 24, 1, 2565, 1782, 57, 5, 226, 1509, 2192, 4, 476, 140, 137, 6167, 1, 3, 5670, 2476, 2, 14583, 16, 8, 2893, 4, 46, 140, 837, 1757, 1729, 2192, 13169, 122, 40, 95, 6, 2385, 3, 61, 6, 46, 2414, 13169, 1349, 122, 40, 9557, 1686, 92, 7056, 8, 2497, 198, 192, 16, 173, 23, 3, 218, 1, 24, 21, 897, 114, 636, 2, 99, 1, 34494, 1349, 9, 13169, 9, 7, 5, 406, 4, 3, 12170, 5810, 15, 18260, 1374, 4, 953, 3, 61, 6, 3, 5670, 2476, 15, 14583, 822, 6818, 114, 1595, 2614, 61, 66, 381, 7, 1310, 406, 11, 80, 76, 39, 321, 29, 3, 5670, 2476, 2, 14583, 23, 260, 1484, 1535, 270, 1441, 84, 54, 11, 14853, 1931, 9, 2192, 408, 1, 2061, 1, 61, 6, 3, 5670, 2476, 15, 14583, 11, 515, 9, 13169, 34494, 270, 1220, 872, 2, 1484, 1535, 270, 10, 6263, 2, 311, 75, 3, 19159, 26723, 33, 27, 24, 1349, 398, 2540, 2972, 9277, 1853, 9, 1729, 2192, 2, 13169, 11, 194, 415, 6, 3, 1349, 283, 433, 2, 5670, 10180, 11, 275, 20, 61, 433, 8638, 2, 12025, 558, 981, 6, 1507, 3, 372, 1, 3, 338, 1853, 198, 13169, 10, 95, 3, 57207, 2313, 9, 8, 1321, 57208, 23, 3, 24, 218, 4501, 3, 98, 7, 11, 4, 3, 718, 5331, 348, 24, 21, 897, 169, 7, 5, 387, 57, 2, 169, 5, 3718, 415, 11, 7204, 6, 1081, 3071, 2746, 6, 3, 493, 6, 921, 8945, 328, 1623, 20, 659, 6, 350, 3130, 30, 2225, 1869, 29, 18, 431, 6, 66, 878, 494, 313, 33, 67, 494, 4, 365, 1, 3, 437, 7, 3, 2540, 2972, 9277, 2242, 8035, 989, 1, 189, 61, 187, 5178, 5670, 2476, 2614, 23, 3, 877, 1, 48, 2139, 1, 283, 433, 689, 3584, 415, 1, 67, 67, 6, 179, 660, 381, 11, 899, 5, 3, 2540, 2972, 9277, 1853, 187, 5178, 66, 381, 6, 3, 5670, 10180, 13169, 2313, 689, 415, 1, 179, 6, 456, 381, 75, 3, 827, 5670, 10180, 61, 4575, 77, 521, 47, 489, 2, 62, 57, 47, 958, 585, 1192, 24, 313, 166, 126, 727, 201, 2035, 21, 4629, 26, 1194, 1312, 31293, 3, 1129, 9, 13169, 2952, 9, 380, 69, 8300, 2, 2547, 1473, 98, 119]",2415.0,18580777,Novalis intensity-modulated radiosurgery methods pretreatment planning,0,0.0
Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer.,Head & neck,Head Neck,2009-03-01,"Medullary thyroid cancer (MTC) commonly metastasizes to lymph nodes in the central and lateral neck, but spread to distant organs also occurs, typically involving lung, liver, and bone. Metastases to pituitary gland are rare for this tumor. We describe an unusual case and peculiar presentation of pituitary metastasis from MTC. We report clinical, genetic, and laboratory data of this patient. A young woman with multiple endocrine neoplasia type 2B was seen with recent onset of classic symptoms and signs of panhypopituitarism, mild diabetes insipidus, and optic chiasmatic compression. Transphenoidal resection of an intrapituitary mass confirmed the presence of metastatic MTC. MTC recurrence may present solely with subacute pituitary symptomatology, even in the context of a very lengthy interval after initial surgery, atypically low calcitonin plasma levels, carcinoembryonic antigen doubling times, and the concomitant absence of other tell-tale signs of disseminated metastatic disease.",Case Reports,3978.0,14.0,Medullary thyroid MTC commonly metastasizes lymph nodes central lateral neck spread distant organs occurs typically involving lung liver bone Metastases pituitary gland rare unusual case peculiar presentation pituitary metastasis MTC report clinical genetic laboratory patient young woman multiple endocrine neoplasia type 2B seen recent onset classic symptoms signs panhypopituitarism mild diabetes insipidus optic chiasmatic compression Transphenoidal resection intrapituitary mass confirmed presence metastatic MTC MTC recurrence present solely subacute pituitary symptomatology context lengthy interval initial surgery atypically low calcitonin plasma levels carcinoembryonic antigen doubling times concomitant absence tell-tale signs disseminated metastatic disease,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[4564, 12, 3959, 841, 10151, 6, 263, 502, 4, 3, 854, 2, 3855, 84, 2579, 6, 626, 2285, 120, 1780, 1969, 1267, 2, 196, 6, 2326, 32, 622, 9, 26, 30, 21, 897, 35, 4015, 473, 2, 21179, 1031, 1, 278, 29, 3959, 21, 414, 38, 336, 2, 1624, 74, 1, 26, 69, 8, 1169, 2854, 5, 232, 1293, 2298, 267, 3381, 10, 527, 5, 435, 1707, 1, 3168, 507, 2, 3408, 1, 28464, 1980, 1978, 16366, 2, 5670, 23289, 3481, 57368, 170, 1, 35, 57369, 782, 557, 3, 463, 1, 113, 3959, 3959, 146, 68, 364, 5558, 5, 15181, 12279, 871, 4, 3, 1533, 1, 8, 923, 14487, 268, 50, 388, 152, 34551, 154, 11314, 554, 148, 5139, 448, 4342, 1072, 2, 3, 1781, 1127, 1, 127, 26122, 45260, 3408, 1, 3605, 113, 34]",917.0,18798312,Diabetes insipidus panhypopituitarism intrasellar metastasis medullary thyroid,0,0.0
Pituitary tumor type affects the chance of biochemical remission after radiosurgery of hormone-secreting pituitary adenomas.,Neurosurgery,Neurosurgery,2008-06-01,"Reported biochemical remission rates have ranged widely after stereotactic radiosurgery for patients with hormone-secreting pituitary adenomas. Confounding variables include histology, radiation dose, use of pituitary-suppressive medications, and length of follow-up. A retrospective review of 46 patients with pituitary adenomas (growth hormone-secreting, n = 27; prolactin-secreting, n = 11; adrenocorticotropin-secreting, n = 8) undergoing radiosurgery between January 1990 and December 2003 was conducted. All received a tumor margin dose of 18 Gy or more and were off pituitary-suppressive medications for at least 1 month before radiosurgery. The groups were similar with regard to irradiated volume, radiation dose, and follow-up. The median endocrinological follow-up after radiosurgery was 54 months. The 4-year remission rates were 87% for patients with Cushing's disease, 67% for patients with acromegaly, and 18% for patients with prolactinomas. Patients with oversecretion of adrenocorticotropin or growth hormone were more likely to achieve remission after radiosurgery than patients with prolactinomas (hazard ratio, 4.4; 95% confidence interval, 1.1-18.2; P = 0.04). Of 44 patients with normal or partial anterior pituitary function before radiosurgery, 16 (36%) developed one or more new anterior pituitary deficits. The incidence of new anterior pituitary deficits was 26% at 4 years. No differences were noted in the incidence of new anterior deficits among the groups. There seems to be a differential sensitivity after radiosurgery for hormone-secreting pituitary adenomas. Remission rates are greater for patients with Cushing's disease and acromegaly, whereas radiosurgery is less effective in achieving biochemical remission for patients with prolactinomas.",Journal Article,4251.0,51.0,Reported biochemical remission rates ranged widely stereotactic radiosurgery patients hormone-secreting pituitary adenomas Confounding variables include histology radiation dose use pituitary-suppressive medications length follow-up retrospective review 46 patients pituitary adenomas growth hormone-secreting n 27 prolactin-secreting n 11 adrenocorticotropin-secreting n 8 undergoing radiosurgery January 1990 December 2003 conducted received margin dose 18 Gy pituitary-suppressive medications 1 month radiosurgery groups similar regard irradiated volume radiation dose follow-up median endocrinological follow-up radiosurgery 54 months 4-year remission rates 87 patients Cushing 's disease 67 patients acromegaly 18 patients prolactinomas Patients oversecretion adrenocorticotropin growth hormone likely achieve remission radiosurgery patients prolactinomas hazard ratio 4.4 95 confidence interval 1.1-18.2 P 0.04 44 patients normal partial anterior pituitary function radiosurgery 16 36 developed new anterior pituitary deficits incidence new anterior pituitary deficits 26 4 years differences noted incidence new anterior deficits groups differential sensitivity radiosurgery hormone-secreting pituitary adenomas Remission rates greater patients Cushing 's disease acromegaly radiosurgery effective achieving biochemical remission patients prolactinomas,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[210, 1487, 734, 151, 47, 1869, 1792, 50, 1729, 2192, 9, 7, 5, 785, 5052, 2751, 4339, 682, 643, 784, 121, 61, 119, 1, 12098, 3707, 2679, 2, 1318, 1, 166, 126, 8, 459, 206, 1, 641, 7, 5, 2751, 129, 785, 5052, 78, 428, 10841, 5052, 78, 175, 30299, 5052, 78, 66, 479, 2192, 59, 1024, 2289, 2, 1397, 1522, 10, 426, 62, 103, 8, 30, 959, 61, 1, 203, 381, 15, 80, 2, 11, 1889, 12098, 3707, 2679, 9, 28, 506, 14, 811, 348, 2192, 3, 271, 11, 288, 5, 2539, 6, 2398, 433, 121, 61, 2, 166, 126, 3, 52, 28148, 166, 126, 50, 2192, 10, 667, 53, 3, 39, 111, 734, 151, 11, 912, 9, 7, 5, 16258, 292, 34, 598, 9, 7, 5, 28682, 2, 203, 9, 7, 5, 26749, 7, 5, 43321, 1, 30299, 15, 129, 785, 11, 80, 322, 6, 1359, 734, 50, 2192, 76, 7, 5, 26749, 360, 197, 39, 39, 48, 307, 268, 14, 14, 203, 18, 19, 13, 755, 1, 584, 7, 5, 295, 15, 450, 2882, 343, 348, 2192, 245, 511, 276, 104, 15, 80, 217, 2882, 2752, 3, 287, 1, 217, 2882, 2752, 10, 432, 28, 39, 60, 77, 362, 11, 1051, 4, 3, 287, 1, 217, 2882, 2752, 107, 3, 271, 125, 2744, 6, 40, 8, 1777, 485, 50, 2192, 9, 785, 5052, 2751, 734, 151, 32, 378, 9, 7, 5, 16258, 292, 34, 2, 28682, 547, 2192, 16, 299, 323, 4, 1785, 1487, 734, 9, 7, 5, 26749]",1672.0,18824993,Pituitary type affects chance biochemical remission radiosurgery hormone-secreting pituitary adenomas,1,0.009433962264150943
Radiation-induced optic neuritis after pituitary adenoma radiosurgery in a patient with multiple sclerosis: case report.,Journal of neuro-oncology,J. Neurooncol.,2008-12-20,"To describe a rare case of optic neuritis onset after Gamma Knife stereotactic radiosurgery. Nine years after transsphenoidal subtotal resection of a pituitary adenoma, this 43-year-old woman had elevated serum prolactin levels and headaches. Gamma Knife stereotactic radiosurgery to residual pituitary tumor. To our knowledge, this is the first report of radiation-induced optic neuritis after radiosurgery in a patient with multiple sclerosis.",Case Reports,4049.0,5.0,rare case optic neuritis onset Gamma Knife stereotactic radiosurgery years transsphenoidal subtotal resection pituitary adenoma 43-year-old woman elevated serum prolactin levels headaches Gamma Knife stereotactic radiosurgery residual pituitary knowledge report radiation-induced optic neuritis radiosurgery patient multiple sclerosis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 897, 8, 622, 473, 1, 5670, 28558, 1707, 50, 1705, 8045, 1729, 2192, 762, 60, 50, 14214, 5503, 170, 1, 8, 2434, 26, 601, 111, 1095, 2854, 42, 804, 524, 10841, 148, 2, 9783, 1705, 8045, 1729, 2192, 6, 753, 30, 6, 114, 922, 26, 16, 3, 157, 414, 1, 121, 277, 5670, 28558, 50, 2192, 4, 8, 69, 5, 232, 7426]",419.0,19099198,Radiation-induced optic neuritis pituitary adenoma radiosurgery patient multiple sclerosis case report,0,0.0
Alterations in pubertal timing following therapy for childhood malignancies.,Endocrine development,Endocr Dev,2009-03-03,"The onset of puberty marks a time of rapid linear growth, sexual development, and transition from childhood to maturity. The diagnosis and treatment of a childhood malignancy prior to the onset of puberty has the potential to profoundly affect the timing and the tempo of puberty. CNS tumors located in the hypothalamic-pituitary (H-P) region, surgical resection in this location, and exposure to CNS radiotherapy are all associated with both precocious and delayed puberty. Also, chemotherapy and radiation can directly damage the gonads, which can result in absent, arrested, or delayed puberty. As a consequence of these alterations of pubertal timing, both male and female survivors of childhood cancer may be at risk of adult short-stature, decreased bone-mineral density, absent or incomplete sexual development, and ultimately, reduced rates of fertility. Appropriate and timely assessment of survivors at high risk of alterations in pubertal development will enable the identification of patients who would benefit from early medical intervention.",Journal Article,3976.0,26.0,onset puberty marks time rapid linear growth sexual development transition childhood maturity diagnosis treatment childhood malignancy prior onset puberty potential profoundly affect timing tempo puberty CNS located hypothalamic-pituitary H-P region surgical resection location exposure CNS radiotherapy associated precocious delayed puberty chemotherapy radiation directly damage gonads absent arrested delayed puberty consequence alterations pubertal timing male female survivors childhood risk adult short-stature decreased bone-mineral density absent incomplete sexual development ultimately reduced rates fertility Appropriate timely assessment survivors high risk alterations pubertal development enable identification patients benefit early medical intervention,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1707, 1, 10302, 8418, 8, 98, 1, 1321, 1646, 129, 2232, 193, 2, 1970, 29, 864, 6, 26674, 3, 147, 2, 24, 1, 8, 864, 710, 324, 6, 3, 1707, 1, 10302, 71, 3, 174, 6, 8802, 1158, 3, 1972, 2, 3, 30554, 1, 10302, 1025, 57, 2308, 4, 3, 7531, 12098, 555, 19, 1053, 221, 170, 4, 26, 1147, 2, 645, 6, 1025, 310, 32, 62, 41, 5, 110, 26266, 2, 1612, 10302, 120, 56, 2, 121, 122, 1606, 1350, 3, 23245, 92, 122, 757, 4, 3269, 9762, 15, 1612, 10302, 22, 8, 4177, 1, 46, 593, 1, 10467, 1972, 110, 1045, 2, 1061, 332, 1, 864, 12, 68, 40, 28, 43, 1, 780, 978, 13576, 340, 3417, 5033, 1263, 3269, 15, 2610, 2232, 193, 2, 2050, 405, 151, 1, 2954, 870, 2, 4225, 455, 1, 332, 28, 64, 43, 1, 593, 4, 10467, 193, 303, 3047, 3, 911, 1, 7, 54, 688, 247, 29, 191, 484, 788]",1034.0,19293602,Alterations pubertal timing following therapy childhood malignancies,1,0.009433962264150943
Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study.,Cancer,Cancer,2009-06-01,"Children who receive high-dose radiotherapy to the hypothalamic-pituitary (H-P) axis may be at risk for both early and late puberty. To the authors' knowledge, data regarding the risk of altered timing of menarche after higher dose radiotherapy (RT), as used in the treatment of central nervous system (CNS) tumors, are limited. The authors evaluated 235 female survivors of CNS tumors, diagnosed between 1970 and 1986, and >1000 sibling controls who were participants in the Childhood Cancer Survivor Study, and provided self-reported data concerning age at menarche. Survivors of CNS tumors were more likely to have onset of menarche before age 10 years compared with their siblings (11.9% vs 1.0%) (odds ratio [OR], 14.1; 95% confidence interval [95% CI], 7.0-30.9). Of the 138 survivors who received RT to the H-P axis, 20 (14.5%) had onset of menarche before age 10 years, compared with 4.3% of those who did not receive RT (OR, 3.8; 95% CI, 1.2-16.5). Age <or=4 years at the time of diagnosis was associated with an increased risk (OR, 4.0; 95% CI, 1.7-10.0) of early menarche. In addition, survivors of CNS tumors were more likely than siblings to have onset of menarche after age 16 years (10.6% vs 1.9%) (OR, 6.6; 95% CI, 3.4-11.4). Doses of RT to the H-P axis >50 gray OR, 9.0; 95% CI, 2.3-59.5) and spinal RT conferred an increased risk of late menarche, as did older age (>10 years) at the time of diagnosis (OR, 3.0; 95% CI, 1.3-7.0). Survivors of CNS tumors are at a significantly increased risk of both early and late menarche associated with RT exposure and age at treatment.",Journal Article,3886.0,42.0,Children receive high-dose radiotherapy hypothalamic-pituitary H-P axis risk early late puberty authors knowledge risk altered timing menarche higher dose radiotherapy RT treatment central nervous CNS limited authors evaluated 235 female survivors CNS diagnosed 1970 1986 1000 sibling controls participants Childhood Survivor provided self-reported concerning age menarche Survivors CNS likely onset menarche age 10 years compared siblings 11.9 vs 1.0 odds ratio 14.1 95 confidence interval 95 CI 7.0-30.9 138 survivors received RT H-P axis 20 14.5 onset menarche age 10 years compared 4.3 receive RT 3.8 95 CI 1.2-16.5 Age or=4 years time diagnosis associated increased risk 4.0 95 CI 1.7-10.0 early menarche addition survivors CNS likely siblings onset menarche age 16 years 10.6 vs 1.9 6.6 95 CI 3.4-11.4 Doses RT H-P axis 50 gray 9.0 95 CI 2.3-59.5 spinal RT conferred increased risk late menarche older age 10 years time diagnosis 3.0 95 CI 1.3-7.0 Survivors CNS significantly increased risk early late menarche associated RT exposure age treatment,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[541, 54, 560, 64, 61, 310, 6, 3, 7531, 12098, 555, 19, 2310, 68, 40, 28, 43, 9, 110, 191, 2, 807, 10302, 6, 3, 738, 922, 74, 666, 3, 43, 1, 1495, 1972, 1, 6414, 50, 142, 61, 310, 240, 22, 95, 4, 3, 24, 1, 854, 1880, 398, 1025, 57, 32, 383, 3, 738, 194, 6465, 1061, 332, 1, 1025, 57, 265, 59, 4868, 2, 3751, 2, 2345, 3684, 535, 54, 11, 776, 4, 3, 864, 12, 2628, 45, 2, 1052, 1074, 210, 74, 4243, 89, 28, 6414, 332, 1, 1025, 57, 11, 80, 322, 6, 47, 1707, 1, 6414, 348, 89, 79, 60, 72, 5, 136, 2758, 175, 83, 105, 14, 13, 610, 197, 15, 213, 14, 48, 307, 268, 48, 58, 67, 13, 201, 83, 1, 3, 4478, 332, 54, 103, 240, 6, 3, 555, 19, 2310, 179, 213, 33, 42, 1707, 1, 6414, 348, 89, 79, 60, 72, 5, 39, 27, 1, 135, 54, 205, 44, 560, 240, 15, 27, 66, 48, 58, 14, 18, 245, 33, 89, 15, 39, 60, 28, 3, 98, 1, 147, 10, 41, 5, 35, 101, 43, 15, 39, 13, 48, 58, 14, 67, 79, 13, 1, 191, 6414, 4, 352, 332, 1, 1025, 57, 11, 80, 322, 76, 2758, 6, 47, 1707, 1, 6414, 50, 89, 245, 60, 79, 49, 105, 14, 83, 15, 49, 49, 48, 58, 27, 39, 175, 39, 415, 1, 240, 6, 3, 555, 19, 2310, 212, 4163, 15, 83, 13, 48, 58, 18, 27, 728, 33, 2, 1499, 240, 3851, 35, 101, 43, 1, 807, 6414, 22, 205, 434, 89, 79, 60, 28, 3, 98, 1, 147, 15, 27, 13, 48, 58, 14, 27, 67, 13, 332, 1, 1025, 57, 32, 28, 8, 97, 101, 43, 1, 110, 191, 2, 807, 6414, 41, 5, 240, 645, 2, 89, 28, 24]",1507.0,19309737,Abnormal timing menarche survivors central nervous report Childhood Survivor,0,0.0
Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-04-13,"This study was undertaken to determine the effect, if any, of treatment for cancer diagnosed during childhood or adolescence on fertility. We reviewed the fertility of female participants in the Childhood Cancer Survivor Study (CCSS), which consisted of 5-year survivors, and a cohort of randomly selected siblings who responded to a questionnaire. Medical records of all members of the cohort were abstracted to obtain chemotherapeutic agents administered; the cumulative dose of drug administered for several drugs of interest; and the doses, volumes, and dates of administration of all radiation therapy. There were 5,149 female CCSS participants, and there were 1,441 female siblings of CCSS participants who were age 15 to 44 years. The relative risk (RR) for survivors of ever being pregnant was 0.81 (95% CI, 0.73 to 0.90; P < .001) compared with female siblings. In multivariate models among survivors only, those who received a hypothalamic/pituitary radiation dose > or = 30 Gy (RR, 0.61; 95% CI, 0.44 to 0.83) or an ovarian/uterine radiation dose greater than 5 Gy were less likely to have ever been pregnant (RR, 0.56 for 5 to 10 Gy; 95% CI, 0.37 to 0.85; RR, 0.18 for > 10 Gy; 95% CI, 0.13 to 0.26). Those with a summed alkylating agent dose (AAD) score of three or four or who were treated with lomustine or cyclophosphamide were less likely to have ever been pregnant. This large study demonstrated that fertility is decreased among female CCSS participants. The risk factors identified may be utilized for pretreatment counseling of patients and their parents.",Journal Article,3935.0,283.0,"undertaken determine effect treatment diagnosed childhood adolescence fertility reviewed fertility female participants Childhood Survivor CCSS consisted 5-year survivors cohort randomly selected siblings responded questionnaire Medical records members cohort abstracted obtain chemotherapeutic agents administered cumulative dose drug administered drugs doses volumes dates administration radiation therapy 5,149 female CCSS participants 1,441 female siblings CCSS participants age 15 44 years relative risk RR survivors pregnant 0.81 95 CI 0.73 0.90 P .001 compared female siblings multivariate models survivors received hypothalamic/pituitary radiation dose 30 Gy RR 0.61 95 CI 0.44 0.83 ovarian/uterine radiation dose greater 5 Gy likely pregnant RR 0.56 5 10 Gy 95 CI 0.37 0.85 RR 0.18 10 Gy 95 CI 0.13 0.26 summed alkylating agent dose AAD score treated lomustine cyclophosphamide likely pregnant large demonstrated fertility decreased female CCSS participants risk factors identified utilized pretreatment counseling patients parents",0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[26, 45, 10, 2789, 6, 223, 3, 254, 492, 500, 1, 24, 9, 12, 265, 190, 864, 15, 6964, 23, 2954, 21, 446, 3, 2954, 1, 1061, 776, 4, 3, 864, 12, 2628, 45, 4657, 92, 1695, 1, 33, 111, 332, 2, 8, 180, 1, 1108, 715, 2758, 54, 2211, 6, 8, 1770, 484, 1064, 1, 62, 1684, 1, 3, 180, 11, 4106, 6, 3140, 1573, 183, 468, 3, 967, 61, 1, 234, 468, 9, 392, 600, 1, 1333, 2, 3, 415, 2225, 2, 9561, 1, 634, 1, 62, 121, 36, 125, 11, 33, 4928, 1061, 4657, 776, 2, 125, 11, 14, 10258, 1061, 2758, 1, 4657, 776, 54, 11, 89, 167, 6, 584, 60, 3, 580, 43, 861, 9, 332, 1, 3353, 486, 6086, 10, 13, 865, 48, 58, 13, 803, 6, 13, 424, 19, 144, 72, 5, 1061, 2758, 4, 331, 274, 107, 332, 158, 135, 54, 103, 8, 7531, 12098, 121, 61, 15, 201, 381, 861, 13, 713, 48, 58, 13, 584, 6, 13, 852, 15, 35, 6301, 16369, 121, 61, 378, 76, 33, 381, 11, 299, 322, 6, 47, 3353, 85, 6086, 861, 13, 664, 9, 33, 6, 79, 381, 48, 58, 13, 567, 6, 13, 772, 861, 13, 203, 9, 79, 381, 48, 58, 13, 233, 6, 13, 432, 135, 5, 8, 13232, 3410, 420, 61, 22535, 368, 1, 169, 15, 294, 15, 54, 11, 73, 5, 9181, 15, 1112, 11, 299, 322, 6, 47, 3353, 85, 6086, 26, 375, 45, 264, 17, 2954, 16, 340, 107, 1061, 4657, 776, 3, 43, 130, 108, 68, 40, 2080, 9, 1194, 2011, 1, 7, 2, 136, 2418]",1521.0,19364965,Fertility female survivors childhood report childhood survivor,7,0.0660377358490566
Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.,Pediatric blood & cancer,Pediatr Blood Cancer,2009-09-01,"To determine the risk of thyroid dysfunction and subsequent thyroid cancer among childhood acute lymphoblastic leukemia (ALL) survivors. Rates of self-reported thyroid dysfunction and thyroid cancer were determined among 3,579 ALL survivors participating in the Childhood Cancer Survivor Study, a cohort of 5-year survivors of pediatric cancers diagnosed from 1970 to 1986, and compared with 3,846 siblings and population rates, respectively. The cumulative incidence of hypo- and hyperthyroidism among survivors 15 years following leukemia diagnosis was 1.6% (95% CI 1.1, 2.1) and 0.6% (95% CI 0.3, 1.1), respectively, both significantly increased compared with siblings. In multivariate analysis, survivors who received >or=20 Gy cranial radiotherapy plus any spinal radiotherapy had the highest risk of subsequent hypothyroidism (HR 8.3, 95% CI 3.3, 20.5) compared with those treated with chemotherapy alone. Craniospinal radiotherapy also was associated with an increased risk of subsequent hyperthyroidism (HR 6.1, 95% CI 1.1, 34.2) compared with chemotherapy alone, as well as an increased risk of subsequent thyroid cancers (SIR 30.3, 95% CI 14.5, 55.7) compared with population rates. In radiation dosimetry analysis, pituitary doses >or=20 Gy combined with thyroid doses >or=10 Gy were associated with hypothyroidism, whereas pituitary doses >or=20 Gy combined with thyroid doses >or=15 Gy were associated with hyperthyroidism. The risk of thyroid dysfunction and thyroid cancer was increased among childhood ALL survivors treated with craniospinal radiotherapy. In these individuals, long-term surveillance is warranted as no obvious plateau in risk was seen, even after 25 years of follow-up.",Journal Article,3794.0,66.0,"determine risk thyroid dysfunction subsequent thyroid childhood acute lymphoblastic leukemia survivors Rates self-reported thyroid dysfunction thyroid determined 3,579 survivors participating Childhood Survivor cohort 5-year survivors pediatric diagnosed 1970 1986 compared 3,846 siblings population rates respectively cumulative incidence hypo- hyperthyroidism survivors 15 years following leukemia diagnosis 1.6 95 CI 1.1 2.1 0.6 95 CI 0.3 1.1 respectively significantly increased compared siblings multivariate survivors received or=20 Gy cranial radiotherapy plus spinal radiotherapy highest risk subsequent hypothyroidism HR 8.3 95 CI 3.3 20.5 compared treated chemotherapy Craniospinal radiotherapy associated increased risk subsequent hyperthyroidism HR 6.1 95 CI 1.1 34.2 compared chemotherapy increased risk subsequent thyroid SIR 30.3 95 CI 14.5 55.7 compared population rates radiation dosimetry pituitary doses or=20 Gy combined thyroid doses or=10 Gy associated hypothyroidism pituitary doses or=20 Gy combined thyroid doses or=15 Gy associated hyperthyroidism risk thyroid dysfunction thyroid increased childhood survivors treated craniospinal radiotherapy individuals long-term surveillance warranted obvious plateau risk seen 25 years follow-up",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,"[6, 223, 3, 43, 1, 1527, 2, 706, 12, 107, 864, 286, 1275, 62, 332, 151, 1, 1074, 210, 1527, 2, 12, 11, 509, 107, 27, 11414, 62, 332, 3052, 4, 3, 864, 12, 2628, 45, 8, 180, 1, 33, 111, 332, 1, 815, 163, 265, 29, 4868, 6, 3751, 2, 72, 5, 27, 14842, 2758, 2, 266, 151, 106, 3, 967, 287, 1, 22433, 2, 12096, 107, 332, 167, 60, 366, 147, 10, 14, 49, 48, 58, 14, 14, 18, 14, 2, 13, 49, 48, 58, 13, 27, 14, 14, 106, 110, 97, 101, 72, 5, 2758, 4, 331, 65, 332, 54, 103, 15, 179, 381, 2565, 310, 349, 500, 1499, 310, 42, 3, 1076, 43, 1, 706, 4147, 168, 66, 27, 48, 58, 27, 27, 179, 33, 72, 5, 135, 73, 5, 56, 279, 5748, 310, 120, 10, 41, 5, 35, 101, 43, 1, 706, 12096, 168, 49, 14, 48, 58, 14, 14, 562, 18, 72, 5, 56, 279, 22, 149, 22, 35, 101, 43, 1, 706, 163, 3636, 201, 27, 48, 58, 213, 33, 614, 67, 72, 5, 266, 151, 4, 121, 4113, 65, 415, 15, 179, 381, 397, 5, 415, 15, 79, 381, 11, 41, 5, 4147, 547, 415, 15, 179, 381, 397, 5, 415, 15, 167, 381, 11, 41, 5, 12096, 3, 43, 1, 1527, 2, 12, 10, 101, 107, 864, 62, 332, 73, 5, 5748, 310, 4, 46, 869, 319, 337, 617, 16, 1197, 22, 77, 6228, 6133, 4, 43, 10, 527, 871, 50, 243, 60, 1, 166, 126]",1542.0,19459201,Risk thyroid dysfunction subsequent thyroid survivors acute lymphoblastic leukemia report Childhood Survivor,0,0.0
Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).,BMC cancer,BMC Cancer,2009-07-29,"Gonadotropin releasing hormone (GNRH1) triggers the release of follicle stimulating hormone and luteinizing hormone from the pituitary. Genetic variants in the gene encoding GNRH1 or its receptor may influence breast cancer risk by modulating production of ovarian steroid hormones. We studied the association between breast cancer risk and polymorphisms in genes that code for GNRH1 and its receptor (GNRHR) in the large National Cancer Institute Breast and Prostate Cancer Cohort Consortium (NCI-BPC3). We sequenced exons of GNRH1 and GNRHR in 95 invasive breast cancer cases. Resulting single nucleotide polymorphisms (SNPs) were genotyped and used to identify haplotype-tagging SNPs (htSNPS) in a panel of 349 healthy women. The htSNPs were genotyped in 5,603 invasive breast cancer cases and 7,480 controls from the Cancer Prevention Study-II (CPS-II), European Prospective Investigation on Cancer and Nutrition (EPIC), Multiethnic Cohort (MEC), Nurses' Health Study (NHS), and Women's Health Study (WHS). Circulating levels of sex steroids (androstenedione, estradiol, estrone and testosterone) were also measured in 4713 study subjects. Breast cancer risk was not associated with any polymorphism or haplotype in the GNRH1 and GNRHR genes, nor were there any statistically significant interactions with known breast cancer risk factors. Polymorphisms in these two genes were not strongly associated with circulating hormone levels. Common variants of the GNRH1 and GNRHR genes are not associated with risk of invasive breast cancer in Caucasians.",Journal Article,3828.0,5.0,"Gonadotropin releasing hormone GNRH1 triggers release follicle stimulating hormone luteinizing hormone pituitary Genetic encoding GNRH1 receptor influence breast risk modulating production ovarian steroid hormones studied association breast risk polymorphisms code GNRH1 receptor GNRHR large National Institute Breast Prostate Cohort Consortium NCI-BPC3 sequenced exons GNRH1 GNRHR 95 invasive breast cases Resulting single nucleotide polymorphisms SNPs genotyped identify haplotype-tagging SNPs htSNPS panel 349 healthy women htSNPs genotyped 5,603 invasive breast cases 7,480 controls Prevention Study-II CPS-II European Prospective Investigation Nutrition EPIC Multiethnic Cohort MEC Nurses Health NHS Women 's Health WHS Circulating levels sex steroids androstenedione estradiol estrone testosterone measured 4713 subjects Breast risk associated polymorphism haplotype GNRH1 GNRHR statistically significant interactions known breast risk factors Polymorphisms strongly associated circulating hormone levels Common GNRH1 GNRHR associated risk invasive breast Caucasians",1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6501, 5586, 785, 28931, 5951, 3, 2008, 1, 9109, 2122, 785, 2, 8223, 785, 29, 3, 336, 839, 4, 3, 145, 2362, 28931, 15, 211, 153, 68, 1054, 12, 43, 20, 3712, 1529, 1, 3853, 4927, 21, 656, 3, 248, 59, 12, 43, 2, 1203, 4, 214, 17, 5853, 9, 28931, 2, 211, 153, 34729, 4, 3, 375, 657, 12, 1377, 2, 12, 180, 2404, 2580, 22552, 21, 4040, 3885, 1, 28931, 2, 34729, 4, 48, 416, 12, 140, 1113, 226, 1579, 1203, 1109, 11, 3053, 2, 95, 6, 255, 4179, 9389, 1109, 26682, 4, 8, 993, 1, 9043, 1331, 117, 3, 26682, 11, 3053, 4, 33, 9696, 416, 12, 140, 2, 67, 9108, 535, 29, 3, 12, 1070, 45, 215, 6987, 215, 1865, 482, 940, 23, 12, 2, 5260, 8995, 17756, 180, 7391, 2707, 341, 45, 8157, 2, 117, 292, 341, 45, 45630, 1033, 148, 1, 1035, 4580, 10310, 4507, 11009, 2, 2660, 11, 120, 644, 4, 37776, 45, 976, 12, 43, 10, 44, 41, 5, 500, 1907, 15, 4179, 4, 3, 28931, 2, 34729, 214, 2110, 11, 125, 500, 712, 93, 1286, 5, 440, 12, 43, 130, 1203, 4, 46, 100, 214, 11, 44, 1327, 41, 5, 1033, 785, 148, 186, 839, 1, 3, 28931, 2, 34729, 214, 32, 44, 41, 5, 43, 1, 416, 12, 4, 5396]",1431.0,19640273,Genetic polymorphisms GNRH1 GNRHR risk breast National Institute Breast Prostate Cohort Consortium BPC3,0,0.0
Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function.,Anti-cancer agents in medicinal chemistry,Anticancer Agents Med Chem,2009-12-01,"Prostate cancer is a major cause of cancer-related death in men. Prostate cancer is an androgen-responsive tumor and the treatment of advanced prostate cancer involves hormonal therapy. First-line treatment for advanced prostate cancer is androgen deprivation therapy (ADT), usually with agents that suppress gonadotropins through a pituitary mechanism. Gonadotropin-releasing hormone agonists and antagonists both suppress gonadal release of testosterone, although their activity profiles vary. ADT down-regulates androgen receptor (AR) transcriptional activity in the tumor but the response in metastatic disease is transient and tumors progress as castration-resistant prostate cancer (CRPC). Although serum testosterone concentrations decline dramatically with ADT, CRPC growth remains largely dependent on AR activity. Secondary hormonal therapies are then often employed to further dampen AR-driven transcription. These secondary hormonal therapies either further deplete adrenal or intratumoral androgen synthesis, or directly and competitively antagonize AR. New hormonal agents with both of these mechanisms are in clinical trials and show promising activity in patients with CRPC. Abiraterone acetate is an inhibitor of CYP17, which is an enzyme required for the synthesis of all androgens and estrogens. MDV3100 is an AR antagonist that has a higher affinity for AR than any other AR antagonist in clinic use. In phase I and phase II clinical trials, both agents have significant activity. These agents and the promise of the development of others provide hope that more effective hormonal therapies may soon be offered to patients, which will improve clinical outcomes.",Journal Article,3703.0,9.0,Prostate major cause cancer-related death men Prostate androgen-responsive treatment advanced prostate involves hormonal therapy First-line treatment advanced prostate androgen deprivation therapy ADT usually agents suppress gonadotropins pituitary mechanism Gonadotropin-releasing hormone agonists antagonists suppress gonadal release testosterone activity profiles vary ADT down-regulates androgen receptor AR transcriptional activity response metastatic disease transient progress castration-resistant prostate CRPC serum testosterone concentrations decline dramatically ADT CRPC growth remains largely dependent AR activity Secondary hormonal therapies employed dampen AR-driven transcription secondary hormonal therapies deplete adrenal intratumoral androgen synthesis directly competitively antagonize AR New hormonal agents mechanisms clinical trials promising activity patients CRPC Abiraterone acetate inhibitor CYP17 enzyme required synthesis androgens estrogens MDV3100 AR antagonist higher affinity AR AR antagonist clinic use phase phase II clinical trials agents significant activity agents promise development provide hope effective hormonal therapies soon offered patients improve clinical outcomes,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12, 16, 8, 458, 708, 1, 12, 139, 273, 4, 325, 12, 16, 35, 687, 2443, 30, 2, 3, 24, 1, 131, 12, 2921, 1761, 36, 157, 328, 24, 9, 131, 12, 16, 687, 1868, 36, 1360, 2082, 5, 183, 17, 3134, 34749, 298, 8, 670, 6501, 5586, 785, 4774, 2, 4444, 110, 3134, 7999, 2008, 1, 2660, 242, 136, 128, 1241, 2825, 1360, 1328, 2468, 687, 153, 754, 1431, 128, 4, 3, 30, 84, 3, 51, 4, 113, 34, 16, 2473, 2, 57, 1466, 22, 1517, 436, 12, 1752, 242, 524, 2660, 1003, 1858, 2729, 5, 1360, 1752, 129, 469, 1733, 470, 23, 754, 128, 568, 1761, 235, 32, 818, 629, 2516, 6, 195, 19142, 754, 1621, 866, 46, 568, 1761, 235, 361, 195, 9450, 2987, 15, 2074, 687, 2525, 15, 1606, 2, 15884, 12718, 754, 217, 1761, 183, 5, 110, 1, 46, 483, 32, 4, 38, 143, 2, 514, 721, 128, 4, 7, 5, 1752, 2260, 3424, 16, 35, 230, 1, 9997, 92, 16, 35, 1644, 616, 9, 3, 2525, 1, 62, 5488, 2, 6293, 11516, 16, 35, 754, 3137, 17, 71, 8, 142, 3601, 9, 754, 76, 500, 127, 754, 3137, 4, 1188, 119, 4, 124, 70, 2, 124, 215, 38, 143, 110, 183, 47, 93, 128, 46, 183, 2, 3, 1783, 1, 3, 193, 1, 1749, 377, 3045, 17, 80, 323, 1761, 235, 68, 6176, 40, 2216, 6, 7, 92, 303, 401, 38, 123]",1600.0,19719456,Hormonal therapy prostate unraveling androgen receptor function,0,0.0
Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-11-30,"This study was undertaken to determine the effect of treatment for childhood cancer on male fertility. We reviewed the fertility of male Childhood Cancer Survivor Study survivor and sibling cohorts who completed a questionnaire. We abstracted the chemotherapeutic agents administered, the cumulative dose of drug administered for selected drugs, and the doses and volumes of all radiation therapy from medical records. Risk factors for siring a pregnancy were evaluated using Cox proportional hazards models. The 6,224 survivors age 15 to 44 years who were not surgically sterile were less likely to sire a pregnancy than siblings (hazard ratio [HR], 0.56; 95% CI, -0.49 to 0.63). Among survivors, the HR of siring a pregnancy was decreased by radiation therapy of more than 7.5 Gy to the testes (HR, 0.12; 95% CI, -0.02 to 0.64), higher cumulative alkylating agent dose (AAD) score or treatment with cyclophosphamide (third tertile HR, 0.42; 95% CI, -0.31 to 0.57) or procarbazine (second tertile HR, 0.48; 95% CI, -0.26 to 0.87; third tertile HR, 0.17; 95% CI, -0.07 to 0.41). Compared with siblings, the HR for ever siring a pregnancy for survivors who had an AAD score = 0, a hypothalamic/pituitary radiation dose = 0 Gy, and a testes radiation dose = 0 Gy was 0.91 (95% CI, 0.73 to 1.14; P = .41). This large study identified risk factors for decreased fertility that may be used for counseling male cancer patients.",Journal Article,3704.0,185.0,"undertaken determine effect treatment childhood male fertility reviewed fertility male Childhood Survivor survivor sibling cohorts completed questionnaire abstracted chemotherapeutic agents administered cumulative dose drug administered selected drugs doses volumes radiation therapy medical records Risk factors siring pregnancy evaluated Cox proportional hazards models 6,224 survivors age 15 44 years surgically sterile likely sire pregnancy siblings hazard ratio HR 0.56 95 CI -0.49 0.63 survivors HR siring pregnancy decreased radiation therapy 7.5 Gy testes HR 0.12 95 CI -0.02 0.64 higher cumulative alkylating agent dose AAD score treatment cyclophosphamide tertile HR 0.42 95 CI -0.31 0.57 procarbazine second tertile HR 0.48 95 CI -0.26 0.87 tertile HR 0.17 95 CI -0.07 0.41 Compared siblings HR siring pregnancy survivors AAD score 0 hypothalamic/pituitary radiation dose 0 Gy testes radiation dose 0 Gy 0.91 95 CI 0.73 1.14 P .41 large identified risk factors decreased fertility counseling male patients",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[26, 45, 10, 2789, 6, 223, 3, 254, 1, 24, 9, 864, 12, 23, 1045, 2954, 21, 446, 3, 2954, 1, 1045, 864, 12, 2628, 45, 2628, 2, 3684, 736, 54, 781, 8, 1770, 21, 4106, 3, 1573, 183, 468, 3, 967, 61, 1, 234, 468, 9, 715, 600, 2, 3, 415, 2, 2225, 1, 62, 121, 36, 29, 484, 1064, 43, 130, 9, 25211, 8, 2290, 11, 194, 75, 418, 831, 1017, 274, 3, 49, 5908, 332, 89, 167, 6, 584, 60, 54, 11, 44, 2350, 14406, 11, 299, 322, 6, 58442, 8, 2290, 76, 2758, 360, 197, 168, 13, 664, 48, 58, 13, 739, 6, 13, 676, 107, 332, 3, 168, 1, 25211, 8, 2290, 10, 340, 20, 121, 36, 1, 80, 76, 67, 33, 381, 6, 3, 13100, 168, 13, 133, 48, 58, 13, 588, 6, 13, 660, 142, 967, 3410, 420, 61, 22535, 368, 15, 24, 5, 1112, 1282, 6442, 168, 13, 595, 48, 58, 13, 456, 6, 13, 696, 15, 8860, 419, 6442, 168, 13, 576, 48, 58, 13, 432, 6, 13, 912, 1282, 6442, 168, 13, 269, 48, 58, 13, 1615, 6, 13, 605, 72, 5, 2758, 3, 168, 9, 3353, 25211, 8, 2290, 9, 332, 54, 42, 35, 22535, 368, 13, 8, 7531, 12098, 121, 61, 13, 381, 2, 8, 13100, 121, 61, 13, 381, 10, 13, 970, 48, 58, 13, 803, 6, 14, 213, 19, 605, 26, 375, 45, 108, 43, 130, 9, 340, 2954, 17, 68, 40, 95, 9, 2011, 1045, 12, 7]",1360.0,19949008,Fertility male survivors childhood report Childhood Survivor,6,0.05660377358490566
Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.,"Hormones (Athens, Greece)",Hormones (Athens),,"The patient was a 70-year-old man with a recurrent pituitary tumor. Three surgeries were performed but the tumor recurred. Based on histologic, immunohistochemical and ultrastructural studies, the diagnosis of oncocytic gonadotrophic pituitary adenoma was made. The tumor was a macroadenoma partly immunopositive for LH. Immunohistochemistry for O6 Methylguanine-DNA Methyl-Transferase (MGMT) showed an admixture of immunopositive and immunonegative cells. After recurrence following operations, the patient was treated with Temozolomide, an imidazotetrazine derivative, DNA-alkylating drug. Following Temozolomide administration the MRI demonstrated significant tumor necrosis. A few months later, the patient died of massive pulmonary embolism. No autopsy was performed. The present case indicates that benign, typically slow-growing pituitary adenomas of oncocytic gonadotrophic type may respond to Temozolomide even when the tumor consists of an admixture of MGMT immunopositive and immunonegative cells.",Case Reports,,,patient 70-year-old man recurrent pituitary surgeries performed recurred Based histologic immunohistochemical ultrastructural studies diagnosis oncocytic gonadotrophic pituitary adenoma macroadenoma partly immunopositive LH Immunohistochemistry O6 Methylguanine-DNA Methyl-Transferase MGMT showed admixture immunopositive immunonegative recurrence following operations patient treated Temozolomide imidazotetrazine derivative DNA-alkylating drug Following Temozolomide administration MRI demonstrated significant necrosis months later patient died massive pulmonary embolism autopsy performed present case indicates benign typically slow-growing pituitary adenomas oncocytic gonadotrophic type respond Temozolomide consists admixture MGMT immunopositive immunonegative,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 69, 10, 8, 431, 111, 1095, 3628, 5, 8, 387, 30, 169, 5305, 11, 173, 84, 3, 30, 3363, 90, 23, 884, 1382, 2, 13755, 94, 3, 147, 1, 17287, 45822, 2434, 10, 1229, 3, 30, 10, 8, 27905, 5180, 28231, 9, 6531, 888, 9, 6505, 7015, 261, 5228, 4402, 2661, 224, 35, 16628, 1, 28231, 2, 28975, 37, 50, 146, 366, 3867, 3, 69, 10, 73, 5, 1537, 35, 58529, 4819, 261, 3410, 234, 366, 1537, 634, 3, 704, 264, 93, 30, 1523, 8, 1021, 53, 1559, 3, 69, 1016, 1, 7929, 1087, 5475, 77, 6270, 10, 173, 3, 364, 473, 2640, 17, 1002, 1969, 3645, 1921, 2751, 1, 17287, 45822, 267, 68, 1892, 6, 1537, 871, 198, 3, 30, 5132, 1, 35, 16628, 1, 2661, 28231, 2, 28975, 37]",959.0,20045804,Effect temozolomide patient recurring oncocytic gonadotrophic pituitary adenoma,10,0.09433962264150944
Common alleles of predisposition in endocrine neoplasia.,Current opinion in genetics & development,Curr. Opin. Genet. Dev.,2010-03-06,"The identification of germline high penetrance gain-of-function mutations in the RET proto-oncogene as causative of multiple endocrine neoplasia led to accurate molecular diagnosis, predictive testing and gene-informed preventative medicine. Many syndromic endocrine neoplasias fell under this clinically utile model, although not all endocrine neoplasias were accounted for by these high penetrance predisposition genes associated with the validated practice of clinical cancer genetics. The past decade has seen the identification of low penetrance alleles for various endocrine neoplasias, including medullary and epithelial thyroid carcinomas and isolated pituitary adenomas. Functional characterisation of these effects, which range from subtle expressional or micro-RNA regulation, and the analysis of the conferred risks, which are typically low and below the threshold for medical actionability, remain scientific challenges before these may be incorporated into routine clinical practice.",Journal Article,3608.0,6.0,identification germline high penetrance gain-of-function RET proto-oncogene causative multiple endocrine neoplasia led accurate molecular diagnosis predictive testing gene-informed preventative medicine syndromic endocrine neoplasias fell clinically utile model endocrine neoplasias accounted high penetrance predisposition associated validated practice clinical genetics past decade seen identification low penetrance alleles endocrine neoplasias including medullary epithelial thyroid carcinomas isolated pituitary adenomas Functional characterisation effects range subtle expressional micro-RNA regulation conferred risks typically low threshold medical actionability remain scientific challenges incorporated routine clinical practice,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[3, 911, 1, 1009, 64, 4792, 1803, 1, 343, 138, 4, 3, 2412, 4976, 1836, 22, 8088, 1, 232, 1293, 2298, 836, 6, 1481, 219, 147, 464, 471, 2, 145, 2767, 10435, 1807, 445, 14201, 1293, 8235, 7689, 669, 26, 505, 45916, 202, 242, 44, 62, 1293, 8235, 11, 3688, 9, 20, 46, 64, 4792, 2863, 214, 41, 5, 3, 938, 758, 1, 38, 12, 2894, 3, 1219, 2025, 71, 527, 3, 911, 1, 154, 4792, 2558, 9, 747, 1293, 8235, 141, 4564, 2, 701, 826, 2, 1355, 2751, 583, 18404, 1, 46, 176, 92, 184, 29, 7543, 14750, 15, 4659, 893, 863, 2, 3, 65, 1, 3, 3851, 1098, 92, 32, 1969, 154, 2, 2736, 3, 2390, 9, 484, 16531, 918, 3138, 1427, 348, 46, 68, 40, 2449, 237, 1311, 38, 758]",968.0,20211557,Common alleles predisposition endocrine neoplasia,1,0.009433962264150943
Complications and death among elderly patients undergoing pituitary tumour surgery.,Clinical endocrinology,Clin. Endocrinol. (Oxf),2010-04-23,"Preoperative determinants of surgical risk in elderly patients with pituitary tumour are not fully defined. The aim of this study was to quantify operative risk for these patients. We performed a retrospective analysis of the Nationwide Inpatient Sample (1998-2005), a database containing discharge information from a stratified, random sample of 20% of all non-federal hospitals in 37 states. Patients >65 years old who underwent pituitary tumour resection were identified by ICD-9 coding. Primary outcome was inpatient death. Other outcomes included post-operative complications, length of stay (LOS) and total charges. A total of 8400 patients (53.7% male) were identified. Mean age was 72.2. Mean co-morbidity score was 5.3. A majority were white (82.0%) admitted to academic hospitals (69.5%) for elective procedures (55.7%). Inpatient mortality was 3.8%. The most common complication was fluid and electrolyte abnormalities (14.3%). Mean LOS was 8.5 days. In multivariate analysis, patients >80 years old had 30% greater odds of death, relative to 65-69 year old counterparts. Each complication increased LOS by an average of at least 4 days. These associations were statistically significant (P-values <0.05). New clinically relevant risk stratification information is now available to assist clinicians in operative decision-making for elderly patients with pituitary tumour considering operative intervention.",Journal Article,3560.0,24.0,Preoperative determinants surgical risk elderly patients pituitary tumour fully defined aim quantify operative risk patients performed retrospective Nationwide Inpatient 1998-2005 database containing discharge information stratified random 20 non-federal hospitals 37 states Patients 65 years old underwent pituitary tumour resection identified ICD-9 coding Primary outcome inpatient death outcomes included post-operative complications length stay LOS total charges total 8400 patients 53.7 male identified Mean age 72.2 Mean co-morbidity score 5.3 majority white 82.0 admitted academic hospitals 69.5 elective procedures 55.7 Inpatient mortality 3.8 common complication fluid electrolyte abnormalities 14.3 Mean LOS 8.5 days multivariate patients 80 years old 30 greater odds death relative 65-69 year old counterparts complication increased LOS average 4 days associations statistically significant P-values 0.05 New clinically relevant risk stratification information available assist clinicians operative decision-making elderly patients pituitary tumour considering operative intervention,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[498, 3403, 1, 221, 43, 4, 1216, 7, 5, 770, 32, 44, 1910, 395, 3, 1130, 1, 26, 45, 10, 6, 3091, 1208, 43, 9, 46, 7, 21, 173, 8, 459, 65, 1, 3, 5405, 2420, 1000, 1850, 1242, 8, 609, 1101, 2993, 487, 29, 8, 1173, 2324, 1000, 1, 179, 1, 62, 220, 8536, 1987, 4, 567, 907, 7, 556, 60, 1095, 54, 208, 770, 170, 11, 108, 20, 7320, 83, 3097, 86, 228, 10, 2420, 273, 127, 123, 159, 539, 1208, 521, 1318, 1, 2020, 3649, 2, 181, 7542, 8, 181, 1, 33415, 7, 699, 67, 1045, 11, 108, 313, 89, 10, 720, 18, 313, 1269, 787, 368, 10, 33, 27, 8, 686, 11, 886, 878, 13, 4319, 6, 1916, 1987, 790, 33, 9, 4700, 1369, 614, 67, 2420, 282, 10, 27, 66, 3, 96, 186, 1447, 10, 2357, 2, 10834, 1171, 213, 27, 313, 3649, 10, 66, 33, 162, 4, 331, 65, 7, 493, 60, 1095, 42, 201, 378, 610, 1, 273, 580, 6, 556, 790, 111, 1095, 3953, 296, 1447, 101, 3649, 20, 35, 1011, 1, 28, 506, 39, 162, 46, 685, 11, 712, 93, 19, 1030, 13, 474, 217, 505, 867, 43, 1541, 487, 16, 1134, 390, 6, 3425, 1490, 4, 1208, 948, 1079, 9, 1216, 7, 5, 770, 3075, 1208, 788]",1339.0,20455889,Complications death elderly patients undergoing pituitary tumour surgery,3,0.02830188679245283
Overall and progression-free survival and visual and endocrine outcomes for patients with parasellar lesions treated with intensity-modulated stereotactic radiosurgery.,Journal of neuro-oncology,J. Neurooncol.,2010-05-12,"Linear accelerator single-fraction radiosurgery (SRS) for skull base lesions is usually delivered with dynamic conformal arcs (DCAs), but intensity-modulated radiosurgery (IMRS) is another option when SRS dose is limited by proximity of the optic nerve and chiasm. We review the long-term outcome of patients treated with IMRS for parasellar lesions. Fourteen patients with parasellar lesions were treated with IMRS when standard DCA radiosurgery was limited by optic nerve tolerance. Prospective patient data included endocrine function, visual acuity and field testing, nonoptic nerve cranial neuropathy, and overall survival. In addition, tumor control on serial magnetic resonance imaging is reported as progression-free survival (PFS). Six patients with cavernous sinus meningiomas and eight with recurrent pituitary adenomas were treated. Three of the pituitary tumors were hormonally active (two with Cushing disease, one with acromegaly). The median patient age was 50 years (range 24-70 years). Median follow-up was 54 months. Average tumor treatment volume was 4.99 ml (average dose 16 Gy, average of 10 IMRS fields). Tumor control was achieved in 11 of 14 (79%) patients. Median PFS has not been reached in our patient population. Thirteen patients are alive (one died of an unrelated cancer). No patients developed new endocrinological, ophthalmological, or cranial nerve deficits. IMRS allows for treatment of parasellar lesions when standard DCA SRS is limited by optic nerve tolerance. Although our follow-up period was relatively short and the number of patients was small, it appears that this can be accomplished with a high tumor control rate and survival without new endocrinopathies, optic neuropathies, or other complications in patients who have failed other therapies.",Journal Article,3541.0,5.0,Linear accelerator single-fraction radiosurgery SRS skull base lesions usually delivered dynamic conformal arcs DCAs intensity-modulated radiosurgery IMRS option SRS dose limited proximity optic nerve chiasm review long-term outcome patients treated IMRS parasellar lesions Fourteen patients parasellar lesions treated IMRS standard DCA radiosurgery limited optic nerve tolerance Prospective patient included endocrine function visual acuity field testing nonoptic nerve cranial neuropathy overall survival addition control serial magnetic resonance imaging reported progression-free survival PFS patients cavernous sinus meningiomas recurrent pituitary adenomas treated pituitary hormonally active Cushing disease acromegaly median patient age 50 years range 24-70 years Median follow-up 54 months Average treatment volume 4.99 ml average dose 16 Gy average 10 IMRS fields control achieved 11 14 79 patients Median PFS reached patient population Thirteen patients alive died unrelated patients developed new endocrinological ophthalmological cranial nerve deficits IMRS allows treatment parasellar lesions standard DCA SRS limited optic nerve tolerance follow-up period relatively short number patients small appears accomplished high control rate survival new endocrinopathies optic neuropathies complications patients failed therapies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1646, 10290, 226, 1509, 2192, 1429, 9, 5054, 1782, 406, 16, 2082, 1623, 5, 2540, 2972, 18507, 58942, 84, 837, 1757, 2192, 13169, 16, 1809, 1501, 198, 1429, 61, 16, 383, 20, 6167, 1, 3, 5670, 2476, 2, 14583, 21, 206, 3, 319, 337, 228, 1, 7, 73, 5, 13169, 9, 18260, 406, 3225, 7, 5, 18260, 406, 11, 73, 5, 13169, 198, 260, 11046, 2192, 10, 383, 20, 5670, 2476, 2614, 482, 69, 74, 159, 1293, 343, 3046, 11171, 2, 1067, 471, 46031, 2476, 2565, 1751, 2, 63, 25, 4, 352, 30, 182, 23, 2108, 1484, 1535, 270, 16, 210, 22, 91, 115, 25, 300, 437, 7, 5, 12170, 5810, 3718, 2, 659, 5, 387, 2751, 11, 73, 169, 1, 3, 57, 11, 10710, 544, 100, 5, 16258, 34, 104, 5, 28682, 3, 52, 69, 89, 10, 212, 60, 184, 259, 431, 60, 52, 166, 126, 10, 667, 53, 1011, 30, 24, 433, 10, 39, 1058, 542, 1011, 61, 245, 381, 1011, 1, 79, 13169, 3130, 30, 182, 10, 513, 4, 175, 1, 213, 842, 7, 52, 300, 71, 44, 85, 1300, 4, 114, 69, 266, 3170, 7, 32, 1701, 104, 1016, 1, 35, 2092, 12, 77, 7, 276, 217, 28148, 39322, 15, 2565, 2476, 2752, 13169, 2333, 9, 24, 1, 18260, 406, 198, 260, 11046, 1429, 16, 383, 20, 5670, 2476, 2614, 242, 114, 166, 126, 727, 10, 1352, 978, 2, 3, 207, 1, 7, 10, 302, 192, 1233, 17, 26, 122, 40, 5741, 5, 8, 64, 30, 182, 116, 2, 25, 187, 217, 12081, 5670, 12987, 15, 127, 521, 4, 7, 54, 47, 1551, 127, 235]",1725.0,20461446,Overall progression-free survival visual endocrine outcomes patients parasellar lesions treated intensity-modulated stereotactic radiosurgery,0,0.0
Factors associated with endocrine deficits after stereotactic radiosurgery of pituitary adenomas.,Neurosurgery,Neurosurgery,2010-07-01,"To analyze the factors associated with anterior pituitary deficits after pituitary adenoma stereotactic radiosurgery (SRS). The tumor, pituitary stalk, and pituitary gland were segmented on the dose plans of 82 patients (secreting tumors, n = 53; nonsecreting tumors, n=29) for dose-volume analysis. No patient had undergone prior radiation therapy and all patients had at least 12 months of endocrinological follow-up (median, 63 months; mean, 69 months; range, 13-134). Thirty-four patients (41%) developed new anterior pituitary deficits at a median of 32 months (range, 2-118) after SRS. The risk of developing new anterior pituitary deficits was 16% and 45% at 2 and 5 years, respectively. Multivariate analysis of the entire group showed that poor visualization of the pituitary gland (hazard ratio [HR]=2.63, 95% confidence interval [CI]=1.10-6.25, P=.03) was associated with a higher rate of new anterior pituitary deficits. Dosimetric analysis of 60 patients whose pituitary gland could be clearly identified showed that increasing mean pituitary gland radiation dose correlated with new anterior pituitary deficits (HR=1.11, 95% CI=1.02-1.20, P=.02). New anterior pituitary deficits stratified by mean pituitary gland radiation dose: <or=7.5 Gy, 0% (0/7); 7.6 to 13.2 Gy, 29% (7/24); 13.3 to 19.1 Gy, 39% (9/23); >19.1 Gy, 83% (5/6). New endocrine deficits after pituitary adenoma radiosurgery were correlated with increasing radiation dose to the pituitary gland. Methods that limit the radiation dose to the pituitary gland during SRS may increase the probability of preserving pituitary function.",Journal Article,3491.0,38.0,factors associated anterior pituitary deficits pituitary adenoma stereotactic radiosurgery SRS pituitary stalk pituitary gland segmented dose plans 82 patients secreting n 53 nonsecreting n=29 dose-volume patient undergone prior radiation therapy patients 12 months endocrinological follow-up median 63 months mean 69 months range 13-134 Thirty-four patients 41 developed new anterior pituitary deficits median 32 months range 2-118 SRS risk developing new anterior pituitary deficits 16 45 2 5 years respectively Multivariate entire group showed poor visualization pituitary gland hazard ratio HR =2.63 95 confidence interval CI =1.10-6.25 P=.03 associated higher rate new anterior pituitary deficits Dosimetric 60 patients pituitary gland clearly identified showed increasing mean pituitary gland radiation dose correlated new anterior pituitary deficits HR=1.11 95 CI=1.02-1.20 P=.02 New anterior pituitary deficits stratified mean pituitary gland radiation dose or=7.5 Gy 0 0/7 7.6 13.2 Gy 29 7/24 13.3 19.1 Gy 39 9/23 19.1 Gy 83 5/6 New endocrine deficits pituitary adenoma radiosurgery correlated increasing radiation dose pituitary gland Methods limit radiation dose pituitary gland SRS increase probability preserving pituitary function,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1992, 3, 130, 41, 5, 2882, 2752, 50, 2434, 1729, 2192, 1429, 3, 30, 23392, 2, 2326, 11, 9199, 23, 3, 61, 1853, 1, 878, 7, 5052, 57, 78, 699, 46089, 57, 78, 462, 9, 61, 433, 65, 77, 69, 42, 1989, 324, 121, 36, 2, 62, 7, 42, 28, 506, 133, 53, 1, 28148, 166, 126, 52, 676, 53, 313, 790, 53, 184, 233, 4842, 977, 294, 7, 605, 276, 217, 2882, 2752, 28, 8, 52, 1, 531, 53, 184, 18, 4002, 50, 1429, 3, 43, 1, 931, 217, 2882, 2752, 10, 245, 2, 512, 28, 18, 2, 33, 60, 106, 331, 65, 1, 3, 1797, 87, 224, 17, 334, 6234, 1, 3, 2326, 360, 197, 168, 18, 676, 48, 307, 268, 58, 14, 79, 49, 243, 19, 680, 10, 41, 5, 8, 142, 116, 1, 217, 2882, 2752, 3187, 65, 1, 335, 7, 1310, 2326, 359, 40, 2536, 108, 224, 17, 602, 313, 2326, 121, 61, 438, 5, 217, 2882, 2752, 168, 14, 175, 48, 58, 14, 588, 14, 179, 19, 588, 217, 2882, 2752, 1173, 20, 313, 2326, 121, 61, 15, 67, 33, 381, 13, 13, 67, 67, 49, 6, 233, 18, 381, 462, 67, 259, 233, 27, 6, 326, 14, 381, 587, 83, 382, 326, 14, 381, 852, 33, 49, 217, 1293, 2752, 50, 2434, 2192, 11, 438, 5, 602, 121, 61, 6, 3, 2326, 636, 17, 2385, 3, 121, 61, 6, 3, 2326, 190, 1429, 68, 344, 3, 1320, 1, 4972, 343]",1368.0,20559089,Factors associated endocrine deficits stereotactic radiosurgery pituitary adenomas,2,0.018867924528301886
Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study.,"Lancet (London, England)",Lancet,2010-07-23,"The reproductive implications of mutagenic treatments given to children with cancer are not clear. By studying the risk of untoward pregnancy outcomes, we indirectly assessed the risk of transmission of germline damage to the offspring of survivors of childhood cancer who were given radiotherapy and chemotherapy. We did a retrospective cohort analysis, within the Childhood Cancer Survivor Study (CCSS), of the risk of stillbirth and neonatal death among the offspring of men and women who had survived childhood cancer. Patients in CCSS were younger than 21 years at initial diagnosis of an eligible cancer, were treated at 25 US institutions and one Canadian institution, and had survived for at least 5 years after diagnosis. We quantified the chemotherapy given to patients, and the preconception radiation doses to the testes, ovaries, uterus, and pituitary gland, and related these to the risk of stillbirth or neonatal death using Poisson regression analysis. Among 1148 men and 1657 women who had survived childhood cancer, there were 4946 pregnancies. Irradiation of the testes (16 [1%] of 1270; adjusted relative risk 0.8 [95% CI 0.4-1.6]; mean dose 0.53 Gy [SD 1.40]) and pituitary gland (17 [3%] of 510, 1.1 [0.5-2.4] for more than 20.00 Gy; mean dose 10.20 Gy [13.0] for women), and chemotherapy with alkylating drugs (26 [2%] of 1195 women, 0.9 [0.5-1.5]; ten [1%] of 732 men, 1.2 [0.5-2.5]) were not associated with an increased risk of stillbirth or neonatal death. Uterine and ovarian irradiation significantly increased risk of stillbirth and neonatal death at doses greater than 10.00 Gy (five [18%] of 28, 9.1 [3.4-24.6]). For girls treated before menarche, irradiation of the uterus and ovaries at doses as low as 1.00-2.49 Gy significantly increased the risk of stillbirth or neonatal death (three [4%] of 69, 4.7 [1.2-19.0]). Our findings do not support concern about heritable genetic changes affecting the risk of stillbirth and neonatal death in the offspring of men exposed to gonadal irradiation. However, uterine and ovarian irradiation had serious adverse effects on the offspring that were probably related to uterine damage. Careful management is warranted of pregnancies in women given high doses of pelvic irradiation before puberty. Westlakes Research Institute, National Cancer Institute, and Children's Cancer Research Fund.",Journal Article,3469.0,84.0,reproductive implications mutagenic treatments given children clear studying risk untoward pregnancy outcomes indirectly assessed risk transmission germline damage offspring survivors childhood given radiotherapy chemotherapy retrospective cohort Childhood Survivor CCSS risk stillbirth neonatal death offspring men women survived childhood Patients CCSS younger 21 years initial diagnosis eligible treated 25 institutions Canadian institution survived 5 years diagnosis quantified chemotherapy given patients preconception radiation doses testes ovaries uterus pituitary gland related risk stillbirth neonatal death Poisson regression 1148 men 1657 women survived childhood 4946 pregnancies Irradiation testes 16 1 1270 adjusted relative risk 0.8 95 CI 0.4-1.6 mean dose 0.53 Gy SD 1.40 pituitary gland 17 3 510 1.1 0.5-2.4 20.00 Gy mean dose 10.20 Gy 13.0 women chemotherapy alkylating drugs 26 2 1195 women 0.9 0.5-1.5 1 732 men 1.2 0.5-2.5 associated increased risk stillbirth neonatal death Uterine ovarian irradiation significantly increased risk stillbirth neonatal death doses greater 10.00 Gy 18 28 9.1 3.4-24.6 girls treated menarche irradiation uterus ovaries doses low 1.00-2.49 Gy significantly increased risk stillbirth neonatal death 4 69 4.7 1.2-19.0 findings support concern heritable genetic changes affecting risk stillbirth neonatal death offspring men exposed gonadal irradiation uterine ovarian irradiation adverse effects offspring probably related uterine damage Careful management warranted pregnancies women given high doses pelvic irradiation puberty Westlakes Research Institute National Institute Children 's Research Fund,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[3, 3705, 1268, 1, 14578, 640, 447, 6, 541, 5, 12, 32, 44, 885, 20, 4559, 3, 43, 1, 15514, 2290, 123, 21, 7792, 275, 3, 43, 1, 8151, 1, 1009, 1350, 6, 3, 8304, 1, 332, 1, 864, 12, 54, 11, 447, 310, 2, 56, 21, 205, 8, 459, 180, 65, 262, 3, 864, 12, 2628, 45, 4657, 1, 3, 43, 1, 23370, 2, 14832, 273, 107, 3, 8304, 1, 325, 2, 117, 54, 42, 2996, 864, 12, 7, 4, 4657, 11, 773, 76, 239, 60, 28, 388, 147, 1, 35, 625, 12, 11, 73, 28, 243, 843, 1764, 2, 104, 7170, 731, 2, 42, 2996, 9, 28, 506, 33, 60, 50, 147, 21, 2790, 3, 56, 447, 6, 7, 2, 3, 25985, 121, 415, 6, 3, 13100, 7262, 2, 2326, 2, 139, 46, 6, 3, 43, 1, 23370, 15, 14832, 273, 75, 7668, 320, 65, 107, 26727, 325, 2, 34488, 117, 54, 42, 2996, 864, 12, 125, 11, 39384, 8746, 1104, 1, 3, 13100, 245, 14, 1, 37700, 586, 580, 43, 13, 66, 48, 58, 13, 39, 14, 49, 313, 61, 13, 699, 381, 1270, 14, 327, 2, 2326, 269, 27, 1, 10211, 14, 14, 13, 33, 18, 39, 9, 80, 76, 179, 2038, 381, 313, 61, 79, 179, 381, 233, 13, 9, 117, 2, 56, 5, 3410, 600, 432, 18, 1, 19146, 117, 13, 83, 13, 33, 14, 33, 1618, 14, 1, 10987, 325, 14, 18, 13, 33, 18, 33, 11, 44, 41, 5, 35, 101, 43, 1, 23370, 15, 14832, 273, 2, 1104, 97, 101, 43, 1, 23370, 2, 14832, 273, 28, 415, 378, 76, 79, 2038, 381, 365, 203, 1, 339, 83, 14, 27, 39, 259, 49, 9, 5989, 73, 348, 6414, 1104, 1, 3, 2, 7262, 28, 415, 22, 154, 22, 14, 2038, 18, 739, 381, 97, 101, 3, 43, 1, 23370, 15, 14832, 273, 169, 39, 1, 790, 39, 67, 14, 18, 326, 13, 114, 272, 1022, 44, 538, 2893, 545, 6874, 336, 400, 2319, 3, 43, 1, 23370, 2, 14832, 273, 4, 3, 8304, 1, 325, 2234, 6, 7999, 1104, 137, 2, 1104, 42, 1762, 290, 176, 23, 3, 8304, 17, 11, 4061, 139, 6, 1350, 3465, 284, 16, 1197, 1, 8746, 4, 117, 447, 64, 415, 1, 1110, 1104, 348, 10302, 59185, 389, 1377, 657, 12, 1377, 2, 541, 292, 12, 389, 11859]",2205.0,20655585,Stillbirth neonatal death relation radiation exposure conception retrospective cohort,0,0.0
Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression.,The Journal of clinical endocrinology and metabolism,J. Clin. Endocrinol. Metab.,2010-07-28,"The typically indolent behavior of pituitary tumors is juxtaposed with high rates of tumor cell invasion into adjacent dural structures, and occasional aggressive behavior. Although clinically significant invasion and malignant transformation remain uncommon, there are limited treatment options available for the management of these aggressive tumors. Recently, case reports have described efficacy of temozolomide for the treatment of aggressive pituitary tumors. Seven patients with aggressive pituitary tumors have been treated with temozolomide. We compared O(6)-methylguanine methyltransferase (MGMT) promoter methylation and MGMT expression in 14 surgical specimens from these seven patients and correlated these molecular features with the clinical response to temozolomide. Significant tumor regression was seen in two patients (29%), a 20% reduction in tumor volume with subsequent stable tumor size was noted in one patient, arrest of tumor growth occurred in three patients, and progressive metastatic disease developed during treatment in one patient. The DNA promoter site for MGMT was unmethylated in all 14 adequate specimens, and variable MGMT expression was seen in all 14 cases. There was no correlation between MGMT expression and clinical outcomes. We conclude that medical therapy with temozolomide can be helpful in the management of life-threatening pituitary tumors that have failed to respond to conventional treatments. The optimal duration of treatment in patients with stabilization or reduction of tumor size has not been established, and long-term follow up studies are needed.",Journal Article,3464.0,,typically indolent behavior pituitary juxtaposed high rates invasion adjacent dural structures occasional aggressive behavior clinically significant invasion malignant transformation remain uncommon limited treatment options available management aggressive Recently case reports described efficacy temozolomide treatment aggressive pituitary Seven patients aggressive pituitary treated temozolomide compared 6 -methylguanine methyltransferase MGMT promoter methylation MGMT expression 14 surgical specimens seven patients correlated molecular features clinical response temozolomide Significant regression seen patients 29 20 reduction volume subsequent stable size noted patient arrest growth occurred patients progressive metastatic disease developed treatment patient DNA promoter site MGMT unmethylated 14 adequate specimens variable MGMT expression seen 14 cases correlation MGMT expression clinical outcomes conclude medical therapy temozolomide helpful management life-threatening pituitary failed respond conventional treatments optimal duration treatment patients stabilization reduction size established long-term follow studies needed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1969, 2316, 1710, 1, 57, 16, 25995, 5, 64, 151, 1, 30, 31, 578, 237, 2086, 11124, 2414, 2, 9753, 571, 1710, 242, 505, 93, 578, 2, 393, 1392, 918, 2052, 125, 32, 383, 24, 838, 390, 9, 3, 284, 1, 46, 571, 57, 761, 473, 1198, 47, 1027, 209, 1, 1537, 9, 3, 24, 1, 571, 57, 648, 7, 5, 571, 57, 47, 85, 73, 5, 1537, 21, 72, 1990, 49, 7015, 3747, 2661, 973, 569, 2, 2661, 55, 4, 213, 221, 623, 29, 46, 648, 7, 2, 438, 46, 219, 404, 5, 3, 38, 51, 6, 1537, 93, 30, 320, 10, 527, 4, 100, 7, 462, 8, 179, 628, 4, 30, 433, 5, 706, 585, 30, 444, 10, 1051, 4, 104, 69, 1854, 1, 30, 129, 489, 4, 169, 7, 2, 1014, 113, 34, 276, 190, 24, 4, 104, 69, 3, 261, 973, 606, 9, 2661, 10, 8100, 4, 62, 213, 1658, 623, 2, 1347, 2661, 55, 10, 527, 4, 62, 213, 140, 125, 10, 77, 816, 59, 2661, 55, 2, 38, 123, 21, 2060, 17, 484, 36, 5, 1537, 122, 40, 3951, 4, 3, 284, 1, 358, 3691, 57, 17, 47, 1551, 6, 1892, 6, 809, 640, 3, 665, 654, 1, 24, 4, 7, 5, 3184, 15, 628, 1, 30, 444, 71, 44, 85, 635, 2, 319, 337, 166, 126, 94, 32, 575]",1544.0,20668043,Temozolomide treatment aggressive pituitary correlation clinical outcome 6 -methylguanine methyltransferase MGMT promoter methylation expression,1,0.009433962264150943
Reproductive outcomes for survivors of childhood cancer.,Obstetrics and gynecology,Obstet Gynecol,2010-11-01,"Because of remarkable progress in therapy, long-term survival is expected for 80% of children and adolescents diagnosed with cancer. Infertility remains one of the most common and life-altering complications experienced by adults treated for cancer during childhood. Surgery, radiation, or chemotherapy that negatively affects any component of the hypothalamic-pituitary-gonadal axis may compromise reproductive outcomes in childhood cancer survivors. The risk of infertility is generally related to the tissues or organs involved in cancer and the specific type, dose, and combination of cytotoxic therapy. In addition to anticancer therapy, age at treatment, sex, and likely genetic factors influence the risk of permanent infertility. When possible, contemporary protocols limit cumulative doses of cytotoxic therapy in an effort to optimize reproductive potential. If sterilizing therapy is required for cancer control, then fertility preservation measures should be explored before initiation of therapy. For childhood cancer survivors who maintain fertility, health risks to offspring resulting from their cancer treatment are major concerns. Radiation affecting ovarian and uterine function has been linked to pregnancy complications, including spontaneous abortion, preterm labor, fetal malposition, and low birth weight. The risk of congenital malformations, genetic disorders, and cancer appears to be low, with the exception of cancer risk in offspring born to survivors with germline cancer-predisposing mutations. This review summarizes research about cancer treatment factors affecting fertility and pregnancy outcomes of childhood cancer survivors. The data presented should facilitate the delivery of preventive counseling and age- and sex-appropriate interventions to optimize reproductive outcomes in childhood cancer survivors.",Journal Article,3368.0,80.0,remarkable progress therapy long-term survival expected 80 children adolescents diagnosed Infertility remains common life-altering complications experienced adults treated childhood Surgery radiation chemotherapy negatively affects component hypothalamic-pituitary-gonadal axis compromise reproductive outcomes childhood survivors risk infertility generally related tissues organs involved specific type dose combination cytotoxic therapy addition anticancer therapy age treatment sex likely genetic factors influence risk permanent infertility possible contemporary protocols limit cumulative doses cytotoxic therapy effort optimize reproductive potential sterilizing therapy required control fertility preservation measures explored initiation therapy childhood survivors maintain fertility health risks offspring resulting treatment major concerns Radiation affecting ovarian uterine function linked pregnancy complications including spontaneous abortion preterm labor fetal malposition low birth weight risk congenital malformations genetic disorders appears low exception risk offspring born survivors germline cancer-predisposing review summarizes research treatment factors affecting fertility pregnancy outcomes childhood survivors presented facilitate delivery preventive counseling age- sex-appropriate interventions optimize reproductive outcomes childhood survivors,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,"[408, 1, 3813, 1466, 4, 36, 319, 337, 25, 16, 1336, 9, 493, 1, 541, 2, 3101, 265, 5, 12, 5901, 469, 104, 1, 3, 96, 186, 2, 358, 4831, 521, 592, 20, 857, 73, 9, 12, 190, 864, 152, 121, 15, 56, 17, 2723, 2561, 500, 1249, 1, 3, 7531, 12098, 7999, 2310, 68, 4665, 3705, 123, 4, 864, 12, 332, 3, 43, 1, 5901, 16, 1228, 139, 6, 3, 742, 15, 2285, 646, 4, 12, 2, 3, 112, 267, 61, 2, 150, 1, 759, 36, 4, 352, 6, 1475, 36, 89, 28, 24, 1035, 2, 322, 336, 130, 1054, 3, 43, 1, 4377, 5901, 198, 899, 2667, 2189, 2385, 967, 415, 1, 759, 36, 4, 35, 2919, 6, 2465, 3705, 174, 492, 59465, 36, 16, 616, 9, 12, 182, 818, 2954, 2224, 1018, 257, 40, 1443, 348, 1118, 1, 36, 9, 864, 12, 332, 54, 3040, 2954, 341, 1098, 6, 8304, 1113, 29, 136, 12, 24, 32, 458, 2061, 121, 2319, 2, 343, 71, 85, 1199, 6, 2290, 521, 141, 3280, 21938, 20525, 9557, 6698, 30250, 2, 154, 3809, 924, 3, 43, 1, 6711, 11756, 336, 1997, 2, 12, 1233, 6, 40, 154, 5, 3, 4188, 1, 12, 43, 4, 8304, 8234, 6, 332, 5, 1009, 12, 6885, 138, 26, 206, 2869, 389, 545, 12, 24, 130, 2319, 2954, 2, 2290, 123, 1, 864, 12, 332, 3, 74, 917, 257, 1876, 3, 989, 1, 3494, 2011, 2, 89, 2, 1035, 870, 1151, 6, 2465, 3705, 123, 4, 864, 12, 332]",1799.0,20966703,Reproductive outcomes survivors childhood,6,0.05660377358490566
Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins.,Molecular carcinogenesis,Mol. Carcinog.,2011-01-25,"Methyl 2-cyano-3,11-dioxo-18-olean-1,12-dien-30-oate (CDODA-Me) and the corresponding 2-trifluoromethyl analog (CF(3)DODA-Me) are derived synthetically from the triterpenoid glycyrrhetinic acid, a major component of licorice. CDODA-Me and CF(3)DODA-Me inhibited growth of highly invasive ARO, DRO, K-18, and HTh-74 thyroid cancer cells and this was due, in part, to decreased expression of specificity protein (Sp) transcription factors Sp1, Sp3, and Sp4 that are overexpressed in these cells. CDODA-Me and CF(3)DODA-Me also decreased expression of Sp-dependent genes, such as survivin and vascular endothelial growth factor (VEGF), and induced apoptosis. In addition, pituitary tumor-transforming gene-1 (PTTG-1) protein and mRNA levels were also decreased in thyroid cancer cells treated with CDODA-Me or CF(3)DODA-Me and this was accompanied by decreased expression of PTTG-1-dependent c-Myc and fibroblast growth factor-2 (FGF-2) genes. RNA interference studies against Sp1, Sp3, and Sp4 proteins showed that in thyroid cancer cells, PTTG-1 was an Sp-dependent gene. This study demonstrates for the first time that drugs, such as CDODA-Me and CF(3)DODA-Me, that decrease Sp protein expression also downregulate PTTG-1 in thyroid cancer cells and therefore have potential for clinical treatment of thyroid cancer and other endocrine neoplasias where PTTG-1 is a major pro-oncogenic factor.",Journal Article,3283.0,29.0,"Methyl 2-cyano-3,11-dioxo-18-olean-1,12-dien-30-oate CDODA-Me corresponding 2-trifluoromethyl analog CF 3 DODA-Me derived synthetically triterpenoid glycyrrhetinic acid major component licorice CDODA-Me CF 3 DODA-Me inhibited growth highly invasive ARO DRO K-18 HTh-74 thyroid decreased expression specificity Sp transcription factors Sp1 Sp3 Sp4 overexpressed CDODA-Me CF 3 DODA-Me decreased expression Sp-dependent survivin vascular endothelial growth factor VEGF induced apoptosis addition pituitary tumor-transforming gene-1 PTTG-1 mRNA levels decreased thyroid treated CDODA-Me CF 3 DODA-Me accompanied decreased expression PTTG-1-dependent c-Myc fibroblast growth factor-2 FGF-2 RNA interference studies Sp1 Sp3 Sp4 showed thyroid PTTG-1 Sp-dependent demonstrates time drugs CDODA-Me CF 3 DODA-Me decrease Sp expression downregulate PTTG-1 thyroid potential clinical treatment thyroid endocrine neoplasias PTTG-1 major pro-oncogenic factor",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[5228, 18, 11777, 27, 175, 39533, 59758, 46425, 14, 133, 13030, 201, 33338, 17477, 4816, 2, 3, 1734, 18, 34019, 3497, 5729, 27, 27022, 4816, 32, 526, 24475, 29, 3, 15818, 59759, 971, 8, 458, 1249, 1, 59760, 17477, 4816, 2, 5729, 27, 27022, 4816, 879, 129, 1, 561, 416, 19613, 28365, 1634, 203, 2, 59761, 794, 12, 37, 2, 26, 10, 520, 4, 760, 6, 340, 55, 1, 1121, 178, 4074, 866, 130, 5557, 13919, 2, 19072, 17, 32, 1711, 4, 46, 37, 17477, 4816, 2, 5729, 27, 27022, 4816, 120, 340, 55, 1, 4074, 470, 214, 225, 22, 3160, 2, 756, 845, 129, 161, 618, 2, 277, 351, 4, 352, 30, 3621, 145, 14, 31737, 14, 178, 2, 956, 148, 11, 120, 340, 4, 12, 37, 73, 5, 17477, 4816, 15, 5729, 27, 27022, 4816, 2, 26, 10, 2756, 20, 340, 55, 1, 31737, 14, 470, 256, 1371, 2, 3758, 129, 161, 18, 6517, 18, 214, 893, 3182, 94, 480, 5557, 13919, 2, 19072, 652, 224, 17, 4, 12, 37, 31737, 14, 10, 35, 4074, 470, 145, 26, 45, 1902, 9, 3, 157, 98, 17, 600, 225, 22, 17477, 4816, 2, 5729, 27, 27022, 4816, 17, 775, 4074, 178, 55, 120, 10261, 31737, 14, 4, 12, 37, 2, 673, 47, 174, 9, 38, 24, 1, 12, 2, 127, 1293, 8235, 1257, 31737, 14, 16, 8, 458, 1805, 1302, 161]",1309.0,21268135,Inhibition pituitary tumor-transforming gene-1 thyroid drugs decrease specificity,105,0.9905660377358491
Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas.,World neurosurgery,World Neurosurg,2010-07-01,"To evaluate the efficacy of stereotactic radiosurgery (SRS) for patients with prolactin (PRL)-secreting pituitary adenomas that were refractory to medical management. Retrospective review of 22 patients treated with SRS from 1994 until 2006. All patients were either intolerant or their tumors were unresponsive to dopamine agonist therapy. Nine patients (41%) had undergone prior transsphenoidal surgery. The median serum PRL concentration before SRS was 88.4 ng/mL (range, 25-943). The median treatment volume was 2.2 cm(3) (range, 0.4-29.0); the median margin radiation dose was 25 Gy (range, 16-30). The median endocrinologic follow-up was 60 months (range, 16-129). Tumor control after SRS was 100%. Serum PRL concentration was significantly lower (median, 28.4 ng/mL) (P = 0.006) at last follow-up, but the 4-year actuarial rate of biochemical remission off medications was only 17%. No tested variable was associated with biochemical remission off medications. Overall, four patients (18%) had biochemical remission off medications and clinical improvement, three patients (14%) had normal serum PRL concentrations and clinical improvement on dopamine agonist therapy, seven patients (32%) had improved symptoms off medications but continued to have elevated serum PRL levels, and eight patients (36%) continued to be symptomatic with elevated PRL levels either on (n = 3) or off (n = 5) dopamine agonist therapy. The incidence of new anterior pituitary deficits was 42% at 4 years. SRS was effective in controlling tumor growth for patients with PRL-secreting pituitary adenomas, and the majority of patients were clinically improved.",Journal Article,3491.0,36.0,evaluate efficacy stereotactic radiosurgery SRS patients prolactin PRL -secreting pituitary adenomas refractory medical management Retrospective review 22 patients treated SRS 1994 2006 patients intolerant unresponsive dopamine agonist therapy patients 41 undergone prior transsphenoidal surgery median serum PRL concentration SRS 88.4 ng/mL range 25-943 median treatment volume 2.2 cm 3 range 0.4-29.0 median margin radiation dose 25 Gy range 16-30 median endocrinologic follow-up 60 months range 16-129 control SRS 100 Serum PRL concentration significantly lower median 28.4 ng/mL P 0.006 follow-up 4-year actuarial rate biochemical remission medications 17 tested variable associated biochemical remission medications Overall patients 18 biochemical remission medications clinical improvement patients 14 normal serum PRL concentrations clinical improvement dopamine agonist therapy seven patients 32 improved symptoms medications continued elevated serum PRL levels patients 36 continued symptomatic elevated PRL levels n 3 n 5 dopamine agonist therapy incidence new anterior pituitary deficits 42 4 years SRS effective controlling growth patients PRL-secreting pituitary adenomas majority patients clinically improved,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 3, 209, 1, 1729, 2192, 1429, 9, 7, 5, 10841, 14956, 5052, 2751, 17, 11, 430, 6, 484, 284, 459, 206, 1, 350, 7, 73, 5, 1429, 29, 3023, 1100, 1324, 62, 7, 11, 361, 4944, 15, 136, 57, 11, 7244, 6, 14918, 3821, 36, 762, 7, 605, 42, 1989, 324, 14214, 152, 3, 52, 524, 14956, 1227, 348, 1429, 10, 889, 39, 997, 542, 184, 243, 15852, 3, 52, 24, 433, 10, 18, 18, 494, 27, 184, 13, 39, 462, 13, 3, 52, 959, 121, 61, 10, 243, 381, 184, 245, 201, 3, 52, 39546, 166, 126, 10, 335, 53, 184, 245, 4649, 30, 182, 50, 1429, 10, 394, 524, 14956, 1227, 10, 97, 280, 52, 339, 39, 997, 542, 19, 13, 1861, 28, 1060, 166, 126, 84, 3, 39, 111, 2361, 116, 1, 1487, 734, 1889, 2679, 10, 158, 269, 77, 650, 1347, 10, 41, 5, 1487, 734, 1889, 2679, 63, 294, 7, 203, 42, 1487, 734, 1889, 2679, 2, 38, 767, 169, 7, 213, 42, 295, 524, 14956, 1003, 2, 38, 767, 23, 14918, 3821, 36, 648, 7, 531, 42, 231, 507, 1889, 2679, 84, 1351, 6, 47, 804, 524, 14956, 148, 2, 659, 7, 511, 1351, 6, 40, 1704, 5, 804, 14956, 148, 361, 23, 78, 27, 15, 1889, 78, 33, 14918, 3821, 36, 3, 287, 1, 217, 2882, 2752, 10, 595, 28, 39, 60, 1429, 10, 323, 4, 1893, 30, 129, 9, 7, 5, 14956, 5052, 2751, 2, 3, 686, 1, 7, 11, 505, 231]",1543.0,21300006,Gamma knife radiosurgery patients prolactin-secreting pituitary adenomas,2,0.018867924528301886
Decreased fertility among female childhood cancer survivors who received 22-27 Gy hypothalamic/pituitary irradiation: a report from the Childhood Cancer Survivor Study.,Fertility and sterility,Fertil. Steril.,2011-03-03,"To evaluate the effect of hypothalamic/pituitary radiation (HPT RT) dose on the occurrence of first pregnancy. Retrospective cohort study of childhood cancer 5-year survivors (CCS) diagnosed between 1970 and 1986 before 21 years of age at one of 26 North American pediatric cancer treatment centers. Self-administered questionnaire. A total of 3,619 female CCS who participated in the Childhood Cancer Survivor Study and received no or scatter (0.1 Gy) radiation to the ovaries and 2,081 female siblings (Sibs) of the participants. None. Self-reported pregnancy events. As a group, CCS were as likely to report being pregnant as Sibs (hazard ratio 1.07, 95% confidence interval 0.97-1.19). Multivariable models showed a significant decrease in the risk of pregnancy with HPT RT doses22 Gy compared with those CCS receiving no HPT RT. These results support the hypothesis that exposures of 22-27 Gy HPT RT may be a contributing factor to infertility among female CCS.",Evaluation Study,3246.0,30.0,"evaluate effect hypothalamic/pituitary radiation HPT RT dose occurrence pregnancy Retrospective cohort childhood 5-year survivors CCS diagnosed 1970 1986 21 years age 26 North American pediatric treatment centers Self-administered questionnaire total 3,619 female CCS participated Childhood Survivor received scatter 0.1 Gy radiation ovaries 2,081 female siblings Sibs participants Self-reported pregnancy events group CCS likely report pregnant Sibs hazard ratio 1.07 95 confidence interval 0.97-1.19 Multivariable models showed significant decrease risk pregnancy HPT RT doses22 Gy compared CCS receiving HPT RT support hypothesis exposures 22-27 Gy HPT RT contributing factor infertility female CCS",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 3, 254, 1, 7531, 12098, 121, 20419, 240, 61, 23, 3, 2291, 1, 157, 2290, 459, 180, 45, 1, 864, 12, 33, 111, 332, 5688, 265, 59, 4868, 2, 3751, 348, 239, 60, 1, 89, 28, 104, 1, 432, 2669, 597, 815, 12, 24, 1168, 1074, 468, 1770, 8, 181, 1, 27, 14277, 1061, 5688, 54, 3025, 4, 3, 864, 12, 2628, 45, 2, 103, 77, 15, 9411, 8710, 14, 381, 121, 6, 3, 7262, 2, 18, 16048, 1061, 2758, 46481, 1, 3, 776, 1292, 1074, 210, 2290, 281, 22, 8, 87, 5688, 11, 22, 322, 6, 414, 486, 6086, 22, 46481, 360, 197, 14, 1615, 48, 307, 268, 13, 1015, 14, 326, 658, 274, 224, 8, 93, 775, 4, 3, 43, 1, 2290, 5, 20419, 240, 59898, 381, 72, 5, 135, 5688, 357, 77, 20419, 240, 46, 99, 538, 3, 1492, 17, 3401, 1, 350, 428, 381, 20419, 240, 68, 40, 8, 3156, 161, 6, 5901, 107, 1061, 5688]",946.0,21376314,Decreased fertility female childhood survivors received 22-27 Gy hypothalamic/pituitary irradiation report Childhood Survivor,2,0.018867924528301886
Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.,"Hormones (Athens, Greece)",Hormones (Athens),,"Temozolomide (TMZ) has recently been recommended as a novel approach in the management of aggressive pituitary tumors. Herein, we present the case of a 43-year-old man with a 20-year history of silent subtype 2 pituitary corticotroph adenoma. Nine surgical resections and radiotherapy had failed to provide a cure. Morphological evaluation of the tumor revealed a mildly pleomorphic adenoma, the cells of which showed low-level cell proliferative activity with Ki67, increased topoisomerase II alpha index and conclusive O-6-methylguanine-DNA methyltransferase (MGMT) as well as vascular endothelial growth factor (VEGF) immunoreactivity. Given its aggressive behavior and failure of conventional therapy, TMZ was administered. The treatment was continued even after MGMT immunopositivity was identified, but failed to decrease MGMT immunoexpression and exerted no morphologic effect. Examination of the lesion after TMZ therapy showed neither morphologic nor immunohistochemical alterations. In our case, TMZ administration, despite changing the TMZ dosing regimen to prompt a drug response, was incapable of depleting MGMT stores.",Case Reports,,,Temozolomide TMZ recently recommended novel approach management aggressive pituitary present case 43-year-old man 20-year history silent subtype 2 pituitary corticotroph adenoma surgical resections radiotherapy failed provide cure Morphological evaluation revealed mildly pleomorphic adenoma showed low-level proliferative activity Ki67 increased topoisomerase II alpha index conclusive O-6-methylguanine-DNA methyltransferase MGMT vascular endothelial growth factor VEGF immunoreactivity Given aggressive behavior failure conventional therapy TMZ administered treatment continued MGMT immunopositivity identified failed decrease MGMT immunoexpression exerted morphologic effect Examination lesion TMZ therapy showed morphologic immunohistochemical alterations case TMZ administration despite changing TMZ dosing regimen prompt drug response incapable depleting MGMT stores,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1537, 2081, 71, 761, 85, 793, 22, 8, 229, 353, 4, 3, 284, 1, 571, 57, 1986, 21, 364, 3, 473, 1, 8, 601, 111, 1095, 3628, 5, 8, 179, 111, 532, 1, 9890, 875, 18, 46651, 2434, 762, 221, 2185, 2, 310, 42, 1551, 6, 377, 8, 1722, 4268, 451, 1, 3, 30, 553, 8, 9443, 4581, 2434, 3, 37, 1, 92, 224, 154, 301, 31, 2441, 128, 5, 3654, 101, 3999, 215, 950, 558, 2, 11231, 1990, 49, 7015, 261, 3747, 2661, 22, 149, 22, 756, 845, 129, 161, 618, 4900, 447, 211, 571, 1710, 2, 496, 1, 809, 36, 2081, 10, 468, 3, 24, 10, 1351, 871, 50, 2661, 18964, 10, 108, 84, 1551, 6, 775, 2661, 21668, 2, 8753, 77, 2815, 254, 1385, 1, 3, 1180, 50, 2081, 36, 224, 2174, 2815, 2110, 1382, 593, 4, 114, 473, 2081, 634, 550, 3600, 3, 2081, 1280, 477, 6, 4776, 8, 234, 51, 10, 20290, 1, 9438, 2661, 21026]",1090.0,21724542,Aggressive silent corticotroph adenoma progressing pituitary carcinoma role temozolomide therapy,0,0.0
Nelfinavir induces radiation sensitization in pituitary adenoma cells.,Cancer biology & therapy,Cancer Biol. Ther.,2011-10-01,"Pituitary adenomas with local invasion and high secretory activity remain a therapeutic challenge. The HIV protease inhibitor nelfinavir is a radiosensitizer in multiple tumor models. We tested nelfinavir as a radiosensitizer in pituitary adenoma cells in vitro and in vivo. We examined the effect of nelfinavir with radiation on in vitro cell viability, clonogenic survival, apoptosis, prolactin secretion, cell cycle distribution, and the PI3K-AKT-mTOR pathway. We evaluated tumor growth delay and confirmed nelfinavir's effect on the PI3K-AKT-mTOR pathway in a hind-flank model. Nelfinavir sensitized pituitary adenoma cells to ionizing radiation as shown by viability assays and clonogenic assay with an enhancement ratio of 1.2 (p < 0.05). There is increased apoptotic cell death, as determined by annexin-V expression and cleaved caspase-3 levels. Nelfinavir does not affect prolactin secretion or cell cycle distribution. In vivo, untreated tumors reached 4-fold volume in 12 days, 17 days with nelfinavir treatment, 27 days with radiation 6 Gy, and 41 days with nelfinavir plus radiation (one-way ANOVA p < 0.001). Decreased phospho-S6 on Western blotting in vitro and immunohistochemistry in vivo demonstrated nelfinavir inhibition of the PI3K-AKT-mTOR pathway. Our data suggests a promising combination therapy with nelfinavir plus radiation in pituitary adenomas, which should be investigated in clinical studies.",Journal Article,3034.0,17.0,Pituitary adenomas local invasion high secretory activity remain therapeutic challenge HIV protease inhibitor nelfinavir radiosensitizer multiple models tested nelfinavir radiosensitizer pituitary adenoma vitro vivo examined effect nelfinavir radiation vitro viability clonogenic survival apoptosis prolactin secretion cycle distribution PI3K-AKT-mTOR pathway evaluated growth delay confirmed nelfinavir 's effect PI3K-AKT-mTOR pathway hind-flank model Nelfinavir sensitized pituitary adenoma ionizing radiation shown viability clonogenic enhancement ratio 1.2 p 0.05 increased apoptotic death determined annexin-V expression cleaved caspase-3 levels Nelfinavir affect prolactin secretion cycle distribution vivo untreated reached 4-fold volume 12 days 17 days nelfinavir treatment 27 days radiation 6 Gy 41 days nelfinavir plus radiation one-way ANOVA p 0.001 Decreased phospho-S6 Western blotting vitro immunohistochemistry vivo demonstrated nelfinavir inhibition PI3K-AKT-mTOR pathway suggests promising combination therapy nelfinavir plus radiation pituitary adenomas investigated clinical studies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2751, 5, 293, 578, 2, 64, 7106, 128, 918, 8, 189, 1745, 3, 1942, 5125, 230, 8890, 16, 8, 8853, 4, 232, 30, 274, 21, 650, 8890, 22, 8, 8853, 4, 2434, 37, 4, 439, 2, 4, 386, 21, 409, 3, 254, 1, 8890, 5, 121, 23, 4, 439, 31, 2120, 3798, 25, 351, 10841, 2935, 31, 417, 1395, 2, 3, 974, 649, 873, 308, 21, 194, 30, 129, 1984, 2, 557, 8890, 292, 254, 23, 3, 974, 649, 873, 308, 4, 8, 15899, 5564, 202, 8890, 4242, 2434, 37, 6, 4341, 121, 22, 443, 20, 2120, 1013, 2, 3798, 719, 5, 35, 2461, 197, 1, 14, 18, 19, 13, 474, 125, 16, 101, 1631, 31, 273, 22, 509, 20, 4850, 603, 55, 2, 5885, 1469, 27, 148, 8890, 1097, 44, 1158, 10841, 2935, 15, 31, 417, 1395, 4, 386, 1278, 57, 1300, 39, 1116, 433, 4, 133, 162, 269, 162, 5, 8890, 24, 428, 162, 5, 121, 49, 381, 2, 605, 162, 5, 8890, 349, 121, 104, 2255, 9008, 19, 13, 144, 340, 3125, 4977, 23, 1521, 3661, 4, 439, 2, 888, 4, 386, 264, 8890, 297, 1, 3, 974, 649, 873, 308, 114, 74, 844, 8, 721, 150, 36, 5, 8890, 349, 121, 4, 2751, 92, 257, 40, 565, 4, 38, 94]",1355.0,21811091,Nelfinavir induces radiation sensitization pituitary adenoma,0,0.0
Anti-VEGF therapy in pituitary carcinoma.,Pituitary,Pituitary,2012-09-01,"We report the case of a 44-year-old male patient with an aggressive silent corticotroph cell pituitary adenoma, subtype 2. In that it progressed to carcinoma despite temozolomide administration, anti-VEGF therapy was begun. MRI, PET scan and pathologic analysis were undertaken. After 10 months of anti-VEGF (bevacizumab) treatment no progression of the lesion was noted. The tumor was biopsied and morphological analysis showed severe cell injury, vascular abnormalities and fibrosis. Bevacizumab treatment has continued for additional 16 months to present with stabilization of disease as documented on serial MRI and PET scans. This is the first case of a bevacizumab-treated pituitary carcinoma with long-term, now 26 months, control of disease. The present findings are promising in that anti-angiogenic therapy appears to represent a new option in the treatment of aggressive pituitary tumors.",Case Reports,2698.0,61.0,report case 44-year-old male patient aggressive silent corticotroph pituitary adenoma subtype 2 progressed carcinoma despite temozolomide administration anti-VEGF therapy begun MRI PET scan pathologic undertaken 10 months anti-VEGF bevacizumab treatment progression lesion noted biopsied morphological showed severe injury vascular abnormalities fibrosis Bevacizumab treatment continued additional 16 months present stabilization disease documented serial MRI PET scans case bevacizumab-treated pituitary carcinoma long-term 26 months control disease present findings promising anti-angiogenic therapy appears represent new option treatment aggressive pituitary,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 414, 3, 473, 1, 8, 584, 111, 1095, 1045, 69, 5, 35, 571, 9890, 46651, 31, 2434, 875, 18, 4, 17, 192, 1839, 6, 134, 550, 1537, 634, 312, 618, 36, 10, 6973, 704, 495, 1657, 2, 510, 65, 11, 2789, 50, 79, 53, 1, 312, 618, 599, 24, 77, 91, 1, 3, 1180, 10, 1051, 3, 30, 10, 6775, 2, 4268, 65, 224, 905, 31, 2730, 756, 1171, 2, 3000, 599, 24, 71, 1351, 9, 402, 245, 53, 6, 364, 5, 3184, 1, 34, 22, 1405, 23, 2108, 704, 2, 495, 1441, 26, 16, 3, 157, 473, 1, 8, 599, 73, 134, 5, 319, 337, 1134, 432, 53, 182, 1, 34, 3, 364, 272, 32, 721, 4, 17, 312, 2068, 36, 1233, 6, 1231, 8, 217, 1501, 4, 3, 24, 1, 571, 57]",853.0,21918831,Anti-VEGF therapy pituitary carcinoma,0,0.0
"Endoscopic, endonasal resection of craniopharyngiomas:  analysis of outcome including extent of resection, cerebrospinal fluid leak, return to preoperative productivity, and body mass index.",Neurosurgery,Neurosurgery,2012-01-01,"The endoscopic, endonasal, extended transsphenoidal approach is a minimal-access technique for managing craniopharyngiomas. Outcome measures such as return to employment and body mass index (BMI) have not been reported and are necessary for comparison with open transcranial approaches. Most prior reports of the endoscopic, endonasal approach have reported unacceptably high cerebrospinal fluid (CSF) leak rates. To assess the outcome of endoscopic, endonasal surgery in a consecutive series of craniopharyngiomas with special attention to extent of resection, CSF leak, return to employment, and BMI. Twenty-six surgeries were performed on 24 patients at Weill Cornell Medical College-New York Presbyterian Hospital. Five patients had recurrent lesions. Gross-total resection (GTR) was attempted in 21 surgeries. Indications for intended subtotal resection were advanced age, medical comorbidities, preservation of pituitary function, and hypothalamic invasion. Mean tumor diameter was 2.9 cm. GTR (18 surgeries) or near-total (>95%) resection (2 surgeries) was achieved in 95% when GTR was the goal. Seven patients received postoperative radiation therapy. Mean follow-up was 35 months with no recurrences in GTR cases and stable disease in all patients at last follow-up. Vision improved in 77%. Diabetes insipidus and panhypopituitarism developed in 42% and 38%, respectively. A more than 9% increase in BMI occurred in 39%; 69% returned to their preoperative profession/schooling. The postoperative CSF leak rate was 3.8%. Minimal-access, endoscopic, endonasal surgery for craniopharyngioma can achieve high rates of GTR with low rates of CSF leak. Return to employment and obesity rates are comparable to microscope-assisted transcranial and transsphenoidal reports.",Journal Article,2942.0,107.0,endoscopic endonasal extended transsphenoidal approach minimal-access technique managing craniopharyngiomas Outcome measures return employment body mass index BMI reported necessary comparison open transcranial approaches prior reports endoscopic endonasal approach reported unacceptably high cerebrospinal fluid CSF leak rates assess outcome endoscopic endonasal surgery consecutive series craniopharyngiomas special attention extent resection CSF leak return employment BMI Twenty-six surgeries performed 24 patients Weill Cornell Medical College-New York Presbyterian Hospital patients recurrent lesions Gross-total resection GTR attempted 21 surgeries Indications intended subtotal resection advanced age medical comorbidities preservation pituitary function hypothalamic invasion Mean diameter 2.9 cm GTR 18 surgeries near-total 95 resection 2 surgeries achieved 95 GTR goal Seven patients received postoperative radiation therapy Mean follow-up 35 months recurrences GTR cases stable disease patients follow-up Vision improved 77 Diabetes insipidus panhypopituitarism developed 42 38 respectively 9 increase BMI occurred 39 69 returned preoperative profession/schooling postoperative CSF leak rate 3.8 Minimal-access endoscopic endonasal surgery craniopharyngioma achieve high rates GTR low rates CSF leak Return employment obesity rates comparable microscope-assisted transcranial transsphenoidal reports,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2056, 18636, 1747, 14214, 353, 16, 8, 1048, 1655, 1312, 9, 3969, 10708, 228, 1018, 225, 22, 4656, 6, 5141, 2, 642, 782, 558, 1140, 47, 44, 85, 210, 2, 32, 1493, 9, 1155, 5, 1020, 33172, 611, 96, 324, 1198, 1, 3, 2056, 18636, 353, 47, 210, 11934, 64, 5156, 2357, 1211, 4238, 151, 6, 423, 3, 228, 1, 2056, 18636, 152, 4, 8, 935, 988, 1, 10708, 5, 3714, 2111, 6, 1039, 1, 170, 1211, 4238, 4656, 6, 5141, 2, 1140, 737, 437, 5305, 11, 173, 23, 259, 7, 28, 20587, 19143, 484, 2979, 217, 5050, 21110, 702, 365, 7, 42, 387, 406, 1789, 181, 170, 4833, 10, 4098, 4, 239, 5305, 2406, 9, 4081, 5503, 170, 11, 131, 89, 484, 1909, 2224, 1, 343, 2, 7531, 578, 313, 30, 2549, 10, 18, 83, 494, 4833, 203, 5305, 15, 1829, 181, 48, 170, 18, 5305, 10, 513, 4, 48, 198, 4833, 10, 3, 1326, 648, 7, 103, 573, 121, 36, 313, 166, 126, 10, 465, 53, 5, 77, 1593, 4, 4833, 140, 2, 585, 34, 4, 62, 7, 28, 1060, 166, 126, 5859, 231, 4, 849, 1978, 16366, 2, 28464, 276, 4, 595, 2, 519, 106, 8, 80, 76, 83, 344, 4, 1140, 489, 4, 587, 790, 5157, 6, 136, 498, 31867, 60578, 3, 573, 1211, 4238, 116, 10, 27, 66, 1048, 1655, 2056, 18636, 152, 9, 7205, 122, 1359, 64, 151, 1, 4833, 5, 154, 151, 1, 1211, 4238, 4656, 6, 5141, 2, 1661, 151, 32, 1279, 6, 13061, 2927, 33172, 2, 14214, 1198]",1709.0,21937943,Endoscopic endonasal resection craniopharyngiomas outcome including extent resection cerebrospinal fluid leak return preoperative productivity body mass index,0,0.0
Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas.,Pituitary,Pituitary,2012-12-01,"Nonfunctioning pituitary adenomas (NFPA) are typically benign neoplasms that can cause significant morbidity through local mass effects. MIB-1/Ki-67 and p53 immuno-reactivity are used to predict aggressive behavior but have known limitations. No marker to date is widely used to reliably predict tumor progression. Phospho-histone H3 (pHH3) is a protein phosphorylated during chromatin condensation in mitosis, and thus anti-pHH3 immunocytochemistry is able to assess mitotic activity. Study objectives were to determine the relationship among pHH3, MIB-1/Ki-67, and p53 in NFPA, and to evaluate the relationship between these indices and time to progression (TTP). Seventy-six patients with NFPA operated on by a single neurosurgeon at University of Texas M. D. Anderson Cancer Center from 1992 to 2006 were identified from a database and met all criteria for inclusion in this clinicopathology study. PHH3, MIB-1/Ki-67, and p53 immuno-reactivity was evaluated in each case. Retrospective review was used to determine TTP. With 282 person-years of follow-up, 19 progression events were observed. A correlation was found between MIB-1/Ki-67 and p53 immuno-reactivity (r = 0.25, p = 0.031). PHH3 did not correlate with either. When markers were dichotomized at the median, only MIB-1/Ki-67 correlated with TPP (log rank p = 0.018). Rank correlation analysis confirmed a significant inverse correlation between both MIB-1/Ki-67 (Dxy = -0.33, p = 0.036) and p53 (Dxy = -0.40, 0.016) immuno-reactivity and TTP. Our results support previous data suggesting that MIB-1/Ki-67 and p53 have clinical utility as prognostic markers for tumor progression. PHH3 did not prove to be associated with TTP in this retrospective study limited by few progression events.",Journal Article,2607.0,6.0,Nonfunctioning pituitary adenomas NFPA typically benign neoplasms cause significant morbidity local mass effects MIB-1/Ki-67 p53 immuno-reactivity predict aggressive behavior known limitations marker date widely reliably predict progression Phospho-histone H3 pHH3 phosphorylated chromatin condensation mitosis anti-pHH3 immunocytochemistry able assess mitotic activity objectives determine relationship pHH3 MIB-1/Ki-67 p53 NFPA evaluate relationship indices time progression TTP Seventy-six patients NFPA operated single neurosurgeon University Texas M. D. Anderson Center 1992 2006 identified database met criteria inclusion clinicopathology PHH3 MIB-1/Ki-67 p53 immuno-reactivity evaluated case Retrospective review determine TTP 282 person-years follow-up 19 progression events observed correlation MIB-1/Ki-67 p53 immuno-reactivity r 0.25 p 0.031 PHH3 correlate markers dichotomized median MIB-1/Ki-67 correlated TPP log rank p 0.018 Rank correlation confirmed significant inverse correlation MIB-1/Ki-67 Dxy -0.33 p 0.036 p53 Dxy -0.40 0.016 immuno-reactivity TTP support previous suggesting MIB-1/Ki-67 p53 clinical utility prognostic markers progression PHH3 prove associated TTP retrospective limited progression events,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[18461, 2751, 39825, 32, 1969, 1002, 1179, 17, 122, 708, 93, 787, 298, 293, 782, 176, 8254, 14, 2311, 598, 2, 624, 7644, 4601, 32, 95, 6, 678, 571, 1710, 84, 47, 440, 1939, 77, 952, 6, 1244, 16, 1792, 95, 6, 4092, 678, 30, 91, 3125, 1508, 3739, 15393, 16, 8, 178, 2365, 190, 2287, 17295, 4, 5624, 2, 631, 312, 15393, 13290, 16, 1665, 6, 423, 2346, 128, 45, 2409, 11, 6, 223, 3, 858, 107, 15393, 8254, 14, 2311, 598, 2, 624, 4, 39825, 2, 6, 376, 3, 858, 59, 46, 3824, 2, 98, 6, 91, 2422, 2073, 437, 7, 5, 39825, 7297, 23, 20, 8, 226, 19962, 28, 1652, 1, 2738, 188, 427, 1929, 12, 574, 29, 2846, 6, 1324, 11, 108, 29, 8, 609, 2, 543, 62, 371, 9, 1680, 4, 26, 29118, 45, 15393, 8254, 14, 2311, 598, 2, 624, 7644, 4601, 10, 194, 4, 296, 473, 459, 206, 10, 95, 6, 223, 2422, 5, 8219, 2719, 60, 1, 166, 126, 326, 91, 281, 11, 164, 8, 816, 10, 204, 59, 8254, 14, 2311, 598, 2, 624, 7644, 4601, 668, 13, 243, 19, 13, 5304, 15393, 205, 44, 1513, 5, 361, 198, 525, 11, 6701, 28, 3, 52, 158, 8254, 14, 2311, 598, 438, 5, 60822, 1066, 1026, 19, 13, 4047, 1026, 816, 65, 557, 8, 93, 2931, 816, 59, 110, 8254, 14, 2311, 598, 46904, 13, 466, 19, 13, 5395, 2, 624, 46904, 13, 327, 13, 3820, 7644, 4601, 2, 2422, 114, 99, 538, 698, 74, 802, 17, 8254, 14, 2311, 598, 2, 624, 47, 38, 1207, 22, 177, 525, 9, 30, 91, 15393, 205, 44, 4361, 6, 40, 41, 5, 2422, 4, 26, 459, 45, 383, 20, 1021, 91, 281]",1689.0,22120760,Phospho-histone H3 pHH3 immuno-reactivity prognostic marker non-functioning pituitary adenomas,0,0.0
Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2011-12-19,"Many Childhood Cancer Survivor Study (CCSS) participants are at increased risk for obesity. The etiology of their obesity is likely multifactorial but not well understood. We evaluated the potential contribution of demographic, lifestyle, treatment, and intrapersonal factors and self-reported pharmaceutical use to obesity (body mass index  30 kg/m2) among 9,284 adult (> 18 years of age) CCSS participants. Independent predictors were identified using multivariable regression models. Interrelationships were determined using structural equation modeling (SEM). Independent risk factors for obesity included cancer diagnosed at 5 to 9 years of age (relative risk [RR], 1.12; 95% CI, 1.01 to 1.24; P = .03), abnormal Short Form-36 physical function (RR, 1.19; 95% CI, 1.06 to 1.33; P < .001), hypothalamic/pituitary radiation doses of 20 to 30 Gy (RR, 1.17; 95% CI, 1.05 to 1.30; P = .01), and paroxetine use (RR, 1.29; 95% CI, 1.08 to 1.54; P = .01). Meeting US Centers for Disease Control and Prevention guidelines for vigorous physical activity (RR, 0.90; 95% CI, 0.82 to 0.97; P = .01) and a medium amount of anxiety (RR, 0.86; 95% CI, 0.75 to 0.99; P = .04) reduced the risk of obesity. Results of SEM (N = 8,244; comparative fit index = 0.999; Tucker Lewis index = 0.999; root mean square error of approximation = 0.014; weighted root mean square residual = 0.749) described the hierarchical impact of the direct predictors, moderators, and mediators of obesity. Treatment, lifestyle, and intrapersonal factors, as well as the use of specific antidepressants, may contribute to obesity among survivors. A multifaceted intervention, including alternative drug and other therapies for depression and anxiety, may be required to reduce risk.",Journal Article,2955.0,52.0,"Childhood Survivor CCSS participants increased risk obesity etiology obesity likely multifactorial understood evaluated potential contribution demographic lifestyle treatment intrapersonal factors self-reported pharmaceutical use obesity body mass index  30 kg/m2 9,284 adult 18 years age CCSS participants Independent predictors identified multivariable regression models Interrelationships determined structural equation modeling SEM Independent risk factors obesity included diagnosed 5 9 years age relative risk RR 1.12 95 CI 1.01 1.24 P .03 abnormal Short Form-36 physical function RR 1.19 95 CI 1.06 1.33 P .001 hypothalamic/pituitary radiation doses 20 30 Gy RR 1.17 95 CI 1.05 1.30 P .01 paroxetine use RR 1.29 95 CI 1.08 1.54 P .01 Meeting Centers Disease Control Prevention guidelines vigorous physical activity RR 0.90 95 CI 0.82 0.97 P .01 medium anxiety RR 0.86 95 CI 0.75 0.99 P .04 reduced risk obesity SEM N 8,244 comparative fit index 0.999 Tucker Lewis index 0.999 root mean square error approximation 0.014 weighted root mean square residual 0.749 described hierarchical impact direct predictors moderators mediators obesity Treatment lifestyle intrapersonal factors use specific antidepressants contribute obesity survivors multifaceted intervention including alternative drug therapies depression anxiety required reduce risk",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[445, 864, 12, 2628, 45, 4657, 776, 32, 28, 101, 43, 9, 1661, 3, 2855, 1, 136, 1661, 16, 322, 7059, 84, 44, 149, 1784, 21, 194, 3, 174, 2925, 1, 1540, 3487, 24, 2, 35262, 130, 2, 1074, 210, 6278, 119, 6, 1661, 642, 782, 558, 749, 201, 503, 821, 107, 83, 8843, 780, 203, 60, 1, 89, 4657, 776, 306, 674, 11, 108, 75, 658, 320, 274, 19503, 11, 509, 75, 3281, 5747, 2057, 8719, 306, 43, 130, 9, 1661, 159, 12, 265, 28, 33, 6, 83, 60, 1, 89, 580, 43, 861, 14, 133, 48, 58, 14, 355, 6, 14, 259, 19, 680, 1668, 978, 1297, 511, 900, 343, 861, 14, 326, 48, 58, 14, 1460, 6, 14, 466, 19, 144, 7531, 12098, 121, 415, 1, 179, 6, 201, 381, 861, 14, 269, 48, 58, 14, 474, 6, 14, 201, 19, 355, 2, 15230, 119, 861, 14, 462, 48, 58, 14, 1592, 6, 14, 667, 19, 355, 2238, 843, 1168, 9, 34, 182, 2, 1070, 677, 9, 10309, 900, 128, 861, 13, 424, 48, 58, 13, 878, 6, 13, 1015, 19, 355, 2, 8, 3759, 3108, 1, 2021, 861, 13, 868, 48, 58, 13, 481, 6, 13, 1058, 19, 755, 405, 3, 43, 1, 1661, 99, 1, 8719, 78, 66, 6567, 2352, 2975, 558, 13, 10323, 46951, 9449, 558, 13, 10323, 8386, 313, 3219, 3444, 1, 18592, 13, 3618, 2337, 8386, 313, 3219, 753, 13, 15286, 1027, 3, 4466, 345, 1, 3, 1196, 674, 19964, 2, 4425, 1, 1661, 24, 3487, 2, 35262, 130, 22, 149, 22, 3, 119, 1, 112, 12261, 68, 1248, 6, 1661, 107, 332, 8, 10076, 788, 141, 1091, 234, 2, 127, 235, 9, 1774, 2, 2021, 68, 40, 616, 6, 969, 43]",1640.0,22184380,Risk factors obesity adult survivors childhood report Childhood Survivor,7,0.0660377358490566
Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer.,Cancer,Cancer,2012-04-04,"The objective of this study was to document the differences in testosterone (T) levels between crizotinib-treated and noncrizotinib-treated patients with metastatic nonsmall cell lung cancer (NSCLC). Testosterone levels were measured in 19 men with metastatic NSCLC who received crizotinib and in 19 men with metastatic NSCLC who did not receive crizotinib. Clinical characteristics of the patients were compared, and additional hormone assays were performed as appropriate. Two patients who began crizotinib and 4 patients who had dose interruptions or who stopped crizotinib therapy had serial hormone measurements, permitting the documentation of dynamic hormone changes on and off crizotinib treatment. Total T levels were low (<241 ng/dL) in 19 of 19 (100%) crizotinib-treated men and in 6 of 19 men (32%) with metastatic NSCLC who did not receive crizotinib (mean T levels, 131 ng/dL and 311 ng/dL, respectively; P = .0002). Only 1 in 5 patients who had anaplastic lymphoma kinase (ALK) gene rearrangements and had not yet received crizotinib had low T. The initiation of crizotinib in 2 patients who had previously normal T levels was associated with a rapid decreases in T and in luteinizing hormone and follicle stimulating hormone levels within 14 to 21 days. Discontinuation of crizotinib led to increases back to normal T levels. Crizotinib therapy caused rapid suppression of T levels in men. The current results indicated that the site of action must include a central (hypothalamic or pituitary) effect, but additional direct testicular effects could not be excluded. Further work is required to assess the correlation between low T levels and crizotinib side effects as well as the exact molecular mechanism and site of drug toxicity.",Journal Article,2848.0,58.0,objective document differences testosterone levels crizotinib-treated noncrizotinib-treated patients metastatic nonsmall lung NSCLC Testosterone levels measured 19 men metastatic NSCLC received crizotinib 19 men metastatic NSCLC receive crizotinib Clinical characteristics patients compared additional hormone performed appropriate patients began crizotinib 4 patients dose interruptions stopped crizotinib therapy serial hormone measurements permitting documentation dynamic hormone changes crizotinib treatment Total levels low 241 ng/dL 19 19 100 crizotinib-treated men 6 19 men 32 metastatic NSCLC receive crizotinib mean levels 131 ng/dL 311 ng/dL respectively P .0002 1 5 patients anaplastic lymphoma kinase ALK rearrangements received crizotinib low T. initiation crizotinib 2 patients previously normal levels associated rapid decreases luteinizing hormone follicle stimulating hormone levels 14 21 days Discontinuation crizotinib led increases normal levels Crizotinib therapy caused rapid suppression levels men current indicated site action include central hypothalamic pituitary effect additional direct testicular effects excluded work required assess correlation low levels crizotinib effects exact molecular mechanism site drug toxicity,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 4753, 3, 362, 4, 2660, 102, 148, 59, 2284, 73, 2, 61310, 73, 7, 5, 113, 5667, 31, 12, 304, 2660, 148, 11, 644, 4, 326, 325, 5, 113, 304, 54, 103, 2284, 2, 4, 326, 325, 5, 113, 304, 54, 205, 44, 560, 2284, 38, 374, 1, 3, 7, 11, 72, 2, 402, 785, 1013, 11, 173, 22, 870, 100, 7, 54, 4603, 2284, 2, 39, 7, 54, 42, 61, 7406, 15, 54, 4403, 2284, 36, 42, 2108, 785, 1685, 9621, 3, 4965, 1, 2540, 785, 400, 23, 2, 1889, 2284, 24, 181, 102, 148, 11, 154, 7086, 997, 1826, 4, 326, 1, 326, 394, 2284, 73, 325, 2, 4, 49, 1, 326, 325, 531, 5, 113, 304, 54, 205, 44, 560, 2284, 313, 102, 148, 2229, 997, 1826, 2, 9521, 997, 1826, 106, 19, 3531, 158, 14, 4, 33, 7, 54, 42, 1841, 216, 1023, 145, 2072, 2, 42, 44, 1145, 103, 2284, 42, 154, 102, 3, 1118, 1, 2284, 4, 18, 7, 54, 42, 373, 295, 102, 148, 10, 41, 5, 8, 1321, 2140, 4, 102, 2, 4, 8223, 785, 2, 9109, 2122, 785, 148, 262, 213, 6, 239, 162, 2007, 1, 2284, 836, 6, 1106, 4636, 6, 295, 102, 148, 2284, 36, 1546, 1321, 1332, 1, 102, 148, 4, 325, 3, 291, 99, 1103, 17, 3, 606, 1, 1578, 1642, 643, 8, 854, 7531, 15, 254, 84, 402, 1196, 176, 359, 44, 40, 1800, 195, 1357, 16, 616, 6, 423, 3, 816, 59, 154, 102, 148, 2, 2284, 1152, 176, 22, 149, 22, 3, 2472, 219, 670, 2, 606, 1, 234, 155]",1678.0,22488744,Rapid-onset hypogonadism secondary crizotinib use men metastatic nonsmall lung,1,0.009433962264150943
Temozolomide in aggressive pituitary adenomas and carcinomas.,"Clinics (Sao Paulo, Brazil)",Clinics (Sao Paulo),2012-01-01,"Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6-methylguanine-DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide, thereby counteracting its effects. A Medline search for all of the available publications regarding the use of temozolomide for the treatment of pituitary tumors was performed. To date, 46 cases of adenohypophysial tumors that were treated with temozolomide, including 30 adenomas and 16 carcinomas, have been reported. Eighteen of the 30 (60%) adenomas and 11 of the 16 (69%) carcinomas responded favorably to treatment. One patient with multiple endocrine neoplasia type 1 and an aggressive prolactin-producing adenoma was also treated and demonstrated a good response. No significant complications have been attributed to temozolomide therapy. Thus, temozolomide is an effective treatment for the majority of aggressive adenomas and carcinomas. Evidence indicates that there is an inverse correlation between levels of O6-methylguanine-DNA methyltransferase immunoexpression and therapeutic response. Alternatively, high-level O6-methylguanine-DNA methyltransferase immunoexpression correlates with an unfavorable response. Here, we review the use of temozolomide for treating pituitary neoplasms.",Journal Article,2942.0,40.0,Temozolomide alkylating agent treatment gliomas recently aggressive pituitary adenomas carcinomas Temozolomide methylates DNA antitumor effects O6-methylguanine-DNA methyltransferase DNA repair enzyme removes alkylating adducts induced temozolomide counteracting effects Medline search available publications use temozolomide treatment pituitary performed date 46 cases adenohypophysial treated temozolomide including 30 adenomas 16 carcinomas reported Eighteen 30 60 adenomas 11 16 69 carcinomas responded favorably treatment patient multiple endocrine neoplasia type 1 aggressive prolactin-producing adenoma treated demonstrated good response significant complications attributed temozolomide therapy temozolomide effective treatment majority aggressive adenomas carcinomas Evidence indicates inverse correlation levels O6-methylguanine-DNA methyltransferase immunoexpression therapeutic response Alternatively high-level O6-methylguanine-DNA methyltransferase immunoexpression correlates unfavorable response review use temozolomide treating pituitary neoplasms,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1537, 16, 35, 3410, 420, 95, 4, 3, 24, 1, 1287, 2, 80, 761, 571, 2751, 2, 826, 1537, 26616, 261, 2, 2267, 71, 579, 176, 6505, 7015, 261, 3747, 8, 261, 972, 1644, 17699, 3, 3410, 9722, 17, 32, 277, 20, 1537, 2267, 22628, 211, 176, 8, 3388, 1901, 9, 62, 1, 3, 390, 4463, 666, 3, 119, 1, 1537, 9, 3, 24, 1, 57, 10, 173, 6, 1244, 641, 140, 1, 61450, 57, 17, 11, 73, 5, 1537, 141, 201, 2751, 2, 245, 826, 47, 85, 210, 3195, 1, 3, 201, 335, 2751, 2, 175, 1, 3, 245, 790, 826, 2211, 5001, 6, 24, 104, 69, 5, 232, 1293, 2298, 267, 14, 2, 35, 571, 10841, 3787, 2434, 10, 120, 73, 2, 264, 8, 1178, 51, 77, 93, 521, 47, 85, 3073, 6, 1537, 36, 631, 1537, 16, 35, 323, 24, 9, 3, 686, 1, 571, 2751, 2, 826, 241, 2640, 17, 125, 16, 35, 2931, 816, 59, 148, 1, 6505, 7015, 261, 3747, 21668, 2, 189, 51, 7133, 64, 301, 6505, 7015, 261, 3747, 21668, 1871, 5, 35, 2483, 51, 467, 21, 206, 3, 119, 1, 1537, 9, 1367, 1179]",1365.0,22584716,Temozolomide aggressive pituitary adenomas carcinomas,12,0.11320754716981132
Diabetes insipidus following resection of pituitary tumors.,Clinical neurology and neurosurgery,Clin Neurol Neurosurg,2012-08-24,"Diabetes insipidus (DI) is a common complication following pituitary surgery and can be transient or permanent. Neurogenic DI occurs following injury to the magnocellular neurons in the hypothalamus that produce and transport arginine vasopressin (AVP) and form the hypothalamo-hypophyseal tract. DI is defined by a constellation of signs and symptoms resulting in dilute high-volume urine output and increasing serum osmolality. The body's inability to concentrate urine leaves the patient dehydrated and leads to metabolic abnormalities that can be life threatening if not recognized and treated in a timely manner with an exogenous AVP analog. The reported incidence of postsurgical central DI varies from 1 to 67%. This wide range likely reflects inconsistencies in the working definition of DI across the literature. Factors affecting the rate of DI include pituitary tumor size, adherence to surrounding structures, surgical approach, and histopathology of pituitary lesion. The likelihood of postoperative DI can be reduced by careful preservation of the neurovascular structures of the hypothalamus, infundibulum, and neurohypophysis. Vigilance and meticulous surgical technique are essential to minimize injury to these critical regions that can lead to postsurgical DI.",Journal Article,2706.0,31.0,Diabetes insipidus DI common complication following pituitary surgery transient permanent Neurogenic DI occurs following injury magnocellular neurons hypothalamus produce transport arginine vasopressin AVP form hypothalamo-hypophyseal tract DI defined constellation signs symptoms resulting dilute high-volume urine output increasing serum osmolality body 's inability concentrate urine leaves patient dehydrated leads metabolic abnormalities life threatening recognized treated timely manner exogenous AVP analog reported incidence postsurgical central DI varies 1 67 wide range likely reflects inconsistencies working definition DI literature Factors affecting rate DI include pituitary size adherence surrounding structures surgical approach histopathology pituitary lesion likelihood postoperative DI reduced careful preservation neurovascular structures hypothalamus infundibulum neurohypophysis Vigilance meticulous surgical technique essential minimize injury critical regions lead postsurgical DI,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1978, 16366, 6641, 16, 8, 186, 1447, 366, 152, 2, 122, 40, 2473, 15, 4377, 16731, 6641, 1780, 366, 2730, 6, 3, 61804, 11930, 4, 3, 12717, 17, 2410, 2, 4294, 5392, 34043, 26483, 2, 1297, 3, 61805, 61806, 1696, 6641, 16, 395, 20, 8, 13862, 1, 3408, 2, 507, 1113, 4, 24498, 64, 433, 2646, 6911, 2, 602, 524, 38112, 3, 642, 292, 4985, 6, 15838, 2646, 15229, 3, 69, 43198, 2, 1940, 6, 1436, 1171, 17, 122, 40, 358, 3691, 492, 44, 1904, 2, 73, 4, 8, 4225, 1708, 5, 35, 4181, 26483, 3497, 3, 210, 287, 1, 6891, 854, 6641, 4037, 29, 14, 6, 598, 26, 1019, 184, 322, 5224, 14974, 4, 3, 2644, 2470, 1, 6641, 716, 3, 789, 130, 2319, 3, 116, 1, 6641, 643, 30, 444, 2149, 6, 2976, 2414, 221, 353, 2, 3831, 1, 1180, 3, 1420, 1, 573, 6641, 122, 40, 405, 20, 3465, 2224, 1, 3, 9848, 2414, 1, 3, 12717, 44870, 2, 47358, 13264, 2, 13764, 221, 1312, 32, 1452, 6, 3241, 2730, 6, 46, 740, 1374, 17, 122, 1122, 6, 6891, 6641]",1231.0,22921808,Diabetes insipidus following resection pituitary,0,0.0
Fertility (male and female) and menopause.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-09-24,"The impact of oncologic treatments on fertility and menopausal symptoms is often significant for patients with cancer. Surgery, radiation, and chemotherapy can all damage the reproductive organs or the hypothalamic pituitary axis that controls them, impairing fertility and causing hormonally mediated symptoms such as hot flashes. Understanding these risks and strategies to mitigate them may substantially improve cancer survivorship care. For both female and male patients who desire a future biologic child, there are a variety of fertility preservation techniques that should be considered. For cancer survivors who experience menopausal symptoms, lifestyle changes may be beneficial, and hormonal and nonhormonal pharmacologic agents are well proven to reduce symptom burden.",Journal Article,2675.0,30.0,impact oncologic treatments fertility menopausal symptoms significant patients Surgery radiation chemotherapy damage reproductive organs hypothalamic pituitary axis controls impairing fertility causing hormonally mediated symptoms hot flashes Understanding risks strategies mitigate substantially improve survivorship care female male patients desire future biologic child variety fertility preservation techniques considered survivors experience menopausal symptoms lifestyle changes beneficial hormonal nonhormonal pharmacologic agents proven reduce symptom burden,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 345, 1, 1998, 640, 23, 2954, 2, 3565, 507, 16, 629, 93, 9, 7, 5, 12, 152, 121, 2, 56, 122, 62, 1350, 3, 3705, 2285, 15, 3, 7531, 2310, 17, 535, 1370, 12880, 2954, 2, 3440, 10710, 517, 507, 225, 22, 2859, 4193, 612, 46, 1098, 2, 422, 6, 5626, 1370, 68, 2109, 401, 12, 2560, 165, 9, 110, 1061, 2, 1045, 7, 54, 5278, 8, 508, 1283, 2566, 125, 32, 8, 1362, 1, 2954, 2224, 1092, 17, 257, 40, 515, 9, 12, 332, 54, 730, 3565, 507, 3487, 400, 68, 40, 2524, 2, 1761, 2, 16196, 2788, 183, 32, 149, 1930, 6, 969, 934, 892]",760.0,23008319,Fertility male female menopause,6,0.05660377358490566
Clinical ascertainment of health outcomes among adults treated for childhood cancer.,JAMA,JAMA,2013-06-01,"Adult survivors of childhood cancer are known to be at risk for treatment-related adverse health outcomes. A large population of survivors has not been evaluated using a comprehensive systematic clinical assessment to determine the prevalence of chronic health conditions. To determine the prevalence of adverse health outcomes and the proportion associated with treatment-related exposures in a large cohort of adult survivors of childhood cancer. Presence of health outcomes was ascertained using systematic exposure-based medical assessments among 1713 adult (median age, 32 [range, 18-60] years) survivors of childhood cancer (median time from diagnosis, 25 [range, 10-47] years) enrolled in the St Jude Lifetime Cohort Study since October 1, 2007, and undergoing follow-up through October 31, 2012. Age-specific cumulative prevalence of adverse outcomes by organ system. Using clinical criteria, the crude prevalence of adverse health outcomes was highest for pulmonary (abnormal pulmonary function, 65.2% [95% CI, 60.4%-69.8%]), auditory (hearing loss, 62.1% [95% CI, 55.8%-68.2%]), endocrine or reproductive (any endocrine condition, such as hypothalamic-pituitary axis disorders and male germ cell dysfunction, 62.0% [95% CI, 59.5%-64.6%]), cardiac (any cardiac condition, such as heart valve disorders, 56.4% [95% CI, 53.5%-59.2%]), and neurocognitive (neurocognitive impairment, 48.0% [95% CI, 44.9%-51.0%]) function, whereas abnormalities involving hepatic (liver dysfunction, 13.0% [95% CI, 10.8%-15.3%]), skeletal (osteoporosis, 9.6% [95% CI, 8.0%-11.5%]), renal (kidney dysfunction, 5.0% [95% CI, 4.0%-6.3%]), and hematopoietic (abnormal blood cell counts, 3.0% [95% CI, 2.1%-3.9%]) function were less common. Among survivors at risk for adverse outcomes following specific cancer treatment modalities, the estimated cumulative prevalence at age 50 years was 21.6% (95% CI, 19.3%-23.9%) for cardiomyopathy, 83.5% (95% CI, 80.2%-86.8%) for heart valve disorder, 81.3% (95% CI, 77.6%-85.0%) for pulmonary dysfunction, 76.8% (95% CI, 73.6%-80.0%) for pituitary dysfunction, 86.5% (95% CI, 82.3%-90.7%) for hearing loss, 31.9% (95% CI, 28.0%-35.8%) for primary ovarian failure, 31.1% (95% CI, 27.3%-34.9%) for Leydig cell failure, and 40.9% (95% CI, 32.0%-49.8%) for breast cancer. At age 45 years, the estimated cumulative prevalence of any chronic health condition was 95.5% (95% CI, 94.8%-98.6%) and 80.5% (95% CI, 73.0%-86.6%) for a serious/disabling or life-threatening chronic condition. Among adult survivors of childhood cancer, the prevalence of adverse health outcomes was high, and a systematic risk-based medical assessment identified a substantial number of previously undiagnosed problems that are more prevalent in an older population. These findings underscore the importance of ongoing health monitoring for adults who survive childhood cancer.",Journal Article,2425.0,475.0,Adult survivors childhood known risk treatment-related adverse health outcomes large population survivors evaluated comprehensive systematic clinical assessment determine prevalence chronic health conditions determine prevalence adverse health outcomes proportion associated treatment-related exposures large cohort adult survivors childhood Presence health outcomes ascertained systematic exposure-based medical assessments 1713 adult median age 32 range 18-60 years survivors childhood median time diagnosis 25 range 10-47 years enrolled St Jude Lifetime Cohort October 1 2007 undergoing follow-up October 31 2012 Age-specific cumulative prevalence adverse outcomes organ clinical criteria crude prevalence adverse health outcomes highest pulmonary abnormal pulmonary function 65.2 95 CI 60.4 -69.8 auditory hearing loss 62.1 95 CI 55.8 -68.2 endocrine reproductive endocrine condition hypothalamic-pituitary axis disorders male germ dysfunction 62.0 95 CI 59.5 -64.6 cardiac cardiac condition heart valve disorders 56.4 95 CI 53.5 -59.2 neurocognitive neurocognitive impairment 48.0 95 CI 44.9 -51.0 function abnormalities involving hepatic liver dysfunction 13.0 95 CI 10.8 -15.3 skeletal osteoporosis 9.6 95 CI 8.0 -11.5 renal kidney dysfunction 5.0 95 CI 4.0 -6.3 hematopoietic abnormal blood counts 3.0 95 CI 2.1 -3.9 function common survivors risk adverse outcomes following specific treatment modalities estimated cumulative prevalence age 50 years 21.6 95 CI 19.3 -23.9 cardiomyopathy 83.5 95 CI 80.2 -86.8 heart valve disorder 81.3 95 CI 77.6 -85.0 pulmonary dysfunction 76.8 95 CI 73.6 -80.0 pituitary dysfunction 86.5 95 CI 82.3 -90.7 hearing loss 31.9 95 CI 28.0 -35.8 primary ovarian failure 31.1 95 CI 27.3 -34.9 Leydig failure 40.9 95 CI 32.0 -49.8 breast age 45 years estimated cumulative prevalence chronic health condition 95.5 95 CI 94.8 -98.6 80.5 95 CI 73.0 -86.6 serious/disabling life-threatening chronic condition adult survivors childhood prevalence adverse health outcomes high systematic risk-based medical assessment identified substantial number previously undiagnosed problems prevalent older population findings underscore importance ongoing health monitoring adults survive childhood,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,"[780, 332, 1, 864, 12, 32, 440, 6, 40, 28, 43, 9, 24, 139, 290, 341, 123, 8, 375, 266, 1, 332, 71, 44, 85, 194, 75, 8, 949, 1556, 38, 455, 6, 223, 3, 1078, 1, 442, 341, 1298, 6, 223, 3, 1078, 1, 290, 341, 123, 2, 3, 920, 41, 5, 24, 139, 3401, 4, 8, 375, 180, 1, 780, 332, 1, 864, 12, 463, 1, 341, 123, 10, 5240, 75, 1556, 645, 90, 484, 2182, 107, 29354, 780, 52, 89, 531, 184, 203, 335, 60, 332, 1, 864, 12, 52, 98, 29, 147, 243, 184, 79, 662, 60, 346, 4, 3, 3062, 4841, 2898, 180, 45, 1192, 2551, 14, 1307, 2, 479, 166, 126, 298, 2551, 456, 1195, 89, 112, 967, 1078, 1, 290, 123, 20, 1259, 398, 75, 38, 371, 3, 6622, 1078, 1, 290, 341, 123, 10, 1076, 9, 1087, 1668, 1087, 343, 556, 18, 48, 58, 335, 39, 790, 66, 11991, 4396, 407, 744, 14, 48, 58, 614, 66, 806, 18, 1293, 15, 3705, 500, 1293, 2850, 225, 22, 7531, 12098, 2310, 1997, 2, 1045, 2280, 31, 1527, 744, 13, 48, 58, 728, 33, 660, 49, 500, 2850, 225, 22, 16293, 1997, 664, 39, 48, 58, 699, 33, 728, 18, 2, 2958, 2958, 2315, 576, 13, 48, 58, 584, 83, 725, 13, 343, 547, 1171, 1267, 939, 1527, 233, 13, 48, 58, 79, 66, 167, 27, 2621, 4970, 83, 49, 48, 58, 66, 13, 175, 33, 1527, 33, 13, 48, 58, 39, 13, 49, 27, 2, 1007, 1668, 315, 31, 1911, 27, 13, 48, 58, 18, 14, 27, 83, 343, 11, 299, 186, 107, 332, 28, 43, 9, 290, 123, 366, 112, 12, 24, 1558, 3, 661, 967, 1078, 28, 89, 212, 60, 10, 239, 49, 48, 58, 326, 27, 382, 83, 9, 6460, 852, 33, 48, 58, 493, 18, 868, 66, 9, 16293, 2645, 865, 27, 48, 58, 849, 49, 772, 13, 9, 1087, 1527, 846, 66, 48, 58, 803, 49, 493, 13, 9, 1527, 868, 33, 48, 58, 878, 27, 424, 67, 9, 4396, 407, 456, 83, 48, 58, 339, 13, 465, 66, 9, 86, 496, 456, 14, 48, 58, 428, 27, 562, 83, 9, 23505, 31, 496, 2, 327, 83, 48, 58, 531, 13, 739, 66, 9, 12, 28, 89, 512, 60, 3, 661, 967, 1078, 1, 500, 442, 341, 2850, 10, 48, 33, 48, 58, 960, 66, 1096, 49, 2, 493, 33, 48, 58, 803, 13, 868, 49, 9, 8, 1762, 12492, 15, 358, 3691, 442, 2850, 107, 780, 332, 1, 864, 12, 3, 1078, 1, 290, 341, 123, 10, 64, 2, 8, 1556, 43, 90, 484, 455, 108, 8, 1281, 207, 1, 373, 11615, 2408, 17, 32, 80, 2485, 4, 35, 434, 266, 46, 272, 5531, 3, 1187, 1, 942, 341, 1315, 9, 857, 54, 4573, 864, 12]",2611.0,23757085,Clinical ascertainment health outcomes adults treated childhood,0,0.0
"Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation.",Neuro-oncology,Neuro-oncology,2013-12-04,"Proton craniospinal irradiation (p-CSI) has been proposed to reduce side effects associated with CSI. We evaluated acute toxicities and preliminary clinical outcomes in a series of adults treated with p-CSI. We reviewed medical records for 50 patients (aged 16-63 y) with malignancies of varying histologies treated consecutively with vertebral body-sparing p-CSI at MD Anderson Cancer Center from 2007 to 2011. Median CSI and total boost doses were 30.6 and 54 Gy. Forty patients received chemotherapy, varying by histology. Median follow-up was 20.1 months (range, 0.3-59). Median doses to the thyroid gland, pituitary gland, hypothalamus, and cochleae were 0.003 Gy-relative biological effectiveness (RBE; range, 0.001-8.5), 36.1 Gy-RBE (22.5-53.0), 37.1 Gy-RBE (22.3-54.4), and 33.9 Gy-RBE (22.2-52.4), respectively. Median percent weight loss during CSI was 1.6% (range, 10% weight loss to 14% weight gain). Mild nausea/vomiting was common (grade 1 = 46%, grade 2 = 20%); however, only 5 patients experienced grade 2 anorexia (weight loss >5% baseline weight). Median percent baseline white blood cells, hemoglobin, and platelets at nadir were 52% (range, 13%-100%), 97% (65%-112%), and 61% (10%-270%), respectively. Four patients developed grade 3 cytopenias. Overall and progression-free survival rates were 96% and 82%, respectively, at 2 years and 84% and 68% at 5 years. This large series of patients treated with p-CSI confirms low rates of acute toxicity, consistent with dosimetric models. Vertebral body-sparing p-CSI is feasible and should be considered as a way to reduce acute gastrointestinal and hematologic toxicity in adults requiring CSI.",Journal Article,2239.0,11.0,Proton craniospinal irradiation p-CSI proposed reduce effects associated CSI evaluated acute toxicities preliminary clinical outcomes series adults treated p-CSI reviewed medical records 50 patients aged 16-63 malignancies varying histologies treated consecutively vertebral body-sparing p-CSI MD Anderson Center 2007 2011 Median CSI total boost doses 30.6 54 Gy patients received chemotherapy varying histology Median follow-up 20.1 months range 0.3-59 Median doses thyroid gland pituitary gland hypothalamus cochleae 0.003 Gy-relative effectiveness RBE range 0.001-8.5 36.1 Gy-RBE 22.5-53.0 37.1 Gy-RBE 22.3-54.4 33.9 Gy-RBE 22.2-52.4 respectively Median percent weight loss CSI 1.6 range 10 weight loss 14 weight gain Mild nausea/vomiting common grade 1 46 grade 2 20 5 patients experienced grade 2 anorexia weight loss 5 baseline weight Median percent baseline white blood hemoglobin platelets nadir 52 range 13 -100 97 65 -112 61 10 -270 respectively patients developed grade 3 cytopenias Overall progression-free survival rates 96 82 respectively 2 years 84 68 5 years large series patients treated p-CSI confirms low rates acute toxicity consistent dosimetric models Vertebral body-sparing p-CSI feasible considered way reduce acute gastrointestinal hematologic toxicity adults requiring CSI,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[2095, 5748, 1104, 19, 4293, 71, 85, 1587, 6, 969, 1152, 176, 41, 5, 4293, 21, 194, 286, 385, 2, 1676, 38, 123, 4, 8, 988, 1, 857, 73, 5, 19, 4293, 21, 446, 484, 1064, 9, 212, 7, 1032, 245, 676, 2055, 5, 441, 1, 2990, 3489, 73, 7380, 5, 4731, 642, 1851, 19, 4293, 28, 2244, 1929, 12, 574, 29, 1307, 6, 1132, 52, 4293, 2, 181, 2569, 415, 11, 201, 49, 2, 667, 381, 1213, 7, 103, 56, 2990, 20, 784, 52, 166, 126, 10, 179, 14, 53, 184, 13, 27, 728, 52, 415, 6, 3, 2326, 2326, 12717, 2, 26692, 11, 13, 1421, 381, 580, 1037, 1236, 7037, 184, 13, 144, 66, 33, 511, 14, 381, 7037, 350, 33, 699, 13, 567, 14, 381, 7037, 350, 27, 667, 39, 2, 466, 83, 381, 7037, 350, 18, 653, 39, 106, 52, 714, 924, 407, 190, 4293, 10, 14, 49, 184, 79, 924, 407, 6, 213, 924, 1803, 1980, 1218, 1966, 10, 186, 88, 14, 641, 88, 18, 179, 137, 158, 33, 7, 592, 88, 3107, 3373, 924, 407, 33, 330, 924, 52, 714, 330, 886, 315, 37, 2222, 2, 4407, 28, 3686, 11, 653, 184, 233, 394, 1015, 556, 3726, 2, 713, 79, 6666, 106, 294, 7, 276, 88, 2608, 5635, 63, 2, 91, 115, 25, 151, 11, 921, 2, 878, 106, 28, 18, 60, 2, 874, 2, 806, 28, 33, 60, 26, 375, 988, 1, 7, 73, 5, 19, 4293, 5120, 154, 151, 1, 286, 155, 925, 5, 3187, 274, 4731, 642, 1851, 19, 4293, 16, 1313, 2, 257, 40, 515, 22, 8, 2255, 6, 969, 286, 2, 813, 155, 4, 857, 1888, 4293]",1542.0,24311638,Technique outcomes acute toxicities adults treated proton beam craniospinal irradiation,0,0.0
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.,Nature genetics,Nat. Genet.,2014-01-12,"Craniopharyngiomas are epithelial tumors that typically arise in the suprasellar region of the brain. Patients experience substantial clinical sequelae from both extension of the tumors and therapeutic interventions that damage the optic chiasm, the pituitary stalk and the hypothalamic area. Using whole-exome sequencing, we identified mutations in CTNNB1 (-catenin) in nearly all adamantinomatous craniopharyngiomas examined (11/12, 92%) and recurrent mutations in BRAF (resulting in p.Val600Glu) in all papillary craniopharyngiomas (3/3, 100%). Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors). The CTNNB1 and BRAF mutations were clonal in each tumor subtype, and we detected no other recurrent mutations or genomic aberrations in either subtype. Adamantinomatous and papillary craniopharyngiomas harbor mutations that are mutually exclusive and clonal. These findings have important implications for the diagnosis and treatment of these neoplasms. ",Journal Article,2200.0,174.0,Craniopharyngiomas epithelial typically arise suprasellar region brain Patients experience substantial clinical sequelae extension therapeutic interventions damage optic chiasm pituitary stalk hypothalamic area whole-exome sequencing identified CTNNB1 -catenin nearly adamantinomatous craniopharyngiomas examined 11/12 92 recurrent BRAF resulting p.Val600Glu papillary craniopharyngiomas 3/3 100 Targeted genotyping revealed BRAF p.Val600Glu 95 papillary craniopharyngiomas 36 39 CTNNB1 96 adamantinomatous craniopharyngiomas 51 53 CTNNB1 BRAF clonal subtype detected recurrent genomic aberrations subtype Adamantinomatous papillary craniopharyngiomas harbor mutually exclusive clonal findings important implications diagnosis treatment neoplasms,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[10708, 32, 701, 57, 17, 1969, 3043, 4, 3, 13122, 1053, 1, 3, 342, 7, 730, 1281, 38, 4156, 29, 110, 2401, 1, 3, 57, 2, 189, 1151, 17, 1350, 3, 5670, 14583, 3, 23392, 2, 3, 7531, 965, 75, 902, 2865, 615, 21, 108, 138, 4, 4485, 1458, 1778, 4, 1857, 62, 22825, 10708, 409, 175, 133, 937, 2, 387, 138, 4, 566, 1113, 4, 19, 16999, 4, 62, 1796, 10708, 27, 27, 394, 238, 2686, 553, 566, 19, 16999, 4, 48, 1, 1796, 10708, 511, 1, 587, 57, 2, 258, 1, 4485, 4, 921, 1, 22825, 10708, 725, 1, 699, 57, 3, 4485, 2, 566, 138, 11, 1946, 4, 296, 30, 875, 2, 21, 530, 77, 127, 387, 138, 15, 572, 2152, 4, 361, 875, 22825, 2, 1796, 10708, 2760, 138, 17, 32, 5575, 4804, 2, 1946, 46, 272, 47, 305, 1268, 9, 3, 147, 2, 24, 1, 46, 1179]",1055.0,24413733,Exome sequencing identifies BRAF papillary craniopharyngiomas,0,0.0
When and when not to use testosterone for palliation in cancer care.,Current oncology reports,Curr Oncol Rep,2014-04-01,"Hypogonadism is common throughout the illness trajectory of patients with cancer. About two thirds of male patients with advanced cancer have hypothalamic-pituitary-gonadal dysfunction and low testosterone levels. Chronic inflammation, comorbidities, cachexia, chemotherapy, and medications such as opioids, megestrol acetate, and corticosteroids contribute to primary and secondary hypogonadism. Studies have reported increased symptom burden, diminished quality of life, and poor prognosis associated with low testosterone levels in males with cancer. The Endocrine Society has published clinical practice guidelines for replacing testosterone in symptomatic patients with chronic illness and in patients receiving opioids; however, the role of testosterone therapy specifically in patients with cancer is not addressed. This review explores the potential benefits and limitations of testosterone replacement on the basis of current evidence. ",Journal Article,2121.0,6.0,Hypogonadism common illness trajectory patients thirds male patients advanced hypothalamic-pituitary-gonadal dysfunction low testosterone levels Chronic inflammation comorbidities cachexia chemotherapy medications opioids megestrol acetate corticosteroids contribute primary secondary hypogonadism Studies reported increased symptom burden diminished quality life poor prognosis associated low testosterone levels males Endocrine Society published clinical practice guidelines replacing testosterone symptomatic patients chronic illness patients receiving opioids role testosterone therapy specifically patients addressed review explores potential benefits limitations testosterone replacement basis current evidence,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[10616, 16, 186, 2432, 3, 2973, 6118, 1, 7, 5, 12, 545, 100, 5438, 1, 1045, 7, 5, 131, 12, 47, 7531, 12098, 7999, 1527, 2, 154, 2660, 148, 442, 1815, 1909, 4807, 56, 2, 2679, 225, 22, 4353, 9740, 3424, 2, 3876, 1248, 6, 86, 2, 568, 10616, 94, 47, 210, 101, 934, 892, 2849, 372, 1, 358, 2, 334, 356, 41, 5, 154, 2660, 148, 4, 2296, 5, 12, 3, 1293, 1174, 71, 983, 38, 758, 677, 9, 9574, 2660, 4, 1704, 7, 5, 442, 2973, 2, 4, 7, 357, 4353, 137, 3, 200, 1, 2660, 36, 1225, 4, 7, 5, 12, 16, 44, 2814, 26, 206, 6829, 3, 174, 1141, 2, 1939, 1, 2660, 3892, 23, 3, 877, 1, 291, 241]",928.0,24510740,use testosterone palliation care,10,0.09433962264150944
Combined high-field intraoperative magnetic resonance imaging and endoscopy increase extent of resection and progression-free survival for pituitary adenomas.,Pituitary,Pituitary,2015-02-01,"The clinical benefit of combined intraoperative magnetic resonance imaging (iMRI) and endoscopy for transsphenoidal pituitary adenoma resection has not been completely characterized. This study assessed the impact of microscopy, endoscopy, and/or iMRI on progression-free survival, extent of resection status (gross-, near-, and sub-total resection), and operative complications. Retrospective analyses were performed on 446 transsphenoidal pituitary adenoma surgeries at a single institution between 1998 and 2012. Multivariate analyses were used to control for baseline characteristics, differences during extent of resection status, and progression-free survival analysis. Additional surgery was performed after iMRI in 56/156 cases (35.9%), which led to increased extent of resection status in 15/156 cases (9.6%). Multivariate ordinal logistic regression revealed no increase in extent of resection status following iMRI or endoscopy alone; however, combining these modalities increased extent of resection status (odds ratio 2.05, 95% CI 1.21-3.46) compared to conventional transsphenoidal microsurgery. Multivariate Cox regression revealed that reduced extent of resection status shortened progression-free survival for near- versus gross-total resection [hazard ratio (HR) 2.87, 95% CI 1.24-6.65] and sub- versus near-total resection (HR 2.10; 95% CI 1.00-4.40). Complication comparisons between microscopy, endoscopy, and iMRI revealed increased perioperative deaths for endoscopy versus microscopy (4/209 and 0/237, respectively), but this difference was non-significant considering multiple post hoc comparisons (Fisher exact, p = 0.24). Combined use of endoscopy and iMRI increased pituitary adenoma extent of resection status compared to conventional transsphenoidal microsurgery, and increased extent of resection status was associated with longer progression-free survival. Treatment modality combination did not significantly impact complication rate.",Journal Article,1815.0,27.0,clinical benefit combined intraoperative magnetic resonance imaging iMRI endoscopy transsphenoidal pituitary adenoma resection completely characterized assessed impact microscopy endoscopy and/or iMRI progression-free survival extent resection status gross- near- sub-total resection operative complications Retrospective performed 446 transsphenoidal pituitary adenoma surgeries single institution 1998 2012 Multivariate control baseline characteristics differences extent resection status progression-free survival Additional surgery performed iMRI 56/156 cases 35.9 led increased extent resection status 15/156 cases 9.6 Multivariate ordinal logistic regression revealed increase extent resection status following iMRI endoscopy combining modalities increased extent resection status odds ratio 2.05 95 CI 1.21-3.46 compared conventional transsphenoidal microsurgery Multivariate Cox regression revealed reduced extent resection status shortened progression-free survival near- versus gross-total resection hazard ratio HR 2.87 95 CI 1.24-6.65 sub- versus near-total resection HR 2.10 95 CI 1.00-4.40 Complication comparisons microscopy endoscopy iMRI revealed increased perioperative deaths endoscopy versus microscopy 4/209 0/237 respectively difference non-significant considering multiple post hoc comparisons Fisher exact p 0.24 Combined use endoscopy iMRI increased pituitary adenoma extent resection status compared conventional transsphenoidal microsurgery increased extent resection status associated longer progression-free survival Treatment modality combination significantly impact complication rate,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 38, 247, 1, 397, 1720, 1484, 1535, 270, 22833, 2, 4199, 9, 14214, 2434, 170, 71, 44, 85, 2500, 765, 26, 45, 275, 3, 345, 1, 3804, 4199, 2, 15, 22833, 23, 91, 115, 25, 1039, 1, 170, 156, 1789, 1829, 2, 551, 181, 170, 2, 1208, 521, 459, 318, 11, 173, 23, 9849, 14214, 2434, 5305, 28, 8, 226, 731, 59, 1850, 2, 1195, 331, 318, 11, 95, 6, 182, 9, 330, 374, 362, 190, 1039, 1, 170, 156, 2, 91, 115, 25, 65, 402, 152, 10, 173, 50, 22833, 4, 664, 5693, 140, 465, 83, 92, 836, 6, 101, 1039, 1, 170, 156, 4, 167, 5693, 140, 83, 49, 331, 9608, 812, 320, 553, 77, 344, 4, 1039, 1, 170, 156, 366, 22833, 15, 4199, 279, 137, 1525, 46, 1558, 101, 1039, 1, 170, 156, 610, 197, 18, 474, 48, 58, 14, 239, 27, 641, 72, 6, 809, 14214, 16857, 331, 418, 320, 553, 17, 405, 1039, 1, 170, 156, 6151, 91, 115, 25, 9, 1829, 185, 1789, 181, 170, 360, 197, 168, 18, 912, 48, 58, 14, 259, 49, 556, 2, 551, 185, 1829, 181, 170, 168, 18, 79, 48, 58, 14, 2038, 39, 327, 1447, 2213, 59, 3804, 4199, 2, 22833, 553, 101, 1547, 1043, 9, 4199, 185, 3804, 39, 5941, 2, 13, 7296, 106, 84, 26, 523, 10, 220, 93, 3075, 232, 539, 5428, 2213, 3135, 2472, 19, 13, 259, 397, 119, 1, 4199, 2, 22833, 101, 2434, 1039, 1, 170, 156, 72, 6, 809, 14214, 16857, 2, 101, 1039, 1, 170, 156, 10, 41, 5, 589, 91, 115, 25, 24, 1396, 150, 205, 44, 97, 345, 1447, 116]",1880.0,24599833,Combined high-field intraoperative magnetic resonance imaging endoscopy increase extent resection progression-free survival pituitary adenomas,0,0.0
Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.,Science translational medicine,Sci Transl Med,2014-04-01,"Hypophysitis is a chronic inflammation of the pituitary gland of unknown (primary forms) or recognizable (secondary forms) etiology, such as the use of ipilimumab in cancer immunotherapy. Ipilimumab, which blocks the T cell inhibitory molecule CTLA-4 (cytotoxic T lymphocyte antigen-4), induces hypophysitis in about 4% of patients through unknown mechanisms. We first established a model of secondary hypophysitis by repeated injections of a CTLA-4 blocking antibody into SJL/J or C57BL/6J mice, and showed that they developed lymphocytic infiltration of the pituitary gland and circulating pituitary antibodies. We next assessed the prevalence of pituitary antibodies in a cohort of 20 patients with advanced melanoma or prostate cancer, 7 with a clinical diagnosis of hypophysitis, before and after ipilimumab administration. Pituitary antibodies, negative at baseline, developed in the 7 patients with hypophysitis but not in the 13 without it; these antibodies predominantly recognized thyrotropin-, follicle-stimulating hormone-, and corticotropin-secreting cells. We then hypothesized that the injected CTLA-4 antibody could cause pituitary toxicity if bound to CTLA-4 antigen expressed ""ectopically"" on pituitary endocrine cells. Pituitary glands indeed expressed CTLA-4 at both RNA and protein levels, particularly in a subset of prolactin- and thyrotropin-secreting cells. Notably, these cells became the site of complement activation, featuring deposition of C3d and C4d components and an inflammatory cascade akin to that seen in type II hypersensitivity. In summary, the study offers a mechanism to explain the pituitary toxicity observed in patients receiving ipilimumab, and highlights the utility of measuring pituitary antibodies in this form of secondary hypophysitis. ",Clinical Trial,2121.0,209.0,Hypophysitis chronic inflammation pituitary gland unknown primary forms recognizable secondary forms etiology use ipilimumab immunotherapy Ipilimumab blocks inhibitory molecule CTLA-4 cytotoxic lymphocyte antigen-4 induces hypophysitis 4 patients unknown mechanisms established model secondary hypophysitis repeated injections CTLA-4 blocking antibody SJL/J C57BL/6J mice showed developed lymphocytic infiltration pituitary gland circulating pituitary antibodies assessed prevalence pituitary antibodies cohort 20 patients advanced melanoma prostate 7 clinical diagnosis hypophysitis ipilimumab administration Pituitary antibodies negative baseline developed 7 patients hypophysitis 13 antibodies predominantly recognized thyrotropin- follicle-stimulating hormone- corticotropin-secreting hypothesized injected CTLA-4 antibody cause pituitary toxicity bound CTLA-4 antigen expressed `` ectopically '' pituitary endocrine Pituitary glands expressed CTLA-4 RNA levels particularly subset prolactin- thyrotropin-secreting Notably site complement activation featuring deposition C3d C4d components inflammatory cascade akin seen type II hypersensitivity summary offers mechanism explain pituitary toxicity observed patients receiving ipilimumab highlights utility measuring pituitary antibodies form secondary hypophysitis,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12333, 16, 8, 442, 1815, 1, 3, 2326, 1, 860, 86, 2377, 15, 13908, 568, 2377, 2855, 225, 22, 3, 119, 1, 1306, 4, 12, 726, 1306, 92, 2860, 3, 102, 31, 1810, 1354, 2127, 39, 759, 102, 1448, 448, 39, 1516, 12333, 4, 545, 39, 1, 7, 298, 860, 483, 21, 157, 635, 8, 202, 1, 568, 12333, 20, 2113, 4344, 1, 8, 2127, 39, 2521, 548, 237, 64144, 3543, 15, 7049, 16688, 399, 2, 224, 17, 491, 276, 1193, 2084, 1, 3, 2326, 2, 1033, 890, 21, 1305, 275, 3, 1078, 1, 890, 4, 8, 180, 1, 179, 7, 5, 131, 15, 12, 67, 5, 8, 38, 147, 1, 12333, 348, 2, 50, 1306, 634, 890, 199, 28, 330, 276, 4, 3, 67, 7, 5, 12333, 84, 44, 4, 3, 233, 187, 192, 46, 890, 2117, 1904, 16665, 9109, 2122, 785, 2, 45450, 5052, 37, 21, 818, 1237, 17, 3, 2651, 2127, 39, 548, 359, 708, 155, 492, 2951, 6, 2127, 39, 448, 570, 11744, 522, 23, 1293, 37, 3966, 4462, 570, 2127, 39, 28, 110, 893, 2, 178, 148, 823, 4, 8, 697, 1, 10841, 2, 16665, 5052, 37, 2552, 46, 37, 3451, 3, 606, 1, 3731, 363, 15937, 6686, 1, 64145, 2, 64146, 1628, 2, 35, 1291, 4678, 16693, 6, 17, 527, 4, 267, 215, 4034, 4, 1962, 3, 45, 2339, 8, 670, 6, 2943, 3, 155, 164, 4, 7, 357, 1306, 2, 2527, 3, 1207, 1, 2978, 890, 4, 26, 1297, 1, 568, 12333]",1640.0,24695685,Pituitary expression CTLA-4 mediates hypophysitis secondary administration CTLA-4 blocking antibody,0,0.0
"Descriptive epidemiology of pituitary tumors in the United States, 2004-2009.",Journal of neurosurgery,J. Neurosurg.,2014-06-13,"Pituitary tumors are abnormal growths that develop in the pituitary gland. The Central Brain Tumor Registry of the United States (CBTRUS) contains the largest aggregation of population-based data on the incidence of primary CNS tumors in the US. These data were used to determine the incidence of tumors of the pituitary and associated trends between 2004 and 2009. Using incidence data from 49 population-based state cancer registries, 2004-2009, age-adjusted incidence rates per 100,000 population for pituitary tumors with ICD-O-3 (International Classification of Diseases for Oncology, Third Edition) histology codes 8040, 8140, 8146, 8246, 8260, 8270, 8271, 8272, 8280, 8281, 8290, 8300, 8310, 8323, 9492 (site C75.1 only), and 9582 were calculated overall and by patient sex, race, Hispanic ethnicity, and age at diagnosis. Corresponding annual percent change (APC) scores and 95% confidence intervals were also calculated using Joinpoint to characterize trends in incidence rates over time. Diagnostic confirmation by subregion of the US was also examined. The overall annual incidence rate increased from 2.52 (95% CI 2.46-2.58) in 2004 to 3.13 (95% CI 3.07-3.20) in 2009. Associated time trend yielded an APC of 4.25% (95% CI 2.91%-5.61%). When stratifying by patient sex, the annual incidence rate increased from 2.42 (95% CI 2.33-2.50) to 2.94 (95% CI 2.85-3.03) in men and 2.70 (95% CI 2.62-2.79) to 3.40 (95% CI 3.31-3.49) in women, with APCs of 4.35% (95% CI 3.21%-5.51%) and 4.34% (95% CI 2.23%-6.49%), respectively. When stratifying by race, the annual incidence rate increased from 2.31 (95% CI 2.25-2.37) to 2.81 (95% CI 2.74-2.88) in whites, 3.99 (95% CI 3.77-4.23) to 5.31 (95% CI 5.06-5.56) in blacks, 1.77 (95% CI 1.26-2.42) to 2.52 (95% CI 1.96-3.19) in American Indians or Alaska Natives, and 1.86 (95% CI 1.62-2.13) to 2.03 (95% CI 1.80-2.28) in Asians or Pacific Islanders, with APCs of 3.91% (95% CI 2.88%-4.95%), 5.25% (95% CI 3.19%-7.36%), 5.31% (95% CI -0.11% to 11.03%), and 2.40% (95% CI -3.20% to 8.31%), respectively. When stratifying by Hispanic ethnicity, the annual incidence rate increased from 2.46 (95% CI 2.40-2.52) to 3.03 (95% CI 2.97-3.10) in non-Hispanics and 3.12 (95% CI 2.91-3.34) to 4.01 (95% CI 3.80-4.24) in Hispanics, with APCs of 4.15% (95% CI 2.67%-5.65%) and 5.01% (95% CI 4.42%-5.60%), respectively. When stratifying by age at diagnosis, the incidence of pituitary tumor was highest for those 65-74 years old and lowest for those 15-24 years old, with corresponding overall age-adjusted incidence rates of 6.39 (95% CI 6.24-6.54) and 1.56 (95% CI 1.51-1.61), respectively. In this large patient cohort, the incidence of pituitary tumors reported between 2004 and 2009 was found to increase. Possible explanations for this increase include changes in documentation, changes in the diagnosis and registration of these tumors, improved diagnostics, improved data collection, increased awareness of pituitary diseases among physicians and the public, longer life expectancies, and/or an actual increase in the incidence of these tumors in the US population.",Journal Article,2048.0,45.0,"Pituitary abnormal growths develop pituitary gland Central Brain Registry United States CBTRUS contains largest aggregation population-based incidence primary CNS determine incidence pituitary associated trends 2004 2009 incidence 49 population-based state registries 2004-2009 age-adjusted incidence rates 100,000 population pituitary ICD-O-3 International Classification Diseases Oncology Edition histology codes 8040 8140 8146 8246 8260 8270 8271 8272 8280 8281 8290 8300 8310 8323 9492 site C75.1 9582 calculated overall patient sex race Hispanic ethnicity age diagnosis Corresponding annual percent change APC scores 95 confidence intervals calculated Joinpoint characterize trends incidence rates time Diagnostic confirmation subregion examined overall annual incidence rate increased 2.52 95 CI 2.46-2.58 2004 3.13 95 CI 3.07-3.20 2009 Associated time trend yielded APC 4.25 95 CI 2.91 -5.61 stratifying patient sex annual incidence rate increased 2.42 95 CI 2.33-2.50 2.94 95 CI 2.85-3.03 men 2.70 95 CI 2.62-2.79 3.40 95 CI 3.31-3.49 women APCs 4.35 95 CI 3.21 -5.51 4.34 95 CI 2.23 -6.49 respectively stratifying race annual incidence rate increased 2.31 95 CI 2.25-2.37 2.81 95 CI 2.74-2.88 whites 3.99 95 CI 3.77-4.23 5.31 95 CI 5.06-5.56 blacks 1.77 95 CI 1.26-2.42 2.52 95 CI 1.96-3.19 American Indians Alaska Natives 1.86 95 CI 1.62-2.13 2.03 95 CI 1.80-2.28 Asians Pacific Islanders APCs 3.91 95 CI 2.88 -4.95 5.25 95 CI 3.19 -7.36 5.31 95 CI -0.11 11.03 2.40 95 CI -3.20 8.31 respectively stratifying Hispanic ethnicity annual incidence rate increased 2.46 95 CI 2.40-2.52 3.03 95 CI 2.97-3.10 non-Hispanics 3.12 95 CI 2.91-3.34 4.01 95 CI 3.80-4.24 Hispanics APCs 4.15 95 CI 2.67 -5.65 5.01 95 CI 4.42 -5.60 respectively stratifying age diagnosis incidence pituitary highest 65-74 years old lowest 15-24 years old corresponding overall age-adjusted incidence rates 6.39 95 CI 6.24-6.54 1.56 95 CI 1.51-1.61 respectively large patient cohort incidence pituitary reported 2004 2009 increase Possible explanations increase include changes documentation changes diagnosis registration improved diagnostics improved collection increased awareness pituitary diseases physicians public longer life expectancies and/or actual increase incidence population",0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[57, 32, 1668, 21451, 17, 690, 4, 3, 2326, 3, 854, 342, 30, 1608, 1, 3, 1088, 907, 35829, 4862, 3, 2166, 6598, 1, 266, 90, 74, 23, 3, 287, 1, 86, 1025, 57, 4, 3, 843, 46, 74, 11, 95, 6, 223, 3, 287, 1, 57, 1, 3, 2, 41, 1963, 59, 1131, 2, 1238, 75, 287, 74, 29, 739, 266, 90, 1309, 12, 3768, 1131, 1238, 89, 586, 287, 151, 379, 394, 984, 266, 9, 57, 5, 7320, 1990, 27, 944, 947, 1, 1342, 9, 413, 1282, 3580, 784, 5271, 46571, 40756, 64503, 64504, 40757, 64505, 48430, 64506, 64507, 64508, 48431, 38733, 64509, 64510, 48432, 606, 20400, 14, 158, 2, 64511, 11, 981, 63, 2, 20, 69, 1035, 1047, 1776, 2091, 2, 89, 28, 147, 1734, 2114, 714, 707, 2528, 703, 2, 48, 307, 1582, 11, 120, 981, 75, 16025, 6, 1507, 1963, 4, 287, 151, 252, 98, 752, 3551, 20, 31914, 1, 3, 843, 10, 120, 409, 3, 63, 2114, 287, 116, 101, 29, 18, 653, 48, 58, 18, 641, 18, 717, 4, 1131, 6, 27, 233, 48, 58, 27, 1615, 27, 179, 4, 1238, 41, 98, 853, 2178, 35, 2528, 1, 39, 243, 48, 58, 18, 970, 33, 713, 198, 5035, 20, 69, 1035, 3, 2114, 287, 116, 101, 29, 18, 595, 48, 58, 18, 466, 18, 212, 6, 18, 960, 48, 58, 18, 772, 27, 680, 4, 325, 2, 18, 431, 48, 58, 18, 744, 18, 842, 6, 27, 327, 48, 58, 27, 456, 27, 739, 4, 117, 5, 6966, 1, 39, 465, 48, 58, 27, 239, 33, 725, 2, 39, 562, 48, 58, 18, 382, 49, 739, 106, 198, 5035, 20, 1047, 3, 2114, 287, 116, 101, 29, 18, 456, 48, 58, 18, 243, 18, 567, 6, 18, 865, 48, 58, 18, 794, 18, 889, 4, 2556, 27, 1058, 48, 58, 27, 849, 39, 382, 6, 33, 456, 48, 58, 33, 1460, 33, 664, 4, 3544, 14, 849, 48, 58, 14, 432, 18, 595, 6, 18, 653, 48, 58, 14, 921, 27, 326, 4, 597, 17235, 15, 13762, 18481, 2, 14, 868, 48, 58, 14, 744, 18, 233, 6, 18, 680, 48, 58, 14, 493, 18, 339, 4, 5108, 15, 7450, 11846, 5, 6966, 1, 27, 970, 48, 58, 18, 889, 39, 48, 33, 243, 48, 58, 27, 326, 67, 511, 33, 456, 48, 58, 13, 175, 6, 175, 680, 2, 18, 327, 48, 58, 27, 179, 6, 66, 456, 106, 198, 5035, 20, 1776, 2091, 3, 2114, 287, 116, 101, 29, 18, 641, 48, 58, 18, 327, 18, 653, 6, 27, 680, 48, 58, 18, 1015, 27, 79, 4, 220, 3850, 2, 27, 133, 48, 58, 18, 970, 27, 562, 6, 39, 355, 48, 58, 27, 493, 39, 259, 4, 3850, 5, 6966, 1, 39, 167, 48, 58, 18, 598, 33, 556, 2, 33, 355, 48, 58, 39, 595, 33, 335, 106, 198, 5035, 20, 89, 28, 147, 3, 287, 1, 30, 10, 1076, 9, 135, 556, 794, 60, 1095, 2, 2101, 9, 135, 167, 259, 60, 1095, 5, 1734, 63, 89, 586, 287, 151, 1, 49, 587, 48, 58, 49, 259, 49, 667, 2, 14, 664, 48, 58, 14, 725, 14, 713, 106, 4, 26, 375, 69, 180, 3, 287, 1, 57, 210, 59, 1131, 2, 1238, 10, 204, 6, 344, 899, 11616, 9, 26, 344, 643, 400, 4, 4965, 400, 4, 3, 147, 2, 3169, 1, 46, 57, 231, 5197, 231, 74, 2442, 101, 3310, 1, 1342, 107, 1261, 2, 3, 3067, 589, 358, 15505, 2, 15, 35, 3480, 344, 4, 3, 287, 1, 46, 57, 4, 3, 843, 266]",2863.0,24926650,Descriptive epidemiology pituitary United States 2004-2009,0,0.0
Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche.,Nature,Nature,2014-07-23,"Age at menarche is a marker of timing of puberty in females. It varies widely between individuals, is a heritable trait and is associated with risks for obesity, type 2 diabetes, cardiovascular disease, breast cancer and all-cause mortality. Studies of rare human disorders of puberty and animal models point to a complex hypothalamic-pituitary-hormonal regulation, but the mechanisms that determine pubertal timing and underlie its links to disease risk remain unclear. Here, using genome-wide and custom-genotyping arrays in up to 182,416 women of European descent from 57 studies, we found robust evidence (P<510(-8)) for 123 signals at 106 genomic loci associated with age at menarche. Many loci were associated with other pubertal traits in both sexes, and there was substantial overlap with genes implicated in body mass index and various diseases, including rare disorders of puberty. Menarche signals were enriched in imprinted regions, with three loci (DLK1-WDR25, MKRN3-MAGEL2 and KCNK9) demonstrating parent-of-origin-specific associations concordant with known parental expression patterns. Pathway analyses implicated nuclear hormone receptors, particularly retinoic acid and -aminobutyric acid-B2 receptor signalling, among novel mechanisms that regulate pubertal timing in humans. Our findings suggest a genetic architecture involving at least hundreds of common variants in the coordinated timing of the pubertal transition. ",Journal Article,2008.0,241.0,"Age menarche marker timing puberty females varies widely individuals heritable trait associated risks obesity type 2 diabetes cardiovascular disease breast all-cause mortality Studies rare human disorders puberty animal models point complex hypothalamic-pituitary-hormonal regulation mechanisms determine pubertal timing underlie links disease risk remain unclear genome-wide custom-genotyping arrays 182,416 women European descent 57 studies robust evidence P 5 10 -8 123 signals 106 genomic loci associated age menarche loci associated pubertal traits sexes substantial overlap implicated body mass index diseases including rare disorders puberty Menarche signals enriched imprinted regions loci DLK1-WDR25 MKRN3-MAGEL2 KCNK9 demonstrating parent-of-origin-specific associations concordant known parental expression patterns Pathway implicated nuclear hormone receptors particularly retinoic acid -aminobutyric acid-B2 receptor signalling novel mechanisms regulate pubertal timing humans findings suggest genetic architecture involving hundreds common coordinated timing pubertal transition",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[89, 28, 6414, 16, 8, 952, 1, 1972, 1, 10302, 4, 2451, 192, 4037, 1792, 59, 869, 16, 8, 6874, 7648, 2, 16, 41, 5, 1098, 9, 1661, 267, 18, 1978, 2179, 34, 12, 2, 62, 708, 282, 94, 1, 622, 171, 1997, 1, 10302, 2, 2026, 274, 741, 6, 8, 840, 7531, 12098, 1761, 863, 84, 3, 483, 17, 223, 10467, 1972, 2, 5875, 211, 6491, 6, 34, 43, 918, 1200, 467, 75, 898, 1019, 2, 6980, 2686, 3923, 4, 126, 6, 5160, 10695, 117, 1, 1865, 9171, 29, 696, 94, 21, 204, 1922, 241, 19, 33, 79, 66, 9, 2698, 2312, 28, 3251, 572, 2012, 41, 5, 89, 28, 6414, 445, 2012, 11, 41, 5, 127, 10467, 8546, 4, 110, 13771, 2, 125, 10, 1281, 4526, 5, 214, 1771, 4, 642, 782, 558, 2, 747, 1342, 141, 622, 1997, 1, 10302, 6414, 2312, 11, 2220, 4, 9268, 1374, 5, 169, 2012, 19012, 64938, 48589, 64939, 2, 64940, 2219, 3841, 1, 1938, 112, 685, 3610, 5, 440, 3418, 55, 764, 308, 318, 1771, 928, 785, 1186, 823, 3887, 971, 2, 2655, 64941, 971, 6617, 153, 3128, 107, 229, 483, 17, 2288, 10467, 1972, 4, 3218, 114, 272, 309, 8, 336, 4447, 1267, 28, 506, 9035, 1, 186, 839, 4, 3, 5725, 1972, 1, 3, 10467, 1970]",1409.0,25231870,Parent-of-origin-specific allelic associations 106 genomic loci age menarche,0,0.0
Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-01-05,"To estimate the prevalence of and risk factors for growth hormone deficiency (GHD), luteinizing hormone/follicle-stimulating hormone deficiencies (LH/FSHD), thyroid-stimulatin hormone deficiency (TSHD), and adrenocorticotropic hormone deficiency (ACTHD) after cranial radiotherapy (CRT) in childhood cancer survivors (CCS) and assess the impact of untreated deficiencies. Retrospective study in an established cohort of CCS with 748 participants treated with CRT (394 men; mean age, 34.2 years [range, 19.4 to 59.6 years] observed for a mean of 27.3 years [range, 10.8 to 47.7 years]). Multivariable logistic regression was used to study associations between demographic and treatment-related risk factors and pituitary deficiencies, as well as associations between untreated deficiencies and cardiovascular health, bone mineral density (BMD), and physical fitness. The estimated point prevalence was 46.5% for GHD, 10.8% for LH/FSHD, 7.5% for TSHD, and 4% for ACTHD, and the cumulative incidence increased with follow-up. GHD and LH/FSHD were not treated in 99.7% and 78.5% of affected individuals, respectively. Male sex and obesity were significantly associated with LH/FSHD; white race was significant associated with LH/FSHD and TSHD. Compared with CRT doses less than 22 Gy, doses of 22 to 29.9 Gy were significantly associated with GHD; doses  22 Gy were associated with LH/FSHD; and doses  30 Gy were associated with TSHD and ACTHD. Untreated GHD was significantly associated with decreased muscle mass and exercise tolerance; untreated LH/FSHD was associated with hypertension, dyslipidemia, low BMD, and slow walking; and both deficits, independently, were associated with with abdominal obesity, low energy expenditure, and muscle weakness. Anterior pituitary deficits are common after CRT. Continued development over time is noted for GHD and LH/FSHD with possible associations between nontreatment of these conditions and poor health outcomes.",Comparative Study,1842.0,78.0,estimate prevalence risk factors growth hormone deficiency GHD luteinizing hormone/follicle-stimulating hormone deficiencies LH/FSHD thyroid-stimulatin hormone deficiency TSHD adrenocorticotropic hormone deficiency ACTHD cranial radiotherapy CRT childhood survivors CCS assess impact untreated deficiencies Retrospective established cohort CCS 748 participants treated CRT 394 men mean age 34.2 years range 19.4 59.6 years observed mean 27.3 years range 10.8 47.7 years Multivariable logistic regression associations demographic treatment-related risk factors pituitary deficiencies associations untreated deficiencies cardiovascular health bone mineral density BMD physical fitness estimated point prevalence 46.5 GHD 10.8 LH/FSHD 7.5 TSHD 4 ACTHD cumulative incidence increased follow-up GHD LH/FSHD treated 99.7 78.5 affected individuals respectively Male sex obesity significantly associated LH/FSHD white race significant associated LH/FSHD TSHD Compared CRT doses 22 Gy doses 22 29.9 Gy significantly associated GHD doses  22 Gy associated LH/FSHD doses  30 Gy associated TSHD ACTHD Untreated GHD significantly associated decreased muscle mass exercise tolerance untreated LH/FSHD associated hypertension dyslipidemia low BMD slow walking deficits independently associated abdominal obesity low energy expenditure muscle weakness Anterior pituitary deficits common CRT Continued development time noted GHD LH/FSHD possible associations nontreatment conditions poor health outcomes,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[6, 1191, 3, 1078, 1, 2, 43, 130, 9, 129, 785, 2299, 14863, 8223, 785, 9109, 2122, 785, 7159, 6531, 20874, 11260, 65427, 785, 2299, 35946, 2, 22401, 785, 2299, 21307, 50, 2565, 310, 1089, 4, 864, 12, 332, 5688, 2, 423, 3, 345, 1, 1278, 7159, 459, 45, 4, 35, 635, 180, 1, 5688, 5, 15714, 776, 73, 5, 1089, 9273, 325, 313, 89, 562, 18, 60, 184, 326, 39, 6, 728, 49, 60, 164, 9, 8, 313, 1, 428, 27, 60, 184, 79, 66, 6, 662, 67, 60, 658, 812, 320, 10, 95, 6, 45, 685, 59, 1540, 2, 24, 139, 43, 130, 2, 7159, 22, 149, 22, 685, 59, 1278, 7159, 2, 2179, 341, 5033, 1263, 3503, 2, 900, 5959, 3, 661, 741, 1078, 10, 641, 33, 9, 14863, 79, 66, 9, 6531, 20874, 67, 33, 9, 35946, 2, 39, 9, 21307, 2, 3, 967, 287, 101, 5, 166, 126, 14863, 2, 6531, 20874, 11, 44, 73, 4, 1058, 67, 2, 833, 33, 1, 1424, 869, 106, 1045, 1035, 2, 1661, 11, 97, 41, 5, 6531, 20874, 886, 1047, 10, 93, 41, 5, 6531, 20874, 2, 35946, 72, 5, 1089, 415, 299, 76, 350, 381, 415, 1, 350, 6, 462, 83, 381, 11, 97, 41, 5, 14863, 415, 749, 350, 381, 11, 41, 5, 6531, 20874, 2, 415, 749, 201, 381, 11, 41, 5, 35946, 2, 21307, 1278, 14863, 10, 97, 41, 5, 340, 1502, 782, 2, 2277, 2614, 1278, 6531, 20874, 10, 41, 5, 1824, 13981, 154, 3503, 2, 3645, 7467, 2, 110, 2752, 1042, 11, 41, 5, 5, 1467, 1661, 154, 2803, 8699, 2, 1502, 6408, 2882, 2752, 32, 186, 50, 1089, 1351, 193, 252, 98, 16, 1051, 9, 14863, 2, 6531, 20874, 5, 899, 685, 59, 23794, 1, 46, 1298, 2, 334, 341, 123]",1869.0,25559807,Anterior hypopituitarism adult survivors childhood treated cranial radiotherapy report St Jude Lifetime Cohort,15,0.14150943396226415
Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice.,The Journal of clinical endocrinology and metabolism,J. Clin. Endocrinol. Metab.,2015-02-19,"Germline mutations in genes coding succinate dehydrogenase (SDH) subunits A, B, C, and D have been identified in familial paragangliomas (PGLs)/pheochromocytomas (PHEOs) and other tumors. We described a GH-secreting pituitary adenoma (PA) caused by SDHD mutation in a patient with familial PGLs. Additional patients with PAs and SDHx defects have since been reported. We studied 168 patients with unselected sporadic PA and with the association of PAs, PGLs, and/or pheochromocytomas, a condition we named the 3P association (3PAs) for SDHx germline mutations. We also studied the pituitary gland and hormonal profile of Sdhb(+/-) mice and their wild-type littermates at different ages. No SDHx mutations were detected among sporadic PA, whereas three of four familial cases were positive for a mutation (75%). Most of the SDHx-deficient PAs were either prolactinomas or somatotropinomas. Pituitaries of Sdhb(+/-) mice older than 12 months had an increased number mainly of prolactin-secreting cells and several ultrastructural abnormalities such as intranuclear inclusions, altered chromatin nuclear pattern, and abnormal mitochondria. Igf-1 levels of mutant mice tended to be higher across age groups, whereas Prl and Gh levels varied according to age and sex. The present study confirms the existence of a new association that we termed 3PAs. It is due mostly to germline SDHx defects, although sporadic cases of 3PAs without SDHx defects also exist. Using Sdhb(+/-) mice, we provide evidence that pituitary hyperplasia in SDHx-deficient cells may be the initial abnormality in the cascade of events leading to PA formation.",Journal Article,1797.0,59.0,Germline coding succinate dehydrogenase SDH subunits B C identified familial paragangliomas PGLs /pheochromocytomas PHEOs described GH-secreting pituitary adenoma PA caused SDHD patient familial PGLs Additional patients PAs SDHx defects reported studied 168 patients unselected sporadic PA association PAs PGLs and/or pheochromocytomas condition named 3P association 3PAs SDHx germline studied pituitary gland hormonal profile Sdhb +/- mice wild-type littermates different ages SDHx detected sporadic PA familial cases positive 75 SDHx-deficient PAs prolactinomas somatotropinomas Pituitaries Sdhb +/- mice older 12 months increased number mainly prolactin-secreting ultrastructural abnormalities intranuclear inclusions altered chromatin nuclear pattern abnormal mitochondria Igf-1 levels mice tended higher age groups Prl Gh levels varied according age sex present confirms existence new association termed 3PAs germline SDHx defects sporadic cases 3PAs SDHx defects exist Sdhb +/- mice provide evidence pituitary hyperplasia SDHx-deficient initial abnormality cascade events leading PA formation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1009, 138, 4, 214, 3097, 8738, 2374, 5672, 6166, 8, 132, 256, 2, 427, 47, 85, 108, 4, 2200, 9034, 16459, 9977, 48863, 2, 127, 57, 21, 1027, 8, 4579, 5052, 2434, 3118, 1546, 20, 6551, 258, 4, 8, 69, 5, 2200, 16459, 402, 7, 5, 10043, 2, 8073, 2945, 47, 1192, 85, 210, 21, 656, 5359, 7, 5, 3594, 1928, 3118, 2, 5, 3, 248, 1, 10043, 16459, 2, 15, 9977, 8, 2850, 21, 8373, 3, 4302, 248, 41000, 9, 8073, 1009, 138, 21, 120, 656, 3, 2326, 2, 1761, 800, 1, 5168, 399, 2, 136, 955, 267, 17780, 28, 338, 2165, 77, 8073, 138, 11, 530, 107, 1928, 3118, 547, 169, 1, 294, 2200, 140, 11, 109, 9, 8, 258, 481, 96, 1, 3, 8073, 1971, 10043, 11, 361, 26749, 15, 65673, 65674, 1, 5168, 399, 434, 76, 133, 53, 42, 35, 101, 207, 2615, 1, 10841, 5052, 37, 2, 392, 13755, 1171, 225, 22, 26544, 16838, 1495, 2287, 928, 1177, 2, 1668, 5443, 1273, 14, 148, 1, 620, 399, 3886, 6, 40, 142, 716, 89, 271, 547, 14956, 2, 4579, 148, 2051, 768, 6, 89, 2, 1035, 3, 364, 45, 5120, 3, 5335, 1, 8, 217, 248, 17, 21, 4183, 41000, 192, 16, 520, 2754, 6, 1009, 8073, 2945, 242, 1928, 140, 1, 41000, 187, 8073, 2945, 120, 1923, 75, 5168, 399, 21, 377, 241, 17, 3176, 4, 8073, 1971, 37, 68, 40, 3, 388, 3698, 4, 3, 4678, 1, 281, 1049, 6, 3118, 1264]",1558.0,25695889,Pituitary adenoma paraganglioma/pheochromocytoma 3PAs succinate dehydrogenase defects humans mice,0,0.0
Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study.,European journal of endocrinology,Eur. J. Endocrinol.,2015-03-25,"Speculation remains that GH treatment is associated with increased neoplasia risk. Studies in GH-treated childhood cancer survivors suggested higher rates of second neoplasms, while cancer risk data for GH-treated and untreated hypopituitary adults have been variable. We present primary cancer risk data from the Hypopituitary Control and Complications Study (HypoCCS) with a focus on specific cancers, and assessment of recurrence rates for pituitary adenomas (PA) and craniopharyngiomas (CP). Incident neoplasms during HypoCCS were evaluated in 8418 GH-treated vs 1268 untreated patients for primary malignancies, 3668 GH-treated vs 720 untreated patients with PA history, and 956 GH-treated vs 102 untreated patients with CP history. Using population cancer rates, standardised incidence ratios (SIRs) were calculated for all primary cancers, breast, prostate, and colorectal cancers. Neoplasm rates in GH-treated vs untreated patients were analysed after propensity score adjustment of baseline treatment group imbalances. During mean follow-up of 4.8 years, 225 primary cancers were identified in GH-treated patients, with SIR of 0.82 (95% CI 0.71-0.93). SIRs (95% CI) for GH-treated patients were 0.59 (0.36-0.90) for breast, 0.80 (0.57-1.10) for prostate, and 0.62 (0.38-0.96) for colorectal cancers. Cancer risk was not statistically different between GH-treated and untreated patients (relative risk (RR)=1.00 (95% CI 0.70-1.41), P=0.98). Adjusted RR for recurrence was 0.91 (0.68-1.22), P=0.53 for PA and 1.32 (0.53-3.31), P=0.55 for CP. There was no increased risk for all-site cancers: breast, prostate or colorectal primary cancers in GH-treated patients during HypoCCS. GH treatment did not increase the risk of PA and CP recurrences.",Journal Article,1763.0,23.0,Speculation remains GH treatment associated increased neoplasia risk Studies GH-treated childhood survivors suggested higher rates second neoplasms risk GH-treated untreated hypopituitary adults variable present primary risk Hypopituitary Control Complications HypoCCS focus specific assessment recurrence rates pituitary adenomas PA craniopharyngiomas CP Incident neoplasms HypoCCS evaluated 8418 GH-treated vs 1268 untreated patients primary malignancies 3668 GH-treated vs 720 untreated patients PA history 956 GH-treated vs 102 untreated patients CP history population rates standardised incidence ratios SIRs calculated primary breast prostate colorectal Neoplasm rates GH-treated vs untreated patients analysed propensity score adjustment baseline treatment group imbalances mean follow-up 4.8 years 225 primary identified GH-treated patients SIR 0.82 95 CI 0.71-0.93 SIRs 95 CI GH-treated patients 0.59 0.36-0.90 breast 0.80 0.57-1.10 prostate 0.62 0.38-0.96 colorectal risk statistically different GH-treated untreated patients relative risk RR =1.00 95 CI 0.70-1.41 P=0.98 Adjusted RR recurrence 0.91 0.68-1.22 P=0.53 PA 1.32 0.53-3.31 P=0.55 CP increased risk all-site breast prostate colorectal primary GH-treated patients HypoCCS GH treatment increase risk PA CP recurrences,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[20453, 469, 17, 4579, 24, 16, 41, 5, 101, 2298, 43, 94, 4, 4579, 73, 864, 12, 332, 1148, 142, 151, 1, 419, 1179, 369, 12, 43, 74, 9, 4579, 73, 2, 1278, 35129, 857, 47, 85, 1347, 21, 364, 86, 12, 43, 74, 29, 3, 35129, 182, 2, 521, 45, 29660, 5, 8, 1222, 23, 112, 163, 2, 455, 1, 146, 151, 9, 2751, 3118, 2, 10708, 2541, 2631, 1179, 190, 29660, 11, 194, 4, 65842, 4579, 73, 105, 35974, 1278, 7, 9, 86, 441, 65843, 4579, 73, 105, 9746, 1278, 7, 5, 3118, 532, 2, 14137, 4579, 73, 105, 2867, 1278, 7, 5, 2541, 532, 75, 266, 12, 151, 14041, 287, 1137, 7120, 11, 981, 9, 62, 86, 163, 2, 163, 2131, 151, 4, 4579, 73, 105, 1278, 7, 11, 3141, 50, 1925, 368, 1852, 1, 330, 24, 87, 10143, 190, 313, 166, 126, 1, 39, 66, 60, 4011, 86, 163, 11, 108, 4, 4579, 73, 7, 5, 3636, 1, 13, 878, 48, 58, 13, 792, 13, 966, 7120, 48, 58, 9, 4579, 73, 7, 11, 13, 728, 13, 511, 13, 424, 9, 13, 493, 13, 696, 14, 79, 9, 2, 13, 744, 13, 519, 13, 921, 9, 163, 12, 43, 10, 44, 712, 338, 59, 4579, 73, 2, 1278, 7, 580, 43, 861, 14, 2038, 48, 58, 13, 431, 14, 605, 19, 13, 1096, 586, 861, 9, 146, 10, 13, 970, 13, 806, 14, 350, 19, 13, 699, 9, 3118, 2, 14, 531, 13, 699, 27, 456, 19, 13, 614, 9, 2541, 125, 10, 77, 101, 43, 9, 62, 606, 163, 15, 86, 163, 4, 4579, 73, 7, 190, 29660, 4579, 24, 205, 44, 344, 3, 43, 1, 3118, 2, 2541, 1593]",1599.0,25810462,Incidence primary intracranial tumour recurrences GH-treated untreated adult hypopituitary patients Hypopituitary Control Complications,0,0.0
Long-term quality of life after endonasal endoscopic resection of adult craniopharyngiomas.,Journal of neurosurgery,J. Neurosurg.,2015-04-17,"Craniopharyngiomas are benign parasellar tumors for which surgical removal, although potentially curative, often leads to morbidity with resulting decreases in quality of life (QOL). The endonasal endoscopic approach is a minimal-access technique for removing these tumors and may reduce postoperative morbidity. The QOL following this method for resection of craniopharyngiomas has not been documented. The authors reviewed a database of consecutive endonasal endoscopic surgeries done at Weill Cornell Medical College. Adult patients with histologically proven craniopharyngiomas were included who had completed either only postoperative (> 9 months) or both pre- and postoperative QOL forms, the Anterior Skull Base Quality of Life (ASBQ) questionnaire, and the 22-Item Sinonasal Outcome Test (SNOT-22). Rates of gross-total resection (GTR), complications, and visual and endocrine function were collected. Retrospective independence (Wen score) was also assigned. A contemporaneous group of patients undergoing endonasal endoscopic pituitary macroadenoma resection was used as a control. This study included 33 procedures performed in 31 patients. The average postoperative ASBQ score was 3.35 and the SNOT-22 score was 19.6. Better QOL was associated with GTR and postoperative radiation. Worse QOL was associated with persistent visual defects, hypopituitarism, tumor recurrence, increase in body mass index, and worsening Wen score. In a subset of 10 patients, both pre- and postoperative (> 9 months) QOL scores were obtained. Both ASBQ and SNOT-22 scores showed stability and a trend toward improvement, from 2.93  0.51 to 2.96  0.47 (ASBQ) and 23.7  10.8 to 18.4  11.6 (SNOT-22). Compared with 62 patients undergoing endoscopic pituitary macroadenoma resection, patients with craniopharyngiomas had worse postoperative QOL on the ASBQ (3.35 vs 3.80; p = 0.023) and SNOT-22 (19.6 vs 13.4; p = 0.12). This report of validated site-specific QOL following endoscopic surgery for craniopharyngiomas shows an overall maintenance of postoperative compared with preoperative QOL. Better QOL could be seen in patients with GTR and radiation therapy, and worse QOL was found in patients with visual or endocrine deficits. Nevertheless, patients with craniopharyngiomas still had worse QOL than those undergoing similar surgery for pituitary macroadenomas, confirming the worse prognosis of craniopharyngiomas even when removed via a minimally invasive approach. These measures should serve as benchmarks for comparison with open transcranial approaches to similar tumors.",Journal Article,1740.0,26.0,Craniopharyngiomas benign parasellar surgical removal potentially curative leads morbidity resulting decreases quality life QOL endonasal endoscopic approach minimal-access technique removing reduce postoperative morbidity QOL following resection craniopharyngiomas documented authors reviewed database consecutive endonasal endoscopic surgeries Weill Cornell Medical College Adult patients histologically proven craniopharyngiomas included completed postoperative 9 months pre- postoperative QOL forms Anterior Skull Base Quality Life ASBQ questionnaire 22-Item Sinonasal Outcome Test SNOT-22 Rates gross-total resection GTR complications visual endocrine function collected Retrospective independence Wen score assigned contemporaneous group patients undergoing endonasal endoscopic pituitary macroadenoma resection control included 33 procedures performed 31 patients average postoperative ASBQ score 3.35 SNOT-22 score 19.6 Better QOL associated GTR postoperative radiation Worse QOL associated persistent visual defects hypopituitarism recurrence increase body mass index worsening Wen score subset 10 patients pre- postoperative 9 months QOL scores obtained ASBQ SNOT-22 scores showed stability trend improvement 2.93  0.51 2.96  0.47 ASBQ 23.7  10.8 18.4  11.6 SNOT-22 Compared 62 patients undergoing endoscopic pituitary macroadenoma resection patients craniopharyngiomas worse postoperative QOL ASBQ 3.35 vs 3.80 p 0.023 SNOT-22 19.6 vs 13.4 p 0.12 report validated site-specific QOL following endoscopic surgery craniopharyngiomas shows overall maintenance postoperative compared preoperative QOL Better QOL seen patients GTR radiation therapy worse QOL patients visual endocrine deficits patients craniopharyngiomas worse QOL undergoing similar surgery pituitary macroadenomas confirming worse prognosis craniopharyngiomas removed minimally invasive approach measures serve benchmarks comparison open transcranial approaches similar,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[10708, 32, 1002, 18260, 57, 9, 92, 221, 2829, 242, 751, 1075, 629, 1940, 6, 787, 5, 1113, 2140, 4, 372, 1, 358, 1001, 3, 18636, 2056, 353, 16, 8, 1048, 1655, 1312, 9, 9026, 46, 57, 2, 68, 969, 573, 787, 3, 1001, 366, 26, 596, 9, 170, 1, 10708, 71, 44, 85, 1405, 3, 738, 446, 8, 609, 1, 935, 18636, 2056, 5305, 1822, 28, 20587, 19143, 484, 2979, 780, 7, 5, 2161, 1930, 10708, 11, 159, 54, 42, 781, 361, 158, 573, 83, 53, 15, 110, 671, 2, 573, 1001, 2377, 3, 2882, 5054, 1782, 372, 1, 358, 32423, 1770, 2, 3, 350, 3471, 7605, 228, 412, 32424, 350, 151, 1, 1789, 181, 170, 4833, 521, 2, 3046, 2, 1293, 343, 11, 786, 459, 5773, 48986, 368, 10, 120, 896, 8, 11633, 87, 1, 7, 479, 18636, 2056, 27905, 170, 10, 95, 22, 8, 182, 26, 45, 159, 466, 1369, 173, 4, 456, 7, 3, 1011, 573, 32423, 368, 10, 27, 465, 2, 3, 32424, 350, 368, 10, 326, 49, 380, 1001, 10, 41, 5, 4833, 2, 573, 121, 639, 1001, 10, 41, 5, 1882, 3046, 2945, 19832, 30, 146, 344, 4, 642, 782, 558, 2, 4323, 48986, 368, 4, 8, 697, 1, 79, 7, 110, 671, 2, 573, 83, 53, 1001, 703, 11, 683, 110, 32423, 2, 32424, 350, 703, 224, 2769, 2, 8, 853, 1317, 767, 29, 18, 966, 810, 13, 725, 6, 18, 921, 810, 13, 662, 32423, 2, 382, 67, 810, 79, 66, 6, 203, 39, 810, 175, 49, 32424, 350, 72, 5, 744, 7, 479, 2056, 27905, 170, 7, 5, 10708, 42, 639, 573, 1001, 23, 3, 32423, 27, 465, 105, 27, 493, 19, 13, 4482, 2, 32424, 350, 326, 49, 105, 233, 39, 19, 13, 133, 26, 414, 1, 938, 606, 112, 1001, 366, 2056, 152, 9, 10708, 1949, 35, 63, 1146, 1, 573, 72, 5, 498, 1001, 380, 1001, 359, 40, 527, 4, 7, 5, 4833, 2, 121, 36, 2, 639, 1001, 10, 204, 4, 7, 5, 3046, 15, 1293, 2752, 3873, 7, 5, 10708, 1234, 42, 639, 1001, 76, 135, 479, 288, 152, 9, 37188, 5030, 3, 639, 356, 1, 10708, 871, 198, 2264, 847, 8, 2144, 416, 353, 46, 1018, 257, 1833, 22, 9945, 9, 1155, 5, 1020, 33172, 611, 6, 288, 57]",2478.0,25884258,Long-term quality life endonasal endoscopic resection adult craniopharyngiomas,1,0.009433962264150943
Identification of targets for rational pharmacological therapy in childhood craniopharyngioma.,Acta neuropathologica communications,Acta Neuropathol Commun,2015-05-21,"Pediatric adamantinomatous craniopharyngioma (ACP) is a histologically benign but clinically aggressive brain tumor that arises from the sellar/suprasellar region. Despite a high survival rate with current surgical and radiation therapy (75-95 % at 10 years), ACP is associated with debilitating visual, endocrine, neurocognitive and psychological morbidity, resulting in excheptionally poor quality of life for survivors. Identification of an effective pharmacological therapy could drastically decrease morbidity and improve long term outcomes for children with ACP. Using mRNA microarray gene expression analysis of 15 ACP patient samples, we have found several pharmaceutical targets that are significantly and consistently overexpressed in our panel of ACP relative to other pediatric brain tumors, pituitary tumors, normal pituitary and normal brain tissue. Among the most highly expressed are several targets of the kinase inhibitor dasatinib - LCK, EPHA2 and SRC; EGFR pathway targets - AREG, EGFR and ERBB3; and other potentially actionable cancer targets - SHH, MMP9 and MMP12. We confirm by western blot that a subset of these targets is highly expressed in ACP primary tumor samples. We report here the first published transcriptome for ACP and the identification of targets for rational therapy. Experimental drugs targeting each of these gene products are currently being tested clinically and pre-clinically for the treatment of other tumor types. This study provides a rationale for further pre-clinical and clinical studies of novel pharmacological treatments for ACP. Development of mouse and cell culture models for ACP will further enable the translation of these targets from the lab to the clinic, potentially ushering in a new era in the treatment of ACP.",Journal Article,1706.0,42.0,Pediatric adamantinomatous craniopharyngioma ACP histologically benign clinically aggressive brain arises sellar/suprasellar region Despite high survival rate current surgical radiation therapy 75-95 10 years ACP associated debilitating visual endocrine neurocognitive psychological morbidity resulting excheptionally poor quality life survivors Identification effective pharmacological therapy drastically decrease morbidity improve long term outcomes children ACP mRNA microarray expression 15 ACP patient pharmaceutical targets significantly consistently overexpressed panel ACP relative pediatric brain pituitary normal pituitary normal brain tissue highly expressed targets kinase inhibitor dasatinib LCK EPHA2 SRC EGFR pathway targets AREG EGFR ERBB3 potentially actionable targets SHH MMP9 MMP12 confirm western blot subset targets highly expressed ACP primary report published transcriptome ACP identification targets rational therapy Experimental drugs targeting products currently tested clinically pre-clinically treatment types provides rationale pre-clinical clinical studies novel pharmacological treatments ACP Development mouse culture models ACP enable translation targets lab clinic potentially ushering new era treatment ACP,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[815, 22825, 7205, 6953, 16, 8, 2161, 1002, 84, 505, 571, 342, 30, 17, 6053, 29, 3, 14479, 13122, 1053, 550, 8, 64, 25, 116, 5, 291, 221, 2, 121, 36, 481, 48, 28, 79, 60, 6953, 16, 41, 5, 8099, 3046, 1293, 2958, 2, 2624, 787, 1113, 4, 66139, 334, 372, 1, 358, 9, 332, 911, 1, 35, 323, 3419, 36, 359, 11900, 775, 787, 2, 401, 319, 337, 123, 9, 541, 5, 6953, 75, 956, 1727, 145, 55, 65, 1, 167, 6953, 69, 347, 21, 47, 204, 392, 6278, 637, 17, 32, 97, 2, 2433, 1711, 4, 114, 993, 1, 6953, 580, 6, 127, 815, 342, 57, 57, 295, 2, 295, 342, 246, 107, 3, 96, 561, 570, 32, 392, 637, 1, 3, 216, 230, 1674, 15355, 5511, 2, 2023, 227, 308, 637, 14301, 227, 2, 6573, 2, 127, 751, 2856, 12, 637, 5170, 10356, 2, 41095, 21, 1843, 20, 1521, 2639, 17, 8, 697, 1, 46, 637, 16, 561, 570, 4, 6953, 86, 30, 347, 21, 414, 467, 3, 157, 983, 3917, 9, 6953, 2, 3, 911, 1, 637, 9, 2696, 36, 1560, 600, 529, 296, 1, 46, 145, 2766, 32, 694, 486, 650, 505, 2, 671, 505, 9, 3, 24, 1, 127, 30, 630, 26, 45, 777, 8, 1728, 9, 195, 671, 38, 2, 38, 94, 1, 229, 3419, 640, 9, 6953, 193, 1, 830, 2, 31, 2099, 274, 9, 6953, 303, 195, 3047, 3, 2691, 1, 46, 637, 29, 3, 14118, 6, 3, 1188, 751, 28591, 4, 8, 217, 1713, 4, 3, 24, 1, 6953]",1723.0,25990246,Identification targets rational pharmacological therapy childhood craniopharyngioma,6,0.05660377358490566
Central precocious puberty following the diagnosis and treatment of paediatric cancer and central nervous system tumours: presentation and long-term outcomes.,Clinical endocrinology,Clin. Endocrinol. (Oxf),2015-11-16,"To estimate the prevalence of central precocious puberty (CPP) after treatment for tumours and malignancies involving the central nervous system (CNS) and examine repercussions on growth and pubertal outcomes. Retrospective study of patients with tumours near and/or exposed to radiotherapy to the hypothalamus/pituitary axis (HPA). Patients with CPP were evaluated at puberty onset, completion of GnRH agonist treatment (GnRHa) and last follow-up. Multivariable analysis was used to test associations between tumour location, sex, age at CPP, GnRHa duration and a diagnosis of CPP with final height <-2SD score (SDS), gonadotropin deficiency (LH/FSHD) and obesity, respectively. Eighty patients (47 females) had CPP and were followed for 114  50 years (mean  SD). The prevalence of CPP was 152% overall, 292% following HPA tumours and 66% after radiotherapy for non-HPA tumours. Height <-2SDS was more common at the last follow-up than at the puberty onset (214% vs 24%, P = 0005). Obesity was more prevalent at the last follow-up than at the completion of GnRHa or the puberty onset (377%, 226% and 208%, respectively, P = 003). Longer duration of GnRHa was associated with increased odds of final height <-2SDS (OR = 21, 95% CI 10-43) and longer follow-up with obesity (OR = 13, 95% CI 11-16). LH/FSHD was diagnosed in 326%. There was no independent association between CPP and final height <-2SDS, and LH/FSHD and obesity in the subset of patients with HPA low-grade gliomas. Patients with organic CPP experience an incomplete recovery of growth and a high prevalence of LH/FSHD and obesity. Early diagnosis and treatment of CPP may limit further deterioration of final height prospects.",Journal Article,1527.0,15.0,estimate prevalence central precocious puberty CPP treatment tumours malignancies involving central nervous CNS examine repercussions growth pubertal outcomes Retrospective patients tumours near and/or exposed radiotherapy hypothalamus/pituitary axis HPA Patients CPP evaluated puberty onset completion GnRH agonist treatment GnRHa follow-up Multivariable test associations tumour location sex age CPP GnRHa duration diagnosis CPP final height -2SD score SDS gonadotropin deficiency LH/FSHD obesity respectively Eighty patients 47 females CPP followed 114  50 years mean  SD prevalence CPP 152 overall 292 following HPA tumours 66 radiotherapy non-HPA tumours Height -2SDS common follow-up puberty onset 214 vs 24 P 0005 Obesity prevalent follow-up completion GnRHa puberty onset 377 226 208 respectively P 003 Longer duration GnRHa associated increased odds final height -2SDS 21 95 CI 10-43 longer follow-up obesity 13 95 CI 11-16 LH/FSHD diagnosed 326 independent association CPP final height -2SDS LH/FSHD obesity subset patients HPA low-grade gliomas Patients organic CPP experience incomplete recovery growth high prevalence LH/FSHD obesity Early diagnosis treatment CPP limit deterioration final height prospects,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1191, 3, 1078, 1, 854, 26266, 10302, 17117, 50, 24, 9, 1319, 2, 441, 1267, 3, 854, 1880, 398, 1025, 2, 1004, 39826, 23, 129, 2, 10467, 123, 459, 45, 1, 7, 5, 1319, 1829, 2, 15, 2234, 6, 310, 6, 3, 12717, 12098, 2310, 14513, 7, 5, 17117, 11, 194, 28, 10302, 1707, 1438, 1, 7926, 3821, 24, 12060, 2, 1060, 166, 126, 658, 65, 10, 95, 6, 412, 685, 59, 770, 1147, 1035, 89, 28, 17117, 12060, 654, 2, 8, 147, 1, 17117, 5, 1457, 4594, 44235, 368, 8668, 6501, 2299, 6531, 20874, 2, 1661, 106, 2207, 7, 662, 2451, 42, 17117, 2, 11, 370, 9, 27168, 810, 21705, 60, 313, 810, 1270, 3, 1078, 1, 17117, 10, 21786, 63, 66960, 366, 14513, 1319, 2, 24012, 50, 310, 9, 220, 14513, 1319, 4594, 41232, 10, 80, 186, 28, 3, 1060, 166, 126, 76, 28, 3, 10302, 1707, 35510, 105, 15045, 19, 18638, 1661, 10, 80, 2485, 28, 3, 1060, 166, 126, 76, 28, 3, 1438, 1, 12060, 15, 3, 10302, 1707, 41233, 35042, 2, 36116, 106, 19, 20835, 589, 654, 1, 12060, 10, 41, 5, 101, 610, 1, 1457, 4594, 41232, 15, 15773, 48, 58, 19294, 21704, 2, 589, 166, 126, 5, 1661, 15, 12440, 48, 58, 19295, 14671, 6531, 20874, 10, 265, 4, 41234, 125, 10, 77, 306, 248, 59, 17117, 2, 1457, 4594, 41232, 2, 6531, 20874, 2, 1661, 4, 3, 697, 1, 7, 5, 14513, 154, 88, 1287, 7, 5, 9486, 17117, 730, 35, 2610, 1602, 1, 129, 2, 8, 64, 1078, 1, 6531, 20874, 2, 1661, 191, 147, 2, 24, 1, 17117, 68, 2385, 195, 4451, 1, 1457, 4594, 9643]",1638.0,26464129,Central precocious puberty following diagnosis treatment paediatric central nervous tumours presentation long-term outcomes,0,0.0
Association between Hyperprolactinemia and Granulomatous Mastitis.,The breast journal,Breast J,2015-12-26,"Granulomatous mastitis (GM) is a relatively uncommon inflammatory breast lesion with multiple suggested etiologies. Although most GM cases show association with lactation and pregnancy, a minority of cases have been linked to hyperprolactinemia caused by either dopamine antagonist medications or with intracranial lesions, such as pituitary adenoma. The goal of this study is to review the GM cases reported in the literature with a specific emphasis on those cases associated with hyperprolactinemia and prolactinomas and to identify cases of GM seen at the Cleveland Clinic Florida which demonstrate co-occurrences of GM and intracranial lesions. CoPath and Epic data bases at Cleveland Clinic Florida were searched for cases describing inflammatory breast lesions in patients with pituitary pathology. Chart reviews were conducted and pertinent medical history was extracted for case reports. H&E-stained paraffin-embedded sections retrieved from Cleveland Clinic Florida pathology storage were evaluated by light microscopy. Four cases showing a co-occurrence of GM and hyperprolactinemia were consequently identified. A prolactin-secreting pituitary adenoma was present in two of the three GM cases. The third case demonstrated a concomitant craniopharyngioma, which was also associated with a rise in serum prolactin. This phenomenon was presumably attributable to compression, resulting in compromised transport of dopamine to the adenohypophysis and subsequent disinhibition of prolactin secretion by lactotrophs. The fourth patient with GM had a similar history of elevated prolactin. Classical histopathological features of GM were found in all four cases, including noncaseating granulomas, multinucleated giant cells, epithelioid histiocytes, and chronic inflammation. Intriguingly, complete resolution of inflammatory breast lesions along with normalization of prolactin levels occurred following the surgical excision of the craniopharyngioma, suggesting that intracranial lesion-induced hyperprolactinemia might be directly causal in GM. Therefore, the authors would suggest screening for pituitary tumors and evaluate prolactin levels in the workup of GM patients without a recent history of lactation and pregnancy and no other identified etiology. ",Case Reports,1487.0,7.0,Granulomatous mastitis GM relatively uncommon inflammatory breast lesion multiple suggested etiologies GM cases association lactation pregnancy minority cases linked hyperprolactinemia caused dopamine antagonist medications intracranial lesions pituitary adenoma goal review GM cases reported literature specific emphasis cases associated hyperprolactinemia prolactinomas identify cases GM seen Cleveland Clinic Florida demonstrate co-occurrences GM intracranial lesions CoPath Epic bases Cleveland Clinic Florida searched cases describing inflammatory breast lesions patients pituitary pathology Chart reviews conducted pertinent medical history extracted case reports H E-stained paraffin-embedded sections retrieved Cleveland Clinic Florida pathology storage evaluated light microscopy cases showing co-occurrence GM hyperprolactinemia consequently identified prolactin-secreting pituitary adenoma present GM cases case demonstrated concomitant craniopharyngioma associated rise serum prolactin phenomenon presumably attributable compression resulting compromised transport dopamine adenohypophysis subsequent disinhibition prolactin secretion lactotrophs fourth patient GM similar history elevated prolactin Classical histopathological features GM cases including noncaseating granulomas multinucleated giant epithelioid histiocytes chronic inflammation Intriguingly complete resolution inflammatory breast lesions normalization prolactin levels occurred following surgical excision craniopharyngioma suggesting intracranial lesion-induced hyperprolactinemia directly causal GM authors suggest screening pituitary evaluate prolactin levels workup GM patients recent history lactation pregnancy identified etiology,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[11186, 46285, 2147, 16, 8, 1352, 2052, 1291, 1180, 5, 232, 1148, 8523, 242, 96, 2147, 140, 514, 248, 5, 12137, 2, 2290, 8, 2652, 1, 140, 47, 85, 1199, 6, 26545, 1546, 20, 361, 14918, 3137, 2679, 15, 5, 2089, 406, 225, 22, 2434, 3, 1326, 1, 26, 45, 16, 6, 206, 3, 2147, 140, 210, 4, 3, 789, 5, 8, 112, 3136, 23, 135, 140, 41, 5, 26545, 2, 26749, 2, 6, 255, 140, 1, 2147, 527, 28, 3, 7317, 1188, 10533, 92, 608, 1269, 8781, 1, 2147, 2, 2089, 406, 67373, 2, 8995, 74, 9412, 28, 7317, 1188, 10533, 11, 3080, 9, 140, 4950, 1291, 406, 4, 7, 5, 1117, 2937, 2004, 11, 426, 2, 5799, 484, 532, 10, 2484, 9, 473, 1198, 555, 563, 3386, 2487, 2505, 3013, 4539, 29, 7317, 1188, 10533, 1117, 7727, 11, 194, 20, 1691, 3804, 294, 140, 2069, 8, 1269, 2291, 1, 2147, 2, 26545, 11, 3244, 108, 8, 10841, 5052, 2434, 10, 364, 4, 100, 1, 3, 169, 2147, 140, 3, 1282, 473, 264, 8, 1781, 7205, 92, 10, 120, 41, 5, 8, 3693, 4, 524, 10841, 26, 3936, 10, 8682, 2971, 6, 3481, 1113, 4, 4867, 4294, 1, 14918, 6, 3, 49482, 2, 706, 36163, 1, 10841, 2935, 20, 67374, 3, 3608, 69, 5, 2147, 42, 8, 288, 532, 1, 804, 10841, 3781, 4370, 404, 1, 2147, 11, 204, 4, 62, 294, 140, 141, 67375, 22821, 15649, 6470, 37, 3838, 16734, 2, 442, 1815, 11550, 236, 2125, 1, 1291, 406, 1510, 5, 5924, 1, 10841, 148, 489, 366, 3, 221, 1366, 1, 3, 7205, 802, 17, 2089, 1180, 277, 26545, 822, 40, 1606, 5163, 4, 2147, 673, 3, 738, 688, 309, 453, 9, 57, 2, 376, 10841, 148, 4, 3, 4755, 1, 2147, 7, 187, 8, 435, 532, 1, 12137, 2, 2290, 2, 77, 127, 108, 2855]",2178.0,26705962,Association Hyperprolactinemia Granulomatous Mastitis,0,0.0
Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.,Pituitary,Pituitary,2016-08-01,"Pituitary carcinomas (PC) are uncommon neuroendocrine tumors, accounting for 0.1% of all pituitary tumors. The diagnosis of PC is based on the presence of metastases from a pituitary adenoma, and not by local invasion or pathological features alone. PC is typically resistant to therapy, with a median overall survival of only 31months. There is no standard treatment for PC, but maximal safe resection and radiation are performed when possible. Encouraging preliminary data on the use of temozolomide (TMZ)-based therapy has been previously reported. We report the response to therapy and safety of radiation with concurrent temozolomide (RT/TMZ) in 2 adult patients with heavily pretreated PC and extraneural metastases. Both patients had prior history of pituitary macroadenoma. At the time of diagnosis of PC, Ki-67% was 24.2 and 10%, with positive p53 staining in one case. Metastatic sites included lymph nodes, liver and bone. Case-1 received RT/TMZ to the tumor bed in the skull base and to the metastases in the cervical lymph nodes. Case-2 received RT/TMZ to recurrent tumor involving portacaval lymph nodes. Both patients achieved excellent long-term control of the sites of treated extraneural metastases, with no significant acute or delayed toxicity. RT/TMZ was safely delivered and might provide sustained control of extraneural metastases in PC. Although this retrospective report has limitations, RT/TMZ can be considered as a therapeutic option for the management of extraneural metastases in PC.",Case Reports,1268.0,8.0,Pituitary carcinomas PC uncommon neuroendocrine accounting 0.1 pituitary diagnosis PC based presence metastases pituitary adenoma local invasion pathological features PC typically resistant therapy median overall survival 31 months standard treatment PC maximal safe resection radiation performed possible Encouraging preliminary use temozolomide TMZ -based therapy previously reported report response therapy safety radiation concurrent temozolomide RT/TMZ 2 adult patients heavily pretreated PC extraneural metastases patients prior history pituitary macroadenoma time diagnosis PC Ki-67 24.2 10 positive p53 staining case Metastatic sites included lymph nodes liver bone Case-1 received RT/TMZ bed skull base metastases cervical lymph nodes Case-2 received RT/TMZ recurrent involving portacaval lymph nodes patients achieved excellent long-term control sites treated extraneural metastases significant acute delayed toxicity RT/TMZ safely delivered provide sustained control extraneural metastases PC retrospective report limitations RT/TMZ considered therapeutic option management extraneural metastases PC,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[826, 1341, 32, 2052, 1542, 57, 3116, 9, 13, 14, 1, 62, 57, 3, 147, 1, 1341, 16, 90, 23, 3, 463, 1, 196, 29, 8, 2434, 2, 44, 20, 293, 578, 15, 1301, 404, 279, 1341, 16, 1969, 436, 6, 36, 5, 8, 52, 63, 25, 1, 158, 456, 53, 125, 16, 77, 260, 24, 9, 1341, 84, 2725, 1165, 170, 2, 121, 32, 173, 198, 899, 2269, 1676, 74, 23, 3, 119, 1, 1537, 2081, 90, 36, 71, 85, 373, 210, 21, 414, 3, 51, 6, 36, 2, 367, 1, 121, 5, 750, 1537, 240, 2081, 4, 18, 780, 7, 5, 2447, 2193, 1341, 2, 16431, 196, 110, 7, 42, 324, 532, 1, 27905, 28, 3, 98, 1, 147, 1, 1341, 2311, 598, 10, 259, 18, 2, 79, 5, 109, 624, 1029, 4, 104, 473, 113, 633, 159, 263, 502, 2, 473, 14, 103, 240, 2081, 6, 3, 30, 2929, 4, 3, 5054, 1782, 2, 6, 3, 196, 4, 3, 263, 502, 473, 18, 103, 240, 2081, 6, 387, 30, 1267, 46882, 263, 502, 110, 7, 513, 1503, 319, 337, 182, 1, 3, 633, 1, 73, 16431, 196, 5, 77, 93, 286, 15, 1612, 155, 240, 2081, 10, 2268, 1623, 2, 822, 377, 2275, 182, 1, 16431, 196, 4, 1341, 242, 26, 459, 414, 71, 1939, 240, 2081, 122, 40, 515, 22, 8, 189, 1501, 9, 3, 284, 1, 16431, 196, 4, 1341]",1424.0,27106209,Radiotherapy concurrent temozolomide management extraneural metastases pituitary carcinoma,12,0.11320754716981132
Endonasal endoscopic reoperation for residual or recurrent craniopharyngiomas.,Journal of neurosurgery,J. Neurosurg.,2016-05-06,"OBJECTIVE Craniopharyngiomas can be difficult to remove completely based on their intimate relationship with surrounding visual and endocrine structures. Reoperations are not uncommon but have been associated with higher rates of complications and lower extents of resection. So radiation is often offered as an alternative to reoperation. The endonasal endoscopic transsphenoidal approach has been used in recent years for craniopharyngiomas previously removed with craniotomy. The impact of this approach on reoperations has not been widely investigated. METHODS The authors reviewed a prospectively acquired database of endonasal endoscopic resections of craniopharyngiomas over 11 years at Weill Cornell Medical College, NewYork-Presbyterian Hospital, performed by the senior authors. Reoperations were separated from first operations. Pre- and postoperative visual and endocrine function, tumor size, body mass index (BMI), quality of life (QOL), extent of resection (EOR), impact of prior radiation, and complications were compared between groups. EOR was divided into gross-total resection (GTR, 100%), near-total resection (NTR, > 95%), and subtotal resection (STR, < 95%). Univariate and multivariate analyses were performed. RESULTS Of the total 57 endonasal surgical procedures, 22 (39%) were reoperations. First-time operations and reoperations did not differ in tumor volume, radiological configuration, or patients' BMI. Hypopituitarism and diabetes insipidus (DI) were more common before reoperations (82% and 55%, respectively) compared with first operations (60% and 8.6%, respectively; p < 0.001). For the 46 patients in whom GTR was intended, rates of GTR and GTR+NTR were not significantly different between first operations (90% and 97%, respectively) and reoperations (80% and 100%, respectively). For reoperations, prior radiation and larger tumor volume had lower rates of GTR. Vision improved equally in first operations (80%) compared with reoperations (73%). New anterior pituitary deficits were more common in first operations compared with reoperations (51% vs 23%, respectively; p = 0.08), while new DI was more common in reoperations compared with first-time operations (80% vs 47%, respectively; p = 0.08). Nonendocrine complications occurred in 2 (3.6%) first-time operations and no reoperations. Tumor regrowth occurred in 6 patients (11%) over a median follow-up of 46 months and was not different between first versus reoperations, but was associated with STR (33%) compared with GTR+NTR (4%; p = 0.02) and with not receiving radiation after STR (67% vs 22%; p = 0.08). The overall BMI increased significantly from 28.7 to 34.8 kg/m<sup>2</sup> over 10 years. Six months after surgery, there was a significant improvement in QOL, which was similar between first-time operations and reoperations, and negatively correlated with STR. CONCLUSIONS Endonasal endoscopic transsphenoidal reoperation results in similar EOR, visual outcome, and improvement in QOL as first-time operations, with no significant increase in complications. EOR is more impacted by tumor volume and prior radiation. Reoperations should be offered to patients with recurrent craniopharyngiomas and may be preferable to radiation in patients in whom GTR or NTR can be achieved.",Journal Article,1355.0,32.0,OBJECTIVE Craniopharyngiomas difficult remove completely based intimate relationship surrounding visual endocrine structures Reoperations uncommon associated higher rates complications lower extents resection radiation offered alternative reoperation endonasal endoscopic transsphenoidal approach recent years craniopharyngiomas previously removed craniotomy impact approach reoperations widely investigated METHODS authors reviewed prospectively acquired database endonasal endoscopic resections craniopharyngiomas 11 years Weill Cornell Medical College NewYork-Presbyterian Hospital performed senior authors Reoperations separated operations Pre- postoperative visual endocrine function size body mass index BMI quality life QOL extent resection EOR impact prior radiation complications compared groups EOR divided gross-total resection GTR 100 near-total resection NTR 95 subtotal resection STR 95 Univariate multivariate performed total 57 endonasal surgical procedures 22 39 reoperations First-time operations reoperations differ volume radiological configuration patients BMI Hypopituitarism diabetes insipidus DI common reoperations 82 55 respectively compared operations 60 8.6 respectively p 0.001 46 patients GTR intended rates GTR GTR+NTR significantly different operations 90 97 respectively reoperations 80 100 respectively reoperations prior radiation larger volume lower rates GTR Vision improved equally operations 80 compared reoperations 73 New anterior pituitary deficits common operations compared reoperations 51 vs 23 respectively p 0.08 new DI common reoperations compared first-time operations 80 vs 47 respectively p 0.08 Nonendocrine complications occurred 2 3.6 first-time operations reoperations regrowth occurred 6 patients 11 median follow-up 46 months different versus reoperations associated STR 33 compared GTR+NTR 4 p 0.02 receiving radiation STR 67 vs 22 p 0.08 overall BMI increased significantly 28.7 34.8 kg/m sup 2 /sup 10 years months surgery significant improvement QOL similar first-time operations reoperations negatively correlated STR CONCLUSIONS Endonasal endoscopic transsphenoidal reoperation similar EOR visual outcome improvement QOL first-time operations significant increase complications EOR impacted volume prior radiation Reoperations offered patients recurrent craniopharyngiomas preferable radiation patients GTR NTR achieved,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[461, 10708, 122, 40, 1740, 6, 7930, 2500, 90, 23, 136, 14894, 858, 5, 2976, 3046, 2, 1293, 2414, 10691, 32, 44, 2052, 84, 47, 85, 41, 5, 142, 151, 1, 521, 2, 280, 24654, 1, 170, 1743, 121, 16, 629, 2216, 22, 35, 1091, 6, 5077, 3, 18636, 2056, 14214, 353, 71, 85, 95, 4, 435, 60, 9, 10708, 373, 2264, 5, 7498, 3, 345, 1, 26, 353, 23, 10691, 71, 44, 85, 1792, 565, 636, 3, 738, 446, 8, 1143, 1294, 609, 1, 18636, 2056, 2185, 1, 10708, 252, 175, 60, 28, 20587, 19143, 484, 2979, 37546, 21110, 702, 173, 20, 3, 10898, 738, 10691, 11, 4910, 29, 157, 3867, 671, 2, 573, 3046, 2, 1293, 343, 30, 444, 642, 782, 558, 1140, 372, 1, 358, 1001, 1039, 1, 170, 9932, 345, 1, 324, 121, 2, 521, 11, 72, 59, 271, 9932, 10, 2176, 237, 1789, 181, 170, 4833, 394, 1829, 181, 170, 16502, 48, 2, 5503, 170, 6448, 48, 880, 2, 331, 318, 11, 173, 99, 1, 3, 181, 696, 18636, 221, 1369, 350, 587, 11, 10691, 157, 98, 3867, 2, 10691, 205, 44, 1505, 4, 30, 433, 4298, 13796, 15, 7, 1140, 19832, 2, 1978, 16366, 6641, 11, 80, 186, 348, 10691, 878, 2, 614, 106, 72, 5, 157, 3867, 335, 2, 66, 49, 106, 19, 13, 144, 9, 3, 641, 7, 4, 953, 4833, 10, 4081, 151, 1, 4833, 2, 4833, 16502, 11, 44, 97, 338, 59, 157, 3867, 424, 2, 1015, 106, 2, 10691, 493, 2, 394, 106, 9, 10691, 324, 121, 2, 1077, 30, 433, 42, 280, 151, 1, 4833, 5859, 231, 4142, 4, 157, 3867, 493, 72, 5, 10691, 803, 217, 2882, 2752, 11, 80, 186, 4, 157, 3867, 72, 5, 10691, 725, 105, 382, 106, 19, 13, 1592, 369, 217, 6641, 10, 80, 186, 4, 10691, 72, 5, 157, 98, 3867, 493, 105, 662, 106, 19, 13, 1592, 38417, 521, 489, 4, 18, 27, 49, 157, 98, 3867, 2, 77, 10691, 30, 8673, 489, 4, 49, 7, 175, 252, 8, 52, 166, 126, 1, 641, 53, 2, 10, 44, 338, 59, 157, 185, 10691, 84, 10, 41, 5, 6448, 466, 72, 5, 4833, 16502, 39, 19, 13, 588, 2, 5, 44, 357, 121, 50, 6448, 598, 105, 350, 19, 13, 1592, 3, 63, 1140, 101, 97, 29, 339, 67, 6, 562, 66, 503, 188, 172, 18, 172, 252, 79, 60, 437, 53, 50, 152, 125, 10, 8, 93, 767, 4, 1001, 92, 10, 288, 59, 157, 98, 3867, 2, 10691, 2, 2723, 438, 5, 6448, 2130, 18636, 2056, 14214, 5077, 99, 4, 288, 9932, 3046, 228, 2, 767, 4, 1001, 22, 157, 98, 3867, 5, 77, 93, 344, 4, 521, 9932, 16, 80, 4619, 20, 30, 433, 2, 324, 121, 10691, 257, 40, 2216, 6, 7, 5, 387, 10708, 2, 68, 40, 7474, 6, 121, 4, 7, 4, 953, 4833, 15, 16502, 122, 40, 513]",3129.0,27153172,Endonasal endoscopic reoperation residual recurrent craniopharyngiomas,2,0.018867924528301886
MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma.,Oncotarget,Oncotarget,2016-06-01,"Pituitary spindle cell oncocytoma (SCO) is an uncommon primary pituitary neoplasm that presents with mass effect on adjacent neurovascular structures, similar to non-hormone-producing pituitary adenomas. To determine the molecular etiology of SCO, we performed exome sequencing on four SCO cases, with matched normal controls, to assess somatic mutations and copy number alterations. Our analysis revealed a low mutation rate and a copy-neutral profile, consistent with the low-grade nature of this tumor. However, we identified a co-occurring somatic HRAS (p.Q61R) activating point mutation and MEN1 frameshift mutation (p.L117fs) present in a primary and recurrent tumor from one patient. Other SCOs demonstrated mutations in SND1 and FAT1, which are associated with MAPK pathway activation. Immunohistochemistry across the SCO cohort demonstrated robust MAPK activity in all cases (n=4), as evidenced by strong phospho-ERK staining, while phospho-AKT levels suggested only basal levels of PI3K pathway activation. Taken together, this identifies the MAPK signaling pathway as a novel therapeutic target for spindle cell oncocytoma, which may offer a powerful adjunct for aggressive tumors refractory to surgical resection.",Journal Article,1329.0,11.0,Pituitary spindle oncocytoma SCO uncommon primary pituitary neoplasm presents mass effect adjacent neurovascular structures similar non-hormone-producing pituitary adenomas determine molecular etiology SCO performed exome sequencing SCO cases matched normal controls assess somatic copy number alterations revealed low rate copy-neutral profile consistent low-grade nature identified co-occurring somatic HRAS p.Q61R activating point MEN1 frameshift p.L117fs present primary recurrent patient SCOs demonstrated SND1 FAT1 associated MAPK pathway activation Immunohistochemistry SCO cohort demonstrated robust MAPK activity cases n=4 evidenced strong phospho-ERK staining phospho-AKT levels suggested basal levels PI3K pathway activation Taken identifies MAPK signaling pathway novel therapeutic target spindle oncocytoma offer powerful adjunct aggressive refractory surgical resection,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4052, 31, 12306, 24243, 16, 35, 2052, 86, 2131, 17, 2740, 5, 782, 254, 23, 2086, 9848, 2414, 288, 6, 220, 785, 3787, 2751, 6, 223, 3, 219, 2855, 1, 24243, 21, 173, 2865, 615, 23, 294, 24243, 140, 5, 655, 295, 535, 6, 423, 1119, 138, 2, 1337, 207, 593, 114, 65, 553, 8, 154, 258, 116, 2, 8, 1337, 6338, 800, 925, 5, 3, 154, 88, 2202, 1, 26, 30, 137, 21, 108, 8, 1269, 1821, 1119, 7174, 19, 26371, 1616, 741, 258, 2, 7923, 9425, 258, 19, 68163, 364, 4, 8, 86, 2, 387, 30, 29, 104, 69, 127, 68164, 264, 138, 4, 68165, 2, 13203, 92, 32, 41, 5, 1748, 308, 363, 888, 716, 3, 24243, 180, 264, 1922, 1748, 128, 4, 62, 140, 78, 39, 22, 4728, 20, 1082, 3125, 1819, 1029, 369, 3125, 649, 148, 1148, 158, 2135, 148, 1, 974, 308, 363, 1633, 1162, 26, 2953, 3, 1748, 314, 308, 22, 8, 229, 189, 283, 9, 4052, 31, 12306, 92, 68, 1918, 8, 3757, 5471, 9, 571, 57, 430, 6, 221, 170]",1169.0,27175596,MAPK activation HRAS identified pituitary spindle oncocytoma,0,0.0
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.,Oncotarget,Oncotarget,2016-11-01,"Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses in multiple malignancies, we explored whether pituitary adenomas express immune-related biomarkers that could suggest suitability for immunotherapy. Specifically, programmed death ligand 1 (PD-L1) has emerged as a potential biomarker whose expression may portend more favorable responses to immune checkpoint blockade therapies. We thus investigated the expression of PD-L1 in pituitary adenomas. PD-L1 RNA and protein expression were evaluated in 48 pituitary tumors, including functioning and non-functioning adenomas as well as atypical and recurrent tumors. Tumor infiltrating lymphocyte populations were also assessed by immunohistochemistry. Pituitary tumors express variable levels of PD-L1 transcript and protein. PD-L1 RNA and protein expression were significantly increased in functioning (growth hormone and prolactin-expressing) pituitary adenomas compared to non-functioning (null cell and silent gonadotroph) adenomas. Moreover, primary pituitary adenomas harbored higher levels of PD-L1 mRNA compared to recurrent tumors. Tumor infiltrating lymphocytes were observed in all pituitary tumors and were positively correlated with increased PD-L1 expression, particularly in the functional subtypes. Human pituitary adenomas harbor PD-L1 across subtypes, with significantly higher expression in functioning adenomas compared to non-functioning adenomas. This expression is accompanied by the presence of tumor infiltrating lymphocytes. These findings suggest the existence of an immune response to pituitary tumors and raise the possibility of considering checkpoint blockade immunotherapy in cases refractory to conventional management.",Journal Article,1176.0,20.0,Subsets pituitary exhibit aggressive clinical courses recur despite surgery radiation chemotherapy modulation immune response inhibition T-cell checkpoints led durable clinical responses multiple malignancies explored pituitary adenomas express immune-related biomarkers suggest suitability immunotherapy Specifically programmed death ligand 1 PD-L1 emerged potential biomarker expression portend favorable responses immune checkpoint blockade therapies investigated expression PD-L1 pituitary adenomas PD-L1 RNA expression evaluated 48 pituitary including functioning non-functioning adenomas atypical recurrent infiltrating lymphocyte populations assessed immunohistochemistry Pituitary express variable levels PD-L1 transcript PD-L1 RNA expression significantly increased functioning growth hormone prolactin-expressing pituitary adenomas compared non-functioning null silent gonadotroph adenomas primary pituitary adenomas harbored higher levels PD-L1 mRNA compared recurrent infiltrating lymphocytes observed pituitary positively correlated increased PD-L1 expression particularly functional subtypes Human pituitary adenomas harbor PD-L1 subtypes significantly higher expression functioning adenomas compared non-functioning adenomas expression accompanied presence infiltrating lymphocytes findings suggest existence immune response pituitary raise possibility considering checkpoint blockade immunotherapy cases refractory conventional management,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1890, 1, 57, 2239, 35, 571, 38, 1993, 2, 5609, 550, 152, 121, 2, 56, 408, 2356, 1, 3, 250, 51, 298, 297, 1, 102, 31, 4704, 71, 836, 6, 1480, 38, 253, 4, 232, 441, 21, 1443, 317, 2751, 1669, 250, 139, 582, 17, 359, 309, 10163, 9, 726, 1225, 1846, 273, 1232, 14, 333, 729, 71, 2054, 22, 8, 174, 901, 1310, 55, 68, 11293, 80, 913, 253, 6, 250, 986, 1189, 235, 21, 631, 565, 3, 55, 1, 333, 729, 4, 2751, 333, 729, 893, 2, 178, 55, 11, 194, 4, 576, 57, 141, 2702, 2, 220, 2702, 2751, 22, 149, 22, 1973, 2, 387, 57, 30, 2097, 1448, 1184, 11, 120, 275, 20, 888, 57, 1669, 1347, 148, 1, 333, 729, 3268, 2, 178, 333, 729, 893, 2, 178, 55, 11, 97, 101, 4, 2702, 129, 785, 2, 10841, 1046, 2751, 72, 6, 220, 2702, 3505, 31, 2, 9890, 69048, 2751, 1393, 86, 2751, 3253, 142, 148, 1, 333, 729, 956, 72, 6, 387, 57, 30, 2097, 1594, 11, 164, 4, 62, 57, 2, 11, 2375, 438, 5, 101, 333, 729, 55, 823, 4, 3, 583, 814, 171, 2751, 2760, 333, 729, 716, 814, 5, 97, 142, 55, 4, 2702, 2751, 72, 6, 220, 2702, 2751, 26, 55, 16, 2756, 20, 3, 463, 1, 30, 2097, 1594, 46, 272, 309, 3, 5335, 1, 35, 250, 51, 6, 57, 2, 5008, 3, 2526, 1, 3075, 986, 1189, 726, 4, 140, 430, 6, 809, 284]",1765.0,27655724,Increased expression programmed death ligand 1 PD-L1 human pituitary,3,0.02830188679245283
Rare presentation of Ewing sarcoma metastasis to the sella and suprasellar cistern.,Clinical imaging,Clin Imaging,2016-10-20,"We present an exceedingly rare case of a Ewing sarcoma metastasis manifesting as a sellar mass mimicking a pituitary adenoma. The differential diagnosis of the young adult with a sellar mass is presented and correlated with a review of available literature, demonstrating this case's unique potential for clinical teaching. More specifically, this case illustrates that in a patient with a clinical history of Ewing sarcoma, a metastasis may involve the sella and suprasellar cistern without apparent osseous involvement.",Case Reports,1188.0,1.0,present exceedingly rare case Ewing sarcoma metastasis manifesting sellar mass mimicking pituitary adenoma differential diagnosis young adult sellar mass presented correlated review available literature demonstrating case 's unique potential clinical teaching specifically case illustrates patient clinical history Ewing sarcoma metastasis involve sella suprasellar cistern apparent osseous involvement,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 364, 35, 10303, 622, 473, 1, 8, 278, 14163, 22, 8, 14479, 782, 8191, 8, 2434, 3, 1777, 147, 1, 3, 1169, 780, 5, 8, 14479, 782, 16, 917, 2, 438, 5, 8, 206, 1, 390, 789, 2219, 26, 473, 292, 991, 174, 9, 38, 6292, 80, 1225, 26, 473, 6342, 17, 4, 8, 69, 5, 8, 38, 532, 1, 8, 278, 68, 3882, 3, 22175, 2, 13122, 39504, 187, 2235, 5230, 799]",478.0,27816880,Rare presentation Ewing sarcoma metastasis sella suprasellar cistern,0,0.0
Association between dehydroepiandrosterone-sulfate and attention in long-term survivors of childhood acute lymphoblastic leukemia treated with only chemotherapy.,Psychoneuroendocrinology,Psychoneuroendocrinology,2016-11-16,"Long-term survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for neurocognitive impairment, as well as compromised hypothalamic-pituitary-adrenal (HPA) function. Dehydroepiandrosterone-sulfate (DHEAS) is an adrenal androgen commonly used as a marker of HPA function. In the general population, a low level of DHEAS has been associated with poorer cognition. At 2years post-treatment, we examined the association of DHEAS with attention outcomes in 35 male and 34 female long-term survivors of childhood ALL (mean[standard deviation] age at evaluation 14.5[4.7] years; 7.5[1.9] years post-diagnosis) who were treated with only chemotherapy and without prophylactic cranial irradiation. Male survivors with low-normal levels of DHEAS had worse performance than male survivors with high levels of DHEAS on multiple measures of attention (all P's<0.05). However, association between DHEAS and attention measures were not found in female survivors. Our results suggest that survivors of ALL who suffer from partial but persistent adrenal insufficiency may be at risk for neurocognitive deficits. This finding should be validated in a larger prospective study, with attention to sex differences in the potential impact of adrenal insufficiency on neurocognitive outcomes.",Journal Article,1161.0,4.0,Long-term survivors childhood acute lymphoblastic leukemia risk neurocognitive impairment compromised hypothalamic-pituitary-adrenal HPA function Dehydroepiandrosterone-sulfate DHEAS adrenal androgen commonly marker HPA function general population low level DHEAS associated poorer cognition 2years post-treatment examined association DHEAS attention outcomes 35 male 34 female long-term survivors childhood mean standard deviation age evaluation 14.5 4.7 years 7.5 1.9 years post-diagnosis treated chemotherapy prophylactic cranial irradiation Male survivors low-normal levels DHEAS worse performance male survivors high levels DHEAS multiple measures attention P 's 0.05 association DHEAS attention measures female survivors suggest survivors suffer partial persistent adrenal insufficiency risk neurocognitive deficits finding validated larger prospective attention sex differences potential impact adrenal insufficiency neurocognitive outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[319, 337, 332, 1, 864, 286, 1275, 62, 32, 28, 43, 9, 2958, 2315, 22, 149, 22, 4867, 7531, 12098, 2987, 14513, 343, 12317, 6424, 16919, 16, 35, 2987, 687, 841, 95, 22, 8, 952, 1, 14513, 343, 4, 3, 1083, 266, 8, 154, 301, 1, 16919, 71, 85, 41, 5, 1769, 8130, 28, 69429, 539, 24, 21, 409, 3, 248, 1, 16919, 5, 2111, 123, 4, 465, 1045, 2, 562, 1061, 319, 337, 332, 1, 864, 62, 313, 260, 3348, 89, 28, 451, 213, 33, 39, 67, 60, 67, 33, 14, 83, 60, 539, 147, 54, 11, 73, 5, 158, 56, 2, 187, 1862, 2565, 1104, 1045, 332, 5, 154, 295, 148, 1, 16919, 42, 639, 528, 76, 1045, 332, 5, 64, 148, 1, 16919, 23, 232, 1018, 1, 2111, 62, 19, 292, 13, 474, 137, 248, 59, 16919, 2, 2111, 1018, 11, 44, 204, 4, 1061, 332, 114, 99, 309, 17, 332, 1, 62, 54, 6506, 29, 450, 84, 1882, 2987, 4360, 68, 40, 28, 43, 9, 2958, 2752, 26, 1567, 257, 40, 938, 4, 8, 1077, 482, 45, 5, 2111, 6, 1035, 362, 4, 3, 174, 345, 1, 2987, 4360, 23, 2958, 123]",1250.0,27907849,Association dehydroepiandrosterone-sulfate attention long-term survivors childhood acute lymphoblastic leukemia treated chemotherapy,0,0.0
Hypothalamic-Pituitary Axis Dysfunction in Survivors of Childhood CNS Tumors: Importance of Systematic Follow-Up and Early Endocrine Consultation.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2016-10-31,"The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. An 11-year-old male with a history of metastatic tectal plate low-grade glioma who was diagnosed at age 2.8 years transferred his care to the long-term follow-up clinic. He completed treatment with multiagent chemotherapy-carboplatin, vincristine, temozolomide, procarbazine, lomustine, and thioguanine-at age 4.5 years and did not require radiotherapy. At primary diagnosis, he presented with hydrocephalus that required ventriculoperitoneal shunt placement, with a subsequent shunt revision at age 6 years. Residual metastatic tumors in the third and fourth ventricles and in the suprasellar region remained stable for more than 5 years. The patient achieved normal developmental milestones and was not taking medications. He was offered screening for hypothalamic-pituitary axis (HPA) dysfunction because of his suprasellar lesion. His height was at the 25th percentile for chronological age, with decline from the 50th percentile noted during the preceding 18 months ( Fig 1 , point c). Pubertal stage was Tanner 4 for pubic hair and penile size, which contrasted with small testes (4.5 mL). Pubic hair and voice changes were noticed 2 to 3 years before this visit. Plasma testosterone level was consistent with Tanner 4 (255 ng/dL = 8.9 nmol/L). An x-ray of the left hand revealed a notably advanced bone age of 15.5 years. Plasma free T4, thyroid-stimulating hormone (TSH), and 8 am cortisol levels were normal. The patient was referred to the endocrinology clinic where he was diagnosed with growth hormone deficiency and was started on replacement therapy. He reached his final adult height of 144.1 cm at age 13.3 years ( Fig 1 , point d).",Journal Article,1177.0,9.0,Oncology Grand Rounds series designed place original reports published Journal clinical context case presentation followed description diagnostic management challenges review relevant literature summary authors suggested management approaches goal series help readers better understand apply key studies including published Journal Clinical Oncology patients seen clinical practice 11-year-old male history metastatic tectal plate low-grade glioma diagnosed age 2.8 years transferred care long-term follow-up clinic completed treatment multiagent chemotherapy-carboplatin vincristine temozolomide procarbazine lomustine thioguanine-at age 4.5 years require radiotherapy primary diagnosis presented hydrocephalus required ventriculoperitoneal shunt placement subsequent shunt revision age 6 years Residual metastatic fourth ventricles suprasellar region remained stable 5 years patient achieved normal developmental milestones taking medications offered screening hypothalamic-pituitary axis HPA dysfunction suprasellar lesion height 25th percentile chronological age decline 50th percentile noted preceding 18 months 1 point c Pubertal stage Tanner 4 pubic hair penile size contrasted small testes 4.5 mL Pubic hair voice changes noticed 2 3 years visit Plasma testosterone level consistent Tanner 4 255 ng/dL 8.9 nmol/L x-ray left hand revealed notably advanced bone age 15.5 years Plasma free T4 thyroid-stimulating hormone TSH 8 cortisol levels normal patient referred endocrinology clinic diagnosed growth hormone deficiency started replacement therapy reached final adult height 144.1 cm age 13.3 years 1 point,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[3, 413, 20904, 7001, 988, 16, 1114, 6, 3536, 2279, 1198, 983, 4, 3, 6685, 237, 38, 1533, 8, 473, 1031, 16, 370, 20, 8, 5263, 1, 752, 2, 284, 1427, 8, 206, 1, 3, 867, 789, 2, 8, 1962, 1, 3, 738, 1148, 284, 611, 3, 1326, 1, 26, 988, 16, 6, 987, 5439, 380, 1640, 832, 6, 4930, 3, 99, 1, 825, 94, 141, 135, 983, 4, 6685, 1, 38, 413, 6, 7, 527, 4, 136, 4165, 38, 758, 35, 175, 111, 1095, 1045, 5, 8, 532, 1, 113, 27458, 9656, 154, 88, 945, 54, 10, 265, 28, 89, 18, 66, 60, 4747, 3224, 165, 6, 3, 319, 337, 166, 126, 1188, 3174, 781, 24, 5, 7148, 56, 927, 2132, 1537, 8860, 9181, 2, 17598, 28, 89, 39, 33, 60, 2, 205, 44, 1353, 310, 28, 86, 147, 3174, 917, 5, 9250, 17, 616, 16283, 8637, 2613, 5, 8, 706, 8637, 5646, 28, 89, 49, 60, 753, 113, 57, 4, 3, 1282, 2, 3608, 25419, 2, 4, 3, 13122, 1053, 958, 585, 9, 80, 76, 33, 60, 3, 69, 513, 295, 4566, 12118, 2, 10, 44, 2727, 2679, 3174, 10, 2216, 453, 9, 7531, 12098, 2310, 14513, 1527, 408, 1, 3224, 13122, 1180, 3224, 4594, 10, 28, 3, 14939, 6392, 9, 14921, 89, 5, 1858, 29, 3, 25065, 6392, 1051, 190, 3, 5892, 203, 53, 14197, 14, 741, 256, 10467, 82, 10, 17471, 39, 9, 24676, 6845, 2, 444, 92, 13257, 5, 302, 13100, 39, 33, 542, 24676, 6845, 2, 6284, 400, 11, 16285, 18, 6, 27, 60, 348, 26, 2807, 554, 2660, 301, 10, 925, 5, 17471, 39, 7826, 997, 1826, 66, 83, 4694, 805, 35, 1006, 5520, 1, 3, 1712, 2833, 553, 8, 2552, 131, 89, 1, 167, 33, 60, 554, 115, 2463, 11260, 2122, 785, 6581, 2, 66, 5886, 9572, 148, 11, 295, 3, 69, 10, 1995, 6, 3, 21338, 1188, 1257, 3174, 10, 265, 5, 129, 785, 2299, 2, 10, 3461, 23, 3892, 36, 3174, 1300, 3224, 1457, 780, 4594, 1, 4415, 14, 494, 28, 89, 233, 27, 60, 14197, 14, 741, 427]",2102.0,27998231,Hypothalamic-Pituitary Axis Dysfunction Survivors Childhood CNS Importance Systematic Follow-Up Early Endocrine Consultation,94,0.8867924528301887
"New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma.",Nature reviews. Endocrinology,Nat Rev Endocrinol,2017-02-03,"Childhood-onset craniopharyngiomas are rare embryonic tumours of low-grade histological malignancy. Novel insights into the molecular pathogenesis of human adamantinomatous craniopharyngioma have started to unveil the possibility of testing novel treatments targeting pathogenic pathways. Hypothalamic involvement and/or treatment-related lesions result in impaired physical and social functionality and in severe neuroendocrine sequelae. Quality of survival in patients with craniopharyngioma with hypothalamic involvement is impaired by severe obesity, physical fatigue and non-optimal psychosocial development. Patients with craniopharyngioma involving hypothalamic structures have reduced 20-year overall survival, but overall and progression-free survival are not related to the degree of surgical resection. Irradiation is effective in the prevention of tumour progression and recurrence. For favourably localized craniopharyngiomas, the preferred treatment of choice is to attempt complete resection with preservation of visual, hypothalamic and pituitary function. For unfavourably localized tumours in close proximity to optic and/or hypothalamic structures, a radical neurosurgical strategy attempting complete resection is not recommended owing to potential severe sequelae. As expertise has been shown to have an impact on post-treatment morbidity, medical societies should establish criteria for adequate professional expertise for the treatment of craniopharyngioma. On the basis of these criteria, health authorities should organize the certification of centres of excellence that are authorized to treat and care for patients with this chronic disease.",Journal Article,1082.0,32.0,Childhood-onset craniopharyngiomas rare embryonic tumours low-grade histological malignancy Novel insights molecular pathogenesis human adamantinomatous craniopharyngioma started unveil possibility testing novel treatments targeting pathogenic pathways Hypothalamic involvement and/or treatment-related lesions impaired physical social functionality severe neuroendocrine sequelae Quality survival patients craniopharyngioma hypothalamic involvement impaired severe obesity physical fatigue non-optimal psychosocial development Patients craniopharyngioma involving hypothalamic structures reduced 20-year overall survival overall progression-free survival related degree surgical resection Irradiation effective prevention tumour progression recurrence favourably localized craniopharyngiomas preferred treatment choice attempt complete resection preservation visual hypothalamic pituitary function unfavourably localized tumours close proximity optic and/or hypothalamic structures radical neurosurgical strategy attempting complete resection recommended owing potential severe sequelae expertise shown impact post-treatment morbidity medical societies establish criteria adequate professional expertise treatment craniopharyngioma basis criteria health authorities organize certification centres excellence authorized treat care patients chronic disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[864, 1707, 10708, 32, 622, 5390, 1319, 1, 154, 88, 1831, 710, 229, 1957, 237, 3, 219, 1384, 1, 171, 22825, 7205, 47, 3461, 6, 16019, 3, 2526, 1, 471, 229, 640, 529, 2806, 460, 7531, 799, 2, 15, 24, 139, 406, 757, 4, 2364, 900, 2, 2032, 8592, 2, 4, 905, 1542, 4156, 372, 1, 25, 4, 7, 5, 7205, 5, 7531, 799, 16, 2364, 20, 905, 1661, 900, 613, 2, 220, 665, 2322, 193, 7, 5, 7205, 1267, 7531, 2414, 47, 405, 179, 111, 63, 25, 84, 63, 2, 91, 115, 25, 32, 44, 139, 6, 3, 1444, 1, 221, 170, 1104, 16, 323, 4, 3, 1070, 1, 770, 91, 2, 146, 9, 20557, 909, 10708, 3, 2514, 24, 1, 1866, 16, 6, 3448, 236, 170, 5, 2224, 1, 3046, 7531, 2, 343, 9, 43351, 909, 1319, 4, 2336, 6167, 6, 5670, 2, 15, 7531, 2414, 8, 711, 10338, 692, 9632, 236, 170, 16, 44, 793, 3421, 6, 174, 905, 4156, 22, 4935, 71, 85, 443, 6, 47, 35, 345, 23, 539, 24, 787, 484, 10600, 257, 1811, 371, 9, 1658, 5341, 4935, 9, 3, 24, 1, 7205, 23, 3, 877, 1, 46, 371, 341, 17637, 257, 30469, 3, 17377, 1, 4496, 1, 11473, 17, 32, 26923, 6, 943, 2, 165, 9, 7, 5, 26, 442, 34]",1641.0,28155902,New outlook diagnosis treatment follow-up childhood-onset craniopharyngioma,0,0.0
Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors.,Endocrinology,Endocrinology,2017-07-01,"Pituitary tumors are the second most common adult primary brain tumor, with a variable clinical course. Recent work has identified a number of genetic determinants of pituitary tumor subtypes, which may augment traditional histopathologic classification schemes. We sought to determine whether pituitary tumors could be stratified based on objective molecular characteristics using a clinical genomics assay. We performed a retrospective analysis of patients operated on at the Brigham and Women's Hospital from 2012 to 2016 whose pituitary tumors were profiled using multiplexed next-generation sequencing. We analyzed 127 pituitary tumors, including 114 adenomas, 5 craniopharyngiomas, and 8 tumors of other histologies. We observed recurrent BRAFV600E mutations in papillary craniopharyngiomas, CTNNB1 mutations in adamantinomatous craniopharyngiomas, and activating GNAS mutations in growth hormone-secreting adenomas. Furthermore, we validated the presence of two distinct genomic subclasses in adenomas (i.e., those with disrupted or quiet copy-number profiles) and the significant association of disruption with functional hormone status (P < 0.05). We report the clinical implementation of next-generation sequencing of pituitary tumors. We confirmed previously identified molecular subclasses for these tumors and show that routine screening as part of clinical practice is both feasible and informative. This large-scale proof-of-principle study may help to guide future institutional efforts for pituitary tumor classification as well as the incorporation of such techniques into prospective analysis as part of clinical trials.",Journal Article,934.0,14.0,Pituitary second common adult primary brain variable clinical course Recent work identified number genetic determinants pituitary subtypes augment traditional histopathologic classification schemes sought determine pituitary stratified based objective molecular characteristics clinical genomics performed retrospective patients operated Brigham Women 's Hospital 2012 2016 pituitary profiled multiplexed next-generation sequencing 127 pituitary including 114 adenomas 5 craniopharyngiomas 8 histologies observed recurrent BRAFV600E papillary craniopharyngiomas CTNNB1 adamantinomatous craniopharyngiomas activating GNAS growth hormone-secreting adenomas Furthermore validated presence distinct genomic subclasses adenomas i.e. disrupted quiet copy-number profiles significant association disruption functional hormone status P 0.05 report clinical implementation next-generation sequencing pituitary confirmed previously identified molecular subclasses routine screening clinical practice feasible informative large-scale proof-of-principle help guide future institutional efforts pituitary classification incorporation techniques prospective clinical trials,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[57, 32, 3, 419, 96, 186, 780, 86, 342, 30, 5, 8, 1347, 38, 906, 435, 1357, 71, 108, 8, 207, 1, 336, 3403, 1, 30, 814, 92, 68, 4369, 1847, 2630, 947, 7103, 21, 990, 6, 223, 317, 57, 359, 40, 1173, 90, 23, 461, 219, 374, 75, 8, 38, 4229, 719, 21, 173, 8, 459, 65, 1, 7, 7297, 23, 28, 3, 10543, 2, 117, 292, 702, 29, 1195, 6, 1390, 1310, 57, 11, 5490, 75, 7734, 1305, 914, 615, 21, 311, 4080, 57, 141, 3803, 2751, 33, 10708, 2, 66, 57, 1, 127, 3489, 21, 164, 387, 9315, 138, 4, 1796, 10708, 4485, 138, 4, 22825, 10708, 2, 1616, 8624, 138, 4, 129, 785, 5052, 2751, 798, 21, 938, 3, 463, 1, 100, 834, 572, 9355, 4, 2751, 70, 563, 135, 5, 5576, 15, 26556, 1337, 207, 1241, 2, 3, 93, 248, 1, 3220, 5, 583, 785, 156, 19, 13, 474, 21, 414, 3, 38, 2393, 1, 1305, 914, 615, 1, 57, 21, 557, 373, 108, 219, 9355, 9, 46, 57, 2, 514, 17, 1311, 453, 22, 760, 1, 38, 758, 16, 110, 1313, 2, 4189, 26, 375, 1124, 3840, 1, 4968, 45, 68, 987, 6, 1597, 508, 1115, 1413, 9, 30, 947, 22, 149, 22, 3, 2838, 1, 225, 1092, 237, 482, 65, 22, 760, 1, 38, 143]",1545.0,28486603,Clinical Identification Oncogenic Drivers Copy-Number Alterations Pituitary,1,0.009433962264150943
"<i>PTEN, DICER1, FH</i>, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2017-06-01,"<i>PTEN</i> hamartoma tumor syndrome (PHTS), <i>DICER1</i> syndrome, and hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome are pleiotropic tumor predisposition syndromes that include benign and malignant neoplasms affecting adults and children. PHTS includes several disorders with shared and distinct clinical features. These are associated with elevated lifetime risk of breast, thyroid, endometrial, colorectal, and renal cancers as well as melanoma. Thyroid cancer represents the predominant cancer risk under age 20 years. <i>DICER1</i> syndrome includes risk for pleuropulmonary blastoma, cystic nephroma, ovarian sex cord-stromal tumors, and multinodular goiter and thyroid carcinoma as well as brain tumors including pineoblastoma and pituitary blastoma. Individuals with HLRCC may develop multiple cutaneous and uterine leiomyomas, and they have an elevated risk of renal cell carcinoma. For each of these syndromes, a summary of the key syndromic features is provided, the underlying genetic events are discussed, and specific screening is recommended. <i>Clin Cancer Res; 23(12); e76-e82. 2017 AACR</i><b>See all articles in the online-only <i>CCR</i> Pediatric Oncology Series.</b>",Journal Article,964.0,43.0,PTEN /i hamartoma syndrome PHTS DICER1 /i syndrome hereditary leiomyomatosis renal HLRCC syndrome pleiotropic predisposition syndromes include benign malignant neoplasms affecting adults children PHTS includes disorders shared distinct clinical features associated elevated lifetime risk breast thyroid endometrial colorectal renal melanoma Thyroid represents predominant risk age 20 years DICER1 /i syndrome includes risk pleuropulmonary blastoma cystic nephroma ovarian sex cord-stromal multinodular goiter thyroid carcinoma brain including pineoblastoma pituitary blastoma Individuals HLRCC develop multiple cutaneous uterine leiomyomas elevated risk renal carcinoma syndromes summary key syndromic features provided underlying genetic events discussed specific screening recommended Clin Res 23 12 e76-e82 2017 AACR /i b articles online-only CCR /i Pediatric Oncology Series. /b,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,"[70, 820, 70, 8025, 30, 681, 7390, 70, 21537, 70, 681, 2, 2305, 18330, 2, 31, 12, 12162, 681, 32, 7872, 30, 2863, 2040, 17, 643, 1002, 2, 393, 1179, 2319, 857, 2, 541, 7390, 1920, 392, 1997, 5, 2664, 2, 834, 38, 404, 46, 32, 41, 5, 804, 2898, 43, 1, 2, 163, 22, 149, 22, 12, 1449, 3, 2750, 12, 43, 669, 89, 179, 60, 70, 21537, 70, 681, 1920, 43, 9, 39259, 25117, 2965, 23263, 1035, 1885, 1126, 57, 2, 12622, 16309, 2, 134, 22, 149, 22, 342, 57, 141, 14221, 2, 25117, 869, 5, 12162, 68, 690, 232, 1486, 2, 12815, 2, 491, 47, 35, 804, 43, 1, 31, 134, 9, 296, 1, 46, 2040, 8, 1962, 1, 3, 825, 14201, 404, 16, 1052, 3, 1181, 336, 281, 32, 1588, 2, 112, 453, 16, 793, 70, 2459, 12, 1936, 382, 133, 70602, 70603, 3194, 1630, 70, 132, 3764, 62, 2384, 4, 3, 4123, 158, 70, 4992, 70, 815, 413, 988, 132]",1063.0,28620008,PTEN DICER1 FH /i Associated Susceptibility Syndromes Clinical Features Genetics Surveillance Recommendations Childhood,0,0.0
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.,Cancer treatment reviews,Cancer Treat. Rev.,2017-06-22,"Agents that modulate immune checkpoint proteins, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD-1), have become a mainstay in cancer treatment. The clinical benefit afforded by immune checkpoint inhibitors can be accompanied by immune-related adverse events (irAE) that affect the skin, gastrointestinal tract, liver, and endocrine system. The types of irAEs associated with immune checkpoint inhibitors are generally consistent across tumor types. Immune-related endocrine events can affect the pituitary, thyroid, and adrenal glands, as well as other downstream target organs. These events are unique when compared with other irAEs because the manifestations are often irreversible. Immune-related endocrine events are typically grade 1/2 in severity and often present with non-specific symptoms, making them difficult to diagnose. The mechanisms underlying immune-related target organ damage in select individuals remain mostly undefined. Management includes close patient monitoring, appropriate laboratory testing for endocrine function, replacement of hormones, and consultation with an endocrinologist when appropriate. An awareness of the symptoms and management of immune-related endocrine events may aid in the safe and appropriate use of immune checkpoint inhibitors in clinical practice.",Journal Article,943.0,69.0,Agents modulate immune checkpoint cytotoxic T-lymphocyte antigen-4 CTLA-4 programmed death receptor-1 PD-1 mainstay treatment clinical benefit afforded immune checkpoint inhibitors accompanied immune-related adverse events irAE affect skin gastrointestinal tract liver endocrine types irAEs associated immune checkpoint inhibitors generally consistent types Immune-related endocrine events affect pituitary thyroid adrenal glands downstream target organs events unique compared irAEs manifestations irreversible Immune-related endocrine events typically grade 1/2 severity present non-specific symptoms making difficult diagnose mechanisms underlying immune-related target organ damage select individuals remain undefined Management includes close patient monitoring appropriate laboratory testing endocrine function replacement hormones consultation endocrinologist appropriate awareness symptoms management immune-related endocrine events aid safe appropriate use immune checkpoint inhibitors clinical practice,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,"[183, 17, 3319, 250, 986, 652, 225, 22, 759, 102, 1448, 448, 39, 2127, 39, 2, 1846, 273, 153, 14, 333, 14, 47, 1417, 8, 4041, 4, 12, 24, 3, 38, 247, 9150, 20, 250, 986, 222, 122, 40, 2756, 20, 250, 139, 290, 281, 8009, 17, 1158, 3, 1696, 2, 1293, 398, 3, 630, 1, 4997, 41, 5, 250, 986, 222, 32, 1228, 925, 716, 30, 630, 250, 139, 1293, 281, 122, 1158, 3, 2, 2987, 3966, 22, 149, 22, 127, 1489, 283, 2285, 46, 281, 32, 991, 198, 72, 5, 127, 4997, 408, 3, 4282, 32, 629, 4422, 250, 139, 1293, 281, 32, 1969, 88, 14, 18, 4, 1702, 2, 629, 364, 5, 220, 112, 507, 1079, 1370, 1740, 6, 6073, 3, 483, 1181, 250, 139, 283, 1259, 1350, 4, 1717, 869, 918, 2754, 5425, 284, 1920, 2336, 69, 1315, 870, 1624, 471, 9, 1293, 343, 3892, 1, 4927, 2, 2981, 5, 35, 25277, 198, 870, 35, 3310, 1, 3, 507, 2, 284, 1, 250, 139, 1293, 281, 68, 2427, 4, 3, 1165, 2, 870, 119, 1, 250, 986, 222, 4, 38, 758]",1265.0,28689073,Endocrine-related adverse events associated immune checkpoint blockade expert insights management,0,0.0
Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.,Journal of neuropathology and experimental neurology,J. Neuropathol. Exp. Neurol.,2017-09-01,"Pediatric adamantinomatous craniopharyngioma (ACP) is a highly solid and cystic tumor, often causing substantial damage to critical neuroendocrine structures such as the hypothalamus, pituitary gland, and optic apparatus. Paracrine signaling mechanisms driving tumor behavior have been hypothesized, with IL-6R overexpression identified as a potential therapeutic target. To identify potential novel therapies, we characterized inflammatory and immunomodulatory factors in ACP cyst fluid and solid tumor components. Cytometric bead analysis revealed a highly pro-inflammatory cytokine pattern in fluid from ACP compared to fluids from another cystic pediatric brain tumor, pilocytic astrocytoma. Cytokines and chemokines with particularly elevated concentrations in ACPs were IL-6, CXCL1 (GRO), CXCL8 (IL-8) and the immunosuppressive cytokine IL-10. These data were concordant with solid tumor compartment transcriptomic data from a larger cohort of ACPs, other pediatric brain tumors and normal brain. The majority of receptors for these cytokines and chemokines were also over-expressed in ACPs. In addition to IL-10, the established immunosuppressive factor IDO-1 was overexpressed by ACPs at the mRNA and protein levels. These data indicate that ACP cyst fluids and solid tumor components are characterized by an inflammatory cytokine and chemokine expression pattern. Further study regarding selective cytokine blockade may inform novel therapeutic interventions.",Journal Article,872.0,14.0,Pediatric adamantinomatous craniopharyngioma ACP highly solid cystic causing substantial damage critical neuroendocrine structures hypothalamus pituitary gland optic apparatus Paracrine signaling mechanisms driving behavior hypothesized IL-6R overexpression identified potential therapeutic target identify potential novel therapies characterized inflammatory immunomodulatory factors ACP cyst fluid solid components Cytometric bead revealed highly pro-inflammatory cytokine pattern fluid ACP compared fluids cystic pediatric brain pilocytic astrocytoma Cytokines chemokines particularly elevated concentrations ACPs IL-6 CXCL1 GRO CXCL8 IL-8 immunosuppressive cytokine IL-10 concordant solid compartment transcriptomic larger cohort ACPs pediatric brain normal brain majority receptors cytokines chemokines over-expressed ACPs addition IL-10 established immunosuppressive factor IDO-1 overexpressed ACPs mRNA levels indicate ACP cyst fluids solid components characterized inflammatory cytokine chemokine expression pattern selective cytokine blockade inform novel therapeutic interventions,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[815, 22825, 7205, 6953, 16, 8, 561, 537, 2, 2965, 30, 629, 3440, 1281, 1350, 6, 740, 1542, 2414, 225, 22, 3, 12717, 2326, 2, 5670, 10180, 6012, 314, 483, 4057, 30, 1710, 47, 85, 1237, 5, 501, 26446, 851, 108, 22, 8, 174, 189, 283, 6, 255, 174, 229, 235, 21, 765, 1291, 2, 2555, 130, 4, 6953, 3364, 2357, 2, 537, 30, 1628, 6226, 9921, 65, 553, 8, 561, 1805, 1291, 1675, 1177, 4, 2357, 29, 6953, 72, 6, 9332, 29, 1809, 2965, 815, 342, 30, 7374, 3822, 1886, 2, 4906, 5, 823, 804, 1003, 4, 12468, 11, 501, 49, 10242, 17370, 23622, 501, 66, 2, 3, 2989, 1675, 501, 79, 46, 74, 11, 3610, 5, 537, 30, 3616, 5983, 74, 29, 8, 1077, 180, 1, 12468, 127, 815, 342, 57, 2, 295, 342, 3, 686, 1, 1186, 9, 46, 1886, 2, 4906, 11, 120, 252, 570, 4, 12468, 4, 352, 6, 501, 79, 3, 635, 2989, 161, 5703, 14, 10, 1711, 20, 12468, 28, 3, 956, 2, 178, 148, 46, 74, 1008, 17, 6953, 3364, 9332, 2, 537, 30, 1628, 32, 765, 20, 35, 1291, 1675, 2, 3596, 55, 1177, 195, 45, 666, 1094, 1675, 1189, 68, 2295, 229, 189, 1151]",1432.0,28859336,Molecular Reveal Inflammatory Mediators Solid Component Cyst Fluid Human Adamantinomatous Craniopharyngioma,0,0.0
SKP2 Activation by Thyroid Hormone Receptor 2 Bypasses Rb-Dependent Proliferation in Rb-Deficient Cells.,Cancer research,Cancer Res.,2017-09-28,"Germline <i>RB1</i> mutations strongly predispose humans to cone precursor-derived retinoblastomas and strongly predispose mice to pituitary tumors, yet shared cell type-specific circuitry that sensitizes these different cell types to the loss of <i>RB1</i> has not been defined. Here we show that the cell type-restricted thyroid hormone receptor isoform TR2 sensitizes to <i>RB1</i> loss in both settings by antagonizing the widely expressed and tumor-suppressive TR1. TR2 promoted expression of the E3 ubiquitin ligase SKP2, a critical factor for <i>RB1</i>-mutant tumors, by enabling EMI1/FBXO5-dependent inhibition of SKP2 degradation. In <i>RB1</i> wild-type neuroblastoma cells, endogenous Rb or ectopic TR2 was required to sustain SKP2 expression as well as cell viability and proliferation. These results suggest that in certain contexts, Rb loss enables TR1-dependent suppression of SKP2 as a safeguard against <i>RB1</i>-deficient tumorigenesis. TR2 counteracts TR1, thus disrupting this safeguard and promoting development of <i>RB1</i>-deficient malignancies. <i>Cancer Res; 77(24); 6838-50. 2017 AACR</i>.",Journal Article,845.0,2.0,Germline RB1 /i strongly predispose humans cone precursor-derived retinoblastomas strongly predispose mice pituitary shared type-specific circuitry sensitizes different types loss RB1 /i defined type-restricted thyroid hormone receptor isoform TR2 sensitizes RB1 /i loss settings antagonizing widely expressed tumor-suppressive TR1 TR2 promoted expression E3 ubiquitin ligase SKP2 critical factor RB1 /i -mutant enabling EMI1/FBXO5-dependent inhibition SKP2 degradation RB1 /i wild-type neuroblastoma endogenous Rb ectopic TR2 required sustain SKP2 expression viability proliferation suggest certain contexts Rb loss enables TR1-dependent suppression SKP2 safeguard RB1 /i -deficient tumorigenesis TR2 counteracts TR1 disrupting safeguard promoting development RB1 /i -deficient malignancies Res 77 24 6838-50 2017 AACR /i,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[1009, 70, 4596, 70, 138, 1327, 6043, 3218, 6, 6939, 2765, 526, 18431, 2, 1327, 6043, 399, 6, 57, 1145, 2664, 31, 267, 112, 19902, 17, 6229, 46, 338, 31, 630, 6, 3, 407, 1, 70, 4596, 70, 71, 44, 85, 395, 467, 21, 514, 17, 3, 31, 267, 2016, 785, 153, 3995, 36488, 6229, 6, 70, 4596, 70, 407, 4, 110, 1947, 20, 16291, 3, 1792, 570, 2, 30, 3707, 41872, 36488, 2992, 55, 1, 3, 7193, 4213, 5839, 7011, 8, 740, 161, 9, 70, 4596, 70, 620, 57, 20, 5257, 27638, 71321, 470, 297, 1, 7011, 2373, 4, 70, 4596, 70, 955, 267, 37, 2682, 2955, 15, 3647, 36488, 10, 616, 6, 8844, 7011, 55, 22, 149, 22, 31, 2120, 2, 457, 46, 99, 309, 17, 4, 1840, 7875, 2955, 407, 4843, 41872, 470, 1332, 1, 7011, 22, 8, 50626, 480, 70, 4596, 70, 1971, 1565, 36488, 23917, 41872, 631, 6242, 26, 50626, 2, 2388, 193, 1, 70, 4596, 70, 1971, 441, 70, 12, 1936, 849, 259, 71322, 212, 3194, 1630, 70]",1065.0,28972075,SKP2 Activation Thyroid Hormone Receptor 2 Bypasses Rb-Dependent Proliferation Rb-Deficient,5,0.04716981132075472
Suprasellar and recurrent pediatric craniopharyngiomas: expanding indications for the extended endoscopic transsphenoidal approach.,Journal of neurosurgery. Pediatrics,J Neurosurg Pediatr,2017-11-10,"OBJECTIVE The expanded endonasal endoscopic transsphenoidal approach has become increasingly used for craniopharyngioma surgery in the pediatric population, but questions still persist regarding its utility in younger children, in recurrent and irradiated tumors, and in masses primarily located in the suprasellar region. The narrow corridor, incomplete pneumatization, and fear of hypothalamic injury have traditionally relegated this approach to application in older children with mostly cystic craniopharyngiomas centered in the sella. The authors present a series of consecutive pediatric patients in whom the endonasal endoscopic approach was used to remove craniopharyngiomas from patients of varied ages, regardless of the location of the tumor and previous treatments or surgeries, to ascertain if the traditional concerns about limitations of this approach are worth reevaluating METHODS Eleven consecutive pediatric patients (age  18 years) underwent surgery via an endoscopic transsphenoidal approach at NewYork-Presbyterian/Weill Cornell Medical Center from 2007 to 2016. The authors recorded the location, consistency, and size of the lesion, assessed for hypothalamic invasion radiographically, calculated skull base measurements, and assessed parameters such as extent of resection, visual function, endocrinological function, weight gain, and return-to-school status. RESULTS The average age at the time of surgery was 7.9 years (range 4-17 years) and the tumor sizes ranged from 1.3 to 41.7 cm<sup>3</sup>. Five cases were purely suprasellar, 5 had solid components, 4 were reoperations, and 5 had a conchal sphenoid aeration. Nevertheless, gross-total resection was achieved in 45% of the patients and 50% of those in whom it was the goal of surgery, without any correlation with the location, tumor consistency, or the age of the patient. Near-total resection, subtotal resection, or biopsy was performed intentionally in the remaining patients to avoid hypothalamic injury. Anterior pituitary dysfunction occurred in 81.8% of the patients, and 63.3% developed diabetes insipidus . Two patients (18%) had a greater than 9% increase in body mass index. Visual function was stable or improved in 73%. All children returned to an academic environment, with 10 of them in the grade appropriate for their age. There was a single case of each of the following: CSF leak, loss of vision unilaterally, and abscess. CONCLUSIONS The endoscopic transsphenoidal approach is suitable for removing pediatric craniopharyngiomas even in young children with suprasellar tumors, conchal sphenoid sinus, recurrent tumors, and tumors with solid components. The extent of resection is dictated by intrinsic hypothalamic tumor invasiveness rather than the approach. The endoscopic transsphenoidal approach affords the ability to directly inspect the hypothalamus to determine invasion, which may help spare the patient from hypothalamic injury. Irrespective of approach, the rates of postoperative endocrinopathy remain high and the learning curve for the approach to a relatively rare tumor is steep.",Journal Article,802.0,17.0,OBJECTIVE expanded endonasal endoscopic transsphenoidal approach increasingly craniopharyngioma surgery pediatric population questions persist utility younger children recurrent irradiated masses primarily located suprasellar region narrow corridor incomplete pneumatization fear hypothalamic injury traditionally relegated approach application older children cystic craniopharyngiomas centered sella authors present series consecutive pediatric patients endonasal endoscopic approach remove craniopharyngiomas patients varied ages regardless location previous treatments surgeries ascertain traditional concerns limitations approach worth reevaluating METHODS consecutive pediatric patients age  18 years underwent surgery endoscopic transsphenoidal approach NewYork-Presbyterian/Weill Cornell Medical Center 2007 2016 authors recorded location consistency size lesion assessed hypothalamic invasion radiographically calculated skull base measurements assessed parameters extent resection visual function endocrinological function weight gain return-to-school status average age time surgery 7.9 years range 4-17 years sizes ranged 1.3 41.7 cm sup 3 /sup cases purely suprasellar 5 solid components 4 reoperations 5 conchal sphenoid aeration gross-total resection achieved 45 patients 50 goal surgery correlation location consistency age patient Near-total resection subtotal resection biopsy performed intentionally remaining patients avoid hypothalamic injury Anterior pituitary dysfunction occurred 81.8 patients 63.3 developed diabetes insipidus patients 18 greater 9 increase body mass index Visual function stable improved 73 children returned academic environment 10 grade appropriate age single case following CSF leak loss vision unilaterally abscess CONCLUSIONS endoscopic transsphenoidal approach suitable removing pediatric craniopharyngiomas young children suprasellar conchal sphenoid sinus recurrent solid components extent resection dictated intrinsic hypothalamic invasiveness approach endoscopic transsphenoidal approach affords ability directly inspect hypothalamus determine invasion help spare patient hypothalamic injury Irrespective approach rates postoperative endocrinopathy remain high learning curve approach relatively rare steep,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[461, 3, 2064, 18636, 2056, 14214, 353, 71, 1417, 1635, 95, 9, 7205, 152, 4, 3, 815, 266, 84, 1937, 1234, 5589, 666, 211, 1207, 4, 773, 541, 4, 387, 2, 2398, 57, 2, 4, 2692, 1561, 2308, 4, 3, 13122, 1053, 3, 6958, 50684, 2610, 71530, 2, 6443, 1, 7531, 2730, 47, 4206, 30600, 26, 353, 6, 1581, 4, 434, 541, 5, 2754, 2965, 10708, 4846, 4, 3, 22175, 3, 738, 364, 8, 988, 1, 935, 815, 7, 4, 953, 3, 18636, 2056, 353, 10, 95, 6, 7930, 10708, 29, 7, 1, 2051, 2165, 1583, 1, 3, 1147, 1, 3, 30, 2, 698, 640, 15, 5305, 6, 6040, 492, 3, 1847, 2061, 545, 1939, 1, 26, 353, 32, 9498, 34090, 636, 2627, 935, 815, 7, 89, 1552, 203, 60, 208, 152, 847, 35, 2056, 14214, 353, 28, 37546, 21110, 20587, 19143, 484, 574, 29, 1307, 6, 1390, 3, 738, 1872, 3, 1147, 5358, 2, 444, 1, 3, 1180, 275, 9, 7531, 578, 5770, 981, 5054, 1782, 1685, 2, 275, 1038, 225, 22, 1039, 1, 170, 3046, 343, 28148, 343, 924, 1803, 2, 4656, 6, 5953, 156, 99, 3, 1011, 89, 28, 3, 98, 1, 152, 10, 67, 83, 60, 184, 39, 269, 60, 2, 3, 30, 4131, 1869, 29, 14, 27, 6, 605, 67, 494, 172, 27, 172, 365, 140, 11, 13033, 13122, 33, 42, 537, 1628, 39, 11, 10691, 2, 33, 42, 8, 50685, 18779, 71531, 3873, 1789, 181, 170, 10, 513, 4, 512, 1, 3, 7, 2, 212, 1, 135, 4, 953, 192, 10, 3, 1326, 1, 152, 187, 500, 816, 5, 3, 1147, 30, 5358, 15, 3, 89, 1, 3, 69, 1829, 181, 170, 5503, 170, 15, 411, 10, 173, 28644, 4, 3, 1844, 7, 6, 3085, 7531, 2730, 2882, 1527, 489, 4, 865, 66, 1, 3, 7, 2, 676, 27, 276, 1978, 16366, 100, 7, 203, 42, 8, 378, 76, 83, 344, 4, 642, 782, 558, 3046, 343, 10, 585, 15, 231, 4, 803, 62, 541, 5157, 6, 35, 1916, 3087, 5, 79, 1, 1370, 4, 3, 88, 870, 9, 136, 89, 125, 10, 8, 226, 473, 1, 296, 1, 3, 366, 1211, 4238, 407, 1, 5859, 20593, 2, 7979, 2130, 3, 2056, 14214, 353, 16, 2884, 9, 9026, 815, 10708, 871, 4, 1169, 541, 5, 13122, 57, 50685, 18779, 5810, 387, 57, 2, 57, 5, 537, 1628, 3, 1039, 1, 170, 16, 10575, 20, 2354, 7531, 30, 3807, 1832, 76, 3, 353, 3, 2056, 14214, 353, 13485, 3, 801, 6, 1606, 39962, 3, 12717, 6, 223, 578, 92, 68, 987, 8539, 3, 69, 29, 7531, 2730, 3500, 1, 353, 3, 151, 1, 573, 13011, 918, 64, 2, 3, 3434, 1496, 9, 3, 353, 6, 8, 1352, 622, 30, 16, 17786]",3023.0,29125446,Suprasellar recurrent pediatric craniopharyngiomas expanding indications extended endoscopic transsphenoidal approach,0,0.0
Ectopic Prolactinoma Presenting as Bacterial Meningitis: A Diagnostic Conundrum.,World neurosurgery,World Neurosurg,2018-01-31,"Prolactinomas may rarely present with meningitis and cerebrospinal fluid (CSF) rhinorrhea secondary to erosion of the wall of the sella turcica. It is even more uncommon for this abnormal communication to be caused by an ectopic prolactinoma arising from the sphenoid sinus and eroding into the sella. This atypical growth pattern makes diagnosis very difficult because there may be no displacement of the normal pituitary gland. The first reported case of a patient with an ectopic prolactinoma originating within the sphenoid sinus presenting primarily with meningitis is presented, and the management strategy and surgical and nonsurgical treatment options are discussed. A 48-year-old woman presented with confusion, low-pressure headache, and fever. A lumbar puncture revealed Streptococcus pneumoniae meningitis, and she was placed on intravenous penicillin G. After initiation of antibiotics, she noticed salty tasting postnasal fluid leakage. Imaging was remarkable for bony erosion of the sphenoid sinus wall by a soft tissue mass growing from within the sinus, with no disruption of the normal pituitary gland. A biopsy was then performed with an endoscopic transnasal transsphenoidal approach, and the CSF leak was repaired with a pedicled nasoseptal flap. The final pathology was prolactinoma, and she was placed on cabergoline. Ectopic prolactinomas may rarely present as meningitis secondary to retrograde transmission of bacteria through a bony defect in the sphenoid sinus, and must be included in the differential diagnosis of any sphenoid sinus mass. Management should first address the infection, followed by surgical repair of the bony defect.",Case Reports,720.0,1.0,Prolactinomas rarely present meningitis cerebrospinal fluid CSF rhinorrhea secondary erosion wall sella turcica uncommon abnormal communication caused ectopic prolactinoma arising sphenoid sinus eroding sella atypical growth pattern makes diagnosis difficult displacement normal pituitary gland reported case patient ectopic prolactinoma originating sphenoid sinus presenting primarily meningitis presented management strategy surgical nonsurgical treatment options discussed 48-year-old woman presented confusion low-pressure headache fever lumbar puncture revealed Streptococcus pneumoniae meningitis placed intravenous penicillin G. initiation antibiotics noticed salty tasting postnasal fluid leakage Imaging remarkable bony erosion sphenoid sinus wall soft tissue mass growing sinus disruption normal pituitary gland biopsy performed endoscopic transnasal transsphenoidal approach CSF leak repaired pedicled nasoseptal flap final pathology prolactinoma placed cabergoline Ectopic prolactinomas rarely present meningitis secondary retrograde transmission bacteria bony defect sphenoid sinus included differential diagnosis sphenoid sinus mass Management address infection followed surgical repair bony defect,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[26749, 68, 2416, 364, 5, 10792, 2, 5156, 2357, 1211, 19396, 568, 6, 14547, 1, 3, 2397, 1, 3, 22175, 72039, 192, 16, 871, 80, 2052, 9, 26, 1668, 2063, 6, 40, 1546, 20, 35, 3647, 41972, 2635, 29, 3, 18779, 5810, 2, 48967, 237, 3, 22175, 26, 1973, 129, 1177, 4677, 147, 923, 1740, 408, 125, 68, 40, 77, 6850, 1, 3, 295, 2326, 3, 157, 210, 473, 1, 8, 69, 5, 35, 3647, 41972, 6794, 262, 3, 18779, 5810, 1656, 1561, 5, 10792, 16, 917, 2, 3, 284, 692, 2, 221, 2, 5544, 24, 838, 32, 1588, 8, 576, 111, 1095, 2854, 917, 5, 7399, 154, 3738, 4538, 2, 2775, 8, 6187, 12104, 553, 16037, 13590, 10792, 2, 3109, 10, 3295, 23, 1262, 27662, 499, 50, 1118, 1, 5214, 3109, 16285, 31078, 48288, 72040, 2357, 9256, 270, 10, 3813, 9, 6552, 14547, 1, 3, 18779, 5810, 2397, 20, 8, 1214, 246, 782, 1921, 29, 262, 3, 5810, 5, 77, 3220, 1, 3, 295, 2326, 8, 411, 10, 818, 173, 5, 35, 2056, 41973, 14214, 353, 2, 3, 1211, 4238, 10, 18437, 5, 8, 11558, 36545, 3942, 3, 1457, 1117, 10, 41972, 2, 3109, 10, 3295, 23, 36546, 3647, 26749, 68, 2416, 364, 22, 10792, 568, 6, 10583, 8151, 1, 8841, 298, 8, 6552, 5398, 4, 3, 18779, 5810, 2, 1642, 40, 159, 4, 3, 1777, 147, 1, 500, 18779, 5810, 782, 284, 257, 157, 1539, 3, 930, 370, 20, 221, 972, 1, 3, 6552, 5398]",1620.0,29378345,Ectopic Prolactinoma Presenting Bacterial Meningitis Diagnostic Conundrum,0,0.0
"Repeat stereotactic radiosurgery for Cushing's disease: outcomes of an international, multicenter study.",Journal of neuro-oncology,J. Neurooncol.,2018-03-03,"Stereotactic radiosurgery (SRS) is frequently used for Cushing's disease (CD) after failed pituitary surgery. Management of patients with persistent CD after failed SRS is complex, as the alternative therapeutic options harbor significant risks. The outcomes of repeat pituitary radiosurgery, however, have not been described. We sought to determine the outcomes of repeat SRS in patients with CD. We pooled data from five institutions participating in the International Gamma Knife Research Foundation for patients with recurrent or persistent CD12months after initial SRS. Patients were included in the study if they had 6months endocrine follow-up after repeat SRS. Twenty patients were included in the study. Repeat single-session SRS was performed 1.3-9.7years after initial SRS. Median endocrine follow-up was 6.6years (1.4-19.1years). Median margin dose was 20Gy (range 10.8-35Gy). Endocrine remission after second SRS was noted in 12 patients (60%), with a median time to remission of 6months (range 2-64months). Biochemical recurrence occurred in two patients (17%) after initial remission. Overall, the cumulative rates of durable endocrine remission at 5 and 10years were 47 and 53%, respectively. Two patients (10%) experienced adverse radiation effects, including transient visual loss and permanent diplopia. Repeat SRS achieves lasting biochemical remission in approximately half of patients with CD refractory to both prior microsurgery and SRS. Because of the morbidity of refractory or recurrent CD, repeat SRS should be considered for carefully selected patients with hypercortisolism confirmed one or more years after initial SRS.",Journal Article,689.0,3.0,Stereotactic radiosurgery SRS frequently Cushing 's disease CD failed pituitary surgery Management patients persistent CD failed SRS complex alternative therapeutic options harbor significant risks outcomes repeat pituitary radiosurgery described sought determine outcomes repeat SRS patients CD pooled institutions participating International Gamma Knife Research Foundation patients recurrent persistent CD  12 months initial SRS Patients included  6 months endocrine follow-up repeat SRS patients included Repeat single-session SRS performed 1.3-9.7 years initial SRS Median endocrine follow-up 6.6 years 1.4-19.1 years Median margin dose 20 Gy range 10.8-35 Gy Endocrine remission second SRS noted 12 patients 60 median time remission 6 months range 2-64 months Biochemical recurrence occurred patients 17 initial remission Overall cumulative rates durable endocrine remission 5 10 years 47 53 respectively patients 10 experienced adverse radiation effects including transient visual loss permanent diplopia Repeat SRS achieves lasting biochemical remission approximately half patients CD refractory prior microsurgery SRS morbidity refractory recurrent CD repeat SRS considered carefully selected patients hypercortisolism confirmed years initial SRS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1729, 2192, 1429, 16, 746, 95, 9, 16258, 292, 34, 4420, 50, 1551, 152, 284, 1, 7, 5, 1882, 4420, 50, 1551, 1429, 16, 840, 22, 3, 1091, 189, 838, 2760, 93, 1098, 3, 123, 1, 2334, 2192, 137, 47, 44, 85, 1027, 21, 990, 6, 223, 3, 123, 1, 2334, 1429, 4, 7, 5, 4420, 21, 1830, 74, 29, 365, 1764, 3052, 4, 3, 944, 1705, 8045, 389, 3247, 9, 7, 5, 387, 15, 1882, 4420, 749, 133, 53, 50, 388, 1429, 7, 11, 159, 4, 3, 45, 492, 491, 42, 749, 49, 53, 1293, 166, 126, 50, 2334, 1429, 737, 7, 11, 159, 4, 3, 45, 2334, 226, 5510, 1429, 10, 173, 14, 27, 83, 67, 60, 50, 388, 1429, 52, 1293, 166, 126, 10, 49, 49, 60, 14, 39, 326, 14, 60, 52, 959, 61, 10, 179, 381, 184, 79, 66, 465, 381, 1293, 734, 50, 419, 1429, 10, 1051, 4, 133, 7, 335, 5, 8, 52, 98, 6, 734, 1, 49, 53, 184, 18, 660, 53, 1487, 146, 489, 4, 100, 7, 269, 50, 388, 734, 63, 3, 967, 151, 1, 1480, 1293, 734, 28, 33, 2, 79, 60, 11, 662, 2, 699, 106, 100, 7, 79, 592, 290, 121, 176, 141, 2473, 3046, 407, 2, 4377, 18862, 2334, 1429, 6358, 3443, 1487, 734, 4, 705, 1303, 1, 7, 5, 4420, 430, 6, 110, 324, 16857, 2, 1429, 408, 1, 3, 787, 1, 430, 15, 387, 4420, 2334, 1429, 257, 40, 515, 9, 3900, 715, 7, 5, 72302, 557, 104, 15, 80, 60, 50, 388, 1429]",1602.0,29500664,Repeat stereotactic radiosurgery Cushing 's disease outcomes international multicenter,0,0.0
Expression of the long non-coding RNA H19 and MALAT-1 in growth hormone-secreting pituitary adenomas and its relationship to tumor behavior.,International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience,Int. J. Dev. Neurosci.,2018-03-28,"Aggressive growth hormone-secreting pituitary adenomas (GHPAs) represent an important clinical problem in patients with acromegaly. Surgical therapy, although often the mainstay of treatment for GHPAs, is less effective in aggressive GHPAs due to their invasive and destructive growth patterns, and their proclivity for infrasellar invasion. LncRNAs are important players in cancer development and emerging in various fundamental biological processes. In the present study, qRT-PCR was performed to examine the expression of lncRNA H19 and MALAT-1 in invasive and non-invasive GHPAs. Our results revealed that the expression of lncRNA H19 was remarkably higher in invasive GHPAs, however, there was no significant differences between the expression of lncRNA MALAT-1 in invasive GHPAs and non-invasive GHPAs, suggesting that lncRNA H19 may play an important role in GHPA invasion. LncRNA H19 might be a target for the study of GHPAs invasion, and a potential index for the diagnosis or prognosis of GHPAs.",Journal Article,664.0,3.0,Aggressive growth hormone-secreting pituitary adenomas GHPAs represent important clinical problem patients acromegaly Surgical therapy mainstay treatment GHPAs effective aggressive GHPAs invasive destructive growth patterns proclivity infrasellar invasion LncRNAs important players development emerging fundamental processes present qRT-PCR performed examine expression lncRNA H19 MALAT-1 invasive non-invasive GHPAs revealed expression lncRNA H19 remarkably higher invasive GHPAs significant differences expression lncRNA MALAT-1 invasive GHPAs non-invasive GHPAs suggesting lncRNA H19 play important role GHPA invasion LncRNA H19 target GHPAs invasion potential index diagnosis prognosis GHPAs,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[571, 129, 785, 5052, 2751, 24322, 1231, 35, 305, 38, 2497, 4, 7, 5, 28682, 221, 36, 242, 629, 3, 4041, 1, 24, 9, 24322, 16, 299, 323, 4, 571, 24322, 520, 6, 136, 416, 2, 11122, 129, 764, 2, 136, 28044, 9, 72480, 578, 6651, 32, 305, 10996, 4, 12, 193, 2, 1478, 4, 747, 4595, 1037, 1849, 4, 3, 364, 45, 5822, 604, 10, 173, 6, 1004, 3, 55, 1, 6381, 8947, 2, 50971, 14, 4, 416, 2, 220, 416, 24322, 114, 99, 553, 17, 3, 55, 1, 6381, 8947, 10, 4856, 142, 4, 416, 24322, 137, 125, 10, 77, 93, 362, 59, 3, 55, 1, 6381, 50971, 14, 4, 416, 24322, 2, 220, 416, 24322, 802, 17, 6381, 8947, 68, 1343, 35, 305, 200, 4, 72481, 578, 6381, 8947, 822, 40, 8, 283, 9, 3, 45, 1, 24322, 578, 2, 8, 174, 558, 9, 3, 147, 15, 356, 1, 24322]",979.0,29604339,Expression long non-coding RNA H19 MALAT-1 growth hormone-secreting pituitary adenomas relationship behavior,0,0.0
Hypopituitarism After Single-Fraction Pituitary Adenoma Radiosurgery: Dosimetric Analysis Based on Patients Treated Using Contemporary Techniques.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2018-03-08,"Toanalyze factors associated with post-stereotactic radiosurgery (SRS) hypopituitarism among radiation-nave patients with pituitary adenomas who underwent single-fraction SRS between 2007 and2014. This was a retrospective review of 97 patients having single-fraction SRS from 2007 until 2014. Eligible patients had no history of prior radiation, normal age- and sex-specific pituitary function before SRS, and at least 24months of endocrine follow-up. Forty patients (41%) had hormone-secreting tumors; 57 patients had nonsecreting tumors (59%). The median prescription isodose volume was 2.8cm<sup>3</sup> (interquartile range [IQR], 1.3-4.7); the median tumor margin dose was 20Gy (IQR, 15-25Gy). The median follow-up after SRS was 48months (IQR, 34-68months). Twenty-seven patients (28%) developed pituitary insufficiency at a median of 22months (IQR, 12-36months) after SRS. The rate of new endocrine deficits was 17% at 2years (95% confidence interval [CI] 10%-25%) and 31% at 5years (95% CI 20%-42%). Male sex (hazard ratio [HR] 2.38, 95% CI 1.05-5.26, P=.04), smaller pituitary gland volume (HR 0.99, 95% CI 0.99-0.99, P=.01), and higher mean pituitary gland dose (HR 1.31, 95% CI 1.16-1.47, P<.001) were associated with post-SRS hypopituitarism in multivariable analysis. The rate of hypopituitarism for patients with a mean gland dose of <11.0Gy at 2years was 2% (95% CI 0%-4%) and at 5years was 5% (95% CI 0%-11%), whereas rate of hypopituitarism for patients with a mean gland dose of 11.0Gy at 2years was 31% (95% CI 17%-43%) and at 5years was 51% (95% CI 34%-65%). Hypopituitarism after pituitary adenoma SRS increases in a time- and dose-dependent manner. Reducing the radiation exposure to the identifiable gland to a mean dose < 11.0Gy whenever feasible may lower the incidence of new hormonal deficits after pituitary adenoma SRS.",Journal Article,684.0,4.0,factors associated post-stereotactic radiosurgery SRS hypopituitarism radiation-nave patients pituitary adenomas underwent single-fraction SRS 2007 2014 retrospective review 97 patients single-fraction SRS 2007 2014 Eligible patients history prior radiation normal age- sex-specific pituitary function SRS 24 months endocrine follow-up patients 41 hormone-secreting 57 patients nonsecreting 59 median prescription isodose volume 2.8 cm sup 3 /sup interquartile range IQR 1.3-4.7 median margin dose 20 Gy IQR 15-25 Gy median follow-up SRS 48 months IQR 34-68 months Twenty-seven patients 28 developed pituitary insufficiency median 22 months IQR 12-36 months SRS rate new endocrine deficits 17 2 years 95 confidence interval CI 10 -25 31 5 years 95 CI 20 -42 Male sex hazard ratio HR 2.38 95 CI 1.05-5.26 P .04 smaller pituitary gland volume HR 0.99 95 CI 0.99-0.99 P .01 higher mean pituitary gland dose HR 1.31 95 CI 1.16-1.47 P .001 associated post-SRS hypopituitarism multivariable rate hypopituitarism patients mean gland dose 11.0 Gy 2 years 2 95 CI 0 -4 5 years 5 95 CI 0 -11 rate hypopituitarism patients mean gland dose 11.0 Gy 2 years 31 95 CI 17 -43 5 years 51 95 CI 34 -65 Hypopituitarism pituitary adenoma SRS increases time- dose-dependent manner Reducing radiation exposure identifiable gland mean dose 11.0 Gy feasible lower incidence new hormonal deficits pituitary adenoma SRS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1992, 130, 41, 5, 539, 1729, 2192, 1429, 19832, 107, 121, 2809, 7, 5, 2751, 54, 208, 226, 1509, 1429, 59, 1307, 2, 1409, 26, 10, 8, 459, 206, 1, 1015, 7, 1041, 226, 1509, 1429, 29, 1307, 1100, 1409, 625, 7, 42, 77, 532, 1, 324, 121, 295, 89, 2, 1035, 112, 343, 348, 1429, 2, 28, 506, 259, 53, 1, 1293, 166, 126, 1213, 7, 605, 42, 785, 5052, 57, 696, 7, 42, 46089, 57, 728, 3, 52, 3584, 8945, 433, 10, 18, 66, 494, 172, 27, 172, 2899, 184, 2245, 14, 27, 39, 67, 3, 52, 30, 959, 61, 10, 179, 381, 2245, 167, 243, 381, 3, 52, 166, 126, 50, 1429, 10, 576, 53, 2245, 562, 806, 53, 737, 648, 7, 339, 276, 4360, 28, 8, 52, 1, 350, 53, 2245, 133, 511, 53, 50, 1429, 3, 116, 1, 217, 1293, 2752, 10, 269, 28, 18, 60, 48, 307, 268, 58, 79, 243, 2, 456, 28, 33, 60, 48, 58, 179, 595, 1045, 1035, 360, 197, 168, 18, 519, 48, 58, 14, 474, 33, 432, 19, 755, 2170, 2326, 433, 168, 13, 1058, 48, 58, 13, 1058, 13, 1058, 19, 355, 2, 142, 313, 2326, 61, 168, 14, 456, 48, 58, 14, 245, 14, 662, 19, 144, 11, 41, 5, 539, 1429, 19832, 4, 658, 65, 3, 116, 1, 19832, 9, 7, 5, 8, 313, 2326, 61, 1, 175, 13, 381, 28, 18, 60, 10, 18, 48, 58, 13, 39, 2, 28, 33, 60, 10, 33, 48, 58, 13, 175, 547, 116, 1, 19832, 9, 7, 5, 8, 313, 2326, 61, 1, 27316, 13, 381, 28, 18, 60, 10, 456, 48, 58, 269, 601, 2, 28, 33, 60, 10, 725, 48, 58, 562, 556, 19832, 50, 2434, 1429, 1106, 4, 8, 98, 2, 61, 470, 1708, 1818, 3, 121, 645, 6, 3, 6237, 2326, 6, 8, 313, 61, 175, 13, 381, 8395, 1313, 68, 280, 3, 287, 1, 217, 1761, 2752, 50, 2434, 1429]",1701.0,29678524,Hypopituitarism Single-Fraction Pituitary Adenoma Radiosurgery Dosimetric Based Patients Treated Contemporary Techniques,3,0.02830188679245283
Hypothyroidism after Radiation Therapy for Childhood Cancer: A Report from the Childhood Cancer Survivor Study.,Radiation research,Radiat. Res.,2018-05-15,"While thyroid cancer risks from exposure to ionizing radiation early in life are well characterized quantitatively, the association of radiation with nonmalignant, functional thyroid disorders has been less studied. Here, we report on a risk analysis study of hypothyroidism with radiation dose to the thyroid gland and the hypothalamic-pituitary axis among survivors of childhood cancer. Utilizing data from the Childhood Cancer Survivor Study, a cohort of 14,364 five-year survivors of childhood cancer diagnosed at 26 hospitals in the U.S. and Canada between 1970 and 1986 and followed through 2009, the occurrence of hypothyroidism was ascertained among 12,015 survivors through serial questionnaires. Radiation doses to the thyroid gland and pituitary gland were estimated from radiotherapy records. Binary outcome regression was used to estimate prevalence odds ratios for hypothyroidism at five years from diagnosis of childhood cancer and Poisson regression to model incidence rate ratios (RR) after the first five years. A total of 1,193 cases of hypothyroidism were observed, 777 (65%) of which occurred five or more years after cancer diagnosis. The cumulative proportion affected with hypothyroidism (prevalence at five years after cancer diagnosis plus incidence through 30 years after cancer diagnosis) was highest among five-year survivors of Hodgkin lymphoma (32.3%; 95% CI: 29.5-34.9) and cancers of the central nervous system (17.7%; 95% CI: 15.2-20.4). The incidence rate was significantly associated with radiation dose to the thyroid and pituitary. The joint association of hypothyroidism with thyroid and pituitary dose was sub-additive for pituitary doses greater than 16 Gy. In particular, a very strong thyroid radiation dose dependence at low-to-moderate pituitary/hypothalamic doses was diminished at high pituitary doses. Radiation-related risks were higher in males than females and inversely associated with age at exposure and time since exposure but remained elevated more than 25 years after exposure. Our findings indicated that hypothyroidism was significantly associated with treatment with bleomycin (RR = 3.4; 95% CI: 1.6-7.3) and the alkylating agents cyclohexyl-chloroethyl-nitrosourea (CCNU) (RR = 3.0; 95% CI: 1.5-5.3) and cyclophosphamide (RR = 1.3; 95% CI: 1.0-1.8), with a significant dose response for CCNU ( P < 0.01). The risk of hypothyroidism among childhood cancer survivors treated with radiation depends both on direct, dose-dependent radiation-induced damage to the thyroid gland and on dose-dependent indirect effects secondary to irradiation of the hypothalamic-pituitary axis. The dose-response relationship for each site depends on dose to the other. Radiation-related risk persists for more than 25 years after treatment. Treatment with certain chemotherapy agents may increase the risk of hypothyroidism.",Journal Article,616.0,3.0,"thyroid risks exposure ionizing radiation early life characterized quantitatively association radiation nonmalignant functional thyroid disorders studied report risk hypothyroidism radiation dose thyroid gland hypothalamic-pituitary axis survivors childhood Utilizing Childhood Survivor cohort 14,364 five-year survivors childhood diagnosed 26 hospitals U.S. Canada 1970 1986 followed 2009 occurrence hypothyroidism ascertained 12,015 survivors serial questionnaires Radiation doses thyroid gland pituitary gland estimated radiotherapy records Binary outcome regression estimate prevalence odds ratios hypothyroidism years diagnosis childhood Poisson regression model incidence rate ratios RR years total 1,193 cases hypothyroidism observed 777 65 occurred years diagnosis cumulative proportion affected hypothyroidism prevalence years diagnosis plus incidence 30 years diagnosis highest five-year survivors Hodgkin lymphoma 32.3 95 CI 29.5-34.9 central nervous 17.7 95 CI 15.2-20.4 incidence rate significantly associated radiation dose thyroid pituitary joint association hypothyroidism thyroid pituitary dose sub-additive pituitary doses greater 16 Gy particular strong thyroid radiation dose dependence low-to-moderate pituitary/hypothalamic doses diminished high pituitary doses Radiation-related risks higher males females inversely associated age exposure time exposure remained elevated 25 years exposure findings indicated hypothyroidism significantly associated treatment bleomycin RR 3.4 95 CI 1.6-7.3 alkylating agents cyclohexyl-chloroethyl-nitrosourea CCNU RR 3.0 95 CI 1.5-5.3 cyclophosphamide RR 1.3 95 CI 1.0-1.8 significant dose response CCNU P 0.01 risk hypothyroidism childhood survivors treated radiation depends direct dose-dependent radiation-induced damage thyroid gland dose-dependent indirect effects secondary irradiation hypothalamic-pituitary axis dose-response relationship site depends dose Radiation-related risk persists 25 years treatment Treatment certain chemotherapy agents increase risk hypothyroidism",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[369, 12, 1098, 29, 645, 6, 4341, 121, 191, 4, 358, 32, 149, 765, 5889, 3, 248, 1, 121, 5, 5967, 583, 1997, 71, 85, 299, 656, 467, 21, 414, 23, 8, 43, 65, 45, 1, 4147, 5, 121, 61, 6, 3, 2326, 2, 3, 7531, 12098, 2310, 107, 332, 1, 864, 12, 2600, 74, 29, 3, 864, 12, 2628, 45, 8, 180, 1, 213, 10106, 365, 111, 332, 1, 864, 12, 265, 28, 432, 1987, 4, 3, 1767, 695, 2, 4740, 59, 4868, 2, 3751, 2, 370, 298, 1238, 3, 2291, 1, 4147, 10, 5240, 107, 133, 3433, 332, 298, 2108, 2956, 121, 415, 6, 3, 2326, 2, 2326, 11, 661, 29, 310, 1064, 6405, 228, 320, 10, 95, 6, 1191, 1078, 610, 1137, 9, 4147, 28, 365, 60, 29, 147, 1, 864, 12, 2, 7668, 320, 6, 202, 287, 116, 1137, 861, 50, 3, 157, 365, 60, 8, 181, 1, 14, 5744, 140, 1, 4147, 11, 164, 12021, 556, 1, 92, 489, 365, 15, 80, 60, 50, 12, 147, 3, 967, 920, 1424, 5, 4147, 1078, 28, 365, 60, 50, 12, 147, 349, 287, 298, 201, 60, 50, 12, 147, 10, 1076, 107, 365, 111, 332, 1, 531, 27, 48, 58, 462, 33, 562, 83, 2, 163, 1, 3, 854, 1880, 398, 269, 67, 48, 58, 167, 18, 179, 39, 3, 287, 116, 10, 97, 41, 5, 121, 61, 6, 3, 2, 3, 2093, 248, 1, 4147, 5, 2, 61, 10, 551, 3396, 9, 415, 378, 76, 245, 381, 4, 1454, 8, 923, 1082, 121, 61, 3721, 28, 154, 6, 1163, 12098, 7531, 415, 10, 2849, 28, 64, 415, 121, 139, 1098, 11, 142, 4, 2296, 76, 2451, 2, 2659, 41, 5, 89, 28, 645, 2, 98, 1192, 645, 84, 958, 804, 80, 76, 243, 60, 50, 645, 114, 272, 1103, 17, 4147, 10, 97, 41, 5, 24, 5, 5213, 861, 27, 39, 48, 58, 14, 49, 67, 27, 2, 3, 3410, 183, 36602, 12520, 8305, 16692, 861, 27, 13, 48, 58, 14, 33, 33, 27, 2, 1112, 861, 14, 27, 48, 58, 14, 13, 14, 66, 5, 8, 93, 61, 51, 9, 16692, 19, 13, 355, 3, 43, 1, 4147, 107, 864, 12, 332, 73, 5, 121, 3828, 110, 23, 1196, 61, 470, 121, 277, 1350, 6, 3, 2326, 2, 23, 61, 470, 6110, 176, 568, 6, 1104, 1, 3, 7531, 12098, 2310, 3, 61, 51, 858, 9, 296, 606, 3828, 23, 61, 6, 3, 127, 121, 139, 43, 8936, 9, 80, 76, 243, 60, 50, 24, 24, 5, 1840, 56, 183, 68, 344, 3, 43, 1, 4147]",2661.0,29763379,Hypothyroidism Radiation Therapy Childhood Report Childhood Survivor,1,0.009433962264150943
"Improving Male Reproductive Health After Childhood, Adolescent, and Young Adult Cancer: Progress and Future Directions for Survivorship Research.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2018-06-06,"Reproductive health is a common concern and often a source of distress for male childhood, adolescent, and young adult cancer survivors. Clinical and epidemiologic research in survivor populations has identified alkylating agent chemotherapy, testicular radiation, and surgery or radiation to the genitourinary organs, lower spine, or the hypothalamic-pituitary region as risk factors for adverse reproductive outcomes, including impaired spermatogenesis, testosterone insufficiency, and sexual dysfunction. Much of the research on male survivors has focused on the outcome of fertility, using spermatogenesis, serum gonadotropins, and paternity as the measures. However, these studies often fail to account for the clinically relevant but difficult-to-quantify aspects of fertility such as sexual function, cancer-related delayed psychosocial development, medical comorbidities, and socioeconomic concerns. Clinical and basic science research has made significant contributions to improving reproductive outcomes for survivors, with recent advancements in the areas of fertility preservation, clinical assessment of reproductive function, and treatment of adverse reproductive outcomes. Furthermore, there is an emerging qualitative literature addressing the psychosexual aspects of male reproductive health, the clinical application of which will improve quality of life for survivors. This review summarizes the current survivorship literature on reproductive health outcomes for male survivors, including the epidemiology of impaired spermatogenesis, testosterone insufficiency, and sexual dysfunction; clinical and laboratory assessment of reproductive function; and established and investigational interventions to preserve reproductive function for patients newly diagnosed and survivors. Although survivorship research has made significant contributions to improving reproductive outcomes, additional scientific progress is needed in the areas of fertility preservation, risk assessment, and psychosexual support with the aim of optimizing reproductive health for current and future survivors.",Journal Article,594.0,7.0,Reproductive health common concern source distress male childhood adolescent young adult survivors Clinical epidemiologic research survivor populations identified alkylating agent chemotherapy testicular radiation surgery radiation genitourinary organs lower spine hypothalamic-pituitary region risk factors adverse reproductive outcomes including impaired spermatogenesis testosterone insufficiency sexual dysfunction research male survivors focused outcome fertility spermatogenesis serum gonadotropins paternity measures studies fail account clinically relevant difficult-to-quantify aspects fertility sexual function cancer-related delayed psychosocial development medical comorbidities socioeconomic concerns Clinical basic science research significant contributions improving reproductive outcomes survivors recent advancements areas fertility preservation clinical assessment reproductive function treatment adverse reproductive outcomes Furthermore emerging qualitative literature addressing psychosexual aspects male reproductive health clinical application improve quality life survivors review summarizes current survivorship literature reproductive health outcomes male survivors including epidemiology impaired spermatogenesis testosterone insufficiency sexual dysfunction clinical laboratory assessment reproductive function established investigational interventions preserve reproductive function patients newly diagnosed survivors survivorship research significant contributions improving reproductive outcomes additional scientific progress needed areas fertility preservation risk assessment psychosexual support aim optimizing reproductive health current future survivors,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3705, 341, 16, 8, 186, 2893, 2, 629, 8, 2353, 1, 1462, 9, 1045, 864, 3678, 2, 1169, 780, 12, 332, 38, 2, 3609, 389, 4, 2628, 1184, 71, 108, 3410, 420, 56, 121, 2, 152, 15, 121, 6, 3, 4109, 2285, 280, 2342, 15, 3, 7531, 12098, 1053, 22, 43, 130, 9, 290, 3705, 123, 141, 2364, 24713, 2660, 4360, 2, 2232, 1527, 1802, 1, 3, 389, 23, 1045, 332, 71, 1649, 23, 3, 228, 1, 2954, 75, 24713, 524, 34749, 2, 47160, 22, 3, 1018, 137, 46, 94, 629, 4373, 6, 1967, 9, 3, 505, 867, 84, 1740, 6, 3091, 2695, 1, 2954, 225, 22, 2232, 343, 12, 139, 1612, 2322, 193, 484, 1909, 2, 3331, 2061, 38, 2, 2795, 3797, 389, 71, 1229, 93, 5621, 6, 1673, 3705, 123, 9, 332, 5, 435, 6217, 4, 3, 1361, 1, 2954, 2224, 38, 455, 1, 3705, 343, 2, 24, 1, 290, 3705, 123, 798, 125, 16, 35, 1478, 3926, 789, 3432, 3, 28131, 2695, 1, 1045, 3705, 341, 3, 38, 1581, 1, 92, 303, 401, 372, 1, 358, 9, 332, 26, 206, 2869, 3, 291, 2560, 789, 23, 3705, 341, 123, 9, 1045, 332, 141, 3, 1284, 1, 2364, 24713, 2660, 4360, 2, 2232, 1527, 38, 2, 1624, 455, 1, 3705, 343, 2, 635, 2, 3093, 1151, 6, 6783, 3705, 343, 9, 7, 732, 265, 2, 332, 242, 2560, 389, 71, 1229, 93, 5621, 6, 1673, 3705, 123, 402, 3138, 1466, 16, 575, 4, 3, 1361, 1, 2954, 2224, 43, 455, 2, 28131, 538, 5, 3, 1130, 1, 4336, 3705, 341, 9, 291, 2, 508, 332]",2053.0,29874140,Improving Male Reproductive Health Childhood Adolescent Young Adult Progress Future Directions Survivorship Research,0,0.0
Is spindle cell oncocytoma a true entity or a variant of pituicytoma? A case report with review of literature.,Neurology India,Neurol India,,"Spindle cell oncocytoma (SCO) is a newly described rare entity simulating clinicoradiological features of a nonfunctional pituitary adenoma and is corresponding to the category of World Health Organization grade I tumor. However, because of the reported incidence of recurrence and invasive presentation in some cases, its categorization as a low grade tumor is questionable. Earlier, it was thought to arise from the folliculostellate cells of adenohypophysis. Recently, few reports have described expression of thyroid transcription factor-1 [TTF-1], which is a specific marker for pituicytes of neurohypophysis, suggesting this tumor to be a variant of pituicytoma. We describe a case of SCO in a 28-year-old young female patient with TTF-1 immunopositivity, and ultra-structurally showing abundant mitochondria along with few neurosecretory granules.",Case Reports,,1.0,Spindle oncocytoma SCO newly described rare entity simulating clinicoradiological features nonfunctional pituitary adenoma corresponding category World Health Organization grade reported incidence recurrence invasive presentation cases categorization low grade questionable Earlier thought arise folliculostellate adenohypophysis Recently reports described expression thyroid transcription factor-1 TTF-1 specific marker pituicytes neurohypophysis suggesting pituicytoma case SCO 28-year-old young female patient TTF-1 immunopositivity ultra-structurally showing abundant mitochondria neurosecretory granules,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[4052, 31, 12306, 24243, 16, 8, 732, 1027, 622, 2983, 13352, 32828, 404, 1, 8, 12260, 2434, 2, 16, 1734, 6, 3, 2169, 1, 1956, 341, 2533, 88, 70, 30, 137, 408, 1, 3, 210, 287, 1, 146, 2, 416, 1031, 4, 476, 140, 211, 8872, 22, 8, 154, 88, 30, 16, 14853, 1677, 192, 10, 2739, 6, 3043, 29, 3, 73624, 37, 1, 49482, 761, 1021, 1198, 47, 1027, 55, 1, 866, 161, 14, 4583, 14, 92, 16, 8, 112, 952, 9, 73625, 1, 47358, 802, 26, 30, 6, 40, 8, 1142, 1, 73626, 21, 897, 8, 473, 1, 24243, 4, 8, 339, 111, 1095, 1169, 1061, 69, 5, 4583, 14, 18964, 2, 12223, 8533, 2069, 4834, 5443, 1510, 5, 1021, 38519, 13766]",820.0,30233016,spindle oncocytoma true entity pituicytoma case report review literature,0,0.0
Hyperthyroidism After Radiation Therapy for Childhood Cancer: A Report from the Childhood Cancer Survivor Study.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2019-02-12,"The association of hyperthyroidism with exposure to ionizing radiation is poorly understood. This study addresses the risk of hyperthyroidism in relation to incidental therapeutic radiation dose to the thyroid and pituitary glands in a large cohort of survivors of childhood cancer. Using the Childhood Cancer Survivor Study's cohort of 5-year survivors of childhood cancer diagnosed at hospitals in the United States and Canada between 1970 and 1986, the occurrence of hyperthyroidism through 2009 was ascertained among 12,183 survivors who responded to serial questionnaires. Radiation doses to the thyroid and pituitary glands were estimated from radiation therapy records, and chemotherapy exposures were abstracted from medical records. Binary outcome regression was used to estimate prevalence odds ratios (ORs) for hyperthyroidism at 5years from diagnosis of childhood cancer and Poisson regression to estimate incidence rate ratios (RRs) after the first 5years. Survivors reported 179 cases of hyperthyroidism, of which 148 were diagnosed 5 or more years after their cancer diagnosis. The cumulative proportion of survivors diagnosed with hyperthyroidism by 30years after the cancer diagnosis was 2.5% (95% confidence interval [CI], 2.0%-2.9%) among those who received radiation therapy. A linear relation adequately described the thyroid radiation dose response for prevalence of self-reported hyperthyroidism 5years after cancer diagnosis (excess OR/Gy, 0.24; 95% CI, 0.06-0.95) and incidence rate thereafter (excess RR/Gy, 0.06; 95% CI, 0.03-0.14) over the dose range of 0 to 63Gy. Neither radiation dose to the pituitary gland nor chemotherapy was associated significantly with hyperthyroidism. Radiation-associated risk remained elevated >25years after exposure. Risk of hyperthyroidism after radiation therapy during childhood is positively associated with external radiation dose to the thyroid gland, with radiation-related excess risk persisting for >25years. Neither radiation dose to the pituitary gland nor chemotherapy exposures were associated with hyperthyroidism among childhood cancer survivors through early adulthood.",Journal Article,343.0,1.0,"association hyperthyroidism exposure ionizing radiation poorly understood addresses risk hyperthyroidism relation incidental therapeutic radiation dose thyroid pituitary glands large cohort survivors childhood Childhood Survivor 's cohort 5-year survivors childhood diagnosed hospitals United States Canada 1970 1986 occurrence hyperthyroidism 2009 ascertained 12,183 survivors responded serial questionnaires Radiation doses thyroid pituitary glands estimated radiation therapy records chemotherapy exposures abstracted medical records Binary outcome regression estimate prevalence odds ratios ORs hyperthyroidism 5 years diagnosis childhood Poisson regression estimate incidence rate ratios RRs 5 years Survivors reported 179 cases hyperthyroidism 148 diagnosed 5 years diagnosis cumulative proportion survivors diagnosed hyperthyroidism 30 years diagnosis 2.5 95 confidence interval CI 2.0 -2.9 received radiation therapy linear relation adequately described thyroid radiation dose response prevalence self-reported hyperthyroidism 5 years diagnosis excess OR/Gy 0.24 95 CI 0.06-0.95 incidence rate excess RR/Gy 0.06 95 CI 0.03-0.14 dose range 0 63 Gy radiation dose pituitary gland chemotherapy associated significantly hyperthyroidism Radiation-associated risk remained elevated 25 years exposure Risk hyperthyroidism radiation therapy childhood positively associated external radiation dose thyroid gland radiation-related excess risk persisting 25 years radiation dose pituitary gland chemotherapy exposures associated hyperthyroidism childhood survivors early adulthood",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[3, 248, 1, 12096, 5, 645, 6, 4341, 121, 16, 1240, 1784, 26, 45, 5437, 3, 43, 1, 12096, 4, 2191, 6, 4490, 189, 121, 61, 6, 3, 2, 3966, 4, 8, 375, 180, 1, 332, 1, 864, 12, 75, 3, 864, 12, 2628, 45, 292, 180, 1, 33, 111, 332, 1, 864, 12, 265, 28, 1987, 4, 3, 1088, 907, 2, 4740, 59, 4868, 2, 3751, 3, 2291, 1, 12096, 298, 1238, 10, 5240, 107, 133, 6348, 332, 54, 2211, 6, 2108, 2956, 121, 415, 6, 3, 2, 3966, 11, 661, 29, 121, 36, 1064, 2, 56, 3401, 11, 4106, 29, 484, 1064, 6405, 228, 320, 10, 95, 6, 1191, 1078, 610, 1137, 3694, 9, 12096, 28, 33, 60, 29, 147, 1, 864, 12, 2, 7668, 320, 6, 1191, 287, 116, 1137, 4739, 50, 3, 157, 33, 60, 332, 210, 5977, 140, 1, 12096, 1, 92, 4647, 11, 265, 33, 15, 80, 60, 50, 136, 12, 147, 3, 967, 920, 1, 332, 265, 5, 12096, 20, 201, 60, 50, 3, 12, 147, 10, 18, 33, 48, 307, 268, 58, 18, 13, 18, 83, 107, 135, 54, 103, 121, 36, 8, 1646, 2191, 4215, 1027, 3, 121, 61, 51, 9, 1078, 1, 1074, 210, 12096, 33, 60, 50, 12, 147, 2612, 15, 381, 13, 259, 48, 58, 13, 1460, 13, 48, 2, 287, 116, 3972, 2612, 861, 381, 13, 1460, 48, 58, 13, 680, 13, 213, 252, 3, 61, 184, 1, 13, 6, 676, 381, 2174, 121, 61, 6, 3, 2326, 2110, 56, 10, 41, 97, 5, 12096, 121, 41, 43, 958, 804, 243, 60, 50, 645, 43, 1, 12096, 50, 121, 36, 190, 864, 16, 2375, 41, 5, 1455, 121, 61, 6, 3, 2326, 5, 121, 139, 2612, 43, 12099, 9, 243, 60, 2174, 121, 61, 6, 3, 2326, 2110, 56, 3401, 11, 41, 5, 12096, 107, 864, 12, 332, 298, 191, 6002]",2038.0,30769174,Hyperthyroidism Radiation Therapy Childhood Report Childhood Survivor,1,0.009433962264150943
Dose-Constraint Model to Predict Neuroendocrine Dysfunction in Young Patients With Brain Tumors: Data From a Prospective Study.,Practical radiation oncology,Pract Radiat Oncol,2019-02-28,"We report on a possible dose-constraint model to predict long-term neuroendocrine dysfunction after cranial irradiation in children and young adults with benign and low-grade brain tumors treated with stereotactic conformal radiation therapy (RT) in a prospective clinical trial. Patients treated with stereotactic conformal RT (54Gy in 30 fractions) were included for analysis if their co-registered planning computed tomography and magnetic resonance imaging scans were available, along with baseline and post-RT endocrine assessment for at least 2years. The hypothalamus-pituitary axis (HPA) was contoured on the fused computed tomography-magnetic resonance imaging data set. Worsening of endocrine function was defined biochemically as a new onset endocrine deficit or worsening of preexisting endocrine deficit. Dosimetric indices of HPA, extracted using cumulative dose-volume histograms, were correlated with worsening endocrine function using logistic regression analysis. A total of 51 patients (median age: 13years; range, 5-25years) were included. Worsening post-RT endocrine levels were seen in 27 of 51 patients (47%). Growth hormone was the most commonly affected (70%), followed by cortisol (44%), gonadotropin (40%), and thyroxine (7%). The mean of the maximum and minimum doses to HPA was 42.1Gy and 35.7Gy, respectively. For patients with worsening endocrine levels, the mean maximum dose to HPA was 46.6Gy compared with 36.5Gy in patients with stable functions. The mean minimum dose to HPA was also higher (40.5Gy vs 29.6Gy) in patients with endocrine dysfunction. Logistic regression analysis identified the volume of HPA receiving 50% of the prescribed dose as the only statistically significant parameter predicting endocrine dysfunction. A dose of 27Gy to any volume of HPA was associated with a 4-fold increase in risk of endocrine dysfunction (odds ratio: 4.05; 95% confidence interval, 1.07-15.62; P=.038). Our prospective longitudinal study demonstrates the feasibility of HPA avoidance using modern, high-precision, conformal RT techniques and correlates HPA dosimetry with neuroendocrine dysfunction. We suggest restricting HPA doses to <27Gy to minimize the risk of post-RT neuroendocrine deficits.",Journal Article,327.0,2.0,report possible dose-constraint model predict long-term neuroendocrine dysfunction cranial irradiation children young adults benign low-grade brain treated stereotactic conformal radiation therapy RT prospective clinical trial Patients treated stereotactic conformal RT 54 Gy 30 fractions included co-registered planning computed tomography magnetic resonance imaging scans available baseline post-RT endocrine assessment 2 years hypothalamus-pituitary axis HPA contoured fused computed tomography-magnetic resonance imaging set Worsening endocrine function defined biochemically new onset endocrine deficit worsening preexisting endocrine deficit Dosimetric indices HPA extracted cumulative dose-volume histograms correlated worsening endocrine function logistic regression total 51 patients median age 13 years range 5-25 years included Worsening post-RT endocrine levels seen 27 51 patients 47 Growth hormone commonly affected 70 followed cortisol 44 gonadotropin 40 thyroxine 7 mean maximum minimum doses HPA 42.1 Gy 35.7 Gy respectively patients worsening endocrine levels mean maximum dose HPA 46.6 Gy compared 36.5 Gy patients stable functions mean minimum dose HPA higher 40.5 Gy vs 29.6 Gy patients endocrine dysfunction Logistic regression identified volume HPA receiving 50 prescribed dose statistically significant parameter predicting endocrine dysfunction dose 27 Gy volume HPA associated 4-fold increase risk endocrine dysfunction odds ratio 4.05 95 confidence interval 1.07-15.62 P .038 prospective longitudinal demonstrates feasibility HPA avoidance modern high-precision conformal RT techniques correlates HPA dosimetry neuroendocrine dysfunction suggest restricting HPA doses 27 Gy minimize risk post-RT neuroendocrine deficits,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 414, 23, 8, 899, 61, 11482, 202, 6, 678, 319, 337, 1542, 1527, 50, 2565, 1104, 4, 541, 2, 1169, 857, 5, 1002, 2, 154, 88, 342, 57, 73, 5, 1729, 2972, 121, 36, 240, 4, 8, 482, 38, 160, 7, 73, 5, 1729, 2972, 240, 667, 381, 4, 201, 1550, 11, 159, 9, 65, 492, 136, 1269, 1653, 1349, 1220, 872, 2, 1484, 1535, 270, 1441, 11, 390, 1510, 5, 330, 2, 539, 240, 1293, 455, 9, 28, 506, 18, 60, 3, 12717, 12098, 2310, 14513, 10, 6476, 23, 3, 6263, 1220, 872, 1484, 1535, 270, 74, 916, 4323, 1, 1293, 343, 10, 395, 7944, 22, 8, 217, 1707, 1293, 6819, 15, 4323, 1, 5004, 1293, 6819, 3187, 3824, 1, 14513, 2484, 75, 967, 61, 433, 8638, 11, 438, 5, 4323, 1293, 343, 75, 812, 320, 65, 8, 181, 1, 725, 7, 52, 89, 233, 60, 184, 33, 243, 60, 11, 159, 4323, 539, 240, 1293, 148, 11, 527, 4, 428, 1, 725, 7, 662, 129, 785, 10, 3, 96, 841, 1424, 431, 370, 20, 9572, 584, 6501, 327, 2, 21132, 67, 3, 313, 1, 3, 689, 2, 2499, 415, 6, 14513, 10, 595, 14, 381, 2, 465, 67, 381, 106, 9, 7, 5, 4323, 1293, 148, 3, 313, 689, 61, 6, 14513, 10, 641, 49, 381, 72, 5, 511, 33, 381, 4, 7, 5, 585, 1681, 3, 313, 2499, 61, 6, 14513, 10, 120, 142, 327, 33, 381, 105, 462, 49, 381, 4, 7, 5, 1293, 1527, 812, 320, 65, 108, 3, 433, 1, 14513, 357, 212, 1, 3, 2746, 61, 22, 3, 158, 712, 93, 4219, 1434, 1293, 1527, 8, 61, 1, 25373, 381, 6, 500, 433, 1, 14513, 10, 41, 5, 8, 39, 1116, 344, 4, 43, 1, 1293, 1527, 610, 197, 39, 474, 48, 307, 268, 14, 1615, 167, 744, 19, 5215, 114, 482, 2380, 45, 1902, 3, 1437, 1, 14513, 5863, 75, 2366, 64, 2720, 2972, 240, 1092, 2, 1871, 14513, 4113, 5, 1542, 1527, 21, 309, 9998, 14513, 415, 6, 428, 381, 6, 3241, 3, 43, 1, 539, 240, 1542, 2752]",2180.0,30826479,Dose-Constraint Model Predict Neuroendocrine Dysfunction Young Patients Brain Prospective,2,0.018867924528301886
Ectopic pituitary adenomas: common presentations of a rare entity.,Pituitary,Pituitary,2019-08-01,"Ectopic pituitary adenomas (EPA) are rare tumors thought to arise from embryological remnants along the route of normal pituitary migration. Clinically, these tumors vary in hormonal activity and can exert mass effect based on location and size. We performed a single-center retrospective analysis of patients with diagnosis of ectopic pituitary adenoma from 2001 to 2018. Five patients were identified with EPA: a 48-year-old woman with suprasellar EPA treated with transsphenoidal removal of thetumor, a 44-year-old woman with cavernous EPA treated with transsphenoidal removal of thetumor, a 48-year-old woman with sphenoid EPA treated with cabergoline, a 45-year-old man with clival EPA treated with cabergoline and transsphenoidal surgical resection, and a 54-year-old man with clival EPA treated with cabergoline therapy. EPA should be considered as a differential diagnosis of juxta-sellar lesions. Appropriate hormonal testing may lead to early diagnosis, avoidance of unnecessary biopsy or surgery, and improved outcomes.",Journal Article,173.0,1.0,Ectopic pituitary adenomas EPA rare thought arise embryological remnants route normal pituitary migration Clinically vary hormonal activity exert mass effect based location size performed single-center retrospective patients diagnosis ectopic pituitary adenoma 2001 2018 patients identified EPA 48-year-old woman suprasellar EPA treated transsphenoidal removal 44-year-old woman cavernous EPA treated transsphenoidal removal 48-year-old woman sphenoid EPA treated cabergoline 45-year-old man clival EPA treated cabergoline transsphenoidal surgical resection 54-year-old man clival EPA treated cabergoline therapy EPA considered differential diagnosis juxta-sellar lesions Appropriate hormonal testing lead early diagnosis avoidance unnecessary biopsy surgery improved outcomes,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3647, 2751, 6986, 32, 622, 57, 2739, 6, 3043, 29, 31912, 15733, 1510, 3, 5841, 1, 295, 1381, 505, 46, 57, 2825, 4, 1761, 128, 2, 122, 5448, 782, 254, 90, 23, 1147, 2, 444, 21, 173, 8, 226, 574, 459, 65, 1, 7, 5, 147, 1, 3647, 2434, 29, 1758, 6, 2982, 365, 7, 11, 108, 5, 6986, 8, 576, 111, 1095, 2854, 5, 13122, 6986, 73, 5, 14214, 2829, 1, 3, 30, 8, 584, 111, 1095, 2854, 5, 12170, 6986, 73, 5, 14214, 2829, 1, 3, 30, 8, 576, 111, 1095, 2854, 5, 18779, 6986, 73, 5, 36546, 8, 512, 111, 1095, 3628, 5, 21893, 6986, 73, 5, 36546, 2, 14214, 221, 170, 2, 8, 667, 111, 1095, 3628, 5, 21893, 6986, 73, 5, 36546, 36, 6986, 257, 40, 515, 22, 8, 1777, 147, 1, 30279, 14479, 406, 870, 1761, 471, 68, 1122, 6, 191, 147, 5863, 1, 4224, 411, 15, 152, 2, 231, 123]",986.0,30895500,Ectopic pituitary adenomas common presentations rare entity,0,0.0
